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ABSTRACT 
Haemophilus influenzae type b (Hib) is an infectious bacterium transmitted from person to 
person through close contact. Hib can cause meningitis, pneumonia and a number of rarer 
forms of disease, primarily in children less than five years. Hib conjugate vaccines became 
available during the early 1990s and high-income countries quickly introduced this 
vaccine into their routine programmes and have now achieved a near disappearance of 
Hib disease. However, relatively high vaccine prices and uncertainties about Hib disease 
burden led to a slow uptake in low- and middle-income countries.  
The aim of this PhD is to fill gaps in knowledge about the value of Hib vaccination, in terms 
of whether or not it is a cost-effective intervention in low- and middle-income countries.  
Moreover, since economic evaluation involves gathering evidence about numerous criteria 
that may be considered in isolation by policy makers, such as vaccine efficacy, disease 
burden, meningitis sequelae prevalence and cold chain expansion costs, specific objectives 
are also to address some of the unanswered questions about key inputs and determinants 
of cost-effectiveness.  
The framework of the PhD is shaped around a decision-analytic model designed to 
estimate the cost-utility of Hib vaccination.  The methodology, collection and analysis of 
data inputs needed to populate the model represent a number of sub-studies, which are all 
contributions to new evidence. These include a meta-analysis of Hib vaccine efficacy, 
calculation of Disability Adjusted Life Years due to Hib disease, estimation of treatment 
costs of Hib disease, assessment of productivity costs due to meningitis sequelae, and 
calculation of systems costs of introducing Hib vaccine. Case studies from two countries 
are included in the sub-studies; productivity costs of meningitis sequelae are investigated 
in Senegal and systems costs of Hib vaccine introduction are estimated in Ethiopia. Cost-
utility results generated from the decision-analytic model are presented for two low-
income countries; India and Uzbekistan, and one middle-income country; Belarus.  
This PhD thesis is the first attempt to combine evidence on disease burden, costs and 
impact of Hib vaccine across multiple countries using a consistent framework and 
comparable input parameters. As a result, new insights into the relative cost-utility in 
countries with different economic and epidemiological circumstances are obtained.   
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1 INTRODUCTION 
The overall objective of this PhD is to assess the cost-effectiveness of Hib vaccine in low- 
and middle-income countries, in order to help policy makers determine whether it is good 
value for money to include the vaccine in routine childhood vaccination programmes. It is 
anticipated that this information will be useful not only to policy makers who are yet to 
introduce Hib vaccines, but also for countries with GAVI Alliance assisted provision that is 
due to cease in 2015. When these governments are required to take over financing of the 
vaccine, cost-effectiveness evidence is likely to be vital for ensuring that appropriate levels 
of funding are made available.  
This thesis builds on work I undertook as Director of Cost-effectiveness for the Hib 
Initiative during 2006-2009. The Hib Initiative was a four-year project initiated and 
funded by the GAVI Alliance with the main objective of accelerating evidence-based 
decisions for Hib vaccine introduction in low-income countries [1]. The Initiative was a 
consortium of Johns Hopkins Bloomberg School of Public Health, LSHTM, the WHO, and 
the US Centers for Disease Control (CDC). The Director of the initiative was Dr. Rana 
Hajjeh, who was based partly at Johns Hopkins and at CDC during the project period. At 
LSHTM we were six staff working for the project; Professor Kim Mulholland, who was also 
a member of the Hib Initiative Steering Committee, Dr. Karen Edmond (senior lecturer in 
epidemiology), Mr. Andrew Clark (research fellow in mathematical modelling), Ms. Viola 
Korzcak (research assistant), Fiona Marquet (administrator), and myself (lecturer in 
health economics). The work of the Hib Initiative focused on three topics believed to be 
critical to overcome the barriers for vaccine introduction: (i) communications and 
advocacy, (ii) research and surveillance, and (iii) coordination of programmatic activities, 
such as finance, supply and vaccine logistics. My area of responsibility was cost-
effectiveness analysis of the vaccine, which was integrated within the research and 
surveillance component. Several country-specific analyses, which were part of the 
technical assistance delivered by the Hib Initiative, are presented in this thesis. Country 
studies were either conducted in response to a request by the Ministry of Health or 
commenced by the Hib Initiative with the aim of answering specific research questions.    
The thesis is divided into 13 chapters. Chapters 2 and 3 are introductory chapters 
providing a background to Hib disease and Hib vaccine, respectively. In Chapter 4 the 
purpose of economic evaluation is described. Chapter 5 presents two literature reviews; 
one of economic evaluations of Hib vaccine and one of treatment cost studies of Hib 
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disease in low- and middle-income coutries.  Based on identified limitations with the 
existing evidence base, the thesis aims, objectives and conceptual framework are outlined 
in Chapter 6. The decision-analytic model used for the economic evaluation is presented in 
Chapter 7. Subsequent chapters consist of studies aimed at generating the required input 
parameters for the model. A meta-analysis of Hib vaccine efficacy estimates is presented in 
Chapter 8, health related quality of life from Hib disease is the topic of Chapter 9, and 
treatment and productivity costs of Hib disease are presented in Chapter 10, including a 
case study from Senegal on the costs of meningitis sequelae. Costs of Hib vaccine 
introduction are analysed in Chapter 11, exemplified with a study on incremental systems 
costs from Ethiopia. Hib vaccine cost-utility results from three countries, Belarus, India 
and Uzbekistan, are presented in Chapter 12. The final chapter contains thesis conclusions 
and considerations on the usefulness of economic evaluation for decision making in low- 
and middle-income countries.  A number of reflections on the challenges of undertaking 
health economic studies in resource poor settings are also given in this chapter. 
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2 BACKGROUND TO HAEMOPHILUS INFLUENZAE TYPE B 
DISEASE 
This introductory chapter contains background information on Haemophilus influenzae 
type b (Hib) disease. The issues described in this chapter are crucial for understanding the 
reasoning behind the methods used when developing the decision-analytic model and for 
recognizing the overall importance of the topic. The chapter is divided into six sections. In 
the first two sections the Hib bacterium and how it causes infection and disease are 
described. The different types of Hib diseases are summarized in section 2.3, followed by 
an overview of treatment practices. In section 2.5 an account of the difficulties regarding 
diagnostic procedures for detecting Hib are given. The epidemiology of Hib disease is 
described in section 2.6.  
2.1 THE HAEMOPHILUS INFLUENZAE BACTERIUM 
Haemophilus Influenzae (HI) is a gram negative bacterium that resides in the noses and 
throats of humans. HI was first discovered in 1892 by the German scientist Robert Pfeiffer 
who worked with Robert Koch. Robert Koch was the first scientist to devise a series of 
postulates used to verify the “germ theory of disease”, which proposes that 
microorganisms are the cause of many diseases [2]. Robert Pfeiffer isolated HI from the 
lung and sputum of patients during the 1889-1892 global influenza pandemic  and 
proposed that HI was the cause of influenza [3]. The organism was thus initially known as 
the “Pfeiffer influenza bacillus”. However, during the 1918 influenza pandemic, which 
spread to nearly every part of the world and is commonly referred to as the Spanish flu, 
the etiological role of HI as a cause of influenza was rejected. In 1920 the Society of 
American Bacteriologists renamed the organism Haemophilus influenzae to acknowledge 
the historic association with influenza and to reflect the requirement for blood when 
growing the organism [3]. The word “haemophilus” is Greek and means “blood-loving”.  
When the influenza virus was discovered by Smith et al. in 1933 any remaining confusion 
about the erroneous association between HI and influenza was finally dismissed [3].  
 
In the 1930s Margaret Pittman, who worked at the Rockefeller Institute in New York, 
isolated six HI serotypes as well as “non-typable” HI. Pittman designated the six distinct 
serotypes as a, b, c, d, e and f, and she discovered that most isolates from cerebrospinal 
fluid and blood of patients were type b, indicating that mainly this type causes serious 
disease [4]. This was groundbreaking work, which eventually paved the way for 
development of a vaccine. A culture plate growing HI is seen in Figure 2.2. The surface of 
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HI is composed of a cell wall and polysaccharide capsule. Polysaccharide capsules are 
common cell-surface components of bacterial pathogens that cause systemic disease [5].  
 
Figure 2.1: The discoverers of Haemophilus influenzae type b  
  
Professors Koch and Pfeiffer investigating  
the plague in Bombay 
(Photograph attributed to Captain C. Moss, 1897) 
Margaret Pittman (1901-1995) 
 
 
 
 
 
Figure 2.2:  
A culture plate growing Haemophilus Influenzae bacteria 
 
Source: WHO laboratory manual [6] 
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2.2 HAEMOPHILUS INFLUENZAE CARRIAGE AND TRANSMISSION 
Humans are the only natural hosts of HI [7]. The bacterium is carried in the moist mucosa 
of the human nasopharynx (Figure 2.3) and transmitted from person to person via 
respiratory droplets or by direct contact with respiratory secretions [3]. Similar to other 
encapsulated bacteria, such as Neisseria meningitides and Streptococcus pneumoniae, HI is 
not particularly contagious; it requires close contact for transmission. The spread thus 
mainly occurs within families and day-care institutions. From the nasopharynx, HI can 
spread and cause both local and systemic disease [5], as the polysaccharide capsule 
mentioned above enables HI to evade the immune system in young children. Invasion 
occurs when there is dissemination of bacteria from the nasopharynx mucosa to the 
bloodstream and elsewhere in the body [3]. The time between infection and the 
appearance of symptoms is thought to be between two and ten days [5].  
Figure 2.3: The nasopharynx 
 
The relationship between carriage and subsequent development of disease is however not 
well understood. Only a very small fraction of those acquiring carriage of HI will develop 
disease. HI may pass from a patient with disease through many people who remain 
asymptomatic carriers before it again causes illness in a susceptible person. Hence, the 
incubation period and the pattern of transmission is difficult to determine [3]. Spread of 
infection has been documented in places with low carriage rates while no evident disease 
has been reported from areas with high carrier rates [8]. Three factors have been 
identified to have the potential to increase the risk of disease; lack of antibody levels, the 
size of the bacterial inoculum [9] and the presence of a concomitant viral infection [10]. 
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HI carriage studies aim to determine the proportion of a defined population who are HI 
carriers, classified as persons with HI colonization in the nasopharynx mucosa. Many such 
studies, which are undertaken by collecting nasopharyngeal swabs from a sample of the 
population, have been conducted around the world [11, 12, 13, 14].  However, due to the 
low prevalence of HI carriage, relatively large sample sizes are needed for accurate 
estimates. Most studies in developed countries have found Hib carriage prevalence rates 
between 1% and 5% in young children, but most unimmunized children become colonized 
with Hib at some point during their first 2-5 years of life [7]. A modelling study from the 
UK has estimated the duration of carriage to be approximately five months [10]. HI 
carriage can be considerably higher in crowded areas, such as day-care centres, and 
carriage rates increase with the number of siblings in a family [15, 16]. For these reasons, 
HI carriage is generally higher in low-income than in high-income countries. In a study 
from Massachusetts, USA, before Hib vaccine introduction, samples were taken from 832 
children less than 14 years attending day-care centres. It was found that 15.1% were 
colonized with Hib and 49% with other HI strains than type b [16]. A recent study in 
Northern India found a Hib carriage rate in children less than two years of 10% in rural 
areas, 7% in slum areas and 3% in urban areas [13]. In a study from Turkey, Hib carriage 
in children less than two years was found to be 7.2%, and there was no significant 
difference between children who had received Hib vaccine (6.8%) and those who had not 
(8.4%) [14]. While other studies have found substantial decreases in Hib carriage rate 
following Hib vaccine introduction [17, 18], there have been large variations among 
studies, and the specific interactions that explain how the vaccine limit Hib colonization 
are poorly understood [8].  
2.3 HAEMOPHILUS INFLUENZAE DISEASES 
HI can infect many parts of the body. Tissues most usually infected are summarized in 
Table 2.1. Common to all of these diseases are that they can be caused by many other 
pathogens than HI, with the exception of epiglottitis, which is only due to HI [19]. As a 
result, accurate laboratory diagnosis is crucial for determining both appropriate treatment 
and also whether HI should be considered a problem in the respective population.  
In epidemiological studies, HI disease is generally divided into two categories; invasive 
disease and non-invasive disease. While approximately 95% of invasive HI diseases are 
due to type b, most non-invasive diseases are caused by nontypable HI strains [3]. Invasive 
HI disease is commonly defined as the isolation of HI from a sterile site such as the blood 
stream, synovial fluid or cerebrospinal fluid [20]. On the other hand, the term non-invasive 
disease is used when HI has been isolated from a non-sterile site, such as an external ear  
Chapter 2: Background to Hib disease 
 
7 
 
Table 2.1: Types of Haemophilus influenzae diseases 
HI disease Infected tissue Common clinical presentation 
Invasive  diseases:   
Meningitis Lining of the brain 
Fever, lethargy and poor feeding for infants. 
Headache, fever and stiff neck for older children 
Epiglottitis Epiglottis 
Fever, sore throat, toxicity and upper airway 
obstruction 
Septicemia Blood 
Fever without any apparent focus of infection which 
may lead to septic shock 
Pneumonia Lungs Fever, cough and fast breathing 
Cellulitis Skin 
Fever, skin swelling and redness, most commonly 
periorbital. Often associated with septicaemia 
Septic arthritis Joints 
Fever, swelling and pain in large joints, such as knee, 
hip, ankle and elbow. Usually only one joint at a time 
Osteomyelitis Bones Fever and bone swelling and tenderness 
Pericarditis Lining of the heart Fever and respiratory distress 
Non-invasive diseases:    
Otitis media Middle ear Fever and ear pain 
Sinusitis Sinuses Fever and painful nasal passages 
Source: Crawford and Daum (2004) [21] 
or throat swab.  Invasive diseases can be life threatening while non-invasive diseases are 
not fatal. The definitions can however coincide and are sometimes a cause of confusion. 
This is particularly the case for Hib pneumonia. Pneumonia is in the large majority of cases 
non-bacteraemic (meaning that the bacterium cannot be detected in blood) and therefore 
sometimes not classified as an invasive disease in epidemiological studies. However, since 
lung tissue can be classified as usually sterile, pneumonia is technically an invasive 
disease, but lung taps are rarely done. In many ways, the classifications are dependent on 
what can be detected in the laboratory, as explained in section 2.5 below.   
One of the most severe forms of Hib disease is bacterial meningitis, which is characterized 
as an inflammation of the membranes that cover the brain and the spinal cord. If left 
untreated meningitis will in almost all cases lead to death [22]. Moreover, survivors of Hib 
meningitis can suffer from lifelong disabilities, such as deafness and a range of 
neurological problems that can be severe [23]. Other severe forms of Hib disease are 
epiglottitis, septicemia and pneumonia. Epiglottitis is a swelling and inflammation of the 
epiglottis and surrounding structures. The disease is considered a medical emergency 
because of the risk of sudden death from acute airways obstruction [21]. Septicemia 
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occurs when an organism such as Hib enters the blood stream. It may cause no symptoms 
and resolve without treatment, but it can also be a serious, life-threatening infection.  If 
left untreated, Hib septicemia develop to meningitis in approximately 25% of cases [21]. 
Pneumonia is an inflammatory illness of the lung, usually caused by infection. While a 
large proportion of pneumonia cases are relatively mild and can be treated without 
hospitalization, pneumonia can also develop into a severe and critical form. Pneumonia is 
classified as community- and hospital-acquired pneumonia, in order to differentiate those 
cases that occur in hospitalized patients, usually due to bacteria circulating in the hospital, 
and those who are infected in the community. Hib is one of many causes of community-
acquired pneumonia.  
Rarer forms of invasive HI diseases are osteomyelitis, septic arthritis and pericarditis, 
which are infections of the bones, joints and lining of the heart, respectively. However, 
these are predominantly caused by microbial agents other than HI. When HI infects the 
middle ear and the sinuses it causes otitis media and sinusitis.  While these non-invasive 
diseases are less severe, they are widespread. Otitis media is the most common infection 
of childhood [21]. However, most HI isolates causing otitis media and sinusitis are non-
typable and therefore not preventable by Hib vaccine [21]. One of the largest studies ever 
undertaken on otitis media is an American study published in 1983. This study found that 
out of 2,625 cases of HI otitis media, approximately 6.3% were due to type b [24]. 
Many country-specific studies on Hib epidemiology have analysed the distribution of 
different invasive Hib diseases. These were all undertaken as sentinel surveillance in 
hospitals with contemporary laboratory facilities. Examples from the Czech Republic, 
England, Gambia and Thailand are seen in Table 2.2.   
Meningitis was the most common type of invasive Hib disease detected in all four settings, 
comprising between 52% and 78% of all confirmed invasive Hib cases. However, the  
Table 2.2: Distribution of different types of invasive Hib diseases in Czech Republic, 
Thailand, England and the Gambia 
First 
author  
[ref.] 
Country 
Study 
sample 
size 
Meningitis Septicemia 
Septic 
arthritis 
Epiglottitis Pneumonia Cellulites 
Lebedova 
[25] 
Czech 
Republic 94 52% 5% 2% 33% 7% 0% 
Likitnukul 
[26] Thailand 79 56% 15% 1% 0% 25% 3% 
Williams 
[27] England 200 71% 3% 6% 12% 3% 6% 
Adegbola 
[28] Gambia 180 78% 2% 2% 0% 17% 1% 
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remaining distribution of different types of Hib diseases was quite different. Most 
importantly, while epiglottitis comprised 33% and 12% in the Czech Republic and 
England, respectively, this disease was not diagnosed at all in the Gambia and Thailand. 
Low rates of epiglottitis have also been observed in other developing countries and in 
indigenous populations in developed countries such as Australian Aboriginals [7, 29]. The 
reason for this geographic and population specific difference is unclear, but may relate to 
age exposure [30]. Epilottitis is most often seen in children above two years of age, so if 
Hib disease mainly occurs in children younger than two years, the incidence of epiglottitis 
is likely to be low.   
Pneumonia constituted 7% of Hib diseases in the Czech Republic, 3% in England, 17% in 
the Gambia and 25% in Thailand. Pneumonia is one of the most common childhood 
illnesses and is believed to be the most frequent form of Hib disease globally [31].  It is 
estimated that pneumonia caused approximately 18% of global deaths in children under 
the age of five in 2008 [32] and Hib vaccines are seen as an important tool to reduce this 
mortality. However, the true incidence of Hib pneumonia in children is unknown because 
the signs and symptoms of Hib pneumonia cannot be differentiated from those of 
pneumonia caused by many other microorganisms and only a proportion of Hib 
pneumonia is bacteraemic.  Invasive lung tap procedures are required to obtain cultures 
that can prove the proportion of Hib pneumonia and these are seldom performed. It is 
thus possible that the prevalence of Hib pneumonia is under-estimated in the four studies 
referred to above. The uncertainty about the proportion of total pneumonia episodes and 
deaths caused by Hib is a major topic of this thesis, as it is pivotal for determining the cost-
effectiveness of the vaccine. No cases of osteomyelitis and pericarditis were identified in 
the four example studies, confirming that these are rare Hib diseases.      
2.4 RECOMMENDED TREATMENT  
Antibiotics kill or damage bacteria and are today among the most frequently prescribed 
medications in the world. All Hib diseases are treated in largely the same way; through an 
intensive and sustained course of antibiotics [3]. Antibiotics are classified according to 
their chemical structure, which determines their effectiveness, toxicity, and allergic 
potential. Most antibiotics were discovered during the 1940s and 1950s, but new agents 
within the same class are continually being developed. The main reason for development 
of new agents is antibiotic resistance, which has become a growing problem since the 
1970s. When bacteria are exposed to the same antibiotics repeatedly, they can change and 
no longer be affected by the drug. This mounting problem is caused by the widespread use 
of antibiotics both inside and outside the medical system. Within the medical system the 
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biggest problem is inappropriate and over-prescribing of antibiotics, which apply selective 
pressure to potentially pathogenic bacteria that are carried by children with minor, 
usually viral illnesses. When the bacteria are found or suspected to be resistant to first 
generation antibiotics, treatment has to be switched to second- or third-generation drugs, 
which are generally considerably more expensive and sometimes more toxic. In low-
income countries the high cost of such replacement drugs is prohibitive, with the result 
that some diseases, particularly meningitis, can no longer be treated in areas where 
resistance to first-line drugs is widespread. Hib vaccine thus has the added advantage of 
potentially reducing the demand for antibiotics, thereby slowing the spread of antibiotic 
resistance. 
Penicillin became available after the Second World War and was initially active against 
Hib, but resistance soon developed.  Chloramphenicol was the first broad spectrum 
antibiotic, first licensed in 1950, and ampicillin/amoxicillin became available in the 1970s. 
The 3rd generation cephalosporins, the first of which was cefotaxime, was licensed in 
1983 and have become the standard for treatment of invasive Hib disease and meningitis 
in general. 
Since all Hib diseases are treated through an intensive and sustained course of antibiotics, 
this is the most important type of drug to include in treatment cost estimates. However, 
total treatment costs vary according to setting and mode of drugs delivery. Antibiotics can 
be administered intravenously (IV), intramuscularly (IM) or orally. While hospital 
admission is generally needed for IV and IM administration, oral delivery can take place in 
outpatient settings and at home.    
WHO recommended treatment procedures for Hib diseases are outlined in Annex 1. The 
purpose of these standard recommendations is first of all to reduce mortality, but also to 
support the rational use of antibiotics [33]. Treatment of meningitis routinely requires 
hospitalisation with IV antibiotics, and the course of antibiotics should last for a total of 
three weeks. Similarly, for treatment of epiglottitis, cellulitis, septic arthritis, serticemia 
and osteomyelitis hospitalisation with IV or IM antibiotics is necessary. The appropriate 
treatment of pneumonia varies according to severity. While very severe and severe 
pneumonia require hospitalisation with IV or IM antibiotics, children with non-severe 
pneumonia should receive antibiotics as outpatients.  
The WHO recommendations on the different types of antibiotics to be used, as specified in 
Annex 1, are guided by known antibiotic resistance patterns and global market prices of 
the drug. Examples of prices of antibiotics recommended by the WHO for treatment of 
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bacterial meningitis and pneumonia are summarised in Table 2.3. These were compiled 
from the International Drug Price Indicator; a comparative guide of drug prices from 
pharmaceutical suppliers, international development organizations, and government 
agencies published by the Management Sciences for Health and the WHO 
(http://erc.msh.org). The procurement prices quoted for International Mission Hospitals 
were chosen for this example. It is seen that the most expensive IM compound, ceftriaxone, 
is five times as expensive as IM ampicillin. While the WHO recommends both drugs for 
treatment of meningitis, Hib is now resistant to ampicillin in many settings [34].   
Table 2.3: Unit prices of selected antibiotic compounds used for treatment of Hib 
disease procured by International Mission Hospitals (2009) 
Generic name Strength 
Dosage 
form 
Route 
of 
admin. 
Package 
Package 
price 
(US$) 
Unit price 
(US$) 
Sulfamethoxazole 
+ Trimethoprim 200+40mg/5ml  Liquid Oral 
1 bottle 
 (100 ml)     0.39 0.0039/ml 
Amoxicillin 250 mg/5 ml  Liquid Oral 
1 bottle 
 (100 ml)    0.56 0.0056/ml 
Ampicillin 500 mg  Vial IM 50 vials 5.30 0.106/vial 
Cefotaxime 500 mg  Vial IM 1 vial 0.16 0.1556 /vial 
Penicillin 2.4 mu  Powder IM 50 vials 10.87 0.2174/vial 
Chloramphenicol  1 g  Vial IM 50 vials 12.44 0.2488/vial 
Ceftriaxone 500 mg  Vial IM 1 vial 0.53 0.5300/vial 
Source: (http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language=english) 
IM: Intramuscularly 
2.5 LABORATORY DIAGNOSIS 
Laboratory diagnosis of Hib disease is essential for two reasons. At the hospital, accurate 
diagnosis is necessary for the clinician to be able to administer the most effective 
treatment to the patient. This is particularly important in settings with antibiotic 
resistance.  Another fundamental purpose of laboratory diagnosis is to be able to 
determine the overall burden of Hib disease. All the Hib diseases described in section 2.3, 
apart from epiglottitis, are also frequently caused by other organisms, including other 
bacteria, such as Streptococcus pneumoniae and Neisseria meningitidis, as well as viruses 
and parasites, and it is therefore only possible to determine whether Hib is the source if 
the bacterium is identified in a laboratory from a sterile site.  
Meningitis is the most studied type of Hib disease for three key reasons: (i) it is the most 
severe form of Hib disease, (ii) it has a relatively straightforward clinical diagnosis, and 
(iii) it is the type of Hib disease that can be most easily diagnosed in a laboratory. The 
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bacterial agents of meningitis can be identified by culture of cerebrospinal fluid (CSF) 
from patients with clinical symptoms of meningitis [35]. Moreover, because severe 
meningitis in children is always caused by bacterial agents, the yield from CSF cultures of 
these patients is greater than from blood cultures of patients with most other Hib 
syndromes. Pneumonia can for instance occur due to many different types of viruses and 
parasites as well as bacteria, so an extraordinary large sample of patients would be needed 
to demonstrate disease burden due to Hib. Since only a relatively small proportion of 
pneumonia is bacteraemic, the best way to establish the etiology of pneumonia is by lung 
puncture or open lung biopsy. However, the risks of these procedures are relatively high, 
so they are used only in special clinical circumstances  [36]. 
Recommended procedures for diagnosing Hib meningitis are outlined in Figure 2.4. In 
low-income countries with relatively limited laboratory capacities, it can be intrinsically 
difficult to grow Hib from CSF and/or blood. Hib is demanding in its growth requirements, 
so the process summarized in Figure 2.4 only needs to be sub-optimal in one small area 
and Hib will not be detected in the culture, leading to underestimates of Hib disease 
prevalence. Moreover, use of antibiotics before the CSF is taken reduces the sensitivity of 
the culture considerably [20].  
A common problem seen in laboratories in low-income countries is the use of discarded 
human blood instead of sheep blood, horse blood, or commercially available chocolate 
agar for primary isolation [37]. In low-income country hospitals it is thus common that 
Hib has never been diagnosed from any CSF. This was for instance the case after a review 
of seven hospital laboratories in Uzbekistan in 2002 [38]. Similarly, in Latvia in 1993, it 
was reported that out of 291 cases of bacterial meningitis, a definite bacterial aetiology 
was only established in 50% of cases, and these were mainly Steptococcus pneumonia and 
Neisseria meningitidis while none were Hib. After an evaluation of the reagents used in the 
laboratory, it was shown that with the addition of agar supplements, it was possible to 
grow Hib [39].   
Due to the laboratory constraints it is thus not straight forward to demonstrate whether 
Hib is a problem or not in low-income settings. The problems arising with regard to 
assessing the true burden of Hib disease and subsequently the cost-effectiveness of the 
vaccine are explained in detail within this thesis. 
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Figure 2.4: Step-by-step procedures for laboratory diagnosis of Hib meningitis 
 
  Source: WHO laboratory manual for bacterial meningitis (1999) [6] 
2.6 HIB EPIDEMIOLOGY  
Hib disease is mainly seen in children less than two years of age and rarely in children 
above five years or adults [7]. While the incidence of Hib disease is relatively low during 
the first few months of life, the risk increases as maternal immunity wanes. The highest 
risk period is usually between six and 18 months, although in high-risk African countries 
more than half of all cases are in children less than six months of age. By the age of five 
years the incidence of Hib disease is universally low and remains low throughout 
adulthood with only a small increase in the incidence in the very elderly [5]. Figure 2.5 
shows the age distribution of Hib meningitis in Australia and the Gambia before Hib 
vaccine introduction. A general difference that has been observed between low- and high-
income countries is seen. While studies from developed countries demonstrate a peak in 
the incidence around two years, the majority of cases in developing countries occur during 
the first year of life [30]. 
  
4. Gram stain to diagnose Hib, S. Pneumoniae, N. Meningitidis and other bacteria
Hib can be distinguished as being small, pleomorphic Gram-negative rods 
or coccobacilli with random arrangements
3. Inoculation of primary culture media
Bacterial growth requires chocolate agar and another medium containing accessory factors 
haemin and Nicotinamide Adenine Dinucleotide.  Sheep or horse blood can also be used.
2. Transport of CSF to microbiology laboratory
The specimen should be analysed within 
one hour of collection to ensure sensitivity
Exposure to extreme heat or cold 
will reduce the sensitivity
1. Lumbar puncture for collection of CSF
An invasive procedure which should only be performed by experienced clinicians under aseptic conditions
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Figure 2.5: Age distribution of Hib meningitis cases in Australia and the Gambia  
Australia Gambia 
  
Source: McIntyre et al. (1991) [40] and Adegbola et al. (1996) [28]  
Establishment of Hib disease incidence in children less than five years in different 
countries and regions of the world has been the subject of much research and some 
controversy.  Since invasive Hib disease is not reliably reported, population based 
epidemiological studies are needed to determine the incidence. The WHO has developed 
guidelines for population based surveillance of Hib disease [35] and several studies 
following these recommendations have been undertaken during the past two decades [41, 
42, 43, 44].  Hib meningitis incidences per 100,000 children less than five years for a 
selection of settings are summarized in Table 2.4.  
A comparison of study results shows considerable variability between countries, and 
many authors have tried to explain this difference [22]. It can probably be concluded that 
while some of the differences are due to the laboratory and epidemiological methods used, 
there is also a real difference among populations. One of the most debated topics has been 
the disease incidence in Asia [45, 46, 47].  Some population based studies in this region 
have shown incidence rates one tenth of those observed in North America and Europe, and 
there is still not enough knowledge to conclude whether these results reflect a true low 
disease burden, or whether they are due to problems in detection, such as widespread use 
of antibiotics before hospitalization and/or suboptimal microbiologic methods for 
culturing Hib. Use of antibiotics before clinical assessment has two distinct effects: It can 
treat the child during the bacteraemic phase, thus preventing meningitis, or it simply 
suppresses the culture positivity. 
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Table 2.4: Hib meningitis disease incidence before  
Hib vaccine introduction in selected countries 
 Incidence per 
100,000  
children < 5 years 
Source 
Africa:   
Senegal 36 Cadez (1981) [48] 
Gambia 60 Bijlmer (1990) [49] 
Niger 51 Campagne (1999) [50] 
America:   
USA 22 Wenger (1998) [51] 
Asia:   
Thailand 4 Rerks-Ngarm (2004)[45] 
Hong Kong 2 Lau (1995) [52] 
Vietnam 12 Anh (2006) [53] 
Europe:   
France  13 Reinert  (1993) [54] 
England 24 Tudor-Williams (1989) [55] 
Not all individuals within a population are at equal risk of Hib disease and a number of 
factors associated with an increased risk have been identified [5]. In the United States, Hib 
disease has been noted to be 1.2-1.5 times higher in boys than in girls and to be 2-4 times 
higher for black than for white children less than five years old [51]. Indigenous 
populations, such as Aboriginals in Australia, Alaskan Eskimos and Apache and Navajo 
Indians have been shown to have the greatest known risk of invasive Hib disease with 
rates as high as 400 per 100,000 children [56]. The reasons for these very high rates are 
likely to be a combination of genetic and environmental interactions [5].  
During 2004-2009 particular efforts were made to generate country-specific Hib disease 
incidence and case fatality rates for all WHO member states for the year 2000. The “Global 
Burden of Disease (GBD) of Hib and pneumococcal diseases project” was undertaken as 
collaboration between the WHO, the Hib Initiative and the Pneumococcal Vaccines 
Accelerated Development and Introduction Plan (PnemoADIP) project. The methods and 
results of this project were published in the Lancet in 2009 [31, 57, 58]. The paper by Watt 
et al. provides a table with estimates of Hib cases, deaths, incidence rates and case fatality 
rates according to WHO regions [31]. The mortality table is replicated in Table 2.5, 
showing that a total of 370,200 deaths were estimated in 2000, with 49% occurring in 
Sub-Saharan Africa.  79% of Hib deaths were estimated to be caused by pneumonia.  
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Country specific estimates are only available in letters sent by the WHO to Ministries of 
Health of all member states informing them about the estimates and inviting them to 
provide additional information.  Countries with no population-based Hib surveillance data 
available could use these numbers for illustrating impact and cost-effectiveness of the 
vaccine. As will be seen in Chapter 7, the decision-analytic model developed for this thesis 
has been designed so that the GBD estimates can be easily used as input data.     
Table 2.5: Global estimated deaths due to Hib disease in year 2000 
Type of 
Hib 
disease 
Africa Americas 
Eastern 
Mediter- 
ranean 
Europe 
South 
East 
Asia 
Western 
Pacific 
Total 
Pneumonia 
              
146,000  
                  
4,900  
                
41,600  
                  
6,500  
                
75,300   17,600  
         
291,900  
Meningitis 
                
34,600  
                  
3,500  
                  
6,800  
                  
2,000  
                
21,800     9,500  
           
78,200  
NPNM 100   <100   <100   <100   <100   <100  
                 
100  
Total 
              
180,700  
                  
8,400  
                
48,400  
                  
8,500  
                
97,100   27,100  
         
370,200  
 Source: Watt et al. (2009) [31] 
NPNM: Non-pneumonia, non-meningitis 
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3 BACKGROUND TO HAEMOPHILUS INFLUENZAE TYPE B 
VACCINES 
3.1 AVAILABLE HIB VACCINES 
The first vaccine developed against Hib was produced in the early 1970s and was 
composed of purified Hib capsular polysaccharide. This vaccine was however only 
effective in adults and children above two years of age, as young children have poor 
immune responses to T-cell-independent antigens such as polysaccharides [59]. 
Subsequently, more immunogenic vaccines were developed by conjugating capsular 
polysaccharides to protein carriers. The first conjugated Hib vaccine was licensed in 1987 
in the USA. Four different Hib conjugate vaccines that differ in the carrier protein, the 
structure and lengths of the polysaccharide, polyribosol-ribitol phosphate (PRP) element 
and the method of conjugation, have been developed [20]. The four vaccines are known as 
PRP-D, PRP-OMP, HbOC and PRP-T (Table 3.1).  
The PRP-D vaccine was licensed following a successful trial in Finnish children [60]. 
However, the vaccine was the least immunogenic of the four vaccines, and when it 
subsequently proved ineffective in preventing Hib disease in Alaskan children [61], it was 
taken out of production [7]. The three currently available vaccines are produced by 
different companies and it should be noted that the PRP-T has never been patented. The 
immune response of the different vaccines varies. As shown in Figure 3.1, the PRP-OMP 
elicits a greater response after the first dose, but the geometric mean titres elicited after 
three doses are higher for the other vaccine types, although this does not mean greater 
effectiveness. Consequently, the PRP-OMP is seen as the vaccine of clinical choice  
Table 3.1: Conjugate Hib vaccines that underwent clinical trials or controlled 
intervention studies during the 1980s and early 1990s 
Product 
type 
Carrier protein 
Original 
manufacturer 
Year 
licensed in 
the USA 
Status 
PRP-D Diphteria toxoid Connaught  1987 
Not 
available 
PRP-OMP 
Neisseria meningitidis group B outer 
membrane protein complex Merck  1990 Available 
HbOC Mutant non-toxic diphteria toxoid  Praxis Biologics 1991 Available 
PRP-T Tetanus toxoid Pasteur Merieux 1993 Available 
Source: Chandran et al. (2008) [30] 
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in populations with high Hib disease incidence in very young children where a good 
response is needed after the first dose. In other populations, the PRP-T or the HbOC 
vaccines are likely to be the best options. It should however be noted that the HbOC seems 
to need two months between the doses to provide adequate immunity whereas PRP-T 
does not, so HbOC may not be suitable for all schedules. Vaccine efficacy of the different 
vaccines has been evaluated in a meta-analysis as part of this thesis, which is presented in 
Chapter 8.  
There are numerous different types of Hib vaccine presentations available, such as 
monovalent vaccine or as a combination vaccine with several other vaccines. Since Hib 
vaccine can be delivered at the same time as diphtheria-tetanus-pertussis (DTP) vaccine, 
combination vaccines are widely used as these are generally preferred by both health care 
workers and parents because the number of injections needed is reduced.  The different 
vaccine presentations are reviewed in conjunction with Hib vaccine prices in Chapter 11. 
Figure 3.1: Comparison of antibody response to  
four different Hib conjugate vaccines 
 
Source: Watt et al. (2003) [20]  
3.2 TRENDS IN HIB VACCINE UPTAKE  
During the 1980s, substantial investments were made in routine vaccination programmes 
around the world, with global vaccination coverage of the third dose of DTP vaccine 
reaching 75% in 1990 compared to 20% in 1980 [62]. These efforts were led by WHO and 
Unicef through the Universal Child Immunization Initiative [63]. Hence, during the early 
1990s, most programmes had become sufficiently mature to manage the introduction of a 
new vaccine. High-income countries relatively quickly introduced Hib vaccine into their 
routine schedules. However, as was the case with hepatitis B vaccine, uptake of Hib 
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vaccine was slow in low- and middle-income countries. As seen in Figure 3.2, the first time 
Hib vaccine was introduced into a low-income country was in 1997. This country was the 
Gambia where the only African Hib vaccine trial took place and Hib vaccine introduction 
was made possible through a donation from the vaccine manufacturer that had supplied 
vaccine for the trial. In 2001, Kenya and Ghana were the first two low-income countries to 
introduce the vaccine with GAVI Alliance support.  
The uptake of Hib vaccine has recently increased substantially. As of July 2011, 172 of the 
world’s 196 countries (88%) have adopted the vaccine into their routine programmes, but 
50% of these have only done so only during the past eight years (Figure 3.2). Most low- 
and lower-middle income countries have introduced the vaccine with support from the 
GAVI Alliance, amounting to 37% of the 172 countries that have introduced. The 
international attention GAVI has given to Hib vaccine may also have influenced upper-
middle-income countries, as their uptake has also increased during the past few years. 
During 2010, four upper middle-income countries (Botswana, Bulgaria, Gabon and 
Seychelles) adopted the vaccine. The two countries that introduced in 2011 were 
Azerbaijan and Vanuatu.  
Figure 3.2: Number of countries introducing Hib vaccine 1989-2011 according to 
2010 World Bank income groups 
 
Source: The Hib Initiative, the WHO and the GAVI Alliance 
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3.3 GAVI ALLIANCE POLICY ON HIB VACCINE  
Since 2000, the GAVI Alliance has provided financial support for Hib vaccine to the poorest 
countries in the world. During GAVI’s first phase (2000–2005), eligibility was determined 
by 1998 Gross National Income (GNI) per capita of less than US$ 1,000, making 77 
countries eligible for support [64]. For the second phase (2006 – 2010) the criteria was 
adjusted to 2003 per capita GNI of less than US$ 1,000, which led to 72 eligible countries. 
The current eligibility threshold, established in 2011, is per capita GNI of less than US$ 
1,500 and this threshold will be adjusted annually for inflation to remain constant in real 
terms. Of the 72 countries eligible in the second phase, 16 now have per capita GNI levels 
in excess of US$ 1,500 per annum and the assistance to these countries will therefore end 
when their current support terminates in 2015 [64]. The graduating countries are: Angola, 
Armenia, Azerbaijan, Bhutan, Bolivia, Congo, Cuba, Georgia, Honduras, Indonesia, Kiribati, 
Moldova, Mongolia, Sri Lanka, Timor-Leste and Ukraine. 
In addition to the GNI criteria, it is also a condition that countries must have DTP 
vaccination coverage rates above 50% to be eligible to apply for new vaccine support [65]. 
The rationale for this condition is that programmes need to be relatively strong to be able 
to effectively introduce a new vaccine, and DTP vaccine coverage is considered a valid 
approximation for measuring programme strength.   
Despite the availability of financial support since year 2000, the introduction of Hib 
vaccine remained uncommon among the GAVI eligible countries during the first phase. 
Figure 3.3 shows that while 48 countries introduced hepatitis B vaccine between 2000 and 
2005, only 14 chose to apply for Hib vaccine.  In response, in June 2005, the GAVI Alliance 
established the Hib Initiative with the aim of accelerating the use of evidence-informed 
decision-making about Hib vaccine in GAVI-eligible countries. As mentioned in the 
introduction, the consortium’s members were Johns Hopkins Bloomberg School of Public 
Health, the WHO, the US Centers for Disease Control and Prevention and the LSHTM. The 
Hib Initiative’s strategy focused on communication, research and coordination with 
various partners, especially the WHO regional offices [66].  
Between 2004 and 2008, uptake among GAVI-eligible countries increased by 56% and out 
of the 77 initially GAVI eligible countries, 65 had introduced the vaccine by 2011 (Figure 
3.4). Honduras, Nicaragua, Turkmenistan and Ukraine were GAVI eligible in the first two  
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Figure 3.3: Hepatitis B and Hib vaccine introduction in GAVI eligible countries 2000-
2005 
 
Source: GAVI Alliance secretariat 
 
 
Figure 3.4: Hib vaccine introduction supported by the GAVI Alliance 2000-2011 
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phases, but these countries had either already introduced the vaccine when GAVI was 
established or they chose to introduce it using government funds; they have thus not taken 
advantage of GAVI support for Hib vaccine. 
The remaining initially GAVI eligible countries which in early 2012 have still not 
introduced the vaccine at a national level are China, DPR Korea, Haiti, India, Indonesia, 
Myanmar, Nigeria, Somalia, South Sudan and Timor Leste. All of these countries are 
regarded as “special cases”, either because of internal political issues or because of their 
GAVI eligibility status. China was only eligible in phase one and did not apply for Hib 
vaccine at that time. Somalia, Nigeria and Haiti have until recently reported DTP vaccine 
coverage rates less than 50% and have thus not been able to apply to GAVI for new 
vaccines, including Hib vaccine. However, reported coverage has been above 50% during 
the past few years in all three countries and they all applied, and were approved, for Hib 
vaccine in May 2011. Hence, introduction should happen during 2012. DPR Korea and 
Timor Leste were also approved for Hib vaccine support in May 2011. The population 
sizes of India and Indonesia have been too large for GAVI to be able to grant these 
countries full support. Although these limitations have recently been loosened and India 
and Indonesia have now applied for Hib vaccine support, the assistance has not yet been 
fully granted due to several challenging issues. The case of India is explained in this thesis. 
Myanmar and South Sudan are thus the only GAVI eligible countries that have not yet 
applied for the vaccine.   
During the first phase of GAVI, 100% of the costs of the new vaccines and injection 
supplies were granted to countries, normally for a five-year period. In GAVI phase II, it was 
decided to introduce co-financing for new vaccines. This policy and its implications for 
recipient countries are explored with the Indian and Uzbekistan case studies in Chapter 
12.  
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4 BACKGROUND TO ECONOMIC EVALUATION  
This chapter provides a brief introduction to the field of economic evaluation. In section 
4.1 and 4.2, the objectives and the basic principles of economic evaluation are explained. 
Analytical frameworks are summarized in section 4.3, discounting in section 4.4, the 
incremental cost-effectiveness ratio is explained in section 4.5, and issues specifically 
related to economic evaluation of vaccines are discussed in section 4.6.   
4.1 OBJECTIVES OF ECONOMIC EVALUATION 
The foundation of economics is a scarcity of resources. Scarcity has two sides; the infinite 
nature of human wants and the finite or limited nature of resources available to produce 
goods and services. Health care in our time is marked by infinite demands partly due to an 
increase in real income, a growing proportion of elderly in the population, development of 
new drugs and medical technologies, and new emerging diseases, such as HIV, type 2  
diabetes and obesity. Resources, including staff, health facilities, medical technologies and 
knowledge, however remain limited. Economic evaluation is one of the most applied 
branches of health economics, as it provides researchers with a set of methodologies to 
estimate how to optimise the use of scarce resources with respect to maximising health 
gain.  
Economic evaluation can be defined as a “comparative analysis of alternative courses of 
action in terms of both their costs and their consequence”[67], and it attempts to identify 
ways in which scarce resources can be employed efficiently so that healthcare resources 
are being used to obtain the best “value for money”.  Adopting the criterion of value for 
money or “efficiency” implies that society makes choices that maximize the health 
outcomes gained from the resources allocated to health care. Inefficiency exists when 
resources could be reallocated in a way which would increase the health outcomes 
produced [68]. There are three types of efficiency; technical, economic and allocative.  
Technical efficiency refers to the physical relation between resources and outcomes and 
addresses the issue of using given resources to maximum advantage. Economic efficiency 
refers to the maximization of outcomes for given costs and is thus about choosing different 
combinations of resources to achieve the maximum health benefit or given level of output 
at least cost [68]. The concept of allocative efficiency takes into account not only economic 
efficiency with which healthcare resources are used to produce health outcomes, but also 
that the generated goods and services are in accordance with societal preferences [69]. 
Economic evaluation can be viewed as a method of assessing these notions of efficiency. 
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4.2 BASIC PRINCIPLES OF ECONOMIC EVALUATION 
An economic evaluation consists of a comparison between two or more alternative 
courses of action. The alternative that produces the most health effects is often also the 
most costly and we are therefore looking at the incremental costs of achieving incremental 
health effects. If the analysis shows that the least costly alternative also produces the most 
health effects, this is said to dominate the other alternatives [67]. 
The perspective of an analysis refers to the types of costs included and this need to be 
determined from the outset. There are generally two perspectives to consider; the health 
sector and society. When using a health sector perspective, only the costs incurred by the 
health service provider are included, while costs such as medicines bought by patients and 
patients’ travel costs are excluded. In the societal perspective all costs are included 
irrespective of who pays. Time costs, also referred to as productivity or indirect costs, can 
also be included in this perspective. Three types of cost data are relevant for an economic 
evaluation of a vaccine: (i) costs of vaccine delivery, (ii) disease treatment costs and (iii) 
productivity losses. Vaccine delivery costs include the costs of the vaccine, injection 
supplies and items such as vaccine storage and transport. Treatment costs for the disease 
in question are comprised of outpatient visits and hospitalizations during the acute 
disease period and any long-term costs due to disability. Productivity loss from disease 
could be included if a societal perspective is taken. For example, for childhood diseases the 
time loss of parents while looking after a sick child can be incorporated.   
Economic evaluations can be divided into three different types, which vary according to 
the chosen outcome measure. While costs are always expressed in monetary values, there 
are a number of options for measuring and valuing effects (Table 4.1). In a cost-
effectiveness analysis, the health effect is measured in natural units, such as numbers of 
infections or life years. However, the usefulness of this analysis may be limited because the 
outcomes measures are not comparable to those used for measuring the impact of other 
interventions. The costs per life years gained are for instance only comparable to analyses 
of other interventions where premature deaths are prevented and cannot be compared to 
interventions that solely prevent or treat morbidity. Moreover, some of the outcome 
Table 4.1: Three types of economic evaluation methods 
  Type  Cost measurement  Effect measurement  
Cost-effectiveness analysis  $  Natural units (cases, life years)  
Cost-utility analysis  $  Healthy years (QALYs/DALYs)  
Cost-benefit analysis  $  $  
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measures used in cost-effectiveness analysis, such as costs per child vaccinated or costs 
per infection prevented, are intermediate instead of final outcome measures and are 
therefore often not adequate as a guide for overall resource allocation decision making 
because they are difficult to interpret and ignore longer term costs and consequences. 
The main limitations of cost-effectiveness analysis are usually addressed in cost-utility 
analysis where the outcome measure is expressed in terms of morbidity and mortality, 
combined in a single measure.  The two most commonly used measures are Quality 
Adjusted Life Years (QALYs) and Disability Adjusted Life Years (DALYs).  QALYs are 
derived by weighting time spent in a particular health state with a corresponding 
preference score. The preference scores are collected from both the general population 
(“community preferences”) and from patients in different health states using validated 
tools. However, in many cost-utility analyses from low-income countries, DALYs are used 
instead, as preference scores are rarely collected in these countries. For DALYs, generic, 
disease-specific disability weights are used, which do not involve country-specific data 
collection. The differences between DALYs and QALYs with respect to health related 
quality of life due to Hib disease are explored in Chapter 9. 
Cost-benefit analysis (CBA) is the original type of economic evaluation, dating back to 
around 1820 when the British economist Alfred Marshall devised the formal concepts of 
the approach. In CBA, all costs and benefits of a particular project are compared in 
monetary terms; if benefits exceed the costs, the project is considered worthwhile. Today 
the method is widely used in many sectors and businesses, such as for evaluating water 
dams or motorways. Within the transport sector, a common method for determining the 
monetary value of traffic fatalities is the “value of a statistical life” approach [70].  
In a CBA of a health intervention, such as Hib vaccine, the costs of disease in terms of 
treatment costs and lost productivity due to mortality and morbidity are compared 
against the costs of delivering the intervention.  The estimates are combined in a benefit-
cost ratio and if the ratio exceeds one, the intervention is considered advantageous, as the 
benefits are greater than its costs.  The two most common methods for determining a 
monetary value of health are the human capital and the willingness to pay approaches 
[67]. In the human capital approach a market wage is used to place a monetary weight on 
healthy time, while in the willingness to pay approach the value is either directly assessed 
by survey or inferred from decisions actually made that involve trade-offs between health 
and money [67]. Since only the willingness to pay approach assesses the actual value 
people place on a life, it is usually considered the stronger method of the two [67].  
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4.3 ANALYTICAL FRAMEWORKS 
Broadly speaking, three main frameworks are commonly used to undertake an economic 
evaluation; alongside a controlled clinical trial, using a decision-analytic model or a 
mixture of the two.  The advantage of conducting economic evaluations alongside a clinical 
trial is the relatively easy availability of patient-specific data on both costs and outcomes. 
Moreover, given the large costs of conducting a clinical trial, the marginal costs of adding 
economic data collection to the study may be modest. There is however broad consensus 
that a purely trial-based study poses several problems [67]. One issue is that the 
comparison therapy might not be the most relevant for economic analysis. Secondly, 
clinical trials frequently make use of surrogate instead of final health outcomes and 
thirdly, since clinical trials have limited follow-up time, long-term effects remain unknown 
in a purely trial-based economic evaluation. Hence, decision-analytic models, which are 
able to predict final health impacts, are generally considered to be unavoidable when 
undertaking an economic evaluation [71].  
Decision analysis is defined as “a systematic approach to decision making under 
conditions of imperfect knowledge”[72]. It entails the use of a model representing the 
alternative courses of action, the identification of possible costs and outcomes related to 
these options, and the assignment of probabilities to each of these. Hence, decision 
analysis facilitates the handling of situations where a decision is required despite 
uncertainty in some of the aspects that determine final outcome. The events could for 
instance be provision of vaccines and treatment, and the outcomes could be the impact on 
people’s health. Since the model must depict the natural history of the disease and the 
sequence in which the events take place, it can be simple or more sophisticated, depending 
on the disease epidemiology and the relevant decision problem. Decision-analytic models 
for Hib disease are reviewed in Chapters 5 and 7. 
The impact on the result (or the decision) of parameter and structural uncertainties 
should be assessed in sensitivity analysis. Deterministic sensitivity analysis is performed 
by changing one or more parameter estimates at a time and re-running the evaluation.  
Probabilistic sensitivity analysis (PSA) is undertaken by specifying parameters as 
distributions rather than point estimates and simultaneously varying all parameter 
estimates in a Monte-Carlo simulation. Thus, PSA based analyses not only provide 
estimates of mean expected costs and effects, but also accompanying uncertainty ranges, 
typically expressed as cost-effectiveness acceptability curves or frontiers [67]. 
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4.4 DISCOUNTING FUTURE VALUES 
Evidence suggests that society has a positive rate of time preference; that is, a preference 
for benefits today rather than in the future and prefer to postpone costs [67]. Hence, a key 
element in economic evaluation is to ensure that all values are appropriately adjusted for 
differential timing, so that sensible comparison can be made between interventions where 
costs and effects occur at different time points. To do this, future values are discounted to 
reflect the fact that these have less weight than money spent or health effects gained 
today.  The present value, PV, is typically calculated as:   
PV = 1/(1 + r)t  
where r is the discount rate and t is the number of years after year zero.   
For costs the rationale for discounting is warranted by returns to investment in the 
market place and the choice of discount rate should therefore reflect the real rate of 
return, which can be approximated by, for instance, the real market interest rate. 
Jurisdictions in many countries advise on the discount rate analysts should use, which is 
most commonly between 3% and 5% per year [73]. Discounting of health effects has to do 
with the strength of preferences for consumption now rather than later, which is more 
difficult to measure empirically [67].  
The mainstream practice is to discount effects at the same rate as costs, but the principle 
of discounting effects is an ongoing methodological debate. Some analysts maintain that 
costs and effects should be discounted by the same rate, others argue that effects should 
be discounted at a lesser rate than costs, and a third group makes the case that effects 
should not be discounted at all [74, 75]. Arguments against discounting of health effects 
include that this give less weight to future generations compared to the present one and 
that empirical evidence shows that individuals discount future health at a lesser rate than 
monetary benefits. One of the key arguments for discounting costs and effects at a similar 
rate is that this insures consistency in reasoning by treating health care projects in a 
similar way to those in other sectors of the economy. However, Nord has recently shown 
that these arguments are logically flawed [74]. He argues that “discounting of future health 
effects is less a matter of pure logic and more a matter of empirical research and societal 
values than what has been suggested by leading health economists for decades” [74]. The 
debate is still ongoing, so even though most guidelines currently specify that an equal 
discount rate should be used for costs and effects this could change in the future. As an 
example, initially, the UK’s National Institute for Health and Clinical Excellence (NICE) 
required that costs be discounted at 6% per year and effects at 1.5%. However, NICE 
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amended its discounting guidance in 2004 and required that both costs and effects should 
be discounted at 3.5% per year [76].       
Since there is always a time lag between when a vaccine is delivered and when health 
effects can be seen, discounting is an important issue in economic evaluations of vaccines. 
For childhood diseases like measles, pertussis, varicella, polio and Hib, the health impact is 
normally seen within about five years, so discounting may not be a major issue, although 
the time lag does need to be accounted for. However, for vaccines such as human 
pappiloma virus and hepatitis B discounting is a critical factor, as the health effects are 
realised much later than when the costs of vaccine provision are incurred. 
4.5 THE INCREMENTAL COST-EFFECTIVENESS RATIO 
Cost-effectiveness is traditionally expressed in terms of the incremental cost-effectiveness 
ratio (ICER). Depending on the effect measure, the ICER could for instance be “incremental 
costs per life years gained” or “incremental costs per QALY gained”. The definition of the 
ICER is: 
      
                                            
                                                
 
If the intervention evaluated turns out to be cost-saving and clinically superior, the 
conclusion should be to implement the intervention and the ICER should not be used in 
this case because negative ICERs have little meaning. However, since the more effective 
interventions are most often also more costly, appropriate interpretation of the ICER is 
crucial.  Two overall approaches are currently recommended. First, one can compare the 
ICER against ICERs of other interventions that have been studied with the aim of 
determining which of these interventions should be prioritised. A problem with this 
approach is however that relatively few studies are normally available to compare with, 
and if there are studies, different methodologies may have been used. The second option is 
to apply an explicit threshold where any intervention with an ICER below the threshold is 
considered cost-effective [77]. NICE is one of the few reimbursement agencies that have 
formally published a cost-effectiveness threshold.  According to NICE, if the cost per QALY 
gained is shown to be below £20,000, the decision to recommend the use of the technology 
is normally based on this result. If the cost-effectiveness estimate is between £20,000 and 
£30,000 per QALY gained, judgements take into account factors such as the degree of 
certainty of the estimate and the innovative nature of the technology. If the cost per QALY 
gained is above £30,000 the technology is unlikely to be adopted without considerable 
debate [78].  
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The WHO has established the following cost-effectiveness threshold values using DALYs 
[79]:  
• Cost per discounted DALY averted < GDP per capita: The intervention is very cost-
effective 
• Costs per discounted DALY averted 1-3 x GDP per capita: The intervention can be 
considered cost-effective 
• Costs per discounted DALY averted > 3 x GDP per capita: The intervention cannot 
be considered cost-effective. 
In 2010, the United Kingdom GDP per capita was approximately £ 23,500. Hence, the basic 
principle of considering those interventions that cost less than GDP per capita for each 
health related quality of life year gained for cost-effective is a common feature of the NICE 
policy and the WHO recommendations. 
The use of cost-effectiveness analysis for decision making is discussed in Chapter 13 of 
this thesis.     
4.6 GUIDELINES FOR ECONOMIC EVALUATION OF VACCINES 
There are numerous guidelines available on economic evaluation and for designing 
decision-analytic models [67, 69, 80, 81]. Economic evaluations of vaccines should follow 
the broad principles of these guidelines, which in many ways can be considered as 
standard procedures with step-by-step approaches. However, certain features are specific 
to vaccines and it has been suggested that economic evaluation of these should be 
undertaken with special considerations compared to analysis of other health care 
interventions [82, 83, 84, 85].  
The most critical attribute that distinguishes vaccines from analysis of other interventions 
is that most vaccine preventable diseases are infectious. The effect of vaccination against 
an infectious disease is two-fold. First, a vaccine induces individual protection against a 
disease for the vaccinated person and secondly, vaccination reduces the susceptibility of 
an individual so that there is a reduced chance of transmitting the infection to others [86]. 
Hence, vaccination not only protects those who are vaccinated, but also the unvaccinated 
because of a decrease in the circulation of the pathogen.  This latter effect is known as herd 
immunity. To accurately account for herd immunity, a dynamic infectious disease model is 
required [87]. In such as model, the probability of an individual acquiring an infection is 
dependent on the contact patterns of that individual, the transmissibility of the infection, 
and the distribution of the infection within the population over time [82].  Differences 
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between static and dynamic models with a focus on Hib vaccination and disease are 
addressed in Chapter 7. 
In 2008, the WHO published guidelines for standardization of economic evaluation of 
immunization programmes [88]. The primary target audiences for the guidelines are 
economists and health service researchers who conduct and critically appraise economic 
evaluations of immunization programmes at national, regional and global levels. The 
guidelines provide recommendations on framing the analysis, how to assess the costs and 
effects of a vaccination programme, modelling, discounting and how to present and 
interpret cost-effectiveness data.  A checklist for appraising the quality of economic 
evaluation of immunization programmes is also included [88].  
In a paper published in 2008 by Kim and Goldie, recommendations for modelling 
approaches in cost-effectiveness analysis of vaccination programmes were given [89]. The 
authors emphasized that there is a need for improving modelling methods for economic 
evaluation of vaccines, specifically model choice, construction, assessment and validation. 
A framework for classifying models according to three main attributes was proposed:  
i. Static or dynamic 
ii. Stochastic or deterministic  
iii. Aggregate or individual 
This framework is explained further in Chapter 7 and the decision-analytic model 
developed for this thesis is described and categorised accordingly. 
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5 ECONOMIC EVALUATIONS OF HIB VACCINE AND HIB 
DISEASE TREATMENT COST STUDIES: REVIEWS OF THE 
LITERATURE1  
Two literature reviews are presented in this chapter. First, a systematic review of 
economic evaluations of Hib vaccine was undertaken with three overall objectives: (i) to 
ascertain the quantity of published papers, in particular for low- and middle-income 
countries, (ii) to evaluate the methods used in the published studies and (iii) to determine 
the main limitations with the existing evaluations and then identify knowledge gaps which 
should be addressed. The second literature review is on Hib disease treatment cost 
studies. The objectives of this review were to establish in which low- and middle-income 
countries such research has been undertaken, to compare methods and results of the 
studies, and to make broad conclusions about the costs of treating Hib disease. Further 
more, in the context of the PhD, objectives were to identify which cost components are 
important to include in an economic evaluation and to assess if it would be suitable to use 
any of the study results in the present analysis.  
5.1 LITERATURE REVIEW OF ECONOMIC EVALUATIONS OF HIB VACCINE 
5.1.1 METHODS 
5.1.1.1 Search strategy 
Papers were identified from PubMed using the search terms “Haemophilus influenzae type 
b” and “vaccine” and “cost”. Two health economic evaluation databases were also 
searched; the National Health Service Economic Evaluation Database [90] and the Health 
Economic Evaluation Database [91]. References in the retrieved articles were reviewed for 
relevant papers. There was no time limit on older papers and the search ended in 
February 2009. All languages were included. The criteria for inclusion was that a study 
should assess both the incremental costs and health consequences of Hib conjugate 
vaccine compared to a situation without the vaccine in the routine childhood 
immunization schedule. Reported cost data were converted to 2010 US$ values based on 
local consumer price indices and average annual exchange rates [92].  
 
                                                             
1 A modified version of this chapter has been published as: Griffiths UK, Miners A, Cost-effectiveness 
of Hib vaccine: A systematic review of the literature, Expert Review of Pharmacoeconomics and 
Outcome Research, 2009 August (4):333-46 
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5.1.1.2 Assessment of study quality 
Several comprehensive checklists, which to a large extent are overlapping, have been 
developed to guide quality assessments of economic evaluations [67, 93]. Quality scoring 
systems have also been devised, but since these are subjective they are not considered to 
be sufficiently valid and consistent as a method of quality assessment [93]. The quality and 
relevance of each identified study was evaluated by using the standard checklists coupled 
with criteria that were a priori considered to be important for Hib vaccine economic 
evaluations.  In particular, the following issues were evaluated: 
Study design:  
1. Were details of any decision-analytic model given? 
2. Was herd immunity included in the impact estimates? 
Data collection: 
3. Were the Hib disease syndromes clearly stated and did the disease incidence 
estimates have a reliable source? 
4. Was Hib pneumonia included in the impact estimates? 
5. Was there a clear explanation of the methods used to value health states and other 
benefits of vaccination? 
6. Were both acute illness in young children and life-long sequelae for a proportion of 
meningitis cases included in the outcome measures? 
7. Were treatment cost data transparently presented and disaggregated into 
quantities and unit costs?  
8. Were treatment costs of sequelae from meningitis included? 
9. Were vaccine delivery costs included? 
Interpretation of results: 
10. If productivity costs due to mortality and morbidity were included, were these 
reported separately and was the relevance of these to the overall result discussed? 
11. Was sensitivity analysis undertaken? 
5.1.2 RESULTS 
5.1.2.1 Study selection 
The search identified a total of 175 papers (Figure 5.1). After reviewing titles and  
abstracts, 28 of these were considered potentially relevant. One paper was in Spanish [94], 
one in Italian [95], one in Dutch [96] and the remaining in the English language. Eleven 
papers were excluded before the data abstraction process; the Italian paper was excluded 
because it compared different Hib vaccination schedules only, a paper from the USA 
evaluated Hib vaccine along with several other vaccines without separately presenting the  
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Figure 5.1 Study selection for literature review  
 
Hib specific cost-effectiveness results [97], two papers analysed only the cost implications 
of switching from monovalent Hib vaccine to a combination vaccine [98, 99] and seven 
papers were excluded because they were cost comparison studies only [96, 100, 101, 102, 
103, 104, 105]. In these seven studies the costs of vaccination were compared directly 
against the costs of treating prevented Hib disease without placing a value on the health 
effects of the vaccine. As this type of partial evaluation implies that we should only 
implement programmes that are cost saving, it is not as useful to decision makers as a full 
economic evaluation that also values health effects [67]. Three of the cost comparison 
studies were incorrectly labelled as cost-benefit analysis (CBA) [101, 104, 105] and one as 
a cost-effectiveness analysis [102]. As mentioned in Chapter 4, the definition of a CBA is 
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that a monetary value is assigned to health outcomes [67], but this was not done in the 
papers.  A total of 17 articles were included in the review. 
Two other reviews of economic evaluations of Hib vaccine were identified: one by 
Clements from 1994 [100] and one by Brinsmead and colleagues ten years later [106]. 
When Clements published his review only six economic studies had been published and 
two of these were for the polysaccharide Hib vaccine [107, 108]. In the review by 
Brinsmead et al., 18 studies were included. Their inclusion criterion was broader than in 
the present review, as both cost comparisons studies and international economic analyses 
were included alongside country-specific economic evaluations. Another difference is the 
methods used to assess methodology and quality of the studies. While Brinsmead et al. 
evaluated the overall methods used in the studies, a direct comparison of key parameter 
values was not presented and their review did not assess the methodological differences 
between studies conducted in high- versus low- and middle-income countries. 
5.1.2.2 Study settings 
The 17 papers included in the review cover a total of 14 countries (Table 5.1). According 
to 2010 World Bank classifications [109], seven of the countries are high-income (GNI per 
capita of US$ 12,276 or more) two are upper middle-income (GNI between US$ 3,976 - 
US$ 12,275 per capita), three are lower middle-income (GNI between US$ 1,006 - US$ 
3,975 per capita) and two are low-income countries (GNI below US$ 1,005 per capita). 
Most of the studies from high-income countries are from the early 1990s when these 
countries were making decisions about Hib vaccine. The earliest paper is an Israeli study 
from 1993 [110]. The US study by Zhou et al. was undertaken nine years after Hib vaccine 
introduction, making it possible to use Hib disease surveillance data from before and after 
the vaccine introduction to assess health impact [111].  All the studies from low- and 
middle-income countries except the one from South Africa [112] are subsequent to year 
2000, reflecting that most of these countries have only relatively recently started the 
decision-making process regarding Hib vaccine introduction. 
5.1.2.3 Study quality and comparison of methods and parameter values 
In Table 5.1, the 17 studies are assessed according to the selected quality factors. The 
more crosses a study has, the higher the quality. It is seen that none of the papers fulfil all 
quality factors.  Three studies (from Papua New Guinea (PNG) [113], Colombia [94] and 
the Philippines [114]) fulfilled none, one or only two of the indicators and are thus of very 
low quality. The weakest aspect of all the papers was the methods used for calculating and 
reporting treatment costs. Only six papers did this in a transparent way.   
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Table 5.1: Assessment of key quality indicators of Hib economic evaluation studies included in the review (“x” indicates that study comply with criteria) 
Country income 
group and first 
author [ref.] 
Country (year) 
Use of 
decision 
analytic 
model 
Hib disease 
incidence 
rates clearly 
reported 
with reliable 
data source 
Hib 
pneumonia 
included in 
effectiveness 
measure 
Full disease 
impact 
included in 
outcome 
measure 
Treatment 
costs 
reported in 
transparent 
and reliable 
way 
Treatment 
costs of 
sequelae 
included 
Vaccine 
delivery 
costs 
included 
Productivity 
changes 
reported 
transparently 
Sensitivity 
analysis 
undertaken 
High income           
Ginsberg [110] Israel (1993)  X  X  X X X X 
McIntyre [115] Australia(1994) X     X X NA X 
Harris [116] Australia (1994) X X    X X NA X 
Trollfors [117] Sweden (1994)    X  X  X  
Garpenholt [118] Sweden (1998) X X  X X X X  X 
Livartowski [119] France (1996) X X    X   X 
Pokorn [120] Slovenia (2001) X X X X  X X X X 
Zhou [111] USA (2002) X X X X  X X  X 
Shin [121] South Korea (2008) X X X X  X X  X 
Middle income           
Hussey [112] South Africa (1995)   X X   X X X 
Platonov [122]  Russia (2006) X X  X X X  NA X 
Limcangco [114] Philippines (2001) X   X     X 
Guzmán [94] Colombia (2006)   X    X  X 
Broughton [123] Indonesia (2007) X X X X  X  NA X 
Gessner [124] Indonesia (2008) X X X X X   NA X 
Low income           
Duke [113] PNG (2002)        NA  
Akumu [125] Kenya (2007) X X X X X   NA X 
NA: Non applicable as productivity costs were not included in the analysis 
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Modelling methods  
A decision-analytic model was presented in 12 of the 17 studies. Most of the models were 
designed in a decision tree structure with branches representing the different types of Hib 
disease included in the analysis. However, in five of the studies (the Swedish paper by 
Trollfors and the papers from PNG, Colombia, South Africa and Israel) no model was 
presented and insufficient detail was provided on how the health and cost impacts were 
estimated and combined, indicating that fairly simplistic approaches were used. 
None of the studies attempted to model the transmission dynamics of Hib disease when 
estimating vaccine impact. Instead, static models that follow fixed size cohorts over time 
and predict Hib disease using constant rates of infection were used. Only Akumu et al. in 
the Kenyan paper mentioned the potential impact of herd immunity and performed a 
crude sensitivity analysis by assuming elimination of Hib disease in the long run [125].  
 
Hib disease syndromes 
The papers incorporated different types of Hib disease syndromes, although all included 
Hib meningitis (Table 5.2). Eight of the 17 papers included pneumonia, but the reliability 
of the evidence provided for this disease burden varied considerably. For instance, the 
South Korean paper [121] used data from the USA, which is unlikely to be valid for Asia 
due to different risk factors in the two populations. The Indonesian papers presented the 
most reliable Hib pneumonia burden estimates, as these were based on results from a Hib 
vaccine probe study [123, 124].   
Table 5.2: Hib disease syndromes included in the economic evaluation studies 
Syndromes 
No. of 
papers 
Reference 
Meningitis only 3 [113, 114, 122] 
Meningitis, epiglottitis and “other” Hib disease 3 [115, 116, 118] 
Meningitis, pneumonia and “other” Hib disease 2 [121, 123] 
Meningitis, bacteraemia and pneumonia 2 [112, 125] 
Meningitis and pneumonia 2 [94, 124] 
Meningitis and epiglottitis 1 [117] 
Meningitis and “other” Hib disease 1 [110] 
Hib invasive disease 1 [105] 
Meningitis, epiglottitis and septicaemia 1 [119] 
Meningitis, epiglottitis, arthritis, cellulitis, bacteraemia and pneumonia 1 [120] 
Meningitis, epiglottitis, arthritis, cellulitis, pneumonia, septicaemia and 
other Hib disease 
1 [111] 
 
Hib disease incidence rates 
Hib disease incidence rates per 100,000 children less than five years varied considerably 
between the studies. Since the difference between the highest and lowest disease 
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incidence was as much as 1,982 cases per 100,000 children, a logarithmic scale has been 
used to show this in Figure 5.2. The Hib meningitis incidence rate ranged from six in the 
Russian study [122] to 158 in the Indonesian study [124]. Hib pneumonia incidence was 
assumed to be 1,825 per 100,000 children less than five years in the Indonesia study by 
Gessner et al. [124], but most other studies did not even include pneumonia. While most 
researchers agree that Hib disease incidence rates differ between geographic regions, the 
range of estimates seen in the studies also reflects different methods. For example, in the 
Kenyan study and in one of the Indonesian studies [124, 125], hospital derived incidence 
rates were adjusted upwards to account for limited access to hospital care, but this 
adjustment was not made in other countries where this might be an issue, such as the 
Philippines and Colombia.  
Figure 5.2: Logarithmic scale of Hib disease incidence per 100,000  
children less than 5 years used in the economic evaluation studies 
 
Methods used to value health states 
The choice of health outcome measure is a key difference between the studies. Of the 17 
papers reviewed, eight are cost-benefit analysis, seven are cost-utility analysis and two are 
cost-effectiveness analysis using “costs per life saved” as the outcome measure (Table 5.3).  
In a Hib vaccine cost-benefit study, a monetary value can be placed on premature death 
and on the loss of productivity due to meningitis sequelae. The willingness to pay 
approach was used in the two Swedish studies while the human capital approach was used 
in the remaining six studies; four of these used the average wage rate [111, 112, 114, 121] 
and two studies used GDP per capita to approximate the value of a life (Israel and 
Slovenia) [110, 120]. There were wide differences in the results reflecting the distinct 
income levels between countries. It is moreover apparent that the Swedish willingness to 
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Table 5.3: Costs of Hib disease used in the studies (2010 US$) 
First author [ref.] Country 
Monetary 
value of a life 
Lifetime 
productivity loss 
due to 
meningitis 
sequelae 
Average length of 
stay in hospital 
of a meningitis 
case (days) 
Average treatment 
costs of a meningitis 
case 
Discounted 
lifetime 
treatment costs 
of a meningitis 
sequelae case 
Cost-benefit studies         
Garpenholt [118] Sweden            2,279,525               2,279,525  12.0   10,490                   2,569,295  
Trollfors  [117] Sweden            2,388,630  NI NS NS                  1,821,627  
Ginsberg [110] Israel              380,029  NI 11.8   13,043                      610,748  
Hussey [112] South Africa              167,158                 167,158  14.6     1,702      448  
Limcangco [114] Philippines  NS  NS NS NS NS 
Pokorn [120] Slovenia              565,210  NI 18.9     8,366                      924,314  
Shin [121] South Korea              536,984                 536,984  NS     3,509                      215,436  
Zhou [111] USA  NS  NS 7.2   12,881   NS  
Cost-utility studies            
Akumu [125] Kenya  NI  NI 11.7        332  NI 
Broughton [123] Indonesia  NI  NI 13.0           1,353    6,580  
Gessner [124] Indonesia  NI  NI 8.1        292  NI 
Harris [116] Australia  NI  NI NS   16,650                      827,724  
Livartowski [119] France  NI  NI NS   11,570  NS 
McIntyre [115] Australia  NI  NI NS     9,886                      722,008  
Platonov [122] Russia  NI                 157,132  30.0     5,616  56,229  
Cost-effectiveness studies            
Duke [113] Papua New Guinea  NI  NI  NS  51  NI 
Guzmán [94] Columbia  NI  NI NS     1,800  NI 
NI: The parameter is not included in the analysis 
NS: The parameter is included in the analysis, but the value is not stated 
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pay approach resulted in considerably higher values than the human capital approach 
(Table 5.3). 
There are seven cost-utility studies: three from high-income countries that use QALYs as 
the outcome measure [115, 116, 119] and four from low- and middle-income countries 
where outcomes are expressed in DALYs [122, 123, 124, 125]. In the three QALY papers, 
only the impact of mortality and life-long meningitis sequelae were included in the QALY 
estimate while Hib disease episodes due to meningitis, epiglottitis, pneumonia, etc., were 
excluded. When attaching a preference score to life-long meningitis sequelae, widely 
different values were used in the three papers. In the French paper, preference scores 
were based on experts’ opinion and found to be 0.371 for severe sequelae, 0.84 for 
moderate sequelae and 0.977 for isolated auditory sequelae [119]. Harris et al. used a 
preference score of 0.8 for mild disability and 0.6 for severe disability [116] and McIntyre 
et al. used -0.12 for severe disability, 0.80 for less severe disability, 0.86 for hearing aid 
and 0.91 for less severe hearing loss [115]. The methods used to determine these 
preference scores were not explained in any of the Australian papers.   
In the four DALY papers the formula and disability weights developed by Murray and 
Lopez for the 1996 GBD study were referenced [126], except in one of the Indonesian 
papers where the specific disability weights used were not specified or referenced [123]. 
The three other papers used the standard GBD disability weights for bacterial meningitis 
and pneumonia, but different assumptions about types and proportions of disabilities 
were used when calculating DALYs due to meningitis sequelae [122, 124, 125]. 
Treatment costs  
Most studies included treatment costs of the same syndromes as included in the effect 
estimates. Hence, all studies except two (Philippines and Sweden) [114, 117] reported the 
average costs of treating a meningitis case. This was usually estimated by multiplying the 
average length of stay in hospital for each syndrome by the cost per bed day. However, the 
majority of studies provided inadequate details on the methods used for the treatment 
costs estimates. For example, only five studies reported disease specific costs of drugs and 
diagnostics [94, 110, 111, 124, 125]. Of the studies from low- and middle-income 
countries, arguably the study by Gessner et al. provided the most reliable treatment cost 
estimates, as patient specific treatment costs were collected by reviewing patient records 
and undertaking exit interviews alongside a Hib vaccine probe study. Hence, standard 
deviations around a mean value were given for many of the cost items [124]. 
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As seen in Table 5.3, considerably higher meningitis treatments costs were reported in 
high-income than low-income countries, ranging from US$ 51 in PNG to US$ 16,650 in 
Australia. There is a clear correlation between GNI per capita and treatment costs of an 
acute meningitis case (Figure 5.3). 
Figure 5.3: Correlation between GNI per capita and treatment costs of an acute 
meningitis case (2010 US$) 
 
The inconsistencies are that the South Korean estimate is noticeably less than those for the 
other high-income countries, one of the Australian estimates are twice as high as the other, 
one of the Indonesian papers reports a value five times higher than the other paper from 
Indonesia, and the estimate from PNG is five times less than in Kenya, the other low-
income country. While the reason for the South Korean divergence is not clear, the source 
for the hospital bed day costs in the Indonesian paper by Broughton were reportedly an 
Indonesian travel guide suggesting that private sector prices were used [123], and in the 
PNG study it seems as if drugs were the only cost item included [113].  
Treatment costs of meningitis sequelae were included in all but four studies (Table 5.3). 
The studies from  Kenya, Indonesia, PNG and Colombia did not include these costs, most 
likely because treatment of disabilities are limited in these countries and these data are 
thus scarce. The highest lifetime treatment costs of meningitis sequelae were reported in 
the two Swedish studies (Table 5.3).    
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Hib vaccine assumptions 
Assumptions on Hib vaccine efficacy against Hib meningitis varied between 90%-100% 
among the studies (Table 5.4).   All except three of the studies [94, 112, 120] provided a 
source for this estimate, which was generally referenced to a single randomized controlled 
trial of Hib vaccine. None of the studies performed a meta-analysis on vaccine efficacy 
evidence. In the studies from the USA and Indonesia it was not necessary to include an 
efficacy assumption as the Hib vaccine impact was generated from surveillance data and a 
vaccine probe study, respectively [111, 124]. Three studies evaluated a four-dose Hib 
vaccine schedule, two analysed both three and four doses and the remaining 12 used three 
doses only (Table 5.4). The large majority of studies assumed use of monovalent Hib 
vaccine. This is partly because combination vaccines were not yet available when many of 
the studies were undertaken, but probably also because vaccine costs are simpler to 
estimate when a monovalent vaccine is assumed. The studies from Indonesia and Kenya 
assumed use of the combined DTP-Hepatitis B-Hib vaccine, also known as the 
“pentavalent” vaccine, which is the vaccine of choice in most GAVI Alliance supported 
countries. The costs of Hib vaccine was estimated as the difference between pentavalent 
and DTP-hepatitis B vaccine. The range of vaccine prices is consistent with the different 
bargaining powers of countries. Kenya and Indonesia are eligible for procurement through 
UNICEF, which can obtain cheaper prices due to bulk procurement. Similarly, the public 
price in the USA is likely to be less than in other high-income countries because of the 
larger quantities procured. Nine of the studies included costs of vaccine delivery in 
addition to the vaccine costs while the remaining eight studies excluded this cost. Of the 
low- and middle- income country studies only the South African study included this.  None 
of the studies provided much detail on the source of these cost estimates.  
5.1.2.4 Study results 
Comparison of some of the study results is not straight forward due to the different 
methods used for valuing health states. As seen in Table 5.5, five of the cost-benefit studies 
presented a positive benefit-cost ratio while it was negative in South Korea [121]. 
However, contrary to standard guidelines, in three of the cost-benefit studies a ratio was 
not calculated. Instead, the difference between the annual costs of Hib vaccination and Hib 
disease were presented, illustrating cost savings in both settings (Sweden and the 
Philippines). 
The two Australian studies presented results in terms of costs per QALY gained and these 
values are in a comparable range. The costs per QALY gained were higher in the French 
study, probably due to the lower disease incidence (Figure 5.2) and higher vaccine prices   
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Table 5.4: Hib vaccine assumptions used in the studies 
First author [ref] Type of Hib vaccine 
Vaccine 
efficacy 
against Hib 
meningitis 
Number of 
Hib vaccine 
doses 
Hib vaccine 
price per dose 
(2010 US$) 
Vaccine 
delivery costs 
per dose 
(2010 US$) 
High income          
Ginsberg [110] Hib monovalent 100% 3 and 4 15.72 1.35 
McIntyre [115]  Hib monovalent 90% 3 16.07 4.02 
Harris [116] Hib monovalent 95% 3 8.93 0.63 
Trollfors [117] Hib monovalent 90% 3 25.30 NI 
Garpenholt [118] Hib monovalent 95% 3 25.11 1.55 
Livartowski [119]  DTP-Hib 100% 4 26.82 NI 
Pokorn [120] Hib monovalent 95% 3 12.24 0.76 
Zhou [111] Hib monovalent and others NI 3 and 4 6.96 7.70 
Shin [121] Hib monovalent 99% 3 24.93 5.71 
Middle income        
Hussey [112] Hib monovalent 100% 4 22.67 0.53 
Platonov [122] Hib monovalent 95% 4 15.15 NI 
Limcangco [114]  Hib monovalent 90% 3 6.60 NI 
Guzmán [94] Hib monovalent 90% 3 4.87 NI 
Broughton [123] DTP-HepB-Hib 95% 3 3.70 NI 
Gessner [124] DTP-HepB-Hib NI 3 3.79 NI 
Low income       NI 
Duke [113]  NS NS 3 NS NI 
Akumu [125] DTP-HepB-Hib NS 3 3.70 NI 
NI: Parameter value not included in the study 
NS: Parameter value included, but value not stated 
DTP: Diphteria-tetanus-pertussis vaccine 
HepB: Hepatitis B vaccine 
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(Table 5.5). The Russia study estimated considerably higher costs per DALY averted than 
the studies from Kenya and Indonesia. Again, this is arguably due to a combination of a 
higher vaccine price and a lower Hib disease incidence rate used in this analysis.  
The two cost-effectiveness studies from PNG and Colombia produced widely different 
results. However, none of these estimates can be considered reliable. The overall quality of 
the study from PNG is weak and many of the parameter assumptions do not seem 
trustworthy. As an example, it was assumed that meningitis causes 13% of all child deaths; 
such a high figure is implausible. While the parameter assumptions in the Colombia study 
can be considered valid, the cost-effectiveness results are reported in a confusing and 
incorrect way. It is for instance stated that the “costs per life saved is US$ 2.38 with 
vaccination and US$ 3.81 without vaccination” [94], which most likely reflects the  use of 
average cost-effectiveness ratios of the two alternatives instead of only the incremental 
cost-effectiveness ratio.      
Table 5.5: Base case results reported in the studies (2010 US$) 
Country [ref.] Result measure 
Cost-benefit  
Benefit-cost ratio with 
productivity costs 
included 
Benefit-cost ratio without 
productivity costs 
Israel [110] 1.45 1.26 
South Africa [112] 1.43 Will be < 1 
Slovenia [120] 1.39 0.99 
South Korea [121] 0.77 NI 
USA [97] 5.40 3.40 
Cost-benefit  
Annual cost savings with 
productivity costs 
included 
Annual cost savings without 
productivity costs 
Sweden [118] 16,999,651 NI 
Philippines [114] 24,629,930 11,215,415 
Sweden [117] 5,464,880 1,821,627 
Cost-utility  
Costs per discounted QALY 
gained 
Costs per discounted DALY 
averted 
Kenya [125] NI 96 
Indonesia [123] NI 117 
Indonesia [124] NI 90 
Russia [122] NI 38,536 
Australia [116] 1,816 NI 
Australia [115] 1,649 NI 
France [119] 8,418 NI 
Cost-effectiveness Costs per life year saved 
 
Papua New Guinea [113] 2,056  
Columbia [94] 20  
NI: Result measure not included in the analysis 
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All papers except those from South Korea and Russia concluded that Hib vaccine was good 
value for money and recommended introduction of the vaccine into the routine 
vaccination schedule. The main reason for negative conclusions in South Korea and Russia 
are the assumptions about relatively low Hib disease burden, as was shown in Figure 5.2. 
5.1.2.5 Sensitivity analysis 
In all the studies except two (PNG and Sweden) [113, 117] sensitivity analyses of the most 
uncertain variables were presented. While most of the studies used one-way sensitivity 
analysis, four studies included probabilistic sensitivity analysis by assigning a statistical 
distribution to uncertain parameters and running Monte Carlo simulations [122, 123, 124, 
125]. This analysis enabled the authors to present cost-effectiveness ratios around an 
uncertainty range. In the majority of studies the one-way sensitivity analysis was 
comprehensive. One study varied as many as 19 parameters [119]. The most common 
parameters to vary were vaccine price and Hib disease incidence, which almost all the 
authors referred to as the most important determinants of the result. Other parameter 
values varied included discount rates, vaccine coverage and the proportion of meningitis 
cases suffering from sequelae.  
5.1.3 DISCUSSION 
The aim of the review was to assess the quality of existing economic evaluations of Hib 
vaccine with a particular focus on papers from low- and middle-income countries.  Only 
five of the studies were considered to be of high quality according to the different criteria 
assessed. In particular, the studies from Kenya and Indonesia showed good examples of 
how results from epidemiological studies can become much more policy relevant when 
used in conjunction with economic decision-analytic models. The overall finding of the 
review is, however, that there are important limitations with the existing literature, both 
in terms of methodological quality and general level of reporting.  Eight studies from low- 
and middle-income countries were included in the review, but three of these (PNG, 
Philippines and Columbia) [94, 113, 114] were of such poor quality with respect to data 
inputs and presentation of results that their results are either unlikely to be useful for 
decision-making purposes or could lead to erroneous policy decisions.  
Some of the most important limitations of the papers were unreliable disease burden 
estimates and non-transparent methods used for treatment cost calculations. In addition, 
the model descriptions were inadequate, reliable sources were not given for quality of life 
estimates, in particular for meningitis sequelae, and none of the studies from low-income 
countries included treatment and productivity costs of meningitis sequelae. Moreover, the 
differences between studies with regard to Hib disease syndromes included have 
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contributed to confusion about the health impact of the vaccine. In particular, the impact 
on pneumonia has not been satisfactorily addressed.  
Evidence on the cost-effectiveness of Hib vaccine is not yet available from certain 
geographical areas, as there are no studies from central Asia and the Middle East. Central 
Asia is a region where there is considerable uncertainty about Hib disease burden and 
where policy makers are consequently not fully convinced about the value of the vaccine. 
While it cannot be recommended to undertake cost-effectiveness studies of Hib vaccine in 
all countries of the world, it is widely known within the vaccine field that policy makers 
are reluctant to utilize evidence from other countries than their own [127, 128]. It is thus 
essential that methodologically robust studies at least are available from countries that 
account for a relatively large proportion of the global Hib disease burden, such as India.   
5.2 REVIEW OF HIB DISEASE TREATMENT COST STUDIES IN LOW- AND MIDDLE-INCOME 
COUNTRIES 
Prediction of treatment costs averted is an important component of any economic 
evaluation of a vaccine. Treatment costs of Hib disease are comprised of costs to the health 
sector as a result of delivering care and to households as a result of requiring care. As 
explained in Chapter 4, the types of treatment costs included in the analysis depend on the 
perspective taken. If a government health sector perspective is considered, costs are 
limited to resources financed by the public health sector while with a societal perspective 
costs incurred by households should also be included. In low-income countries, household 
costs are generally comprised of user fees paid for consultations and hospitalizations, 
expenses for drugs and diagnostic tests, transport costs to get to and from the health 
facility and other costs, such as food purchased while receiving treatment. The objectives 
of this review were to compare methods and results of studies in which treatment costs of 
childhood meningitis and pneumonia have been estimated, to identify which cost 
components are important to include in a Hib vaccine economic evaluation, and to assess 
the feasibility of using any of the study results for the economic evaluation.  
5.2.1 METHODS 
5.2.1.1 Study selection 
Only studies with the overall aim of estimating costs of treating childhood pneumonia and 
meningitis in low- and middle-income countries were reviewed; estimates provided 
within cost-effectiveness studies were not included. No systematic search was undertaken 
to identify the studies. Instead, the papers were gathered gradually during the course of 
preparing this thesis. I have been directly involved in a number of the treatment cost 
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studies and this has lead to identification of other studies for comparison of our study 
results. Since I have a relatively large network of colleagues working within the field who I 
communicate with frequently, it is unlikely that any important studies have been missed in 
the review.  
5.2.1.2 Data analysis 
To facilitate quality assessment of the studies, recommended methods for estimating 
treatment costs in low-income settings were established. These are summarized in Texbox 
5.1 and further details given in Annex 2.  
For each study, the following methodological issues were reviewed: 
i. The type of health facility where data were collected. 
ii. Methods used for estimating bed-day and/or visit costs. 
iii. The sample size used for collecting patient specific cost data.  
iv. Whether household out-of-pocket costs were included in the study. 
Costs were converted to 2010 US$ values using consumer price indices 
(imf.org/external/data.htm) and average annual exchange rates 
(oanda.com/currency/historical-rates/).   
5.2.2 RESULTS 
5.2.2.1 Comparison of study methods 
The eleven identified studies are summarised in Table 5.6. Treatment costs of pneumonia 
were included in all eleven papers and meningitis in five.  Patient specific resource 
utilization items, such as drugs, supplies and diagnostic tests, were determined either by 
retrospectively reviewing patient records or by collecting data prospectively. Sample sizes 
for estimating patient specific costs ranged from 56 patients in one of the two Indian 
studies to 980 patients in the study from Vietnam. In six of the studies caregivers were 
interviewed about their out-of-pocket costs, such as user fees and transport costs. A 
government health sector perspective was taken in the remaining five studies, in which no 
household cost data were collected.  
Seven of the studies used micro-costing methods of varying intensity for calculating the 
costs per hospital bed-day. In the studies by Guzman et al. and Constenla insufficient 
details were however given for the reader to understand the methods used for collecting 
these data. In the studies by Krishnan et al., Hussain et al., Chola et al., Madsen et al. and 
Sinha et al., data on the annual costs of repairs, maintenance, electricity, consumables, 
institutional overheads, staff, capital costs, etc. were collected and analysed in close  
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Textbox 5.1: Overview of recommended methods for estimating treatment costs 
 
collaboration with the accountancy departments of the health facilities, and the estimated 
costs per bed-day were reported in these studies.  
In the studies by Ayieko et al. (Kenya) and Temple et al. (Fiji), detailed patient-specific cost 
data were collected by reviewing patient records and conducting caregiver interviews, but 
hospital bed-day and outpatient visit costs were not estimated for the participating 
facilities. Ayieko used a published study from Kenya to approximate bed-day costs, but 
Temple excluded outpatient visit costs, except for personnel expenses. In the Vietnamese 
study by Anh, a so called “ratio of costs to charges method” was used, giving reference to 
Estimating costs from the perspective of a government health facility: 
Costs should be divided into two components:  
(a) Hospital bed-day costs / out-patient visit costs 
(b) Patient specific costs  
(a) Bed-day and visit costs:  
 All cost items shared between patients admitted to a hospital or receiving an outpatient 
consultation are included. These are the building, kitchen services, laundry services, 
cleaning, maintenance, administration, etc. 
 Even though clinical personnel strictly speaking is a patient specific cost item because 
some patients take up more staff time than others, all personnel costs are generally 
included in bed-day/visit costs due to the difficulty in measuring precisely how much 
time is spent with an individual patient.  
 Since health facilities in low-income settings rarely have computerised accountancy 
systems, it can be a substantial task to determine bed-day and visit costs.  
(b) Patient specific costs: 
 These are resources that vary between patients, such as drugs, medical supplies and 
diagnostic tests.  
 Primary data collection on resource utilisation from a sample of patients is needed to 
determine the costs accurately, with data sources either being patient records or 
specially designed data collection forms.  
 Resource items are multiplied by their respective unit costs to generate total costs per 
patient.  
 In low-income settings, unit costs are often difficult to establish due to inadequate cost-
accounting systems, numerous procurement mechanisms and donations in kind. 
Estimating costs from the household perspective: 
A sample of patients or caregivers should be interviewed about their out-of-pocket costs 
using data collection forms designed for the purpose.  
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Table 5.6: Overview of studies estimating the costs of pneumonia and meningitis treatment in children less than five years in low- and 
middle-income countries 
First author  
[ref] 
Country Year Types of diseases included 
Facilities 
included 
No. of inpatient 
records 
reviewed* 
 
Method 
used for 
bed-day 
costs 
Method 
used for 
outpatient 
visit costs 
Number of 
patient 
interviews for 
household 
costs* 
Krishnan [129] India 2001 
Pneumonia, meningitis and 
diarrhoea < 5 years 
2 primary, 4 
secondary and 
2 tertiary 
hospitals 372 
Micro-
costing 
Micro-
costing 355 
Guzman [130] Columbia 2005 Pneumonia in children < 2 years 
3 tertiary 
hospitals 128 
Micro-
costing 
Micro-
costing Not included 
Hussain [131] Pakistan 2006 
Pneumonia and meningitis in 
children < 5 years 
2 primary, 2 
secondary and 
1 tertiary 
hospital 589 
Micro-
costing 
Micro-
costing Not included 
Constenla [132] 
Brazil, Chile 
and Uruguay 2007 
Pneumonia and meningitis in 
children < 5 years 
33 hospitals 
and 10 
outpatient 
centres 753 
Micro-
costing 
Micro-
costing Not included 
Hussain [133] Pakistan 2008 
Pneumonia, severe pneumonia 
and very severe febrile disease in 
children < 5 years 
15 hospitals 
and clinics NA NA NA 112 
Chola [134] Zambia 2009 
Pneumonia and diarrhoea in 
children < 5 years 
1 primary 
hospital 829 
Micro-
costing 
Micro-
costing Not included 
Ayieko [133] Kenya 2009 
Pneumonia, malaria and 
meningitis in children < 5 years 
3 primary, 3 
secondary and 
1 tertiary 
hospital 307 
Other 
Kenyan 
study NA 205 
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First author  
[ref] 
Country Year Types of diseases included 
Facilities 
included 
No. of inpatient 
records 
reviewed* 
 
Method 
used for 
bed-day 
costs 
Method 
used for 
outpatient 
visit costs 
Number of 
patient 
interviews for 
household 
costs* 
Madsen [135] India 2009 
Severe pneumonia in children < 3 
years 
1 secondary 
and 1 tertiary 
hospital 56 
Micro-
costing NA 56 
Anh [136] Vietnam 2010 
Pneumonia, meningitis and sepsis 
in children < 5 years 
1 tertiary 
hospital 980 
Ratio of costs 
to charges NA Not included 
Temple [137] Fiji 2011 
Outpatient pneumonia in children 
< 5 years 
2 tertiary 
hospital 
outpatient 
departments 400 NA Not included 400 
Sinha [138] South Africa 2012 Pneumonia in children < 5 years 
1 tertiary 
hospital 745 
Micro-
costing NA 325 
*Count only for pneumonia and meningitis patients. If other diseases were included in the study, these patients were excluded from the count. 
NA: Non-applicable.
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an approach from the USA. Hussain et al only took a household perspective in their 2008 
study from Pakistan, so it was not relevant to include bed-day or outpatient visit costs 
5.2.2.2 Comparison of results 
The mean costs of meningitis treatment per patient varied from US$ 211 in Vietnam to 
US$ 5,855 in Chile (Table 5.7). According to the author, the costs in Chile were 
considerably higher than even in the two other South American countries of the same 
study because of higher hospitalisation costs. However, the underlying reasons for these 
higher hospitalisation costs were not explained and unit costs and quantities of resource 
items were not presented in the paper [132]. The mean meningitis treatment costs in 
Pakistan were significantly higher than in the three other low-income countries (Kenya, 
India and Vietnam). A likely reason for this is that the study facility in Pakistan was owned 
by an NGO while government facilities were evaluated in the other countries. 
The mean costs per case of outpatient pneumonia ranged from US$ 3.4 in India to US$ 56 
in Zambia (Table 5.8). One reason why the Indian and Fiji estimates are relatively low is 
that not all visit cost components, such as the building and utilities are included in these 
studies.  
The costs of inpatient pneumonia treatment varied from US$ 36 in Vietnam for non-severe 
pneumonia to US$ 4,502 in Chile for severe pneumonia (Table 5.9). The South American 
study by Constenla showed a considerable cost difference between confirmed 
pneumococcal pneumonia compared to pneumonia from other causes (Table 5.9) [132]. 
Hib pneumonia would most likely not have been among the other causes because the three 
countries had used Hib vaccine routinely for several years prior to the study. Since Hib 
pneumonia is also bacterial, treatment costs of pneumococcal and Hib pneumonia are 
likely to be in a comparable range.   
Table 5.7: Mean meningitis treatment costs per case in tertiary hospitals (2010 US$) 
Country Type of meningitis Mean costs (SD) Ref. 
Vietnam Bacterial 211 (172) [136] 
Kenya All-cause       434 (365)  [139] 
India All-cause 750 [129] 
Brazil Pneumococcal          1,474  [132] 
Pakistan All-cause      2,758  [131] 
Uruguay Pneumococcal      4,203  [132] 
Chile Pneumococcal         5,855  [132] 
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Table 5.8: Mean outpatient pneumonia treatment costs per case (2010 US$) 
Country Types of hospital 
Mean costs 
(95% CI) 
Ref. 
India Public secondary 3.2 [129] 
Fiji Public tertiary      7 (6 .16 - 7.23)   [137] 
Pakistan Public secondary and NGO          18  [133] 
South Africa Public tertiary 19 [138] 
Zambia Public secondary   56  [134] 
 
Table 5.9: Mean inpatient pneumonia treatment costs per case (2010 US$) 
Country 
Type of 
pneumonia 
Type of 
hospital 
Mean costs 
(SD or 95% CI) 
Ref. 
Vietnam Non-severe Tertiary   36 (33) [136] 
Vietnam Severe Tertiary    42 (47) [136] 
Uruguay All-cause Tertiary    80  [132] 
Vietnam Very severe Tertiary       89 (85) [136] 
India All-cause Secondary 93 (72-114) [135] 
India All-cause Secondary 94 [129] 
Kenya All-cause Secondary    95  [139] 
Pakistan Non-severe Secondary 96  [131] 
Brazil All-cause Tertiary    127  [132] 
Zambia All-cause Primary  252  [134] 
India All-cause Tertiary 162 (133-191) [135] 
Kenya All-cause Tertiary 270 (316) [139] 
Chile All-cause Tertiary     284 [132] 
Pakistan Severe Secondary   317  [131] 
India All-cause Tertiary 319 [129] 
Brazil Pneumococcal Tertiary 628 [132] 
South Africa Severe Primary 651 (607-694) [138] 
South Africa Severe Secondary 849 (793-906) [138] 
Columbia Bacterial Tertiary 1,063 (914-1,211)  [130] 
South Africa Severe Tertiary 1,160 (1,083-1,237) [138] 
Uruguay Pneumococcal Tertiary 2,052 [132] 
Chile Pneumococcal Tertiary 4,502 [132] 
Household out-of-pocket costs of pneumonia treatment were determined from patient 
interviews in Fiji, India, Kenya, Pakistan and South Africa (Table 5.10). While the study 
from Fiji only included outpatient treatment, the remaining studies evaluated the costs of 
a severe episode where both inpatient and outpatient treatment were received. The 
highest cost was in the Indian NGO tertiary hospital where households on average paid 
US$ 149 (95% CI US$ 115, 183) per episode. In this study, out-of-pocket expenses were 
comprised of user fees (47%), drugs (19%), diagnostic tests (17%), transport (8%) and 
other expenses, such as food, phone calls, soap, etc. (9%) [135]. 
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As shown for meningitis in the previous literature review, there was correlation between 
GNI per capita and the costs of treating severe pneumonia (Figure 5.4). In the five low-
income countries, the mean costs per case ranged between US$ 42 in Vietnam and US$ 317 
in Pakistan while in the middle-income countries, the mean costs were between US$ 628 
and US$ 4,502. Brazil and Chile are outliers with relatively low and high costs per case, 
respectively, compared to their GNI per capita. As already mentioned, it is unfortunately 
not possible to understand the underlying reasons for the cost differences between the 
three South American countries in the paper by Constenla.   
Only six of the studies (from Columbia, Kenya, Vietnam, Fiji, India and South Africa) 
presented descriptive statistics around the mean cost estimates, such as standard 
deviation or a 95% confidence interval (Tables 5.7 – 5.10).  All of these showed great 
variation in costs between patients, with some of the standard deviations exceeding the 
mean costs. This confirms a standard tendency of treatment costs (see Annex 2).  
Table 5.10: Mean household out-of-pocket costs of pneumonia treatment  
(2010 US$) 
Country Type of hospital 
Mean costs 
(95% CI) 
Ref. 
Fiji Public tertiary outpatient 2.82 (2.28, 3.46)  [137] 
Pakistan  Secondary and NGO (non-severe) 5 [133] 
South Africa Public tertiary 21 (12,  34) [138] 
Kenya Public primary   22  [139] 
India NGO secondary 46 (36, 55)  [135] 
Kenya Public secondary   46  [139] 
Pakistan  Secondary and (severe) 55 [133] 
Kenya NGO secondary  97  [139] 
Kenya Public tertiary  98  [139] 
India NGO tertiary 149 (115, 183)  [135] 
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Figure 5.4: Correlation between GNI per capita and costs of treating severe 
pneumonia (2010 US$)  
 
5.2.3 DISCUSSION 
This is the first time the literature on the costs of treating childhood pneumonia and 
meningitis in low- and middle-income countries has been reviewed and results compared 
across settings. Treatment cost studies are available from five low-income countries; Fiji, 
India, Kenya, Pakistan, Vietnam and Zambia, and from five middle-income countries; 
Columbia, Chile, Brazil, South Africa and Uruguay.  
In the seven studies where both meningitis and pneumonia treatment costs were 
estimated,  it was found that the costs of treating meningitis is between two and eight 
times higher than pneumonia treatment costs, depending on setting and type of hospital. It 
was also found that the costs of treating pneumonia in a tertiary hospital were between 
1.3 and 2.8 times higher than treatment in a secondary hospital in the same country. 
Inpatient pneumonia treatment in a secondary hospital was five times more expensive 
than outpatient treatment in Zambia and Pakistan, 30 times higher in India and 34 times 
higher in South Africa. The differences between countries are especially large with regard 
to outpatient costs and it is likely that this is explained by methodological study variation. 
In the Indian study, several cost components were for instance not included in the 
outpatient cost estimate, but they were included in the inpatient bed-day cost figures 
[129].  
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In all of the five studies where treatment costs were estimated from the perspective of 
households, it was concluded that out-of-pocket expenses comprised a relatively large 
proportion of household income and were unaffordable for a large share of the population. 
In the study from Pakistan it was found that the average household costs of one episode of 
hospitalised pneumonia was considerably higher than total annual health expenditure per 
capita. Similarly, in the Fiji study it was concluded that household costs of outpatient 
pneumonia treatment accounted for a quarter of the annual per capita outpatient 
expenditures. In the Kenya study the authors showed that costs of pneumonia hospital 
treatment were equivalent to approximately one month of total household expenses and 
that user fees comprised around 40% of total treatment costs in the tertiary government 
hospital. 
As explained in Annex 2, estimation of hospital treatment costs in low- and middle-income 
countries is typically a relatively large undertaking. Since cost-accounting systems are 
seldom computerised and costs not tracked systematically and routinely, investigators 
need to collect resource quantities and unit costs from several different sources and this 
can be a time consuming task. For the studies included in the review, it took on average 
five years from data collection was started until the study was published, ranging from one 
year for the Indian study by Madsen et al., and ten years for the South African study by 
Sinha et al. 
The methodological quality varied between the studies. It is postive that all the studies 
included patient specific cost data from a sample of patients, but it is a shortcoming that 
only six of the eleven studies presented descriptive statistics of these data. The majority of 
studies estimated costs per hospital bed-day using micro-costing methods, but 
unfortunately the quality of reporting was inadequate in several papers with insufficient 
details provided on methods and only a few, selected unit costs shown. 
An important limitation of these types of studies is that it is uncertain to what extent data 
from one or two health facilities can reliably be extrapolated to a national level, which is 
needed for economic evaluation of Hib vaccine. Since health facilities within a country 
differ in management systems, capacity, size and efficiency, the mean costs per patient 
differ between facilities. It is particularly important not to use results from a tertiary 
university teaching hospital for estimating treatment costs in a whole country as costs in 
this type of facility are considerably higher than lower level facilities, as was shown in 
some of the studies. However, while the problem of extrapolation from a few facilities to 
the national level is important to bear in mind there are no immediate solutions in sight. 
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Resources for undertaking these types of studies are limited, so it is not realistic to collect 
data from more than a relatively small selection of facilities within a study. Until countries 
invest in systems for routine monitoring of costs, it will not be possible to establish precise 
national level estimates and to make robust conclusions about how costs vary according to 
facility level and type.    
Even though considerable variations in mean treatment costs between countries and 
between facilities within a country were shown in the studies, it is possible to make some 
broad conclusions about the costs of treating meningitis and pneumonia in low- and 
middle-income countries. It is clear that mean costs are positively correlated with GNI per 
capita and that the costs of meningitis treatment are considerably higher than pneumonia 
treatment. In the South American study it was moreover found that bacterial pneumonia 
was substantially more costly to treat than pneumonia due to other causes. In low-income 
countries, the mean costs of treating childhood pneumonia in a hospital were in the range 
of US$ 36 - US$ 96 per case and the costs of treating meningitis were between US$ 211 - 
US$ 434 per case.  
5.3 CONCLUSION 
Two complementary literature reviews were presented in this chapter. Seventeen country 
specific economic evaluations of Hib vaccine were assessed with regard to modelling 
methods, input parameter values and overall results. In 15 of the studies it was concluded 
that Hib vaccine can be considered a cost-effectiveness intervention, but in the studies 
from South Korea and Russia it was argued that the vaccine should not be regarded as a 
priority compared to other health interventions. Only two studies were available from 
low-income countries; the study from Kenya was of relatively high quality, but the study 
from PNG was of extremely low quality.  
A total of eleven studies were identified in the review on treatment cost studies of 
childhood pneumonia and meningitis in low- and middle-income countries. From this 
review, it can be concluded that it is crucial to integrate health care seeking behaviour 
within the economic evaluation. Costs per patient treated varied considerably according to 
facility ownership, levels of care and between inpatient and outpatient treatment, so it is 
imperative to determine what proportion of patients seeks treatment where when 
estimating the costs at a national level. Even though costs are considerably higher at 
tertiary level, focus on estimating these costs precisely are only justified if a considerable 
proportion of the population receive care at thi level.   
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The study results from the treatment cost review provide a relatively robust basis for 
comparison with the estimates generated as part of this PhD. Moreover, two studies were 
identified from India, which is one of the study countries. In Chapter 10 it is explained how 
these studies are used in the economic evaluation. 
Based on the findings of the literature reviews, the intention of this PhD is to undertake a 
detailed and complete economic evaluation of Hib vaccine in a selection of low- and 
middle-income countries.  The current literature on this topic is limited for these countries 
and the studies undertaken in high-income countries have used fairly simplistic methods.  
All the inadequacies identified in the current economic evaluations are addressed in this 
thesis.  
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6 THESIS AIMS, OBJECTIVES AND CONCEPTUAL FRAMEWORK 
The overall aim of this thesis is to estimate the health and economic impact of Hib vaccine 
in low- and middle-income countries. A decision-analytic model is used to estimate the 
cost-utility of Hib vaccine. Input parameters used in the model are derived from a 
thorough and critical review of the Hib disease burden literature, meta-analysis of Hib 
vaccine trials, and from collection of primary data in the study countries. This PhD thesis is 
the first attempt to combine evidence on disease burden, costs and cost-utility of Hib 
vaccine across multiple countries using a consistent framework and comparable input 
parameters. As a result, useful insights into the relative cost-utility in countries with 
different economic and epidemiological circumstances are generated.   
The research has eight objectives, which are all sub-components of the overall aim: 
1. Development of Hib vaccine decision-analytic model.  
2. Generation of Hib vaccine efficacy estimates from a meta-analysis. 
3. Estimation of change in health related quality of life due to actute Hib disease and 
Hib meningitis sequelae. 
4. Estimation of the costs of treating Hib disease in a selection of low- and middle-
income countries. 
5. Assessment of the household costs of meningitis sequelae. 
6. Estimation of system costs of Hib vaccine introduction. 
7. Comparison of the incremental cost-utility of Hib vaccine in three countries; 
Belarus, India, and Uzbekistan. 
8. Use of the findings and the decision-analytic model to address relevant policy 
questions for Hib vaccine priority setting in low- and middle-income countries: 
 Can Hib vaccine be considered cost-effective? Does the conclusion vary 
according country income groups and epidemiological setting? 
 In what ways can the economic evaluation be used to enhance 
sustainability of Hib vaccine in GAVI supported countries? 
In addition to these overall objectives, there are specific needs for the economic evaluation 
in the three study countries. These countries were chosen because they requested the 
analysis from the Hib Initiative during 2005-2009, but since they have distinct Hib vaccine 
policy issues, they also provide excellent examples on how economic evaluation can be 
used for decision making. They are moreover representatives of different country income 
groups and Hib epidemiology.   
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In this thesis, the Belarus analysis is representative for middle-income countries that are 
not eligible for GAVI support. It is apparent that policy making on new vaccine 
introduction is considerably different in these countries compared to countries that can 
apply to GAVI for new vaccines [140, 141]. As was shown in Chapter 3, most of the Hib 
vaccine introductions in middle-income countries have only taken place in recent years 
and several countries in this income bracket have not yet introduced the vaccine. In 
Belarus, the local government of Minsk city introduced Hib vaccination in 2008, covering 
around one-fifth of the birth cohort.  The national government has since considered 
whether to expand the programme to the rest of the country and the economic evaluation 
was requested by the manager of the national immunization programme to help guide this 
decision. 
India is an example of a GAVI eligible country where policy makers are in doubt about the 
value of the vaccine and concerned about financial sustainability when GAVI support 
comes to an end. This scepticism has been seen in several South East Asian and Western 
Pacific countries because of continuing uncertainty about Hib disease burden. Due to 
India’s large birth cohort, the GAVI Alliance has placed an upper limit on its support to the 
country so the whole country can only be covered for 1-2 years of vaccine use. The Indian 
government decided to introduce the vaccine in 2008, but some groups have questioned 
the strength of the evidence, and the level of priority Hib vaccine should be given.  In 
December 2009, a high court petition was filed by seven public health figures in India, 
including a former Health Secretary and a former advisor to the Finance Ministry. This 
petition was filed in the public interest to highlight “how irrational vaccines are being 
introduced in the public health system by the government, under the influence of vaccine 
manufacturers and international agencies” [142].  Specifically, the petitioners argue that 
new vaccines against Hepatitis B and Hib are being introduced without proper 
epidemiological and medical studies, while at the same time, basic more affordable 
vaccines such as DTP and measles are not being made available to approximately half the 
children of India. Hib vaccine was introduced with GAVI support in two of the 28 Indian 
states (Karala and Tamil Nadu) in December 2011, but expansion to the rest of the country 
has not yet been decided upon. The economic evaluation presented in this thesis is thus 
crucial for Indian decision makers as it shows to what extent the vaccine is good value for 
money. While the study was not directly requested by the Ministry of Health and Family 
Welfare, it was undertaken in close collaboration with Indian partners who also worked 
with the Hib Initiative on epidemiological studies. 
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Uzbekistan is representative of a more typical GAVI eligible country compared to India. As 
many other GAVI countries, Uzbekistan introduced hepatitis B vaccine shortly after this 
was offered by GAVI, and when GAVI stopped supporting monovalent hepatitis B vaccine 
after five years, the country switched to pentavalent vaccine. Uzbekistan introduced 
hepatitits B vaccine in 2001. However, the Uzbek government had initially serious doubts 
about the value of Hib vaccine and they expressed scepticism about GAVI’s co-financing 
requirements. The application process therefore took several years and Hib vaccine was 
not introduced until 2009. The country has since been in default to GAVI on co-financing 
because the Ministry of Health has problems receiving these funds from the Ministry of 
Finance. The economic evaluation was requested by the manager of the Uzbekistan 
Expanded Programme on Immunization (EPI) who considers it crucial evidence for 
ensuring future financial sustainability of the vaccine. 
In addition to the three main study countries, the thesis includes sub-studies from Senegal 
and Ethiopia.  Household costs of meningitis sequelae were investigated in Senegal and 
system costs of Hib vaccine introduction were evaluated in Ethiopia. These studies were 
undertaken in response to research priorities identified by the Hib Initiative. Of all the 
sub-studies included in this thesis, research ethics approval was only necessary for the 
study in Senegal and this was obtained accordingly.  
6.1 CONCEPTUAL FRAMEWORK 
The conceptual framework of the thesis is shown in Figure 6.1. The decision-analytic 
model is used to address policy questions regarding Hib vaccine in low- and middle-
income countries. This is done with case studies from Belarus, India and Uzbekistan. The 
input parameters needed for the model are each an individual subject within the thesis. 
The broad subject areas are vaccine efficacy, vaccine costs, disease burden, treatment 
costs of acute Hib disease and meningitis sequelae, as shown by the circles in Figure 6.1.  
Different types of research questions and study methodologies were used to address these 
broad topics, as shown by the quadrilateral shapes at the bottom of the figure. A meta-
analysis of clinical trial evidence was undertaken to determine Hib vaccine efficacy.  
Vaccine delivery costs were split into vaccine costs and systems costs, including data from 
a case study in Ethiopia. On the subject of disease burden, a focus was placed on methods 
for valuing health related quality of life using Disability Adjusted Life Years. When 
estimating treatment costs, it was investigated to what extent health care seeking 
behaviour and access to health services impacts the overall result. The costs of meningitis 
sequelae were estimated by a case study from Senegal where the opportunity costs of 
parents’ time due to the burden of caring for a disabled child were quantified.    
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Figure 6.1: Conceptual framework for assessment of impact, costs and incremental 
cost-utility of Hib vaccine in low- and middle-income countries 
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7 DECISION-ANALYTIC MODEL  
The aims of this chapter are to describe the overall structure of the decision-analytic 
model, discuss the considerations that were taken into account when choosing its design, 
and to sign post in which subsequent chapters particular input parameters are addressed.  
To understand the model considerations that were made, the differences between static 
and dynamic models are explained in section 7.1 and published dynamic models of Hib 
disease are reviewed in section 7.2. The decision-analytic model is presented in section 
7.3.  
The decision-analytic model was developed in close collaboration with Mr. Andrew Clark, 
research fellow at LSHTM. When I joined the Hib Initiative in May 2006 as Director of 
Cost-effectiveness, I initiated development of a decision-analytic model for use in GAVI 
eligible countries. In 2007, Mr. Clark began to work with me on this. The division of our 
work on the model is explained at the end of this chapter. 
7.1 THE CHOICE OF STATIC VERSUS DYNAMIC HIB DISEASE MODEL 
In the systematic literature review of Chapter 5 it was found that all the published 
economic evaluation studies evaluated the impact of Hib vaccination on a single birth 
cohort over time. These models are “static” as the risk of infection is independent of time 
and the impact of herd immunity ignored.  Most vaccines prevent not only disease 
outcomes in the infected individual, but also prevent acquisition of the pathogen from 
other infectious individuals. In a dynamic transmission model the force of infection (the 
probability that a susceptible person acquires infection per unit of time) changes over 
time. Hence, as more children are vaccinated and the vaccine prevents transmission of the 
pathogen from infectious to susceptible persons, the proportion of infectious people in the 
population will decrease. Consequently, the force of infection acting on the remaining 
susceptible declines as well.  A dynamic model takes this into account by cyclically 
recalculating the force of infection from the proportion of susceptible and infectious 
people at each point in time [88]. A key parameter in a dynamic model is the basic 
reproduction number, often denoted as R0.  This is the mean number of secondary cases a 
typical single infected case will cause in a fully susceptible population, i.e. a population 
with no immunity to the disease in the absence of interventions to control the infection 
[143]. This metric is useful because it helps determine whether or not an infectious 
disease will spread through a population. When R0 < 1, the infection will die out in the long 
run, but if R0 > 1, the infection will be able to spread in a population. R0 is affected by 
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several factors, including the duration of infectivity of affected patients, the infectiousness 
of the organism, and the number of susceptible people the infectious carrier is in contact 
with. The proportion of the population that needs to be vaccinated to provide herd 
immunity and prevent sustained spread of the infection is given by 1 − 1/R0 [143].  
Use of a dynamic model in economic evaluation of Hib vaccine is likely to generate more 
precise results as it allows for assessment of change in cost-effectiveness over time in line 
with changes in herd immunity. In most instances, the vaccination effect will be 
underestimated when using a static model, as herd immunity is not included. However, for 
certain vaccines negative dynamic effects also need to be accounted for. This is for 
instance the case with rubella vaccine where it is important to accurately predict the 
impact of shifts in the average age of infection, as rubella infection in pregnant women is 
considerably more damaging to health than infection during childhood [144].  
Dynamic models thus take into account changes in the risk of infection over time and they 
can be used to estimate elimination thresholds, defined as the level of vaccination 
coverage which results in elimination of the pathogen. This is not the case for static 
models. However, in reality R0 will differ according to geography, patterns of travel and 
socioeconomic status and dynamic models are thus inherently more complicated and 
require data that can be difficult to gather, such as carriage rates and population mixing 
[87]. The data needed for static models are simpler to generate and these models are also 
less complicated to develop. Hence, static models are overwhelmingly the most common 
models used for economic evaluation of vaccination programmes, despite their limitations, 
and known biases [82]. Researchers need to assess whether the additional benefits of a 
dynamic model outweigh the additional costs and efforts needed to build it. In low- and 
middle-income countries, there is increasing emphasis on building the capacity of 
Ministries of Health to conduct their own economic evaluations. In this context, static 
models are easier to explain, and may be more suited to the limited data available in many 
countries.   
Kim and Goldie reviewed modelling approaches for cost-effectiveness studies of 
vaccination programmes published between 1976 and 2007 [89]. They categorized 
models for economic evaluation of vaccines into six different types, as shown in Table 7.1, 
and recommended that model developers clearly describe which type their model belongs 
to.  According to the framework, models are either (i) dynamic or static, (ii) changes to the 
model occur at random (stochastic) or are fixed (deterministic), (iii) the model aggregates 
the behaviour of populations (aggregate) or track’s individuals (individual-level), (iv) 
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events occur in discrete or continuous time, (v) individuals can enter or leave the 
populations (open) or not (closed), and (vi) the model’s equations are linear or non-linear 
functions of parameters. Kim and Goldie found that out of 276 studies, only 23 (8.3%) 
used a dynamic transmission model while 66.7% used a static model (Table 7.2). In 13.1% 
of the papers the model description was not clear enough to be classified [89]. 
Table 7.1: Classification of mathematical models for economic evaluation of 
vaccines 
 Type 1: Deterministic aggregate-level static 
model 
1.1 Decision trees 
1.2 State-transition model (e.g. Markov model) 
1.3 Hybrid model (e.g. a decision tree 
embedded with Markov models) 
Type 2: Deterministic aggregate-level 
(compartmental) dynamic model 
2.1 Discrete difference equation model                  
2.2 Ordinary difference equation model 
(continuous time) 
2.3 Partial differential equation model 
(continuous time) 
2.4 Other types of models that allow for 
interaction 
Type 3: Stochastic aggregate-level static 
model 
 Monte Carlo simulation of a decision tree 
or a state-transition model 
Type 4: Stochastic aggregate-level dynamic 
model 
 Individual sampling of compartmental 
dynamic model 
Type 5: Static individual level micro 
simulation model 
 Monte Carlo micro simulation of a decision 
tree or a state-transition model 
Type 6: Dynamic individual-level micro 
simulation model 
6.1 Monte Carlo simulation of a Markov model 
with interaction 
6.2 Discrete-event simulation model 
6.3 Agent-based model 
 Source: Kim and Goldie (2008) [89] 
Table 7.2: Model types identified in systematic literature  
review of vaccine economic evaluations 
Model type No. of studies Percent 
Static 184 66.7% 
Dynamic 23 8.3% 
Empirical 18 6.5% 
Monte Carlo simulation 1 0.4% 
Other 14 5.1% 
Unclear 36 13.1% 
Total 276 100% 
       Source: Kim and Goldie (2008) [89] 
7.2 REVIEW OF DYNAMIC HIB DISEASE MODELS 
While none of the published economic evaluations of Hib vaccine used a dynamic model, 
these types of models have been constructed to answer other types of research questions. 
A summary of Hib disease modelling studies identified from a non-systematic review of 
the published literature is seen in Table 7.3. These models belong either to types 2, 4 or 6 
in the framework of Kim and Goldie. 
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Dynamic modelling of Hib disease has been undertaken by three research groups; a team 
in Finland and two different groups in the UK.  As seen in Table 7.3, the Finnish group has 
published the largest amount of papers. Auranen, Leino and others have developed four 
different models to analyse various questions about Hib disease. The first model published  
Table 7.3: Published dynamic Hib disease models 
Author [ref] Year Type of model Objective of analysis 
Studies from Finland: 
Auranen et al. 
[145] 
1996 Susceptible-Carriage-
Susceptible model with 
Markov process  
To predict prevalence and incidence 
of Hib carriage as a function of 
family size and age structure 
Auranen et al. 
[146] 
1999 Hierarchical Bayesian 
regression model 
To predict the duration of immunity 
to Hib carriage and invasive Hib 
disease as a function of 
concentration of serum antibodies 
to capsular polysaccharide of Hib 
Auranen 
[147] 
2000 Baysian non-
parametric intensity 
model 
Back-calculating the age-specific 
incidence of recurrent Hib carriage 
Leino et al. 
[148] 
2000 Hierarchical Bayesian 
regression model 
To estimate the duration of natural 
immunity to Hib under different 
forces of infection 
Leino et al. 
[149] 
2002 Hierarchical Bayesian 
regression model 
To compare two different 
populations before the 
implementation of Hib vaccine 
Makala et al. 
[150] 
2003 Hierarchical Bayesian 
regression model 
To predict antibody persistence 
after initial response to Hib vaccine 
Auranen et al. 
[151] 
 
2004 Individual based 
stochastic simulation 
model 
To model transmission, immunity 
and disease of Hib in a structured 
population 
Leino et al. 
[152] 
2004 Individual based 
stochastic simulation 
model 
To study factors determining the 
magnitude of indirect protection in 
Hib vaccination and  determine the 
indirect and direct vaccination 
effects on carriage and disease   
Studies from the UK: 
Coen et al. 
[153] 
1998 Susceptible-infected-
recovered model 
To explore the relationship between 
Hib carriage and disease 
Coen et al. 
[154] 
1999 Susceptible-infected-
recovered model 
Validation of model by comparing 
Hib vaccine impact results to 
surveillance data 
McVernon et 
al. 
[155] 
2008 Age-structured 
deterministic model.  
To understand interacting factors 
that contributed to a rise in Hib 
infections in the UK during the late 
1990s 
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in 1996 simulated the individual risk of acquiring carriage as a function of historical 
events, e.g. whether an individual gets married, has children, takes their child to a day-care 
centre, etc. The objective was to predict prevalence of Hib carriage in families as a function 
of family size and age structure [145].  
The next two models were developed in a Bayesian structure with data and parameters 
specified as a joint probability distribution [147, 148, 149, 150].  These were used to 
estimate age specific Hib carriage incidence rates [147], the duration of natural immunity 
to Hib under different forces of infection [148], and the relationships between Hib and 
cross-reactive antigens [149]. The final model was a stochastic, individual based 
transmission model where carriage was transmitted from person to person in three 
different contact sites: Family, day-care centre, and school class [150]. This model was 
used to study factors determining the magnitude of herd immunity from Hib vaccine 
[152]. In all of the papers, Finnish population and carriage data were used, supplemented 
by UK data in the 2002 paper by Leino et al. [149].  
Two models have been published by researchers in the UK. Coen et al. used differential 
equations to represent the flows of age-structured groups between states over time as 
susceptible  infectious carrier  susceptible [153]. The authors used this model to 
analyse the impact of Hib vaccine on disease incidence in the Oxford region [154]. The 
objective of McVernon and colleagues’ analysis from 2008 was to understand the reasons 
for a resurgence of Hib disease observed in the UK during the late 1990s. It was concluded 
that a key factor was over-reliance on immunological memory from vaccination, which 
was the reason for not having introduced a booster dose [155].   
When reviewing the published models, it appears that the model presented by Coen et al. 
would be the most suitable for use in an economic evaluation, as this is the only model that 
was developed with the objective of analyzing vaccine impact on disease incidence. This 
model is therefore reviewed in more detail below.  
7.2.1 DYNAMIC HIB DISEASE MODEL DEVELOPED BY COEN AND COLLEAGUES  
Coen et al. developed a mathematical model describing asymptomatic carriage and Hib 
disease, based on a review of UK data on the prevalence of carriage and the incidence of 
disease by age. In a subsequent paper, the model was extended to include the impact of 
vaccination, and the model was validated by comparing the results to surveillance data 
from the Oxford region [154]. The model, which is represented by partial differential 
equations, is seen in Figure 7.1.  
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The force of infection and the disease rate are age-dependent parameters and the force of 
infection also depends on the rate at which susceptibles interact with Hib carriers across 
all ages. Coen et al. divided the population into five age groups and determined the 
interaction by means of “Who Acquires Infection From Whom (WAIFW) matrices; a 
standard method used in infectious disease models for depicting population mixing 
patterns [143].   
The model was used to generate an estimate of the duration of carriage of 5 months, age-
specific force of infection between 0.02 and 0.12, R0 for Hib as 3.275, and a rate of age-
specific Hib disease per carrier per year between 0.0001 and 0.1 [153]. Hib invasive 
disease cases captured from the surveillance system in Oxford were compared with the 
numbers predicted by the model for a variety of assumptions to gain insights about the 
behavior of the vaccine [154].  The main conclusions from the analysis were that Hib 
vaccine seems to block the acquisition of carriage and that other factors than experience of 
Hib carriage are likely to generate acquired immunity to Hib disease prior to vaccine 
introduction. Based on this, Coen et al. concluded that a booster dose would provide very 
little additional benefit in the UK. However, the UK saw a resurgence of Hib disease one 
year after the paper was published and a booster dose was consequently introduced in 
2003 [156].  
Figure 7.1: Schematic of Hib disease model by Coen et al. 
 
Source: Coen et al. (1999)[154] 
 
Susceptibles
Invasive disease
Carriers
Susceptible 
vaccinees
Carriers vaccinees
Vaccine coverage
Loss of protection
Rate of recovery from 
carriage for vacinees
Force of 
infection
Disease 
rate
Rate of 
recovery, r1
Rate of 
recovery, r2
Vaccine waning rate
Vaccine coverage
Chapter 7: Decision-analytic model 
 
67 
 
7.3 HIB VACCINE DECISION-ANALYTIC MODEL  
7.3.1 MODEL DEVELOPMENT CONSIDERATIONS 
Andrew Clark and I spent a substantial amount of time considering the model structure to 
be used. We were initially keen on developing a dynamic model, but after discussions with 
the Hib Initiative Steering Committee, it was decided to restrict the analysis to a static 
model. The main argument of the Steering Committee against a dynamic model was that 
since Hib carriage in a population is not an accurate determinant for Hib disease, it would 
be difficult to generate meaningful disease burden estimates from a model dependent on 
carriage rates. Moreover, reliable carriage data are only available from few developing 
countries.  
Other arguments in favour of a static model were: 
1. The model was developed to be used in all GAVI eligible countries. For a multi-country 
model, a transmission dynamic framework becomes less appropriate given the need to 
populate each individual country with good quality, local estimates on age-specific 
carriage and disease and reliable age-structured mixing patterns. 
2. It was considered important to keep the model relatively simple, as the methods 
needed to be communicated to a number of different stakeholders with various 
backgrounds. Transmission dynamic models can be difficult to explain to policy 
makers due to their inherent complexity while transparent, static models can be more 
easily demonstrated.    
3. If a static model can demonstrate that Hib vaccine is considered to be cost-effective, 
there is no need from a policy perspective to include transmission dynamics, as the 
static model estimate is conservative [87]. Hence, in this case there may be limited 
benefit in investing time and energy in accurately estimating the herd immunity 
benefits for the unvaccinated population.    
The decision to limit the analysis to a static model was discussed extensively during my 
PhD upgrading, and the upgrading committee, which consisted of Professor John Edmunds 
and Dr. Rosa Legood, also came to the conclusion that a static model was the preferable 
approach. 
The GBD project mentioned in Chapter 2 was being finalized during the time when we 
developed the decision-analytic model. Since it was apparent that country-specific Hib 
disease incidence and case fatality estimates generated by the GBD project would be key 
input parameters in the model for several countries, it was essential to develop a 
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framework that was compatible with these figures, and we therefore decided to structure 
the model in a comparable way to the GBD estimates.  
The first activity of the GBD project was to conduct a comprehensive literature review to 
determine the availability and quality of country-specific disease burden data. Based on 
this literature review, it was decided to divide Hib diseases into three different groups; (i) 
meningitis, (ii) pneumonia and (iii) invasive non-pneumonia-non-meningitis (NPNM), and 
different modelling methods were developed for these three syndromes. For pneumonia, 
disease burden was estimated as an etiologic fraction of all-cause pneumonia cases and 
deaths. For Hib meningitis, an incidence-based approach was used wherein incidence and 
case fatality rates were derived from the literature. For Hib NPNM disease syndromes, 
incidence and case fatality rates were estimated indirectly based on the reported 
relationship between NPNM and meningitis cases and deaths [58]. We decided to use this 
division of syndromes when structuring our decision-analytic model and also similar 
methods for calculating disease cases. 
The results of the GBD project, in terms of estimated numbers of Hib disease cases and 
deaths in year 2000 according to geographical region, were published in the Lancet in 
September 2009 [31] and the methods were published as a web appendix [58].  
7.3.2 DECISION-ANALYTIC MODEL STRUCTURE 
The model framework is seen in Figure 7.2. According to the Kim and Goldie proposed 
framework, the model can be classified as a type 1.1: A deterministic aggregate-level static 
decision tree model. Projected numbers of person-years lived between 1 and 59 months 
are multiplied by disease incidence rates to estimate Hib cases in each cohort. The time 
horizon is until everyone in the cohort has died. An all-cause pneumonia incidence rate is 
used to calculate total pneumonia cases and it is assumed that a proportion of these are 
caused by Hib. Hib meningitis and Hib NPNM cases are calculated directly from aetiology 
specific incidence rates. A proportion of cases are assumed to seek health care and their 
treatment costs vary according to the type of care received. Hib meningitis, pneumonia 
and NPNM deaths are estimated from case fatality ratios (CFRs). A risk of permanent 
disability is applied to all survivors of Hib meningitis and classified according to type. The 
different sequelae classifications included at the bottom of Figure 7.2 are explained in 
Chapter 9. 
The impact of Hib vaccine is estimated as the difference between scenarios with and 
without vaccination.  In the Hib vaccination scenario, cases are reduced by age-specific 
vaccination coverage rates and dose-specific vaccine efficacy. Incremental cost-  
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(l) Proportion of Hib NPNM cases seeking care 
(m) Proportion of Hib meningitis cases seeking care 
(n) Proportion of Hib meningitis survivors with 
disability 
(o) Proportion with cognitive difficulties only  
(p) Proportion with seizure disorders only 
(q) Proportion with hearing loss only 
(r) Proportion with motor deficit only 
(s) Proportion with visual disturbance only 
(t) Proportion with behavioural problems only 
(u) Proportion with clinical impairments only 
(v) Proportion with multiple disabilities 
Figure 7.2: Hib disease model structure 
(a) Clinical pneumonia incidence in children < 5 yrs 
(b) Percent of clinical pneumonia caused by Hib 
(c) Hib NPNM incidence in children < 5 years 
(d) Hib meningitis incidence in children < 5 years 
(e) Pneumonia CFR without access to care 
(f) Pneumonia CFR with access to care 
(g) Hib NPNM CFR without access to care 
(h) Hib NPNM CFR with access to care 
(i) Hib meningitis CFR without access to care 
(j) Hib meningitis CFR with access to care 
(k) Proportion of Hib pneumonia cases seeking care 
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effectiveness ratios (ICERs) are calculated by subtracting annual treatment costs from 
annual vaccine delivery costs and dividing by incremental health effects, expressed as 
cases, deaths and Disability Adjusted Life Years (DALYs) in children less than five years. 
Future costs and health effects are in the base case scenario discounted by 3% per year, 
following WHO recommendations [88]. 
The model allows for a government health sector as well as a societal perspective. These 
different perspectives are especially important for the treatment cost data. In an analysis 
with a government perspective, only treatment costs incurred by the public health sector 
will be included, while out-of-pocket or health insurance expenses in both public and 
private facilities are also included in a societal perspective. The framework for treatment 
costs is shown in Figure 7.3. Data on health care seeking behaviour in the country in 
question is used to determine the proportions seeking care at primary, secondary and 
tertiary levels, and in the private versus the public health sector. Since treatment cost data 
from private hospitals are more difficult to access than from public facilities and since 
private facilities are relatively homogeneous in many countries, private hospitals have 
been grouped as one, irrespective of level. The circular arrow shows that a patient can 
seek health care from more than one of the facilities during the same illness episode. A 
visit to an outpatient clinic is for instance common before hospital admission and so is 
follow- up visits after discharge. This is accounted for by attaching a number of outpatient 
visits and hospital admissions per case of Hib disease.   
Figure 7.3: Types of health facilities included in the decision-analytic model   
 
IPD:   In-patient Department 
OPD: Out-patient Department 
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The model contains a total of 250 parameter values divided into eight main groups: (i) 
demography, (ii) vaccine coverage, (iii) vaccine efficacy, (iv) vaccine costs, (v) burden of 
disease, (vi) DALY parameters and discount rate, (vii) health services utilization and (viii) 
treatment costs. The broad headings of the parameters are summarized in Table 7.4. The 
next four chapters of this thesis are concerned with reviewing published evidence, data 
collection and analysis with the objective of obtaining robust parameter values. The 
respective chapters are listed in the second column of Table 7.4. 
Table 7.4: Hib decision-analytic model parameters  
Symbol 
in Figure 
7.2 
Parameter name Possible data source or thesis 
chapter where details of 
methods and data for the 
parameter are investigated 
 Demography  
 Number of live births per year UN population division  
 Infant mortality rate (per 1000 live births) UN population division  
 % of infant deaths in the neonatal period (<1m) UN population division  
 Under-5 mortality rate (per 1000 live births) UN population division  
 Life expectancy at birth UN population division  
 Vaccination coverage  
 Vaccine coverage of DTP1, DTP2 and DTP3 in base 
year 
WHO/Unicef or local data 
 % annual change in DTP1 coverage since year 2000 WHO/Unicef or local data 
 % annual change in DTP3 drop-out since year 2000 WHO/Unicef or local data 
 Maximum possible future vaccination coverage Assumption 
 Vaccine efficacy  
 Vaccine efficacy following 3 doses:  
 Hib meningitis Chapter 8 
 Hib invasive NPNM Chapter 8 
 Clinical pneumonia Chapter 8 
 Relative efficacy of fewer doses  
 2 doses only (as  % of 3 dose efficacy) Chapter 8 
 1 dose only (as  % of 3 dose efficacy) Chapter 8 
 Annual decrease in protection (waning immunity) Chapter 12 
 Vaccine costs  
 Vaccine price Chapter 11 
 % decline in vaccine price per year Chapter 11 
 Systems costs of vaccine delivery per child Chapter 11 
 Hib disease burden  
 Ratio of Hib invasive NPNM to Hib meningitis Chapter 12 
 Annual incidence per 100,000 aged 1-59 months:  
(a) Clinical pneumonia Chapter 12 
(d) Hib meningitis Chapter 12 
(c) Hib NPNM Chapter 12 
 % case fatality ratios in ages 1-59 months:  
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Symbol 
in Figure 
7.2 
Parameter name Possible data source or thesis 
chapter where details of 
methods and data for the 
parameter are investigated 
(e), (f) Hib pneumonia Chapter 12 
(i), (j) Hib meningitis Chapter 12 
(g), (h) Hib NPNM Chapter 12 
(b) % pneumonia episodes due to Hib Chapter 12 
(n) % Hib meningitis survivors with permanent 
sequelae 
Chapter 9 
(o-v) % with different types of disabilities Chapter 9 
 DALYs and discounting  
 Discount rate  Assumption 
 Disability weights Chapter 9 
 Age weighting modulation factor Chapter 9 
 Age weighting parameter Chapter 9 
 Health care utilisation  
 Number of outpatient visits per case Chapter 10 
 Number of hospital admissions per case Chapter 10 
 Distribution of visits according to type of provider  Chapter 10 
 Treatment costs  
 Cost per outpatient visit according to type of 
provider 
Chapter 10 
 Cost per admission according to type of provider Chapter 10 
 Lifetime treatment costs of sequelae Chapter 10 
 Lifetime productivity costs of sequelae Chapter 10 
 
7.3.3 SPECIFIC MODEL FEATURES 
7.3.3.1 Age specific vaccination coverage rates 
The exact age of Hib vaccine administration varies between countries according to their 
routine schedule, but the vaccine is generally delivered at the same time as DTP, polio and 
hepatitis B vaccines. The first dose should be given to children at approximately six weeks 
of age and the interval between doses should be at least one month. Most GAVI-eligible 
countries follow a schedule of 6, 10 and 14 weeks.  When modelling the impact of Hib 
vaccination, it is assumed that Hib vaccine coverage will be similar to DTP coverage in the 
respective country. Coverage rates of DTP are routinely collected by the WHO from all 
member states and they can also be extracted from Demographic Household Surveys 
(DHS) [157].  
The third dose of DTP vaccine (DTP3) is frequently used as an indicator for monitoring 
coverage trends. However, due to drop-out rates in many low-income countries, DTP3 
coverage is often considerably lower than coverage of DTP1 and DTP2. Drop-out rates 
measure the proportion of children who have received the first dose, but are not taken 
Chapter 7: Decision-analytic model 
 
73 
 
back to the health facility for their remaining vaccinations. In some countries, drop-out 
rates are as high as 30% [158].  
Another problem seen in several countries is delayed vaccination until after the 
recommended age according to the schedule. Clark and Sanderson used DHS data for 45 
countries between 1996 and 2005 and generated age-specific coverage data for 217,706 
children [159]. They found the median delay in DTP3 coverage to be 6.2 weeks, but there 
was considerable variation among countries.  
The decision-analytic model incorporates the potential negative impact of drop-out rates 
and delayed vaccination by using age-specific vaccination coverage rates for DTP1, DTP2 
and DTP3 in terms of percent of total coverage achieved by 3, 6, 9, 12, 24, 36, 48 and 60 
months.   
7.3.3.2 Waning immunity 
Vaccination failures are called primary when an immune response does not develop and 
secondary when immunity develops initially, but wanes over time. Since Hib vaccine has 
been shown to wane with time [156], most high- and upper-middle income countries 
provide a booster dose to children at around one year of age. However, a booster dose is 
not provided in GAVI eligible countries, partly due to the increased costs and 
administrative complexity, but also because Hib disease occurs in younger ages in low-
income countries and the need for a booster dose has not yet been demonstrated in these 
settings.  The decision-analytic model incorporates the effect of waning immunity by 
allowing for an annual percentage decrease in vaccine efficacy. 
7.3.3.3 Crude approximation of herd immunity 
Since this is a static model, herd immunity is not explicitly integrated into the model. 
However, a feature has been added to incorporate herd immunity in a crude way to be 
used only in a sensitivity analysis. The user of the model can choose a percentage point for 
expressing the additional percentage population protection. The calculation in the model 
is:  
Total vaccine effect = % direct effect / (1 - % herd effect) 
If the direct effect for instance is calculated as 70% and 20% herd effect is assumed, the 
total vaccine effect is 88%. The % herd effect could for instance be derived from estimates 
generated by Wolfson et al. for the Hib GBD study [58]. The authors reviewed six post-
vaccination surveillance studies from the US, Israel, Denmark, Gambia, Brazil and Cuba 
that had estimated population-level impact. By comparing the overall impact to Hib 
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vaccination coverage rates, a least squares-plural regression line was fitted to the six data 
points to obtain an equation linking population-level coverage among children less than 
five years to the reduction in invasive Hib disease. The overall effect on invasive Hib 
disease was approximately 15-30 percentage points higher than coverage of the third 
dose, and depended on the level of vaccination coverage. A herd immunity threshold (i.e. 
elimination) at around 85% coverage of the third dose was suggested [58]. One advantage 
of the Wolfson et al. method is that it is based on real world experience of several 
countries rather than a modelled estimate. However, as emphasised in a recent paper by 
Jit and Brisson, there are a number of dangers when approximating herd immunity in 
static models [87]. One important limitation is that there are inherent differences between 
populations, such as age structure and the size of risk groups, and this can lead to different 
vaccine effects between countries. Hence, unless there is good real world evidence of the 
magnitude of herd immunity from a similar population, the herd immunity feature of the 
model should not be applied in the base-case analysis, but only used to evaluate different 
“what-if” scenarios.  This is done in Chapter 12. 
7.3.4  VERIFICATION OF MODEL STRUCTURE AND PARAMETER ASSUMPTIONS  
As mentioned above, the model structure was heavily influenced by the methods used for 
generating the Hib GBD estimates. The GBD methods were endorsed by an advisory 
committee in a number of meetings organised by the WHO during 2006-2008 [31, 58, 
160].  Subsequent to this, the decision-analytic model structure and parameter 
assumptions were approved by three advisory groups: 
i. Hib Initiative Steering Committee (2007) 
ii. Technical staff at the Immunization, Vaccines and Biologicals Department in the 
WHO, Geneva (2008) 
iii. The WHO Quantitative Immunization and Vaccines Related Research (QUIVER) 
Advisory Committee (2010) 
7.3.5 SENSITIVITY ANALYSIS 
The model has been designed so that all parameter values can be given a base case value 
and high and low limits. Vaccine efficacy could for instance be assumed to be 90% in the 
base case and 95% and 85% in the high and low limits, respectively. In the model, the high 
and low values can be used for single and multiple univariate sensitivity analysis. In 
addition, probabilistic uncertainty analysis using Monte Carlo simulation can be 
undertaken by attaching a distribution to each parameter. In a single univariate analysis, 
one parameter is varied at a time to assess the impact on the cost-effectiveness ratio. 
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Relevant parameters could for instance be the vaccine price, case fatality from Hib 
meningitis, or perhaps the herd immunity factor explained above.  
Multiple univariate sensitivity analysis and probabilistic Monte Carlo simulation are used 
for assessing the sensitivity of results to the uncertainty of several or all parameter values 
simultaneously. The model has been designed so that a bar chart is easily generated in 
multiple univariate sensitivity analysis showing the varying effects on the ICER when 
choosing the higher and lower values of selected parameters. While several parameters 
should be included simultaneously, it is important to focus only on variables that are 
known to have considerable uncertainty or are of particular interest. If all 250 model 
parameters were included, the diagram would become too difficult to interpret.   
The challenge of not being able to include all parameter uncertainties simultaneously is 
dealt with in the probabilistic Monte Carlo simulation. Here, each parameter is attached a 
statistical distribution and repeated random samples are selected. The outputs of this can 
be used to for estimating a 95% uncertainty interval around the ICER and for designing 
cost-effectiveness acceptability curves.  
The different approaches to sensitivity analysis are explored in Chapter 12. In addition to 
parameter uncertainty it is important to evaluate methodological and structural 
uncertainty of the model, and this is also addressed in Chapter 12.   
7.3.6 DISTRIBUTION OF MODELLING WORK 
Andy Clark and I designed the overall structure of the model in close collaboration. The 
initial starting point was a simpler model I had developed when undertaking Hib vaccine 
cost-effectiveness studies in Russia, Kenya and Indonesia [122, 124, 125]. Andy is a 
mathematical programmer, so he was responsible for setting up the model in Excel, 
developing a user friendly interface, and programming several features using Microsoft 
Visual BasicTM. I provided Andy with formulas for estimating incremental vaccine and 
treatment costs and I quality assured the model during all development steps. This has 
been an iterative process, which started in 2007 and is still ongoing. 
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8 HIB VACCINE EFFICACY2 
 One of the important components of any economic evaluation is to establish the effect of 
the intervention.  As described in the previous chapter, dose-specific vaccine efficacy 
against Hib meningitis, Hib pneumonia and Hib NPNM are input parameters in the 
decision-analytic model. In this chapter, a meta-analysis of randomised controlled trials 
(RCTs) of Hib vaccine is undertaken to determine these parameter values. The chapter 
starts off by explaining the differences between vaccine efficacy and vaccine effectiveness. 
An overview of basic methods of meta-analysis is given in section 8.2, previous meta-
analyses of Hib vaccines are summarised in section 8.3, the new meta-analysis is 
presented in section 8.4, and section 8.5 is a summary of the efficacy values used in the 
economic evaluation.      
8.1 DEFINITIONS OF VACCINE EFFICACY AND EFFECTIVENESS  
Vaccine efficacy is defined as the extent to which the vaccine produces a beneficial result 
under ideal conditions [161]. Clinical vaccine trials generally proceed as Phases I, II, and 
III. The aim of phase I trials is to evaluate vaccine safety, tolerability and immunogenicity 
over different dosages or regimens, and they typically involve between 10 and 100 
participants. Phase II trials usually require between 100 and 500 participants and the aim 
is to characterise safety and immunogenicity in the population in which the vaccine is to 
be used. Vaccine candidates that are safe and immunogenic in Phase I and II trials can be 
taken to phase III trials for evaluating efficacy within the population of interest. These 
trials can involve up to 100,000 people and are usually double-blind and randomized with 
one arm assigned to the vaccine and the other arm to placebo.  
Since phase III clinical trials are undertaken under ideal conditions with the aim of 
optimizing detection of the chosen endpoint, it is not possible to predict accurately the 
level of protection that will be achieved in public health practice where the vaccine may be 
refrigerated inadequately and administered inappropriately or late [162]. Vaccine 
effectiveness is defined as the extent to which a vaccine does what it is intended to do for a 
defined population when deployed in the field [161]. This can be evaluated by a screening 
test study, a cohort study, a case-control study or a phase IV study in which a large 
community is randomised by area to receive the vaccine or not. The screening test study 
                                                             
2 A modified version of this chapter has been published in the Journal of Epidemiology and Infection 
as: Griffiths UK, Clark A, Gessner B, Miners A, Sanderson C, Sedyaningsih ER, Mulholland KE, Dose-
specific efficacy of Haemophilus influenzae type b conjugate vaccines: Systematic review and meta-
analysis, Epidemiol Infect. 2012 May 14:1-13. [Epub ahead of print]. 
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involves comparing vaccine coverage among cases and the general community, without 
reference to the possibility of confounders. Cohort studies use longitudinal data on the 
target outcome, such as Hib disease, for a group of vaccinated individuals contrasted with 
an unvaccinated group. The most common method used for establishing Hib vaccine 
effectiveness is however the case-control method. In this, a group of cases with the target 
outcome, most frequently Hib meningitis, is contrasted with a group of controls who did 
not develop the target outcome [162]. The advantages of a case-control study over clinical 
trials are that i) they involve relatively few participants, ii) the necessary information can 
be obtained within a short time, and iii) their results are based on actual field conditions 
[163]. However, case control studies also have many problems. The most important 
challenge is to produce convincing evidence that the vaccinated and unvaccinated 
populations are sufficiently alike in all relevant characteristics other than vaccination to 
allow a reasonable conclusion that differences between groups are attributable to vaccine 
effectiveness [163].  
Vaccine efficacy estimates from RCTs are used as input parameters in the decision-analytic 
model and not effectiveness. The reason for this is partly because of the many 
methodological limitations of observational studies, but also because the decision-analytic 
model separately includes factors for adjusting vaccine efficacy in line with the situation in 
the respective country, such as timing of vaccination through age-specific coverage rates 
and waning protection.    
8.2 OVERVIEW OF META-ANALYSIS METHODS 
The aim of meta-analysis is to summarize the evidence gathered in several studies on a 
variable of interest, such as vaccine efficacy from RCTs, or an effect measure generated 
from observational studies. Summary estimates should however only be calculated if the 
study specific effects appear to be fairly similar. Hence, trials using Hib pneumonia as an 
outcome measure can for example not be analysed together with trials that measure 
vaccine efficacy against Hib meningitis.  
There are two main ways to summarise the results of different studies [164]. The first is 
known as the fixed effects approach. With this method the pooled effect is calculated as a 
simple weighted average of the separate effects. The underlying assumption is that each 
study measures the same effect, with the weighted average estimating the common effect. 
The relative weight assigned to each study will vary from method to method, but should 
reflect the amount of information that each trial contains. One of the most popular 
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techniques is the Mantel-Haenszel method, in which weights are proportional to the 
inverse variance of each study, which in turn is closely related to the sample size [165]. 
The second method is the random effects approach, in which effects of the individual 
studies are assumed to vary around some overall average treatment effect [165]. The 
studies are viewed as a random sample of a population of studies, in which the true effects 
in each study are assumed to be normally distributed around a ‘global’ mean. The most 
common method for the random effects models is the DerSimonian and Laird approach, 
which estimates the magnitude of heterogeneity and assigns a greater variability to the 
estimate of overall treatment effect to account for any heterogeneity [166].  
There is no consensus regarding the choice of fixed or random effect models, although 
they differ only in the presence of heterogeneity, when the random effect model will 
usually be more conservative [165]. Heterogeneity is defined as the extent to which 
studies disagree on the magnitude of effects, or perhaps even on the direction of effects. 
Possible clinical explanations of heterogeneity are that studies use different eligibility 
criteria for participants, different definitions of disease, different methods of measuring or 
defining exposure, or different variations of treatment [164]. Statistical heterogeneity 
could be caused by publication bias whereby those with dramatic results may more often 
be published or poor methodological quality of some trials. If heterogeneity is detected, 
the random effects model may be most appropriate as this takes explicit account of 
variability in the calculations. If there is little heterogeneity across studies the choice of a 
fixed versus random effects model is not crucial, as the two approaches give very similar 
results [164]. The random effects model should however not be viewed as a panacea when 
heterogeneity is large; it would then be  important to consider whether a single summary 
measure is indeed valid [164]. Instead, the reasons for the differences between trial 
results should be investigated and a pooled estimate not reported.  
Heterogeneity can be detected by comparing results of fixed and random effects models. If 
the two approaches lead to different results, heterogeneity could be a problem. Relatively 
simple tests of heterogeneity are also available, mostly based on chi-squared or F 
statistics. The null hypothesis is that there is no significant heterogeneity among study 
results. Hence, if the test is statistically significant, the between trial variability is more 
than would be expected by chance alone. A cut-off significance level of 0.10 is normally 
used. The chi-squared statistics can be supplemented by the I2 statistics to quantify 
heterogeneity [167]. The I2 is the percentage of variation attributable to heterogeneity and 
lies between 0% and 100%. A value of 0% indicates no observed heterogeneity and larger 
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values show increasing heterogeneity. Higgins has tentatively suggested that low I2 values 
are between 25%-50%, moderate are between 50% and 75%, and high are above 75% 
[167]. 
Assessment of risk of bias is a crucial part of meta-analysis, both as an approach to 
investigating causes of heterogeneity and also for assessing the validity of the pooled 
estimate. The Cochrane Collaboration has developed a Risk of Bias Tool to assess internal 
validity of randomized controlled trials [168]. The tool was developed over several years 
as a way to address concerns about the existing methods of assessing study quality in 
Cochrane reviews. The Risk of Bias Tool has six domains: 
i. Sequence generation 
ii. Allocation concealment 
iii. Blinding of participants, personnel and outcome assessors 
iv. Incomplete outcome data 
v. Selective outcome reporting 
vi. Other sources of bias  
Use of the tool is demonstrated in the new Hib vaccine efficacy meta-analysis in section 
8.4.  
8.3 PREVIOUS META-ANALYSES OF HIB VACCINE EFFICACY AND EFFECTIVENESS STUDIES 
The first meta-analysis of Hib conjugate vaccine efficacy studies was published by Stieb 
and colleagues in 1990 [169], but at that time only two efficacy trials had been completed; 
both of the PRP-D vaccine, in Finland and Alaska, respectively. A Cochrane systematic 
review and meta-analysis of Hib vaccine efficacy was published around the year 2002, but 
this has since been removed from the Cochrane system due to lack of updates and is no 
longer available for reference.  
A meta-analysis of Hib vaccine efficacy trials was published by Obonyo and Lau in 2006 
[170]. Three databases were searched in this review: Medline and EMBASE for the period 
1990 to June 2005 and the Cochrane registry of controlled trials from year 2000. The 
authors included published randomized or quasi-randomized studies that reported the 
efficacy of Hib vaccination compared to placebo. A total of eight studies were included; one 
PRP-OMP trial, one HbOC trial, two PRP-D trials and four PRP-T trials [170]. Summary log 
odds ratios were obtained using a random-effects model. Subgroup analysis was 
performed to compare the efficacy of vaccination in developing versus developed 
countries, according to the type of conjugate vaccine, age of children at vaccination, 
number of doses received, baseline risk, and HIV status. While it is stated in the methods 
Chapter 8: Hib vaccine efficacy 
 
80 
 
that the potential for bias in results was evaluated, these issues were not reported in the 
results section. The protective efficacy of three doses of Hib conjugate vaccine was found 
to be 84% against invasive Hib disease, 75% against Hib meningitis, and 69% against Hib 
pneumonia. The efficacy of one and two doses was found to be 72% and 82%, respectively 
[170]. However, not many details were given about the dose-specific estimates. As will be 
shown in the new meta-analysis, different trials use different clinical endpoints and not all 
trials report efficacy according to the number of doses, so there is a need to explain which 
studies are used for which estimates, and what weight each individual study contributes to 
the pooled estimate. 
Observational studies for assessment of Hib vaccine effectiveness were recently evaluated 
by O’Loughlin et al. in a systematic review and meta-analysis [171]. A total of 25 studies 
reporting Hib vaccine effectiveness were included. Fourteen of these were case–control 
studies, three used the surveillance/screening method, two calculated the ratio of 
observed cases (regardless of vaccination history) to expected cases (based on 
assumptions made using pre-vaccine surveillance data), and one study used a vaccine 
probe study design. One of the conclusions from the review was that the effectiveness of 
Hib vaccine has now been well documented and the need for more case-control studies is 
minimal [171]. 
Theodoratou et al. undertook a systematic review and meta-analysis of RCTs and 
observational studies to evaluate the effect of Hib and pneumococcal vaccines on 
childhood pneumonia incidence, severe morbidity and mortality [172]. It was concluded 
that no studies were available to determine the effect of Hib vaccine on childhood 
mortality and that the efficacy against radiological pneumonia was the best approximation 
to use for severe pneumonia [172].    
8.4 EFFICACY OF HIB VACCINES: SYSTEMATIC REVIEW AND META-ANALYSIS 
8.4.1 OBJECTIVES 
The objectives of the new systematic review and meta-analysis are:  
1. To update the literature review of RCTs published by Obonyo and Lau. 
2. To use data from identified studies to derive quantitative estimates of dose-specific 
Hib vaccine efficacy in a way that that can be used be in the decision-analytic model. 
3. To determine whether there is heterogeneity in the study results and if so, to examine 
sources of heterogeneity, including the risk of bias resulting from study design. If 
appropriate, stratify results based on the findings. 
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4. To assess whether there are significant differences in efficacy between the different 
available conjugate vaccines. 
The main differences between the current study and the study by Obonyo and Lau are: 
 Only Hib conjugate vaccines that are currently available have been included in the 
present study. The PRP-D Hib vaccine trial studies are excluded. 
 The literature review is updated since year 2005 when the search by Obonyo and Lau 
ended. 
 The new review includes supplementary information received directly from trial 
authors. 
 The new study includes more detailed dose-specific analyses. 
 A risk-of-bias analysis is performed using the Cochrane Risk of Bias Tool. 
8.4.2 METHODS 
The meta-analysis was undertaken according to recommendations of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [173].  
8.4.2.1 Search strategy and study selection 
Studies were identified from the Cochrane Controlled Trials Register (CCTR) using the 
search term “haemophilus vaccine” in March 2011. The CCTR is a bibliographic database 
of controlled trials systematically identified by the contributors to the Cochrane 
Collaboration. The researchers have identified CCTR records through a combination of 
hand- and database searching that include all those indexed as controlled trials in 
MEDLINE and EMBASE [174]. When looking only for controlled trials there is thus 
generally no immediate need to also search MEDLINE and EMBASE, as these databases are 
already included in the CCTR. However, to quality check the search, the CCTR results were 
compared with a similar search in MEDLINE for 2005. Reference lists in identified papers 
were checked and experts in the field were contacted to confirm that no studies had been 
missed.     
Studies were eligible for inclusion if they compared a commercially available Hib vaccine 
with placebo, if clinical endpoints were reported, and if participants had been allocated 
prospectively using random or quasi-random allocation. To maximise the amount of data 
available for analysis, quality measures were not used as exclusion criteria. There were no 
language restrictions.  
One author kindly provided primary data from his trial. In the paper by Gessner et al., 
results were only given by comparing disease incidences per 100,000 child years in the 
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vaccine versus the placebo group. However, for the vaccine efficacy estimates, the number 
of Hib disease cases in each group according to syndrome and according to number of 
vaccine doses received is needed, as well as the total number of children in each group. I 
received the necessary primary data from Dr. Brad Gessner from Association pour l’Aide a 
la Medicine Preventive (AMP) in Paris, via email.  
The data extracted included setting, type of Hib vaccine, schedule, number of Hib disease 
cases according to study group, and total numbers of children in both groups.  
8.4.2.2 Outcome measures 
The choice of primary outcome measure is one of the most critical aspects of a RCT. 
Vaccines are normally evaluated against disease proven to be due to the pathogen in 
question [175]. For diseases that can be caused by a variety of different pathogens, which 
include all Hib diseases except epiglottitis, it is common practice to look for protection 
against microbiologically proven disease [175]. As explained in Chapter 2, this is in 
particular feasible for Hib meningitis cases, as Hib can be detected from CSF when optimal 
laboratory procedures are followed.  However, the aetiology of childhood pneumonia is 
intrinsically difficult to determine [176]. The only method which would reliably determine 
the aetiology is culture of lung aspirate, but this procedure is invasive and not always 
ethically feasible in an RCT. Moreover, selection bias will occur if antibiotics are commonly 
used before seeking health care as this will markedly reduce the sensitivity of the lung 
aspirate test [177]. Blood culture is only useful when pneumonia is associated with 
bacteraemia, which is only a fraction of cases. The bacterial yield from blood culture in 
patients with pneumonia has ranged from 10% to 30% [178]. Hence, since there are 
currently no validated and specific methods for confirming the pathogen-specific bacterial 
aetiology of pneumonia, several non-specific pneumonia endpoints were used in the 
studies.    
The following outcomes were included in the meta-analysis: (i) confirmed invasive Hib 
disease (ii) confirmed Hib meningitis (iii) confirmed Hib pneumonia, (iv) clinical 
meningitis, (v) radiologically (or chest x-ray) confirmed pneumonia, (vi) hospitalized 
pneumonia and (vii) clinical pneumonia. In addition, efficacy estimates were calculated 
according to the number of doses of Hib vaccine received as: 
i. Only one dose 
ii. Only two doses 
iii. Three doses 
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8.4.2.3 Statistical analysis 
Trial results were expressed as vaccine efficacy with 95% confidence intervals. Vaccine 
efficacy is defined as 100% x (1- relative risk).  Relative risks were calculated as: 
               
                                 
                              
 
       
       
 
where,  
a = disease events in Hib vaccine group  
b = no disease events in Hib vaccine group 
c = disease events in placebo group 
d = no disease events in placebo group   
Since Hib disease is a relatively rare event and the vaccine is highly efficacious, some trials 
report zero events in the vaccine group for certain outcome measures. In these cases, the 
relative risk ratio is zero and the standard error cannot be estimated. For meta-analysis, 
this is a problem because the inverse variance is commonly used as the study weight. A 
standard way to deal with this is to add 0.5 to each cell counts to avoid division by zero 
errors [165], and this method was use in the analysis.  
A random effect model was used. Heterogeneity was assessed using the chi-squared test 
with a p-value of <0.10 indicating statistical significance.  All statistical analyses were 
performed in STATA (version 11). 
8.4.3 RESULTS   
8.4.3.1 Characteristics of eligible trials 
The search strategy yielded 493 references (Figure 8.1). After removing duplicates, 474 
titles and abstracts were screened and 459 papers excluded. The most common reason for 
exclusion at this stage was that the study reported only safety and immunogenicity of the 
vaccine with no clinical endpoints.  
Fifteen papers were retrieved for full-text review and seven of these were excluded. One of 
the excluded studies was a large, Finnish prospective study where children born on even 
numbered days received HBoC vaccine and those born on uneven numbered days received 
PRP-D vaccine [179]. Vaccine efficacy was estimated as 87% (95% CI, 69%, 96%) for the 
PRP-D vaccine and as 95% (95% CI, 76%, 99%) for the HBoC vaccine. These efficacy  
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Figure 8.1: Study selection for Hib vaccine efficacy meta-analysis 
 
  
 
493 articles identified from 
Cochrane Clinical Trial Registry  
 
474 articles screened after  
duplicates removed  
 
459 articles excluded 
- 268 no clinical endpoints 
- 147 not Hib 
- 17 adult vaccination 
- 13  polysaccharide vaccine 
- 12 reviews  
- 2 PRP-D vaccine trials 
 
15 articles assessed for 
eligibility  
7 articles excluded 
- 1 letter 
- 1 carriage study 
- 1 PRP-D vaccine trial 
- 1 descriptive study 
- 2 case-control studies 
- 1 HBoC study without a 
prospective control group 
 
8 articles included in 
meta-analysis 
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estimates were generated by comparing the number of Hib disease cases during the study 
period with the number that would have been expected based on historical, routine 
surveillance data. Hence, the comparison group was not based on prospective data and the 
study was excluded for this reason. 
Characteristics of the eight included studies are seen in Table 8.1. The PRP-T vaccine was 
evaluated in six of the eight papers, the HbOC vaccine in one study, and the PRP-OMP 
vaccine in one paper. The studies by Lagos and Levine used data from the same trial. Three 
of the studies were undertaken in USA and the remaining in England, Chile, Gambia and 
Indonesia. One of the US studies was conducted in a Navajo Indian reservation, targeting a 
group with one of the highest Hib disease incidences in the world [180]. In this trial only 
two doses of Hib vaccine were administered while three doses were evaluated in the 
seven other studies. In all the studies, follow-up stopped after a specified time period. The 
study by Booy had the shortest follow-up time and the study by Mulholland the longest, 
with the oldest children being 18 and 30 months, respectively, when the studies ended. 
Two of the eight studies were not included in the meta-analysis by Obonyo and Lau. In 
their analysis, only the primary Chilean study by Lagos et al. was included while no 
mention was made of the study by Levine et al. The objective of Levine’s study was to 
estimate Hib vaccine efficacy on clinical pneumonia and this endpoint was not part of the 
Obonyo and Lau meta-analysis. The Indonesian study by Gessner et al. is the only study 
published since 2005 when Obonyo and Lau’s search ended. This study was a so-called 
vaccine probe study where a randomized controlled trial design with a vaccine of known 
efficacy is used to determine the vaccine preventable burden of disease. By comparing 
vaccinated and non-vaccinated groups of children, Gessner and colleagues aimed to 
estimate the incidence of vaccine preventable Hib disease in the Indonesian island of 
Lombok [181]. The study, which was funded by USAID, the Gates Foundation, PATH and 
Aventis Pasteur, was undertaken as a response to the persisting uncertainty about Hib 
disease burden in Asia [47].       
8.4.3.2 Outcome measures used in the trials 
The six different outcome measures used in the trials are summarized in Table 8.2 and the 
case definitions in Table 8.3. The studies by Booy, Levine and Vadheim did not report 
vaccine efficacy for less than three vaccine doses. 
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Table 8.1: Characteristics of studies included in the meta-analysis 
First author 
[ref] 
Year 
recruitment 
started 
Location 
Type of Hib 
vaccine 
Vaccine 
manufacturer 
Hib vaccine  
schedule  
(weeks) 
No. of  
children  
enrolled  
in study 
Max age when 
follow-up ended 
(months) 
Black [182] 1988 California, USA PRP-HbOC Praxis Biologics 8, 16, 24 61,080 24 
Booy [183] 1991 Oxfordshire, England PRP-T Pasteur Merieux 8, 12, 16 27,860 18 
Gessner [181] 1998 Lombok, Indonesia PRP-T Aventis Pasteur 6, 10, 14 55,073 24 
Lagos [184] 1992 Santiago, Chile PRP-T Pasteur Merieux 8, 16, 24 76,533 28 
Levine [185] 1992 Santiago, Chile PRP-T Pasteur Merieux 8, 16, 24 21,420 23 
Mulholland [186] 1993 Western region of Gambia PRP-T Pasteur Merieux 8, 12, 16 42,848 30 
Santosham [180] 1988 Navajo Indian Reservation, USA PRP-OMP Merck 6, 12 5,166 23 
Vadheim [187] 1989 California, USA PRP-T Pasteur Merieux 8, 16, 24 10,317 24 
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Table 8.2: Outcome measures available in the studies included in the meta-analysis 
Author 
(reference) 
Confirmed Hib 
invasive 
disease 
Confirmed Hib 
meningitis 
Confirmed Hib 
pneumonia 
Clinical 
meningitis 
Radiological 
pneumonia 
Clinical 
pneumonia 
Hospitalised 
pneumonia 
No. of doses 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
Black [182] x x x                 
Booy [183]   x                 
Gessner [181]    x x x    x x x x x x x x x x x x 
Levine [185]             x      x 
Lagos [184]   x                 
Mulholland [186] x x x x x x x x x    x   x    
Santosham [180] x x  x x  x x            
Vadheim [187]   x                 
No. of studies 3 3 5 3 3 2 2 2 1 1 1 1 1 1 3 1 1 2 1 1 2 
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Table 8.3: Hib disease case definitions used in the Hib vaccine RCTs 
Outcome measure Definition 
Confirmed Hib invasive disease 
Clinical signs of any invasive Hib disease and Hib isolated 
from CSF, blood or other sterile body fluids 
Confirmed Hib meningitis 
Clinical signs of meningitis and Hib isolated from CSF, blood 
or other sterile body fluids 
Confirmed Hib pneumonia 
Clinical signs of pneumonia and Hib isolated from CSF,  
blood or other sterile body fluids 
Clinical meningitis 
Probable: CSF visibly cloudy or a white-blood-cell count > 
10 x 106/L with >80% neutrophils, glucose <2·22 mmol/L, 
or protein >1 g/L 
Possible: CSF white-cell count of >10 x 106/L 
Hospitalised: As determined by the admitting physician, but 
generally based on the presence of convulsions with fever 
Radiological pneumonia 
Clinical signs of pneumonia and substantial alveolar 
consolidation or pleural effusion on chest X-ray 
Clinical pneumonia 
WHO defined ALRI: Respiratory rate ≥ 50 per min for 
children 2-12 months and ≥ 40 per min for those aged 12-
24 months  
Hospitalised pneumonia 
Levine: Five different pneumonia ICD9-codes 
Gessner: Hospitalised with severe clinical pneumonia 
diagnosis 
ALRI: Acute Lower Respiratory Infection 
The outcome measure used by most of the studies was invasive Hib disease, defined as 
“isolation of Hib from a normally sterile body site”. While all types of Hib diseases are 
included within the invasive disease group, meningitis is likely to be the most frequent 
type of disease syndrome detected. In the study by Gessner, the only outcome measure 
that included etiologic confirmation was Hib meningitis. This endpoint could also be 
extracted from the studies by Mulholland and Santosham because cases were summarized 
according to disease syndromes in these two papers. 
Four different types of pneumonia outcomes were included in the studies. Confirmed Hib 
pneumonia was reported by Mulholland and Santosham, along with the other types of 
invasive Hib disease detected (Table 8.2). However, as mentioned above, because only a 
small proportion of Hib pneumonia is bacteraemic, this outcome measure will only 
capture a fraction of all Hib pneumonia in a study population. 
Clinical, non-specific pneumonia outcome measures were included in the RCTs from Chile, 
Gambia and Indonesia. As explained in Chapter 2, pneumonia disease incidence is 
considerably higher in low-income compared to high-income countries, so non-specific 
pneumonia endpoints were not relevant to include in the RCTs from the USA and England. 
However, in low-income countries prevention of pneumonia might be the primary 
argument for introducing Hib vaccine, so it was crucial to try and measure the efficacy 
against pneumonia in these countries. 
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Radiological confirmed pneumonia was used in the studies by Gessner, Levine and 
Mulholland, clinical pneumonia by Gessner and Mulholland, and hospitalized pneumonia 
by Gessner and Levine. All of these outcome measures pose a number of definition 
problems leading to risk of heterogeneity among the studies.   
Radiological confirmed pneumonia was in all three studies defined as pneumonia with 
consolidation or pleural effusion on the chest X-ray. The studies in Gambia and Chile were 
the first studies in the world to use this outcome measure, and their results lead to a WHO 
working group for using chest radiographs as a benchmark for evaluating the efficacy of 
Hib and pneumococcal vaccines [188, 189]. Hence, these specific WHO definitions were 
used in the Indonesia study. However, in spite of a considerable amount of work to 
standardize the definition, it is still common that radiologists and clinicians, and even 
radiologists among themselves, disagree on the presence or absence of infiltrates in 
paediatric chest X-rays [176].  
Hospitalised pneumonia was used as an outcome measure in the studies from Chile and 
Indonesia. In the study from Chile, five different pneumonia ICD-codes were abstracted 
from patient records while in Indonesia the definition was hospital admission due to 
severe pneumonia. These endpoints may be subject to bias because pneumonia is not easy 
to distinguish from other types of Acute Lower Respiratory Infections (ALRIs), such as 
bronchitis, and lower and upper respiratory infections can also be difficult to differentiate. 
Hence, the pneumonia diagnosis given by hospital clinicians may not be accurate. 
Moreover, this endpoint could cause heterogeneity among study sites due to different 
hospital referral patterns, with some settings admitting children with less severe 
pneumonia than others.    
Clinical pneumonia was evaluated by Gessner and Mulholland, defined according to the 
WHO definition of ALRI in both studies [190]. While there are also caveats with regard to 
correct clinical diagnosis for clinical pneumonia, this is likely to be less than for 
hospitalized pneumonia. 
8.4.3.3 Methodological quality of trials 
The domains specified in Cochrane’s Risk of Bias tool are summarized in Table 8.4. The 
only individual RCTs among the included studies were the PRP-T trials by Mulholland and 
Vadheim. However, the Vadheim study ended prematurely due to inclusion of the HbOC 
vaccine in the US routine vaccination schedule while the Vadheim study was ongoing. 
Hence, the sample size of this study ended up being too small 
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Table 8.4: Methodological quality of included trials: Assessment based on Cochrane’s risk of bias tool 
First author 
[ref] 
Unit of 
randomisation 
Sequence 
generation 
Blinding Allocation concealment Outcome reporting 
Black [182] Individual Placebo group was refusers and 
children born on the first 5 days 
of a month. 
No, but microbiologists 
performing tests for Hib were 
unaware of vaccination status.   
NA Enhanced surveillance to detect all Hib 
patients treated in the study area. 
Booy [183] Cluster Hib vaccine districts 
determined from availability of  
computer systems   
No, but microbiologists 
performing tests for Hib were 
unaware of vaccination status.   
NA Enhanced surveillance to detect all Hib 
patients treated in the study area. 
Gessner [181] Cluster Random  Double blinding Vaccine vials identical except 
four colour codes; two for Hib 
and two for placebo. Code in a 
locked vault. 
Education for diagnosis and referral. Young 
women in every village to identify children 
with pneumonia and get them to hospital. 
Families reimbursed treatment costs. 
Lagos [184] Cluster Random  No, but microbiologists 
performing tests for Hib were 
unaware of vaccination status.   
NA Active surveillance at 11 hospitals in 
Santiago. Bacteriology laboratory reports 
reviewed weekly.  
Levine [185] Cluster Random  No   NA Retrospective review of five ICD-9 
pneumonia discharge diagnoses.  
Mulholland 
[186] 
Individual Random  Double blinding Five vaccine vial codes used 
for Hib and the five others for 
placebo. Only safety 
monitoring group knew the 
code. 
Study children presenting to health centres 
due to any illness referred to study 
physician. 
Santosham 
[180] 
Cluster Random  Double blinding Vaccine and placebo vials had 
similar appearances. Code not 
known until end of study.  
Active and passive surveillance throughout 
study area. 
Vadheim 
[187] 
Individual Random  Double blinding No details given on method 
used. 
Active and passive surveillance throughout 
study area.  
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for vaccine efficacy estimates to be presented in the paper [187]. The study by Black and 
colleagues was a controlled, individual trial in which unvaccinated children were either 
those who had refused to participate or children enrolled in the trial who were born on 
the first five days of any month [191].  
A cluster design was used in three of the trials. In the studies by Gessner and Santosham, 
vaccine allocation among clusters was randomly and blindly determined.  However, in the 
study by Booy, choice of Hib vaccine clusters was dictated by availability of computer 
systems needed for planning of a new vaccine schedule [183]. The study from Chile used 
prospective, selective vaccination where one set of 36 health centres delivered combined 
PRP-T/DTP vaccine and another set of 35 centres administered only DTP vaccine.  The 
two sets of health centres were assembled so that they were similar in geographic 
distribution and population size served, and it was randomly decided which of the two 
sets should receive the PRP-T/DTP vaccine.   
From reviewing the five domains, it can be concluded that risks of bias due to 
randomization, sequence generation and allocation concealment were relatively low in all 
the studies.  Even though two studies were not randomised, it seems unlikely that the 
results would be biased for this reason. However, four of the studies were not blinded and 
this leads to risk of bias. In the three studies where confirmed Hib disease was the only 
endpoint, the risk of bias would most likely be low because the microbiologists 
undertaking the tests for Hib were not aware of the child’s vaccination status. However, in 
the Levine study, radiological and hospitalised pneumonia were the chosen endpoints and 
assessments of these were made from hospital records of children with known vaccination 
status, leading to moderate risk of bias. With regard to inclusion of all randomized 
participants, all the studies suffer from high risk of bias due to the inherent difficulties of 
diagnosing Hib. Even in the studies with enhanced surveillance, it is possible that not all 
Hib cases were detected. The risk of detection bias is especially large in the three studies 
with non-specific (or all-cause) pneumonia as an outcome. 
An additional risk of bias in the studies using non-specific pneumonia outcomes is that 
estimated Hib vaccine efficacy will vary with the relative proportion of Hib pneumonia 
occurring during the study period. Since many of the other pathogens that cause 
pneumonia are known to be seasonal, such as for instance respiratory synical virus (RSV) 
or influenza, this could be a problem. Hib vaccine efficacy against clinical pneumonia 
would for instance be less in a year with a RSV pneumonia outbreak than in a year with 
low RSV incidence [192]. Since all the trials lasted for more than one year, seasonal 
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fluctuations might have been evened out to some extent, but the risk of this bias is 
apparent. This is also an important limitation to bear in mind when generalising the 
efficacy values to other settings where the relative proportion of Hib pneumonia may be 
different.  
The risk of publication bias is an additional factor to assess in any meta-analysis [193]. 
This relates to the fact that studies giving positive results are more likely to be published 
than studies in which the intervention has little or no effect. If this is the case, the pooled 
meta-analysis estimate would give a positively biased result. However, for vaccine trials 
risk of publication bias must be considered low.  These are large trials involving thousands 
of children and lasting several years and there is strong pressure on investigators and 
vaccine manufacturers to publish the results. It is thus highly unlikely that any Hib vaccine 
phase III trial has taken place without being published.   
8.4.3.4 Vaccine efficacy compared to placebo 
The Hib vaccine efficacy estimates for five different endpoints are seen in Figures 8.2 – 8.4. 
The pooled efficacy estimate against confirmed, invasive Hib disease following three, two 
and one dose are 93% (95% CI 83, 97), 92% (95% CI 69, 98) and 59% (95% CI -20, 86), 
respectively (Figure 8.2). There is no heterogeneity among the studies for three and two 
doses and only low heterogeneity for one dose (I2 = 20.7%), which is attributable to the 
Santosham study of the PRP-OMP vaccine reporting considerably higher efficacy than the 
three other studies. The pooled estimate of the PRP-T and the HbOC trials, and excluding 
the PRP-OMP trial, is 47% (95% CI -28, 70) with no heterogeneity (I2=0.0%).  
For confirmed Hib meningitis there is no heterogeneity among any of the dose-specific 
estimates, but due to the relatively small sample sizes, the confidence intervals are wide 
for one and two doses (Figure 8.3). Moreover, since the Santosham trial only estimated 
one and two dose efficacy, the pooled value for three doses (88% (95% CI 46, 97)) is less 
than for two doses (92%, 95% CI 37, 99). The pooled one-dose estimate is 62% (95% CI -
29, 89).  
Data on confirmed Hib pneumonia were only available from the Mulholland and 
Santosham studies, and Santosham did not identify any cases following two doses. The 
Mulholland midpoint efficacy estimates of both two and three doses were 91% (95% CI -
66, 99) and the pooled estimate between Mulholland and Santosham following one dose 
was 67% (95% CI -44, 93).   
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Vaccine efficacy against radiological pneumonia with three doses was 22% in both the 
Levine and Mulholland studies, but the result was negative in the study by Gessner, 
causing large heterogeneity (I2=64%) (Figure 8.4). Hence, the pooled estimate has limited 
validity. The pooled estimate without the Gessner study was 22% (95% CI 6, 35) with no 
heterogeneity (I2=0.0%).        
Hib vaccine efficacy against hospitalised pneumonia following three doses of vaccine was 
reported by Gessner and Levine (Figure 8.4).  There is however also large heterogeneity 
between these two studies and the pooled estimate is not meaningful. While Levine found 
a vaccine efficacy of 26% (95% CI 7, 41), Gessner only estimated it as 2% (95% CI -8, 10).  
Clinical pneumonia efficacy after three doses was reported by Gessner and Mulholland and 
found to be 4% (95% CI 1, 7) in both studies (Figure 8.4). However, due to the larger 
number of cases detected in Indonesia compared to the Gambia, the weight of the Gessner 
study in the pooled estimate is as high as 92.3%.   
Clinical meningitis was only included in the study by Gessner and three different types 
were included; probable, possible and hospitalised meningitis (Table 8.5). There were 
consistently less cases in the vaccinated compared to the placebo group and two of the 
efficacy estimates were significant at the 95% level. This indicated that, in the Indonesian 
environment, many cases of Hib meningitis were reaching the health facility, but they 
either did not have a lumbar puncture or lumbar puncture was done and found to have the 
microscopic appearance of meningitis, but for reasons of specimen handling or 
microbiological procedures, Hib was not cultured.  
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Figure 8.2: Hib vaccine efficacy against confirmed invasive Hib disease 
 
Figure 8.3: Hib vaccine efficacy against confirmed Hib meningitis 
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Figure 8.4: Hib vaccine efficacy against non-confirmed pneumonia 
 
Table 8.5: Vaccine efficacy against clinical meningitis in Lombok, Indonesia 
Outcome 
measure 
No. of 
doses 
Cases of Hib disease /  
no. of children with no 
event 
Vaccine 
efficacy 
95% CI P-
value 
  Hib Placebo  Low High  
Probable bacterial 
meningitis 
1 1/3989 6/3816 84% -32% 98% 0.06 
2 5/4006 6/3963 18% -170% 75% 0.77 
3 9/20152 20/19147 57% 6% 81% 0.04* 
Possible bacterial 
meningitis 
1 3/3989 9/3819 68% -18% 91% 0.09 
2 6/4006 6/3963 1% -206% 68% 1.00 
3 17/20152 34/19144 53% 15% 73% 0.01* 
Hospitalised 
meningitis 
1 21/3993 34/3824 41% -2% 66% 0.06 
2 33/4010 41/3971 20% -26% 49% 0.35 
3 118/20144 121/19131 7% -19% 28% 0.56 
*Significant at the 95% level using Fisher’s exact t-test. 
  
.
.
.
Hospitalised
Gessner
Levine
Subtotal  (I-squared = 80.6%, p = 0.023)
Radiological
Gessner
Levine
Mulholland
Subtotal  (I-squared = 68.4%, p = 0.042)
Clinical
Gessner
Mulholland
Subtotal  (I-squared = 0.0%, p = 0.946)
Author
Indonesia
Chile
Indonesia
Chile
Gambia
Indonesia
Gambia
Country
0.98 (0.90, 1.08)
0.74 (0.59, 0.93)
0.87 (0.66, 1.15)
1.10 (0.91, 1.33)
0.78 (0.57, 1.07)
0.78 (0.62, 0.98)
0.89 (0.70, 1.14)
0.96 (0.93, 1.00)
0.96 (0.85, 1.08)
0.96 (0.93, 0.99)
RR (95% CI)
926/19934
131/11146
1057/31080
221/20102
72/11146
132/17794
425/49042
4957/18762
526/17794
5483/36556
Vaccine
Events,
893/18916
163/10274
1056/29190
191/19104
85/10274
170/17919
446/47297
4870/17748
570/18489
5440/36237
Control
Events,
57.12
42.88
100.00
37.83
27.41
34.75
100.00
92.26
7.74
100.00
Weight
%
2 (-8, 10)
26 (7, 41)
13 (-15, 34)
-10 (-33, 9)
22 (-7, 43)
22 (2, 38)
11 (-14, 30)
4 (0, 7)
4 (-8, 15)
4 (1, 7)
efficacy (%)
Vaccine
favours vaccine   
1.01 10
Chapter 8: Hib vaccine efficacy 
96 
 
8.4.4 DISCUSSION 
All the studies demonstrated high vaccine efficacy against confirmed invasive Hib disease 
following two and three doses (93% and 92%), and there was no heterogeneity in the 
pooled estimate. With one dose, the pooled estimate was 59% (95% CI -20, 86) and there 
was only low heterogeneity. Hence, the evidence on Hib vaccine efficacy against invasive 
disease is convincing and robust for all dose regimens. This conclusion is similar to the 
findings of O’Loughlin and colleagues in their meta-analysis of  observational studies 
[171]. The pooled vaccine effectiveness estimate against invasive Hib disease from three 
case-control studies was 95% (95% CI 82, 99) after three doses and 92% (95% CI 81, 97) 
following two doses. In the meta-analysis of RCTs by Obonyo and Lau, vaccine efficacy 
against invasive Hib disease after three doses was only 84% (95% CI 69, 92). The reason 
for the higher pooled estimate in the new analysis is partly the exclusion of the PRP-D 
trials, but also that Obonyo and Lau combined all doses into one analysis, so that children 
receiving only one dose, only two doses and all three doses were included in the same 
calculation. 
The evidence for confirmed Hib meningitis and confirmed Hib pneumonia is less robust 
because few studies report on these outcomes, so the pooled estimates are based on small 
sample sizes, which give wide confidence intervals. As both diseases are contained within 
the overall group of invasive Hib disease, these efficacy estimates should be used instead 
of seeking to categorise according to invasive Hib disease type.  
As expected, the strength of the evidence of vaccine efficacy against the three, non-specific 
pneumonia outcomes is less than for confirmed Hib disease. For hospitalised pneumonia 
the heterogeneity is too large for the efficacy estimate to be meaningful. The large 
heterogeneity between the Indonesian and Chilean studies may partly be due to different 
case detection methods. Pneumonia detection in Indonesia was based on individual 
presentation for medical care, but supported by village health workers whose task was to 
identify children in the community with possible severe respiratory disease and refer 
them for treatment. By contrast, cases were retrospectively identified from patient 
records in Chile. Another possible explanation is differences between the two sites in the 
distribution of non-Hib pneumonia etiologies.  For example, a large burden of RSV 
infection in one site will lower the measured vaccine efficacy even if the two sites have 
similar vaccine-preventable Hib disease incidences, as has been described by Gessner 
[192]. Consequently, for clinical outcomes (rather than microbiologically confirmed), 
vaccine preventable disease incidence may be a better measure than vaccine efficacy and 
effectiveness. 
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The Indonesian trial by Gessner did not detect an impact on radiological pneumonia [181]. 
The study authors have proposed several possible explanations for why pneumonias with 
lobar infiltrate or pleural effusion were not preventable with Hib vaccine. First, Hib may 
not be an important cause of pneumonia in Indonesia; this seems unlikely, since the 
vaccine preventable disease incidence measured against all severe or clinical pneumonias 
was as high or higher than in other studies (24). Secondly, some characteristic of children 
in South East Asia could lead to a different pneumonia presentation; this also seems 
unlikely since many children presented with a lobar infiltrate meeting the WHO case 
definition. Lastly, and perhaps most likely, early antibiotic use through self-medication or 
early identification and intervention could have modified the evolution of Hib pneumonia 
[192].  
The two remaining studies by Mulholland (Gambia) and Levine (Chile) found a remarkably 
similar result of 22% vaccine efficacy against radiological pneumonia, in spite of different 
definitions used (the 95% CIs were -7, 41 in the Chilean study and 2, 38 in the Gambian 
study). In Gambia, standardized radiology readings were used while in Chile radiology 
reports were searched for key words, such as “alveolar consolidation”. The 22% estimate 
is however less than in three case-control studies from Bangladesh, Dominican Republic 
and Columbia, which  reported effectiveness against radiological pneumonia as 32%, 31% 
and 55%, respectively [171].  In a study by Theodoratou et al., these three studies were 
combined with the RCTs of Gessner, Levine and Mulholland and a pooled vaccine 
effectiveness estimate of 18% against radiological pneumonia was generated [194]. There 
was considerable heterogeneity in the pooled estimate, but this problem was not 
addressed [194].   
It must be emphasised that the radiological pneumonia outcome measure imposes a large 
risk of bias due to the many definition problems of reading chest x-rays. This was in 
particular demonstrated in the case-control study from Bangladesh where chest 
radiographs were taken of 2,679 children with clinical pneumonia [195]. According to per-
protocol readings, 17.7% cases were identified as having radiologically confirmed 
pneumonia. However, when the radiographs were read by a WHO panel, it was concluded 
that 26.0% were radiologically confirmed. Only 13.2% of cases were radiologically 
confirmed by both per protocol readings and WHO readings [195]. It is thus difficult to 
determine which estimate to use, and the choice greatly affects the vaccine effectiveness 
estimate. When using the per protocol readings, the preventable fraction of radiological 
confirmed pneumonia was 17% following at least 2 doses of Hib vaccine. When the WHO 
readings were used, the vaccine was associated with 15% protection, and when the subset 
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considered positive by both sets of readings was used the vaccine offered 34% protection 
[195].  
The pooled vaccine efficacy estimate against clinical pneumonia appears robust as there is 
no heterogeneity between the two studies from Gambia and Indonesia. It is noteworthy 
that the two studies found such comparable results as there is a high risk of bias with this 
non-specific outcome measure. However, with only two studies the evidence is limited and 
as discussed earlier, caution should be taken when generalising to other settings due to 
potential fluctuations in clinical pneumonia aetiology between countries and years.      
Vaccine efficacy data against all non-specific outcomes must in general be interpreted 
cautiously. While vaccine efficacy against microbiologically confirmed outcomes reflects 
the ability of the vaccine to induce protective immunity against infection and disease, 
vaccine efficacy against non-specific outcomes reflects vaccine performance in 
combination with the epidemiological context in which the vaccine is used. For example, 
vaccine efficacy may change by number of doses based on a different distribution of 
etiologies at different vaccination ages. 
The PRP-T and the HbOC vaccines showed similar dose-specific efficacy values, but the 
PRP-OMP vaccine, which has different kinetics to the other two vaccines, had larger 
efficacy following one dose. The PRP-OMP vaccine has shown significantly higher 
immunogenicity after the first dose than the two others in all studies comparing the 
vaccines [196]. While all three vaccines are indicated for primary infant immunization, 
PRP-OMP may afford a marginal advantage in populations with high disease burden and 
carriage prevalence in young infants. In Alaska, a change from PRP-OMP to HbOC vaccine 
in 1996 led to an increase in invasive Hib disease incidence in the Alaska Native 
population from 19.8 to 91.1 cases per 100,000 children < 5 years of age [197]. When the 
State subsequently switched back to PRP-OMP vaccine, disease incidence decreased to 0 
per 100,000 in 2004 [197].  Nevertheless, most countries in Africa have reported a high 
Hib disease burden in young infants pre-vaccine, and yet have achieved near elimination 
of Hib disease with PRP-T [198, 199]. 
There was no significant difference between two and three doses, with efficacy against 
invasive Hib disease being 92% and 93% following two and three doses, respectively. In 
theory, then, the routine schedule could be reduced to two instead of three doses. A study 
evaluating this option found that while PRP-T elicited high immune response after two 
doses, this was not universally true of PRP-HbOC, with only 87% of infants reaching 
seroprotective concentrations [200]. The authors concluded that before switching to a 
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two-dose regimen, additional studies would be needed [200]. These studies have not been 
conducted, and moreover, additional barriers to a two-dose schedule exist. First, studies 
would need to confirm vaccine effectiveness against carriage, since indirect protection is a 
critical component of overall disease reduction and secondly, additional studies would 
need to confirm long-term immunity and protection against carriage, as well as booster 
responses with a two-dose schedule. Programmatically, Hib vaccine is now widely 
introduced in combination with DTP and other vaccines with a primary 3-dose schedule, 
which has large advantages. For these reasons, it is unlikely that any country would 
consider a 2-dose primary series without a booster. However, if countries were to switch 
to a 2+1 schedule for pneumococcal vaccines, our analysis supports the use of the same 
schedule for Hib vaccine. 
Waning immunity and the possible need for a booster dose is another important issue to 
consider. While all high-income and some middle-income countries recommend a Hib 
vaccine booster dose at 12 to 15 months, this has not been included in immunization 
schedules in low-income countries. The reason for not including a booster dose is partly 
due to the increased cost, but also because the average age of Hib infection is substantially 
lower in low-income compared to high-income countries [201]. It is however extremely 
important to closely monitor the impact of Hib vaccine in low-income countries to 
establish whether a booster dose is also needed in these settings. A recent study indicates 
that this may be the case in South Africa [202].    
While not evaluated in this analysis, choices of vaccine formulations and schedules must 
also consider the immune status of the population, particularly the effects of human 
immunodeficiency virus (HIV) infection and malnutrition. For example, HIV infection leads 
to decreased immunogenicity [203]; however, population impact against Hib disease in 
HIV endemic areas has varied with South Africa showing reduced impact [204] and 
Malawi showing high impact [205]. 
Investigators of large-scale vaccination trials do not routinely report dose-specific 
outcomes despite their potential importance for the impact and cost-effectiveness of 
immunization programs. Estimates of dose-specific vaccine efficacy provide a direct way 
for analysts and decision makers to account for vaccine impact among partially vaccinated 
children. Models that do not account for partial protection will underestimate overall 
program effectiveness in populations with high drop-out rates between doses.   
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8.5 VACCINE EFFICACY ESTIMATES USED IN THE ECONOMIC EVALUATION 
Pooled vaccine efficacy estimates for use in the decision-analytic model were generated by 
the meta-analysis. The numbers used in the economic evaluation are summarized in Table 
8.6. None of the studies reported efficacy against NPNM, so the pooled estimate for 
invasive Hib disease was used. Moreover, as explained in the discussion above, the 
estimates for confirmed Hib meningitis and Hib pneumonia were not considered robust, 
so the invasive Hib disease estimates were also used for these syndromes.     
The studies included in the pooled estimates of radiological and clinical pneumonia did 
not report on vaccine efficacy for less than three doses. To derive numbers for one and 
two doses only, the ratio between one and two doses and between two and three doses of 
the invasive Hib disease estimates were used for the other two outcome measures.  
The 95% confidence values generated in the meta-analysis were used as high and low 
values in the univariate uncertainty analysis and for fitting a distribution to the data in the 
probabilistic uncertainty analysis. 
Table 8.6: Hib vaccine efficacy estimates used in the economic evaluation 
Disease case 
definition 
1 dose only 2 doses only 3 doses 
Mid Low High Mid Low High Mid Low High 
Hib meningitis 
59% 0% 86% 92% 69% 98% 93% 83% 97% 
Hib 
pneumonia 
59% 0% 86% 92% 69% 98% 93% 83% 97% 
Hib  
NPNM 
59% 0% 86% 92% 69% 98% 93% 83% 97% 
Radiological 
pneumonia 
14% 0% 32% 22% 5% 35% 22% 6% 35% 
Clinical 
pneumonia 
2.3% 0% 6% 4% 0.5% 7% 4% 1% 7% 
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9 DISABILITY ADJUSTED LIFE YEARS DUE TO HIB DISEASE 
As described in Chapter 4, QALYs and DALYs are the two main health related quality of life 
(HR-QOL) measures used in economic evaluation.  In spite of recognised limitations of 
DALYs, these were chosen as the main outcome measure in the economic evaluation. The 
rationale for this choice and the methods applied for estimating DALYs due to Hib disease 
are described in this chapter.  
The DALY estimate for Hib disease is calculated as the sum of three components:  
DALYHib = YLLHib + YLDa +YLDs 
where, 
YLLHib  =  Years of life lost due to premature mortality from Hib disease 
YLDa  =  Years of life with disability from acute Hib disease 
YLDs  =  Years of life with disability from Hib meningitis sequelae  
The overall objective of this chapter is to estimate these three components.  
An overview of methodological issues for measuring HR-QOL used in economic evaluation 
is given in section 9.1, with particular focus on childhood illnesses.  A background to 
DALYs is presented in section 9.2 and estimation of DALYs due to acute Hib disease is 
explained in section 9.3. In section 9.4, it is demonstrated how evidence on the risk of 
different types of sequelae from bacterial meningitis were used for determining DALY 
parameters for this syndrome.  The DALY parameter assumptions used in the three case 
study countries are summarised in section 9.5, and the strengths and limitations of the 
estimates are discussed in section 9.6. 
9.1 OVERVIEW OF METHODS USED FOR VALUING HEALTH RELATED QUALITY OF LIFE 
Possible methods for measuring HR-QOL improvements for cost-utility analysis include 
healthy years equivalent (HYE), QALYs and DALYs. QALYs have gradually become the 
standard type of outcome measure used in cost-utility analyses in high-income countries 
[206]. However, in low- and middle-income countries, resources for collection of 
population preference data and the expertise needed for development of HR-QOL 
instruments and scoring systems are limited, contributing to the fact that DALYs are 
usually used instead.  
There are four general steps when calculating QALYs or DALYs: (a) describing the health 
state, (b) development of preference scores or weights for the health state, (c) determining 
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the time spend in each health state, and (d) combining the information. Development of 
preference scores or weights for the health state is the most methodologically challenging 
and this is one area where DALYs and QALYs particularly differ [207].  
Preference scores for QALY estimates are generally derived using a multi-attribute 
approach. With such a system, patients are asked to complete questionnaires about their 
health status and these data are scored using a multi-attribute scoring function based on 
community preferences. Two types of preference-scored, multi-attribute health status 
classification systems are in widespread use: the EuroQol EQ-5D and the Health Utility 
Index (HUI) [208]. The multi-attribute scoring functions are based on direct preference 
measurement data from random samples of people in the general population of the 
respective country. Multi-attribute scoring functions for the EQ-5D system are available 
for eleven European countries and for Japan, New Zealand, Canada and Zimbabwe 
(http://www.euroqol.org/eq-5d/population-norms.html)  
There are however inherent limitations with preference-based approaches for measuring 
the health status of children. First, children undergo dramatic changes in growth and 
function at different rates, so it can be difficult to attribute improvements to health care 
interventions rather than to normal development [209]. Secondly, children of young ages 
do not have cognitive ability to comprehend and complete a valuation questionnaire, so 
some form of proxy must be used for measurement, most likely by administering the 
instrument to a parent or a clinician [209, 210].  
Almost all the original generic instruments used in the multi-attribute approaches have 
been created for use in adult populations and are generally not suitable for children. The 
exception to this is the Health Utility Index Mark 2 (HUI2), which was developed for proxy 
respondents to assess outcomes among survivors of cancer in childhood. Some domains in 
this tool are thus specific to cancer. The problems with the adult generic instruments are 
that some questions are not relevant for the lives of children and attributes that might be 
more relevant for children than for adults, such as autonomy, cognitive skills and family 
relationships, are not included [209]. However, improvements are underway with several 
groups working on appropriate tools. A version of the EQ-5D instrument for use in 
children and adolescents aged 7-12 years is for instance currently in the validation phase 
[211, 212].  However, no generic tool has yet been developed for children less than five 
years of age [213].  
It is apparent that using QALYs as an outcome measure in cost-utility analysis of Hib 
vaccine would be problematic. There is first of all no generic instrument available for 
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measuring HR-QOL preferences in children less than five years and secondly, multi-
attribute scoring functions have not been developed for any of the study countries 
included in the present analysis. Hence, even if HR-QOL preference data were collected, 
there is no straight forward way of generating QALY values that reflect preferences in the 
particular countries. For these reasons it was decided to use DALYs as the primary 
outcome measure in the present study.   
9.2 BACKGROUND TO DALYS  
DALYs were originally constructed by the World Bank and the WHO as part of the first 
Global Burden of Disease (GBD) study, which aimed at providing a comprehensive 
assessment of the disease burden in 1990. The estimates were presented in the World 
Bank’s 1993 World Development report “Investing in Health” [214]. The aim at the time 
was to objectively quantify and compare the aggregate regional and worldwide health 
burdens caused by many different diseases. Chris Murray states in the first chapter of the 
1996 GBD series that, “a DALY is a health gap measure that combines potential years of life 
lost due to premature death with years of healthy life lost due to individuals being in 
states of poor health or disability” [126]. One DALY can be thought of as one lost year of 
healthy life and the burden of disease in terms of DALYs as a measure of the gap between 
current health status and an ideal situation where everyone lives into old age free from 
disease and disability.  
In DALYs, preference values are termed “disability weights”. These range between 0 and 1, 
with 0 equal to perfect health and 1 to death. Disability weights for a total of 237 different 
types of diseases were included in the original GBD of disease study [126]. The values for 
these weights were derived during a two-day WHO expert meeting in 1995. During this 
meeting, a group of people were asked to value 22 tracer conditions using the person 
trade-off approach. After these were completed, they were asked to distribute the severity 
of the remaining  212 conditions between a number of categories anchored around the 
results of the 22 tracer conditions [215]. During the most recent GBD update, the same  
disability weights were used for YLD calculations as in the original study, but the weights 
are now differently tabulated and the new reference is Annex Table A6 of Mathers et al. 
(2006) [216]. 
DALYs for a particular disease are calculated as the sum of years of life lost (YLLs) and 
years of life with disability (YLDs) due to the particular health condition. There are a 
number of important underlying assumptions of DALYs that differ from the construction 
of QALYs: 
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a. DALYs describe specific diseases, rather than health states. One consequence of 
this is that no distinction is made between severe and non-severe disease.  
b. DALYs make no provision for co-morbidities. For example, the HR-QOL of a person 
who suffers from type 2 diabetes and cardiovascular disease at the same time 
cannot be easily generated.  
c. DALY preference values for diseases have been decided upon by a group of health 
professionals, rather than from preferences of the population as is often the case 
for QALYs. 
d. Both QALY and DALY preference scores/disability weights are numbers between 0 
and 1. However, while a QALY preference score of one represents full health and 
zero represents death, the opposite is true with DALYs. 
e. In DALYs, different value weights are placed on populations based on their age 
structure with the very young and very old valued less than other age groups. The 
justification for age weighting is that adults in their productive life are more 
important for income generation of a country and this group should therefore be 
valued highest.  
f. In the standard DALY recommendations, life expectancy is assumed 82.5 years for 
women and 80 years for men. These numbers were chosen to represent the 
longest life expectancy in the world, which is in Japan. However, in country-
specific analysis, local life expectancies are frequently used by study investigators.  
The GBD study is an ongoing effort that continues to evolve. The study was most recently 
updated in 2004 and the Bill & Melinda Gates Foundation currently provide funding for a 
new GBD study scheduled to be published during 2012. This update is led by the Institute 
for Health Metrics and Evaluation at the University of Washington, with key collaborating 
institutions including the WHO, Harvard University, Johns Hopkins University and the 
University of Queensland [217].  
9.3 DALYS DUE TO ACUTE HIB DISEASE 
9.3.1 YEARS OF LIFE LOST (YLL) 
The formulas for YLLs and YLDs with and without discounting are given in Textbox 9.1. r 
is the discount rate used for adjusting future life years, β is a parameter in the age 
weighting function and C is a constant. In the original form, r equals 3%, β is 0.04 and C is 
0.16243 [126]. Without discounting the formula is simplified. 
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Textbox 9.1: Formulas for calculating YLLs and YLDs  
 
Source: Murray and Lopez (1996) [126] 
In the present economic evaluation the life expectancy of the country in question is 
applied and not the Japanese life expectancy as recommended by the WHO. The rationale 
is that national life expectancy will make the study most relevant to local decision makers. 
Hence, for estimation of YLLs, data on the average age of death from Hib disease and life 
expectancy of the particular country are the only data needed. These data are readily 
available from either national surveys or from the United Nations Population Fund. YLLs 
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Where: 
K= Age weighing modulation factor 
C = Constant 
r = Discount rate 
a = Age of death  
β = Parameter for the age weighing function 
L = Life expectancy at age a 
 
------------------------------------------------------------------------------------------------------------------------  
Discounted YLD: 
Non-discounted YLD: 
Where: 
D = Disability weight 
K  = Age weighing modulation factor 
C  = Constant 
r  = Discount rate 
a  = Age of disease episode  
β  = Parameter for the age weighing function 
L  = Duration of disability 
D = Disability weight 
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due to Hib disease in Uzbekistan during 2010 are estimated in Textbox 9.2 as an 
illustrative example (assumptions about the age distribution of Hib disease are described 
in section 9.4 below). It is seen that discounting of future values makes a considerable 
difference to the YLLs, decreasing number of life years lost by 58% compared to no 
discounting. Age weighting makes less of a difference, increasing the number of life years 
by 13% compared to no age weighting. 
Textbox 9.2: YLL calculations for acute Hib disease in Uzbekistan in 2010* 
(assuming that Hib vaccine was not introduced) 
 
*The 2010 Uzbekistan birth cohort was 558,459 children 
9.3.2 YEARS OF LIFE WITH DISABILITY (YLD) DUE TO ACUTE DISEASE 
YLDs due to Hib disease must be divided into disability during the acute disease episode 
and disability from lifelong meningitis sequelae. As described in Chapter 7, acute Hib 
disease episodes are divided into meningitis, pneumonia and NPNM in the decision- 
analytic model.  Data needed for YLD estimates of these three types of Hib disease are (i) 
the average age of onset of disease, (ii) duration of the disease episode and (iii) the 
disability weight. Numerous studies have reported on the average age of Hib disease and 
the average length of stay in hospital can be used as an approximation for duration of 
disease episode. The disability weight for children between zero and four years for a 
meningitis episode is 0.616 and the disability weight for a lower respiratory infection 
episode is 0.279 [216]. Lower respiratory infection is synonymous to pneumonia, as the 
resulting infection is pneumonia.  
As shown in Chapter 12, it is estimated that a total of 338 Hib disease deaths would have 
occurred in Uzbekistan in 2010 without Hib vaccine. Of these deaths, 207 were due to Hib 
meningitis, 120 due to Hib pneumonia and 11 due to Hib NPNM.   
The following parameter values were assumed for the YLLs estimation: 
K = 1 
C = 0.16243 
β = 0.04 
r = 3% 
L = 68 years 
a = The age of a Hib disease death varies between 0.5 and 4.5 years  
 
When inserting the parameter values in the YLLs formula, it is estimated that Hib disease 
caused 11,197 discounted YLLs, which is on average 33 discounted YLLs per death.  
Without discounting, total YLLs are 26,886 (78 YLLs per deceased case).  
Without age weighting (K = 0), total discounted YLLs amount to 9,732 (29 YLLs per death). 
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There is however no disability weights available in the GBD study for any of the NPNM 
diseases, most likely because these are all relatively rare illnesses. In instances of no 
disability weight available, it is common practice to use a weight for a comparable disease 
[218]. To be able to determine what disability weight to use, epidemiological studies 
reporting on NPNM were reviewed. The studies were identified via email contact to 
collaborators who had worked on the Hib and pneumococcal GBD project, as they had 
conducted a systematic literature review for determining the incidence of NPNM [219]. 
The 21 ascertained studies are summarized in Table 9.1. It is seen that epiglottitis was the 
most common type of NPNM in the majority of the countries, although this disease was not 
established everywhere. This was followed by cellulites, arthritis and sepsis. When 
determining the most suitable disability weights for NPNM in the three study countries 
(Belarus, India and Uzbekistan), only studies from the respective region were used to 
identify the most common types of NPNM. In Belarus, the meningitis disability weight was 
used for NPNM because epiglottitis is the most common type of NPNM in Western 
European countries and the Czech Republic and this illness has comparable severity to 
meningitis. In India and Uzbekistan, the pneumonia disability weight of 0.28 was used, as 
there is currently no evidence of epiglottitis in these countries and the remaining NPNM 
diseases have more comparable severity to pneumonia than to meningitis. 
YLD calculations for acute Hib disease episodes in Uzbekistan in 2010 are summarised in 
Textbox 9.3. Due to the relatively short duration of a disease episode, no more than 5.9 
discounted YLDs were estimated. Moreover, since these episodes are predicted to occur 
within the first five years of the model timeframe, omitting discounting only increases the 
result marginally, to 6.2 YLDs.  When adding the YLLs and the YLDs caused by acute Hib 
disease in Uzbekistan in 2010, 11,203 discounted DALYs are estimated (11,197 YLLS + 5.9 
YLDs). 
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Table 9.1: Number of cases of different types of Hib disease detected in Hib sentinel surveillance studies that included NPNM syndromes 
    Non-pneumonia-non-meningitis (NPNM) Hib diseases 
Author [ref.] Country Menin- 
gitis 
Pneu- 
monia 
Epiglot- 
titis 
Sepsis Cellulitis Arthritis Pericar-
ditis 
Endocar- 
Ditis 
Osteo- 
Myelitis 
Peritoni-
tis 
Cholan-
gitis 
Sinusitis  Total  
Torres [220] Argentina 19 3 1 4 11 4 3   1   46  
Asturias [221] Guatemala 71 24 2 3 6 1                107  
Forbes [222] Jamaica 65 11 1 2  7        86  
Takala[223] Finland 152 11 97 23 21 27                 331  
Peltola [224] Finland 492 17 187 25 19 21                 761  
Booy [225] UK 289 8 48 15 28 21                 409  
Williams [27] UK 142 6 23 5 12 12                 200  
Reinert [54] France 177 17 20 15 11 16                       256  
Martin [226] Spain 37 4 6  5 6                    58  
Muhleman[227] Switzerland 1,270  1,392 62 69 64        2 ,857  
Kojouharova[43] Bulgaria 21 2   1 1                           25  
Lebedova[25] Czech Rep. 49 7 31 5   2                         94  
Dagan [228] Israel 182 72 1 34 45 2 2 1 2  1 1           344  
Madhi [204] South Africa 26 13  1 2        42  
O'Dempsey[229] Gambia 10 18  1          29  
Adegbola [28] Gambia 141 31  3 1 4        180  
Ishiwada[230] Japan 39 0 3 2  3                  47  
Likitnukul [26] Thailand 44 20   12 2 1                         79  
Anglaret[231] N. Caledonia 22 3 1 1 1 3  1                 32  
Gilbert [232] Australia 84 20 94 14 16 6                234  
McIntyre[40] Australia 143 12 91 5 18 13 1                283  
 Total         3,475          299       1,998            233          268            213                6              2                  2                  1                  1                  1        6,500  
Percent of total  53% 5% 31% 4% 4% 3% 0.09% 0.03% 0.03% 0.02% 0.02% 0.02% 100% 
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Textbox 9.3: YLD calculations for acute Hib disease in Uzbekistan in 2010 
 
9.4 YLD DUE TO MENINGITIS SEQUELAE 
9.4.1 BACKGROUND 
As described in Chapter 2, survivors of Hib meningitis risk severe, lifelong sequelae. The 
term “sequelae” refers to any abnormal bodily condition or disease related to or arising 
from a pre-existing disease. To estimate DALYs due to meningitis sequelae, the proportion 
of meningitis survivors suffering from disabilities, the average age of onset, and the 
duration of disability must be determined. Moreover, to be able to decide on the 
appropriate disability weights, it is necessary to know what specific types of sequelae the 
survivors suffer from, and what proportions suffer from what types. This is problematic 
because severity and type of sequelae vary considerably among cases. Complications 
range from subtle forms of cognitive impairment to devastating neurological handicaps, 
and it is furthermore common for children to suffer from multiple sequelae. Severe 
sequelae include sensorineural hearing loss, seizures, motor problems, hydrocephalus and 
mental retardation, while more subtle outcomes are cognitive, academic and behavioural 
problems [233].  Important risk factors for neurological sequelae following bacterial 
meningitis are coma, seizures and prolonged fever for at least seven days [234]. Hence, the 
risk of sequelae increases with limited access to health care, as patients in these settings 
would present late for treatment and thus suffer from the above mentioned risk factors.  
The four steps that have been undertaken for estimating YLDs due to bacterial meningitis 
sequelae are: 
As is shown in Chapter 12, it is estimated that 3,766 Hib disease cases would have occurred in 
Uzbekistan in 2010 without Hib vaccine. 2,994 of these were Hib pneumonia, 492 were Hib 
meningitis and 280 were Hib NPNM cases. 
The following parameter values were used for the YLDs estimates: 
K = 1 
C = 0.16243 
β = 0.04 
r = 3% 
L = 9 days for pneumonia and 11 days for meningitis and NPNM (based on average length of stay in 
hospital as explained in Chapter 10) 
D = 0.616 for meningitis, 0.28 for pneumonia, 0.28 for NPNM 
a = The age of Hib disease episode varies between 0.5 and 4.5 years 
 
When inserting the parameter values in the YLD formula, it is estimated that acute Hib disease 
caused 5.9 discounted YLDs, which is 0.002 YLDs per Hib disease case. Without discounting, YLDs 
amount to 6.2, and without age weighting discounted YLDs are 32.1. 
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1. Definition of the different types of sequelae and identification of their disability 
weights  
2. Assessment of the risk of sequelae caused by bacterial meningitis 
3. Establishment of the proportion of children suffering from the different types of 
sequelae  
4. Calculation of weighted average disability weights for use in DALYs calculations 
To increase the applicability and interpretation of the findings, the three most common 
types of bacterial meningitis were included in the analysis; Hib, meningococcal and 
pneumococcal meningitis.  The two other types of meningitis serve as useful comparators 
to Hib meningitis sequelae. 
Some of the work described in the following sections was derived from a global, 
systematic literature review, which I initiated with the aim of more accurately estimating 
DALYs due to meningitis sequelae. The review was undertaken in collaboration with Hib 
Initiative colleagues and titled “Global and regional risk of disabling sequelae from 
bacterial meningitis”. The study was published in the Lancet Infectious Diseases during 
2010 with Dr. Karen Edmond, my former Hib Initiative colleague, as first author [235]. The 
objectives of the review were to:  
1. Estimate the risks of major and minor sequelae caused by bacterial meningitis 
2. Estimate the distribution of the different types of sequelae 
3. Compare sequelae risk by region and Gross National Income (GNI). 
9.4.2 SEQUELAE CASE DEFINITIONS AND DISABILITY WEIGHTS 
In the systematic literature review mentioned above, sequelae types were divided into 
minor and major forms to facilitate a clear distinction between severe and less severe 
complications. We also included a multiple impairments category for children suffering 
from more than one disability type [235]. The case definitions are summarised in Table 
9.2. Four of the major sequelae case definitions were taken directly from the 1996 GBD 
study; cognitive deficit, seizures, hearing loss and motor deficit. These were the only types 
of meningitis sequelae included in the original GBD study and the associated disability 
weights can be found under the “Meningococcaemia without meningitis” category in the 
GBD disability weight list as “mental retardation”, “seizure disorder”, “deafness” and 
“motor deficit” [216].  
All the minor case definitions and the categories for visionary problems and clinical 
impairments were developed by Dr. Edmond. Hence, there are no associated meningitis  
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Table 9.2: Sequelae case definitions and disability weights 
 Minor sequelae Major sequelae  
Type Case definition Case definition Disability weight 
Cognitive 
deficit 
Learning difficulties or 
deficits with IQ > 70 or 
speech/language impairment  
Mental retardation with IQ 
<70  0.469 
Seizures  - Seizures of any type  0.099 
Hearing loss Unilateral sensorineural 
hearing loss with audiometric 
hearing threshold level 
(averaged over 0.5, 1, 2, 
4kHz) of >26dBHL 
Bilateral sensorineural 
hearing loss with 
audiometric hearing 
threshold level (averaged 
over 0.5, 1, 2, 4kHz  in the 
better ear) of >26dBHL   
0.223 
Motor deficit Isolated hypotonia, motor 
delay, ataxia, gait or 
coordination difficulties  
Impairment, spasticity or 
paresis of one or more 
limbs  
0.388 
Visionary 
problems 
Unilateral visual disturbance, 
diplopia, nystagmus, or 
cranial nerve dysfunction 
Presenting visual acuity in 
the best eye of less than 
6/12 or corresponding 
visual field loss  
0.223 
Clinical 
impairments 
Any behavioural disorder 
attributed to the meningitis 
episode   
Distinct pathologic entity 
with any impairment to 
activities of daily living 
0.359 
Multiple 
impairments 
Distinct pathologic entity 
with no impairment to 
activities of daily living: Mild 
cerebral dilatation 
>1 of above domains  
0.627 
 IQ: Intelligence quotient     
Sources: Edmond (2010)[235] for definitions and Mathers (2006) for  disability weights [216]. 
 
sequelae disability weights for these conditions. As a solution, it was decided not to 
include the minor types of sequelae in the DALY estimates, and to use approximate 
disability weights for major visionary problems and major clinical impairments.  The 
exclusion of minor sequelae is justified by the lack of disability weights and also because 
the diagnoses of these conditions are more difficult to make, leading to large uncertainty 
in the prevalence. For visionary problems, the “low vision” disability weight with a value 
of 0.223 from the corneal scar, onchocerciasis and trachoma categories was used. The 
clinical impairments category was created to depict children with disturbance in the 
function or structure of an organ. Since the majority of children in this category had 
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hydrocephalus (a build-up of fluid inside the skull, leading to brain swelling), the GBD 
disability weight for long term intracranial injury of 0.359 was used for clinical 
impairments. For multiple sequelae a weight of 0.627 was assumed, which is the highest 
value in the GBD disability weight list, similar to dementia [216]. 
9.4.3 RISK OF SEQUELAE FROM BACTERIAL MENINGITIS 
One of the objectives of the systematic literature review mentioned above was to estimate 
the median risk of sequelae from bacterial meningitis according to pathogen and to 
compare the risk by region and country income groups [235]. The results of the review are 
summarised below followed by the risk of sequelae estimates assumed for the three case 
study countries.     
9.4.3.1 Risk of sequelae from bacterial meningitis: Results of the systematic 
literature review 
The literature review covered studies published between 1980 and 2008. Medline and 
WHOLIS databases were searched using the terms “meningitis”, “bacterial” AND 
complications” [235].  A total of 132 papers were included. Of these papers, 87 
investigated meningitis sequelae from all causes, 33 focused on Hib meningitis sequelae, 
27 on pneumococcal meningitis sequelae, and 35 on meningococcal meningitis sequelae. 
Overall, 19,272 survivors of acute bacterial meningitis were examined for sequelae in the 
included studies, with the mean number of children per study being 146. The Hib 
meningitis sequelae analysis is based on a sample of 7,298 children [235]. 
Studies reported sequelae at either the time of discharge from hospital or during a follow- 
up period after discharge. We decided to use the post discharge data, as symptoms from 
acute meningitis persist until hospital discharge and patient responses to hospital 
neurological examinations are usually suboptimal [235].  The mean post discharge follow-
up time was 37.7 months, with the longest time being 16 years after the meningitis 
episode, which was reported in two of the studies [236, 237]. 
The median ages at the time of the meningitis episode and the risk of sequelae according 
to bacterial pathogen are summarised in Table 9.3. Compared to the two other bacterial 
pathogens, Hib is seen to infect children at a younger age. While the median age of Hib 
meningitis was 17 months, it was 36 and 67 months for pneumococcal and meningococcal 
meningitis, respectively. The median risk of developing major sequelae following Hib 
meningitis was 9.5%, with an interquartile range between 7% and 15%. The risk following 
pneumococcal meningitis was 2.6 fold greater with a median value of 24.7%. There were  
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Table 9.3: Global median values for the risk of sequelae from bacterial meningitis 
 All-cause Hib Pneumococcal Meningococcal 
Median age of meningitis episode: 
Number of studies 53 15 4 14 
Age in months (IQR) 32 (20, 67) 17 (12, 25) 36 (31, 136) 67 (33, 96) 
At least one type of any sequelae: 
Number of studies 59 27 20 27 
Risk (IQR) 19.9% (12%, 35%) 14.5% (10%, 27%) 34.7% (28%, 45%) 9.5% (5%, 15%) 
At least one type of major sequelae: 
Number of studies 58 27 20 26 
Risk (IQR) 12.8% (7%, 21%) 9.5% (7%, 15%) 24.7% (16%, 35%) 7.2% (4%, 11%) 
At least one type of minor sequelae: 
Number of studies 37 17 10 11 
Risk (IQR) 8.6% (4%, 15%) 5.7% (2%, 15%) 18.6% (11%, 23%) 2.3% (1%, 12%) 
Source: Edmond (2010)[235] 
 
no statistically significant differences between the risks from meningococcal and Hib 
meningitis [235]  
The interquartile ranges of the risk estimates are relatively wide, reflecting broadly 
different results in the included studies. We investigated whether geographical region and 
country income groups could explain the variation among studies, and it was found that 
the risk of at least one major sequelae following bacterial meningitis was almost three fold 
greater in the WHO African region (25.1%; 95% CI 18.9, 32.0) and the South East Asian 
region (21.6%; 95% CI 13.1, 31.5) compared to the European region (9.4%; 95% CI 7.0, 
12.3) [235]. There was also a progressively higher risk of sequelae as mortality strata 
increased; risk of a major sequelae was three times greater in the highest mortality 
stratum countries (29.1%; 95% CI 20.9, 37.9) than in the lowest stratum (9.1%; 95% CI 
7.2, 11.1) [235].  As mentioned above, the primary reason for higher risk in low- income 
countries is likely to be late presentation to health facilities. There were no clear 
associations between risk and duration of follow up, type of study design, percentage of 
isolates with laboratory confirmation, or decade of data collection [235]. 
The wide variation in sequelae risk across country income groups and mortality strata 
emphasise the need for using local data in country specific studies, or at least data from a 
comparable country. Furthermore, due to the significant higher risk of sequelae from 
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pneumococcal meningitis compared to Hib and meningococcal meningitis, it is desirable to 
use pathogen-specific estimates and not all-cause bacterial meningitis data, which for Hib 
and meningococcal meningitis are likely to overestimate the risk and for pneumococcal 
meningitis would underestimate the risk.  
9.4.3.2 Risk of meningitis sequelae in Belarus, India and Uzbekistan 
Five Indian papers on the risk of sequelae were identified, but there were no published 
studies from Belarus and Uzbekistan. The Indian papers are summarised in Table 9.4. 
Since the papers by Gupta and George did not present pathogen specific data, these were 
excluded. In the paper by Cherukupally only hearing deficit was assessed during the 
follow-up tests, so this paper was also excluded. The studies by Chinchankar and Singhi 
identified a risk of sequelae following Hib meningitis of 46% and 31%, respectively. 
However, as seen in the footnote of Table 9.4, one of the cases was diagnosed with 
behavioural problems, which is categorised as minor sequelae according to the 
classifications in Table 9.1. When excluding this case, a total of nine major sequelae cases 
were detected among 26 confirmed Hib cases, giving a pooled estimate of 35%, and this 
value was used in the India analysis. This corresponds well to the risk of the high-
mortality strata found in the literature review.  
In Belarus, Hib Initiative collaborators conducted Hib meningitis surveillance during 
2002-2007 at the Minsk City Children’s Infectious Disease Hospital (MCCIDH). All children 
that had suffered from meningitis were followed up every three months during the first 
year after discharge and annually for the next two years [238]. The data showed that 12% 
of children with confirmed Hib meningitis suffered from major disability at six months 
follow-up, 75% of whom had reduced hearing. A sequelae risk of 12% was therefore used 
for Belarus.  
There were no data available from Uzbekistan or any of its neighbouring countries. The 
Indian value was used for Uzbekistan, as these two countries have comparable GDP per 
capita and infant mortality rates. In 2010, GDP per capita were US$ 1,370 in India and US$ 
1,380 in Uzbekistan (www.imf.org), and the infant mortality rates were 66 and 36 per 
1,000 live births in India and Uzbekistan, respectively (www.unicef.org).  
9.4.4 DISTRIBUTION OF TYPES OF SEQUELAE DUE TO BACTERIAL MENINGITIS 
The most common type of major sequelae caused by Hib is hearing loss, followed by 
multiple impairments and motor deficit. Visual disturbance is a rare type of sequelae for 
all three pathogens, but especially for Hib with only 0.1% of discharged children 
diagnosed with this (Table 9.5).
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Table 9.4: Summary of Indian bacterial meningitis sequelae studies 
First author 
[ref] 
Year 
Place of 
study 
Number of 
children 
followed up 
Types of 
sequelae 
evaluated 
Pathogen 
confirmation 
Number of 
children 
with sequelae 
Risk of 
sequelae from 
Hib meningitis 
Risk of 
sequelae from 
pneumococcal 
meningitis 
Risk of 
sequelae from 
all-cause 
bacterial 
meningitis 
Gupta [239] 1993 
Varanasi, 
North India 
24 Hearing loss None 5 NA NA 21% 
Chinchankar [240] 2002 
Pune,  
West India 
31 
 
All 
13 Hib 
 17 pneumococcal 
 13 others 
6 Hib* 
13 pneumococcal 
8 others 
46% 76% 63% 
George [241] 2002 
Kerala, South 
India 
100 All None 40 NA NA 40% 
Cherukupally [242] 2004 
Hyderabad, 
South India 
28 
 
Hearing loss 
15 Hib 
8 pneumococcal 
5 tuberculosis 
3 Hib 
3 pneumococcal 
2 tuberculosis 
20% 38% 29% 
Singhi [243] 2006 
Chandigarh, 
North India 
80 
 
All 
13 Hib 
6 pneumococcal 
5 others 
56 not specified 
4 Hib** 
6 pneumococcal 
2 others 
20 not specified 
31% 100% 40% 
*The six Hib cases were: Two persistent seizures, three isolated hearing loss and one moderate to severe development delays 
**The four Hib cases were described as minor sequelae, which in the study were defined as extra-pyramidal movements, hearing loss, hemiparesis, hyperactivitiy, peripheral facila 
palsy, mild mental retardation and language delay.   
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Table 9.5: Percentage breakdown of different types of major sequelae in discharged 
children due to Hib, pneumococcal and meningococcal meningitis   
 Hib Pneumococcal Meningococcal 
 No. of 
studies 
% of 
children 
No. of 
studies 
% of 
children 
No. of 
studies 
% of 
children 
Cognitive difficulties 8 1.0% 7 3.2% 3 0.4% 
Seizure disorder 11 1.5% 8 2.5% 5 0.5% 
Hearing loss 19 3.2% 15 6.7% 16 2.1% 
Motor deficit 14 1.2% 7 3.3% 9 0.8% 
Visual disturbance 4 0.1% 5 1.1% 3 2.1% 
Clinical impairments 4 0.7% 1 3.4% 1 0.3% 
Multiple impairments 24 1.9% 20 4.5% 24 1.0% 
Total 27 9.6% 20 24.7% 26 7.2% 
Source: Edmond (2010) [235] 
9.4.5 WEIGHTED DALY DISABILITY WEIGHTS FOR MENINGITIS SEQUELAE 
Weighted average disability weights for Hib, pneumococcal and meningococcal meningitis 
sequelae were calculated from the disability weights in Table 9.2 and the percentage 
breakdowns in Table 9.5. The weighted disability weights are 0.291 for Hib, 0.356 for 
pneumococcal and 0.307 for meningococcal meningitis sequelae (Table 9.6). 
YLD calculation for meningitis sequelae in Uzbekistan is summarised in Textbox 9.4. Total 
annual YLDs due to meningitis sequelae amount to 964. It is seen that discounting makes a 
considerable difference to the result. With discounting at 3% per year, YLDs per sequelae 
case amount to 9.6 while without discounting the result is 22.8 YLDs per sequelae case. 
Textbox 9.4: YLDs calculation for Hib meningitis sequelae in Uzbekistan 2010 
 
  
  
As shown in Chapter 12, it is estimated that 100 Hib meningitis sequelae cases would have 
occurred in Uzbekistan in 2010 without Hib vaccine. 
The following parameter values were used for the estimating YLDs from these cases: 
K = 1 
C = 0.16243 
β = 0.04 
r = 3% 
L = Lifelong (life expectancy of 68 years) 
D = 0.291 
a = The age of Hib infection varies between 0.5 and 4.5 years 
When inserting the parameter values in the YLD formula, a total of 964 discounted YLDs are 
estimated. This is 9.6 YLDs per sequelae case. Without discounting, YLDs amount to 2,320, or 
22.8 YLDs per sequelae case.  
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Table 9.6: Weighted average disability weights due to bacterial meningitis sequelae  
Type of sequelae 
Disability 
weight 
Percent of 
cases 
Percent 
distribution 
Weighted 
average 
disability 
weight 
Hib:     
Cognitive difficulties 0.469 1.0% 10% 0.049 
Seizure disorder 0.099 1.5% 16% 0.015 
Hearing loss 0.223 3.2% 33% 0.074 
Motor deficit 0.388 1.2% 13% 0.049 
Visual disturbance 0.223 0.1% 1% 0.002 
Clinical impairments 0.359 0.7% 7% 0.026 
Multiple impairments 0.627 1.9% 20% 0.124 
Total   9.6% 100.0% 0.340 
Pneumococcal:  
   Cognitive difficulties 0.469 3.1% 13% 0.059 
Seizure disorder 0.099 2.5% 10% 0.010 
Hearing loss 0.223 6.7% 27% 0.061 
Motor deficit 0.388 3.3% 13% 0.052 
Visual disturbance 0.223 1.1% 4% 0.010 
Clinical impairments 0.359 3.4% 14% 0.050 
Multiple impairments 0.627 4.5% 18% 0.115 
Total  24.7% 100% 0.356 
Meningococcal:  
   Cognitive difficulties 0.469 0.4% 6% 0.026 
Seizure disorder 0.099 0.5% 7% 0.007 
Hearing loss 0.223 2.1% 30% 0.066 
Motor deficit 0.388 0.8% 11% 0.044 
Visual disturbance 0.223 2.1% 30% 0.066 
Clinical impairments 0.359 0.2% 3% 0.050 
Multiple impairments 0.627 1.0% 14% 0.088 
Total  7.2% 100% 0.307 
 
9.5 SENSITIVITY ANALYSIS 
When adding the YLLs and the two types of YLDs, total discounted DALYs for the 2010 
Uzbekistan birth cohort are: 11,197 YLLs + 5.9 YLDs + 964 YLDs = 12,166 DALYs. Hence, 
YLLs account for as much as 92% of the DALY estimate. One reason for this is the 
relatively short duration of acute Hib disease, which in total only amount to 5.9 YLDs for 
the cohort.  YLDs from sequelae are also considerably less than YLLs because there are 
three times fewer sequelae cases than deaths and the value of these are reduced by the 
disability weight of 0.291. 
A number of assumptions were made when deciding on parameters for the DALY 
estimates. To assess the impact of changing these values, one-way sensitivity analysis was 
undertaken for the Uzbekistan example (Table 9.7). The analysis was done for discounted 
and age weighted DALYs; the effects of no discounting and no age weighting have already 
been evaluated in Textboxes 9.1-9.4 above.     
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It can be seen that changes to the YLD parameter values, such as using the meningitis 
disability weight instead of the pneumonia disability weight for NPNM, only increases the 
overall DALY value by 0.0007%. Similarly, reducing the multiple sequelae disability weight 
from 0.627 to 0.469, which is the disability weight for cognitive difficulties, decreases total 
DALYs by no more than 0.8%. Since YLLs account for such a large proportion of the DALY 
estimates, changes to mortality is a key determinant. When decreasing the meningitis CFR 
from 42% to 20%, total DALYs decrease by 26.5%. 
Table 9.7: DALY parameter sensitivity analysis: Uzbekistan 2010 birth cohort 
 
Discounted 
YLLs 
Discounted 
YLDs from 
acute 
disease 
Discounted 
YLDs from 
meningitis 
sequelae 
Discounted 
DALYs 
Percentage 
change 
from base 
case 
Base case 11,197 5.9 964 12,166 - 
Use meningitis disability 
weight for NPNM instead 
of pneumonia disability 
weight 
11,197 6.4 964 12,166 0.0007% 
Decrease risk of sequelae 
from 35% to 12% (use 
Belarus value instead of 
India value for 
Uzbekistan) 
11,197 5.9 330 11,532 -5.2% 
Reduce multiple sequelae 
disability weight from 
0.627 to 0.469 
11,197 5.9 861 12,063 -0.8% 
Increase average, 
weighted sequelae 
disability weight from 
0.340 to 0.600 
11,197 5.9 1,987 
13,189 
 
8.4% 
Reduce meningitis case 
fatality rate from 42% to 
20%* 
7,607 5.9 1,329 8,942 -26.5% 
*The case fatality rate assumptions are explained in Chapter 12. 
9.6 DALY ASSUMPTIONS USED IN THE ECONOMIC EVALUATION 
The DALY parameter assumptions used in the three study countries are summarized in 
Table 9.8 below. Since the age of Hib infection affects both the YLLs and YLDs, relatively 
narrow age ranges were included in the model. Local data on age distributions were 
available from Belarus and India, but data from a global literature review were used for 
Uzbekistan, as specified in the footnote of the table.  
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Table 9.8: DALY parameters used in the four case studies 
Parameter Belarus India Uzbekistan 
Age weighting modulation factor (K) 1 1 1 
Age weighting parameter (β) 0.04 0.04 0.04 
Constant (C) 0.1658 0.1658 0.1658 
Life expectancy 70 65 68 
Age distributions of Hib invasive disease 
episodes*: 
   
  <3 months 5.0% 23% 10.6% 
  3-5 months 5.0% 19% 13.6% 
  6-8 months 5.0% 20% 17.8% 
  9-11 months 5.0% 10% 17.8% 
  12-23 months 23.0% 22% 23.8% 
  24-35 months 27.0% 2% 5.5% 
  36-47 months 20.0% 2% 5.5% 
  48-59 months 10.0% 2% 5.5% 
Risk of meningitis sequelae 12% 35% 35% 
Disability weights:    
   Pneumonia 0.279 0.279 0.279 
   Meningitis 0.616 0.616 0.616 
   NPNM 0.616 0.279 0.279 
   Meningitis sequelae 0.340 0.340 0.340 
Duration of acute illness in days:    
   Pneumonia 13 10 9 
   Meningitis 21 11 11 
   NPNM 21 11 11 
Duration of meningitis sequelae Lifelong Lifelong Lifelong 
*Sources for age distributions:  
 Belarus: Hib meningitis surveillance at Minsk City Children’s Infectious Disease Hospital 
 India: Invasive Hib disease surveillance at several hospitals by Gupta et al. (2011) [244] 
 Uzbekistan: Global literature review by Bennett et al. (2002) [245] 
 
9.7 DISCUSSION 
In this chapter, YLLs from Hib disease mortality, YLDs due to acute Hib meningitis 
episodes and YLDs caused by Hib meningitis sequelae were estimated. By adding up these 
numbers, DALYs due to Hib disease were calculated. The example from Uzbekistan 
demonstrated that discounting of particularly the YLLs makes a large difference to the 
DALY estimates for Hib disease, emphasising the importance of presenting cost-utility 
ratios both with and without discounting of future values. For estimating YLDs due to 
meningitis sequelae, in-depth analysis was undertaken of the risk of sequelae and the 
proportional types of disabilities. This exercise revealed that it is important to 
differentiate between high- and low income countries and between Hib and pneumococcal 
meningitis when deciding on the risk of sequelae assumptions.  
Weighted average disability weights were calculated for Hib, pneumococcal and 
meningococcal meningitis sequelae. Since pneumococcal and meningococcal meningitis 
are also vaccine preventable, these figures are useful for cost-utility studies of these 
vaccines. The single weighted, average values represent an important improvement 
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compared to previous studies where the evidence used for YLDs due to meningitis 
sequelae has been weak. Four of the studies included in the literature review of Hib 
vaccine economic evaluation in Chapter 5 used DALYs as the outcome measure [122, 123, 
124, 125]. In the Indonesian study by Broughton, the disability weights used were not 
reported [123]. In the Kenya study, the motor deficit disability weight was assumed for all 
sequelae cases [125], and in the Russian study the deafness disability weight was used for 
an estimated proportion suffering from hearing loss and the motor deficit weight for 
remaining cases [122]. In the second Indonesian study, meningitis sequelae were divided 
into mental retardation, deafness, blindness, seizure disorder and motor deficit and the 
respective disability weights were applied to each category. However, the proportions 
suffering from the different syndromes were not based on a meta-analysis, but on a single 
study from the Gambia.      
Estimation of DALYs due to Hib disease demonstrates several limitations with the 
measure. First, it is apparent that the approach is not suitable for measuring HR-QOL from 
a disease marked by many different severities. As mentioned in the beginning of this 
chapter, one of the differences between QALYs and DALYs is that while QALYs measure 
health states, DALYs depict specific diseases. Hence, one disability weight is used for each 
disease and it is not possible to distinguish between severities. This is a limitation for 
DALY estimates of all diseases, but the Hib example provides a good illustration of the 
problem. Pneumonia is for instance characterised by three main severities, but only one 
disability weight is available. This is a problem when evaluating the cost-utility of Hib and 
pneumococcal vaccines because bacterial pneumonias are more severe than pneumonia 
caused by for instance viruses [178]. Similarly, a broad range of different severities of 
meningitis sequelae occur in children, but with only a few, distinct disability weights 
available, it was necessary to omit minor sequelae from the analysis. Hence, the DALY 
estimates presented for meningitis sequelae are likely to underestimate the impact on HR-
QOL and give conservative cost-utility estimates.  
A related second limitation is that DALYs do not account for co-morbidities, as the 
disability weights represent single diseases. Approximately 20% of Hib meningitis 
sequelae cases suffer from multiple impairments, but with DALYs there is no standard way 
of valuing the impact of more than one disease at a time. In the present analysis this was 
resolved by using the highest available disability weight (which is for dementia) to 
approximate the impact of multiple sequelae on HR-QOL, but this was a fairly random 
decision, which is open for questioning. However, as shown in the Uzbekistan example, 
changing these values makes hardly any difference to the DALY estimates. 
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Thirdly, the DALY estimates of Hib diseases were constrained by a lack of disability 
weights for several of the syndromes. There were no weights for any of the NPNM 
diseases, so these were approximated by using either the meningitis or pneumonia 
weights, and since there are no disability weights for low vision and clinical impairments 
caused by meningitis sequelae, these were approximated from other disease categories. 
Again, the rationales for these best guesses are not founded on evidence and can be 
challenged. 
The Hib YLD calculations presented in this chapter were evidently complicated by the 
amount of data required and their quality.  However, the results of the analysis suggest 
that YLD contribute only a marginal part of the overall DALY estimate. For example, the 
Uzbekistan example showed that the YLLs entirely dominate the DALY estimate, with 
YLDs only accounting for 7% of the total value. Hence, in high mortality countries YLDs are 
only of marginal importance to the overall result and it therefore seems unnecessary to go 
into great efforts to accurately measure these, as it is not likely to make any difference to 
the cost-effectiveness conclusion.  YLDs could be of relatively greater importance in 
countries where the large majority of Hib cases survive. However, as was also shown in 
the Uzbekistan example, discounting of YLDs decreases the value considerably and it is 
questionable whether the choice between using one particular disability weight instead of 
another would make any difference to the overall cost-effectiveness result. These issues 
are evaluated in uncertainty analysis of the cost-utility estimates presented in Chapter 12. 
It is apparent that calculation of DALYs for Hib diseases was based on a number of 
assumptions, which were not easy to justify, such as determining disability weights for 
diseases not included in the GBD list. This piecemeal approach to HR-QOL valuation must 
be regarded as one of the greatest limitations of using DALYs. When estimated according 
to standard guidelines, there is little doubt that the QALY approach is considerably more 
evidence based than DALYs. Preference scores for QALY estimates are usually based on 
data collected from the general public as well as patients, so there is less need for making 
explicit assumptions when calculating the values.  
A distinct advantage of QALYs is also that they value health states instead of individual 
diseases, so different severities and co-morbidities are implied in the values.  However, as 
mentioned in the beginning of the chapter, the work on developing generic, validated 
instruments and QALY scoring systems for use in low-income countries is still only in its 
early beginning, so DALYs can probably be expected to be the standard measurement used 
for many years to come.  
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A revision of the DALY methods is in progress and expected to be released during 2012. 
The revision, which is being completed by the several different research groups, involves 
updated global burden of disease estimates for all the previous and a number of new 
diseases and sequelae. These estimates are largely based on systematic literature reviews. 
The DALY disability weights will also be revisited and this time they will be based on 
population preference surveys instead of expert opinion [246]. However, details of the 
work are not yet open to the public, so it is not possible to judge the extent of the changes 
and what it means for future analyses. Many of the limitations observed over the years by 
several researchers would most likely have been dealt with in the new methods, so large 
improvements are hoped for.  
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10 COSTS OF HIB DISEASE  
The costs of treating disease should it occur is an important component of any economic 
evaluation, as are costs associated with longer term health outcomes.  The decision-
analytic model is structured so that up to five different types of Hib disease costs can be 
included:  
i. Treatment costs of Hib meningitis 
ii. Treatment costs of Hib pneumonia 
iii. Treatment costs of Hib NPNM 
iv. Lifetime treatment costs of Hib meningitis sequelae 
v. Lifetime productivity costs due to Hib meningitis sequelae 
If a government health sector perspective is taken, only costs incurred by the public health 
sector should be included while with a societal perspective, household costs in the form of 
out-of-pocket payments for public as well as private treatment are also incorporated. 
Lifetime productivity costs due to meningitis sequelae can be included if a societal 
perspective is taken.  
As was shown in the literature review of treatment cost studies in Chapter 5, it is 
important to integrate access to health care and treatment utilization behaviours into the 
analysis. This is essential because treatment costs are potentially reduced if a proportion 
of the population have limited or no access to health care and mean costs per case vary 
between levels of care and between public and private health facilities.  
In this chapter, treatment costs of i) meningitis, ii) pneumonia and iii) NPNM are 
estimated for the three study countries; Belarus, India and Uzbekistan. This is followed by 
a case study from Senegal on iv) lifetime treatment costs of meningitis sequelae, and v) 
lifetime productivity costs of caregivers due to meningitis sequelae.  
10.1 TREATMENT COST ESTIMATES FOR BELARUS, INDIA AND UZBEKISTAN 
10.1.1 STUDY OBJECTIVES AND PERSPECTIVES 
The aim was to estimate total annual costs of treating Hib meningitis, Hib pneumonia and 
Hib NPNM in children less than five years in Belarus, India and Uzbekistan. Secondary 
objectives were:  
1. To determine the proportion of the population accessing health care. 
2. To establish health care utilization behaviours of those with access to care. 
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3. To estimate the mean costs per patient of treating meningitis, pneumonia and 
NPNM, according to type and level of health care provider. 
4. To determine the proportion of total costs financed by the government versus 
households.  
Fundamental aspects of the health systems in the three countries are described in Annex 
3. In India, approximately 70% of all health spending occur in the private sector, which is 
one of the highest proportions in the world. Out-of-pocket payments for health services 
are a considerable burden for poor households in India, and it is estimated that more than 
40% of people have to borrow money or sell assets to cover hospital expenses [247]. 
While the government was the sole provider of health care in Belarus and Uzbekistan 
during Soviet times, private health expenditures has increased rapidly since 
independence, largely due to a widespread problem of informal out-of-pocket payments 
for public services [248]. During 2008, private expenditures comprised around 50% and 
25% of total health sector expenditures in Uzbekistan and Belarus, respectively [249].    
It was decided to restrict the Belarus analysis to the government health sector perspective. 
While it is likely that a proportion of treatment costs for Hib diseases are financed by 
households as unofficial out-of-pocket costs, there is no legitimate information on this. 
Belarus is still ruled by a socialist dictatorship and data collection on household health 
expenditures is not politically feasible. In Uzbekistan and India, societal perspectives were 
taken with treatment costs separated into government and household expenses.  
10.1.2 METHODS 
Data were collected from a mixture of primary and secondary sources in the three 
countries. I visited India in November 2007 and July 2008, Uzbekistan in November 2008, 
and Belarus in December 2008 and June 2009. During these visits I established a working 
relationship with the country collaborators, conducted interviews with key stakeholders, 
determined the need for primary data collection, and trained the collaborators in 
collecting the data.     
10.1.2.1 Access to care and health care utilization 
Penchansky and Thomas define access as a concept that incorporates features of “fit” 
between the patient and the health care system, i.e. the dimensions span over both the 
supply and demand sides. Three main factors influence access [250]:  
1. Affordability: The ability to pay and the impact on livelihoods of households 
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2. Availability: The relationship between the volume and type of relevant health care 
workers, facilities and services on the one hand and the volume and type of patient 
needs on the other. It covers factors such as location of services, availability of 
transport, opening hours and waiting time. 
3. Acceptability: The patient’s attitudes to the characteristics of the providers and the 
attitudes of providers towards patients. This is about how well social and cultural 
aspects of the health system reflect those of communities.   
In the decision-analytic model, assumptions about access to care are expressed in terms of 
number of outpatient visits and hospital admissions per case. According to the WHO 
treatment recommendations for Hib diseases, all Hib syndromes except non-severe 
pneumonia require hospitalisation (see Annex 1). Hence, if all children in a country have 
access to appropriate health care services, each case of meningitis, severe pneumonia and 
NPNM would lead to at least one hospitalisation and most likely also at least one 
outpatient visit, as hospitalisations are generally referred during an outpatient 
consultation. The number of outpatient visits per case would exceed one in places with 
high access to care as clinical follow-up is commonly recommended after hospital 
discharge. If access to health care is limited, the number of outpatient visits and 
hospitalisations per Hib disease case would be less than one.    
For each of the three countries, health sector appraisals, household surveys and published 
literature were reviewed to establish the most reliable assumptions for access to care and 
health care utilization patterns. Routine meningitis and pneumonia surveillance data were 
also used to establish the proportion of cases being treated at the different levels of care.   
10.1.2.2 Estimation of mean treatment costs per case  
In Belarus and Uzbekistan a selection of hospitals were visited for treatment cost data 
collection. In Belarus, the hospitals were the MCCIDH, Minsk Regional Hospital and 
Stolbtsy District Hospital. In Uzbekistan the Infectious Disease Hospital #1, the Paediatrics 
Research Institute, the Children’s Hospital #5 of Yunusobod District, and the Uchtepa 
District Children’s Hospital were visited. A description of the facilities is given in Annex 4. 
Hospital administrators were interviewed through an interpreter. Questions were asked 
about standard treatment procedures for childhood pneumonia and meningitis, the 
average length of stay in hospital of these patients, and the estimated costs per bed day of 
the facility. This information was supplemented by a retrospective review of 
approximately ten pneumonia and ten meningitis patient records at the national referral 
hospitals in each country (the MCCIDH in Belarus and the Infectious Disease Hospital #1 in 
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Uzbekistan), with the purpose of collecting data on common diagnostic tests and drug 
utilization. Unit costs of drugs were gathered from the hospital pharmacies. My study 
collaborators completed this work using a data collection spreadsheet I developed for the 
purpose.  
Since there is no information available on the average costs of an outpatient visit in 
Belarus and Uzbekistan, data from WHO CHOICE were used (see Annex 2). The values 
were US$ 9.31 per visit in Belarus and US$ 1.53 per visit in Uzbekistan [251]. It was 
assumed that meningitis treatment costs were 20% less at secondary than at the tertiary 
hospitals where the meningitis treatment cost data were collected. 
In India, a number of meetings were held with researchers who had worked on treatment 
cost analysis. Health services in India vary considerably between states, so efforts were 
made to identify studies that could be considered nationally representative. After many 
discussions it was decided to estimate household costs from the sixtieth round of the 
Government of India National Sample Survey Organisation (NSSO) socio-economic survey, 
which in 2004 for the first time incorporated questions on morbidity and health [252].  In 
this survey, detailed information was collected from households on medical expenditures 
according to type of disease episode, with data on outpatient treatments and 
hospitalisations collected for the last 15 and 365 days preceding the interview, 
respectively. Household out-of-pocket costs were categorised in a specified manner 
according to medicines, user fees, lodging, transport, etc. The NSSO questionnaire is 
included in Annex 5. Results of the survey on “respiratory ailments” in children less than 
five years old were used for approximating household costs of pneumonia treatment. For 
this disease category, the nationwide sample sizes were 644 outpatient episodes and 238 
inpatient admissions. For meningitis treatment, the respiratory ailments costs were 
adjusted upwards in accordance with the additional lengths of stay in hospital for 
meningitis compared to pneumonia. Hospital length of stay for pneumonia and meningitis 
patients less than five years old were collected from a Hib Initiative supported multi-
centre surveillance study [253]. 
Treatment costs from the Indian government perspective were derived from the study by 
Krishnan and colleagues from the All India Institute of Medical Sciences in New Delhi [129, 
254, 255]. This study was included in the literature review in Chapter 5. A meeting was 
held with Dr. Krishnan to inform him about the Hib economic evaluation, discuss the 
methods he had used in his study, and determine to what extent his results can be 
assumed representative of other government facilities in India. The study by Krishnan et 
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al. was undertaken in the state of Haryana in North India with the aim of estimating 
outpatient and inpatient treatment costs of meningitis, pneumonia and diarrhoea in 
children less than five years. Data were collected from six government hospitals and two 
private hospitals. Both urban and rural areas were included and all three levels of health 
care (primary, secondary and tertiary) were represented [129]. Micro-costing methods 
were used for estimating costs per bed-day and a sample of patient records was reviewed 
for determining patient specific costs. The methods of the Krishnan study and how the 
data have been used for the present analysis are explained in more detail in Annex 4. 
In all three countries, treatment costs of NPNM were assumed similar to hospitalised 
pneumonia as it was not possible to locate costs of these relatively rare diseases.  
In Uzbekistan, only household expenses on drugs were included while in India information 
on other expenses, such as transport to the facility, was available from the NSSO survey. 
Productivity costs of caregivers due to time spent when taking children for treatment 
were excluded in all three analyses. Key informants in all three countries were asked 
whether data or studies on the costs of treating meningitis sequelae were available, but 
nothing was obtainable. This is the topic of the next section in this chapter.    
Costs were estimated in 2010 US$ using exchange rates of 2,793 Belarusian rubles, 45.7 
Indian rupees and 1,464 Uzbek som to one US$ (www.oanda.com/convert/fxhistory).  
Cost data prior to 2010 were adjusted using the average consumer price index 
(www.imf.org). 
10.1.3 RESULTS 
10.1.3.1 Access to care 
There is substantial evidence that access to health care is higher in Belarus than in the two 
other countries. In a quantitative, cross-sectional survey assessing health care seeking 
behaviour in eight former Soviet Union countries by Balabanova et al., Belarus consistently 
came on top of the list [256]. For example, the probability of seeing a health professional 
in the previous year was found to be 67% in Belarus while it was 24% in Georgia, the 
probability of seeking care when it seemed justified was 91% in Belarus, but only 51% in 
Georgia, and in Belarus 56% of adults responded yes when asked whether they would 
consult a health professional in the case of fever for more than three days, while only 16% 
would do so in Armenia [256].  Another indication of relatively high functional access is 
that Belarus has the largest number of doctors and nurses per 1,000 population in Central 
and Eastern Europe [257]. Children’s health is particularly monitored closely with every 
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newborn  seen by their primary care doctor three times during their first month and at 
least once a month up to the age of one year, and every child is supposed to have a general 
check-up by all main specialists annually until they are 18 years [257].  
In Uzbekistan and India, a relatively large proportion of the population has limited access 
to health care. A study on access to care in rural parts of Ferghana Oblast in Uzbekistan 
found that of individuals who reported an illness in the previous 30 days, around 45% 
self-treated with drugs before deciding whether to seek care and only about 50% went on 
to seek care, including visits to traditional healers [258]. Low-income individuals were 
significantly less likely to seek care than those with higher income. The study concluded 
that 21% of people reporting a health problem did not seek health care because they did 
not have enough money and of those who did seek care, 86% paid at least some money out 
of pocket [258]. A comparable conclusion was made in the 2006 Uzbekistan Multiple 
Indicator Cluster Survey (MICS) where data were collected from a representative sample 
of 10,505 households [259]. The data showed that of children aged 0–59 months with 
suspected pneumonia during the two weeks preceding the survey (defined as children 
who had an illness with a cough accompanied by rapid or difficult breathing), 35% of 
those living in rural areas and 26% of urban children were not taken to an appropriate 
health care provider. The national average of children without access to care was 32% 
[259].   
In India, selective, fragmented strategies and lack of resources have made the health 
system disconnected to public health goals and it fails to provide financial risk protection 
to the poor [247]. While there are substantial differences between the 28 states, access to 
health care is generally severely constrained due to geographic locations, bad roads, 
unreliable functioning of health facilities and transport costs [260]. One of the most 
important data sources on access to care is the Indian National Family Health Survey 
(NFHS). The third survey (NFHS-3) was conducted in 2005-2006 and had an interview 
sample of 230,000 people between 15 and 54 years [261]. Similar to the Uzbekistan MICS 
survey, it was asked whether children less than five years had been ill with a cough 
accompanied by short, rapid breathing in the two weeks preceding the survey and if so, if 
he/she had been taken to a health care provider.  It was found that 29% of children with 
Acute Respiratory Infections (ARI) symptoms did not have access to health services, with a 
range between 11% and 79% across the states [261].  
Access to care assumptions for the three countries are summarised in Table 10.1. Based on 
the evidence of high access to care in Belarus, it was assumed that all severe Hib disease 
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cases were hospitalised at least once. In this country it is moreover required that children 
who have suffered from meningitis should be re-hospitalised for follow-up one month and 
again six months after the initial discharge. As part of the present study, collaborators at 
MCCIDH reviewed hospital records of 18 meningitis cases admitted during 2007 and 2008 
and found that two of these children were re-admitted three times, seven two times and 
nine once as part of their follow-up. Based on these data, it was assumed that all children 
with meningitis were re-hospitalised 1.6 times in Belarus. Hence, the total number of 
hospitalisations was 2.6 per meningitis case. Three outpatient visits per pneumonia and 
NPNM episode and seven outpatient visits per meningitis episode were assumed based on 
the evidence of frequent consultations [257].  
In India and Uzbekistan, 0.71 and 0.68 hospital admissions per severe case were assumed, 
based on the findings from the NFHS-3 and MICS surveys, respectively.  Two outpatient 
visits were assumed for each admission of severe pneumonia, meningitis and NPNM, 
following common treatment procedures of one outpatient visit before admission, where 
the referral is made, and one follow-up visit after hospital discharge. For non-severe 
pneumonia, access to outpatient health care was assumed similar to inpatient access for 
severe diseases.   
Table 10.1: Numbers of hospital admissions and  
outpatient visits per Hib disease case 
 Belarus India Uzbekistan 
Number of admissions per case:    
Severe Hib pneumonia 1.0 0.71 0.68 
Hib meningitis 2.6 0.71 0.68 
Hib invasive NPNM 1.0 0.71 0.68 
Number of outpatient visits per case:    
Severe Hib pneumonia 3.0 1.42 1.36 
Hib meningitis  7.0 1.42 1.36 
Hib invasive NPNM 3.0 1.42 1.36 
Non-severe Hib pneumonia 1.0 0.71 0.68 
Sources: Belarus: 2008 health systems review [257], India: 2005-06 NFHS-3 [261], Uzbekistan: 2006        
MICS survey [259]. 
10.1.3.2 Health care utilization 
Assumptions about levels of hospital admissions are seen in Table 10.2. Private facilities 
were excluded from the Belarus and Uzbekistan analyses because private health care is 
only available in urban areas and only used by a marginal proportion of the population 
[257, 262]. Based on the Belarus population distribution, it was assumed that 80% of 
meningitis cases were admitted to secondary hospitals and the remaining 20% to the 
specialised, tertiary hospitals in Minsk. 2008 national pneumonia surveillance data from 
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Belarus showed that 76% of pneumonia admissions were at primary hospitals and 24% at 
secondary or tertiary hospitals.  
According to 2008 surveillance data from Uzbekistan, 4% of clinical meningitis cases were 
admitted to tertiary hospitals, 32% to secondary hospitals, and 64% to primary hospitals, 
and these figures were only slightly different for pneumonia (Table 10.2).   
In India, the NFHS-3 data reported that 41% of children with ARI were admitted to private 
hospitals, 27% to government primary hospitals and 32% to government 
secondary/tertiary hospitals. For the latter category, it was assumed that tertiary-level 
care accounted for 2% of admissions. Similar assumptions were made for meningitis. 
In Belarus and Uzbekistan, it was assumed that all outpatient consultations take place at 
government polyclinics. In India, the NFHS-3 data on outpatient consultations for ARI in 
children less than five years showed that 61% were taken to private clinics, 5% to private 
hospital outpatient departments, 10% purchased drugs in private pharmacies, 9% sought 
treatment from a traditional healer, and only 16% of children were taken to government 
outpatient providers [261].   
Table 10.2: Assumptions about distribution of hospital admissions  
for children less than five years with access to care 
 Belarus India Uzbekistan 
Hib meningitis:    
Government primary hospital 0% 27% 64% 
Government secondary hospital  80% 30% 32% 
Government tertiary hospital  20% 2% 4% 
Private hospital 0% 41% 0% 
Hib pneumonia and NPNM:    
Government primary hospital 76% 27% 66% 
Government secondary hospital  20% 30% 31% 
Government tertiary hospital  4% 2% 3% 
Private hospital 0% 41% 0% 
Sources: Belarus and Uzbekistan: MOH surveillance data gathered for the present study , India: 2005-06     
NFHS-3 [261] 
10.1.3.3 Mean treatment costs per case  
The mean length of stay in hospital was longer in Belarus than in the two other countries 
(Table 10.3). During re-hospitalisation for meningitis in Belarus the mean length of stay 
was nine days, compared to 21 days during the acute episode.  
Table 10.3: Mean length of stay in hospital (days) 
 Belarus India Uzbekistan 
Pneumonia 13 6 9 
Meningitis 21 10 11 
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Details of the resource items and their respective unit costs from the different facilities are 
included in Annex 4. In Belarus, the mean costs per bed-day were US$ 40 at MCCIDH and 
US$ 23 at Stolbtsy District Hospital. Staff costs comprised 59% and 83% of total bed-day 
costs in the two hospitals, respectively. When multiplying by mean length of stay, 
including the days in hospital during re-hospitalisation, and adding patient-specific items, 
such as drugs and diagnostic tests, average meningitis treatment costs amounted to US$ 
1,959 per episode at tertiary level (Table 10.4). Mean pneumonia treatment costs were 
US$ 413, US$ 448 and US$ 542 for primary, secondary and tertiary levels, respectively.  
In Uzbekistan, costs per hospital bed-day in the Infectious Disease Hospital #1 amounted 
to US$ 9.10. Mean costs of treating meningitis were US$ 238, US$ 257 and US$ 276 in 
primary, secondary and tertiary hospitals, respectively. For a very severe case less than 
one year old, drug costs comprised 46%, bed-day costs 40%, diagnostic tests 12% and 
food 2% of total costs The mean costs of pneumonia treatment were approximately 20% 
less than the costs of treating meningitis in primary and secondary hospitals, but only 3% 
less at tertiary level. Approximately 33% and 11% of costs were covered by households as 
out-of-pocket payments for drugs, for meningitis and pneumonia, respectively (Table 
10.4).   
In India, costs per bed-day were estimated as US$ 18 in a government secondary hospital 
and US$ 39 in a tertiary hospital. For primary and secondary government facilities total 
costs were almost similar to those estimated for Uzbekistan, but for meningitis treatment 
at tertiary level, costs were 40% higher in India than in Uzbekistan.  According to the NSSO 
survey data, 35% of household expenditures at government facilities were for drugs. Other 
expenditure categories were oxygen, diagnostic tests, transport and food and lodging. In 
private facilities user fees were the biggest cost item, comprising 57% of total household 
costs [252]. Further details on this are given in Annex 4. 
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Table 10.4: Mean inpatient treatment costs per acute case (2010 US$) 
Provider type Belarus Uzbekistan India 
Hib meningitis Government Government Households Total Government Households Total 
Primary hospital NA 169 86 238 164 81 245 
Secondary hospital  1,567 188 86 257 172 81 253 
Tertiary hospital  1,959 242 86 276 380 81 461 
Private hospital NA NA NA NA NA 241 241 
Hib pneumonia/NPNM        
Primary hospital 413 152 26 195 97 50 141 
Secondary hospital  448 171 26 214 101 50 151 
Tertiary hospital  542 190 26 268 224 50 274 
Private hospital NA NA NA NA NA 149 149 
 
Table 10.5: Mean outpatient treatment costs per visit (2010 US$) 
Provider type Belarus Uzbekistan India 
 Government Government Households Total Government Households Total 
Public clinic 9.31 1.53 5.00 6.53 2.88 12.30 15.18 
Private clinic NA NA NA NA NA 10.70 10.70 
Private hospital outpatient department NA NA NA NA NA 10.70 10.70 
Traditional healer NA NA NA NA NA 6.20 6.20 
Pharmacy NA NA NA NA NA 0.90 0.90 
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10.1.4 DISCUSSION 
In this section, access to care, health care utilization behaviours and the mean treatment 
costs per case of Hib meningitis, Hib pneumonia and Hib NPNM according to different 
levels and providers of care were determined for the three study countries. In Chapter 12, 
these parameter values are combined with disease incidence estimates to generate total 
treatment costs for 2010 birth cohorts, with and without Hib vaccine introduction. 
A finding from the literature review in Chapter 5 was that treatment costs were closely 
related to GNI per capita, with higher mean treatment costs per case in wealthier 
countries. This tendency was confirmed in this chapter as the treatment costs per case in 
Belarus were more than double compared to the two other countries. The 2010 GNI per 
capita were US$ 6,130 in Belarus, US$ 1,340 in India and US$1,280 in Uzbekistan [109]. 
The estimates for the three countries are in a similar range as the comparable study 
results shown in Chapter 5. The costs of treating meningitis at tertiary level in Belarus 
(US$ 1,959) are comparable with the costs in Brazil (US$ 1,474), and the India (US$ 461) 
and Uzbekistan (US$ 276) estimates are in a comparable range to those in Kenya (US$ 
434) and Vietnam (US$ 211).  
There are important strengths and limitations of the methods used for estimating mean 
treatment costs per case. A micro-costing exercise involving collection of resource 
utilization data and associated unit costs from a sample of patients, as done in the studies 
reviewed in Chapter 5, was not undertaken as part of this thesis. Instead, a more 
pragmatic approach of using the best available published data supplemented by 
information collected relatively rapidly was employed.  While there is no doubt that the 
estimates would have been more precise if a micro-costing exercise had been undertaken, 
this was not feasible within the timeframe of the studies. It is moreover unlikely that such 
an approach would have been possible in Belarus due to the political climate.  
An alternative to collecting data relatively rapidly in Belarus and Uzbekistan could have 
been to extrapolate from the results of the more rigorous studies in Chapter 5. However, 
when working in countries during the time of the Hib Initiative it was repeatedly found 
that local researchers and policy makers rarely accept the use of data from other countries 
than their own [66]. Even when data underpinning local estimates are of less quality than 
those from other countries, local estimates are generally preferred. I have moreover 
observed that the interest in the study of policy makers and the general trustworthiness of 
the analysis are substantially enhanced when stakeholders recognize the health facilities 
where data have been collected. An additional advantage was that when visiting health 
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facilities for treatment cost data collection, the opportunity was taken to inform about the 
study and about Hib vaccine in general. This was extremely important for building local 
ownership of the analyses and for fostering collaboration with local researchers. Health 
economics is a relatively new concept in both Belarus and Uzbekistan and the present 
study represent some of the first treatment cost estimates ever generated in these 
countries.    
In India the treatment cost estimates were derived from published sources and limited 
primary data collection was undertaken. This approach was justified because transparent 
and detailed studies already exist in this country. Government health sector costs were 
derived from a high quality micro-costing study by Krishnan et al. and household costs 
were based on NSSO survey data. Both of these sources obtained estimates from large 
sample sizes and in the NSSO survey, households from all 28 states were included. It 
would not have been possible within the normal time and budget constraints of a research 
study to collect data of comparable high quality.           
All the parameter estimates presented in this section are surrounded by uncertainty. It is 
therefore crucial to assess the importance of the treatment cost estimates to the overall 
cost-utility results and this is done in the sensitivity analysis in Chapter 12. Furthermore, 
in the probabilistic uncertainty analysis, all the treatment cost parameters are attached a 
gamma distribution and Monte Carlo analysis is undertaken to generate an uncertainty 
range around the cost-utility estimate, thus taking the uncertainty of parameter values 
into account.   
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10.2 COSTS OF TREATING MENINGITIS AND LIFETIME COSTS OF MENINGITIS SEQUELAE IN 
SENEGAL3  
10.2.1 INTRODUCTION 
A major gap in the literature is information about the societal costs of meningitis sequelae 
in low-income countries. These costs consist of three components: (i) treatment costs of 
sequelae, (ii) productivity costs of caregivers due to time spent looking after a disabled 
child and (iii) future productivity costs because the child will not be able to work in 
productive activities when he/she grows up.  
In all the nine economic evaluations from high-income countries reviewed in Chapter 5, all 
or parts of these costs were included in the studies, but this was not the case for the low- 
and middle-income country studies. In the economic evaluations from high-income 
countries, lifetime treatment costs of meningitis sequelae were based on data collected 
from education agencies, disability services and medical insurance companies on the costs 
of hearing aids, special education, rehabilitation and institutional care [110, 115, 116, 118, 
119, 120, 121]. However, in low- and middle-income countries with limited access to 
health care and hardly any special education institutions, these types of assumptions 
cannot easily be made.  Only two of the eight studies from low- and middle-income 
countries made attempts to include these costs, but the estimates were largely based on 
assumptions with no or limited primary data. In one of the Indonesian studies, treatment 
of sequelae was assumed to consist of four  annual outpatient visits, but there was no 
evidence for this and it was not specified for how many years this would occur [123]. In 
the Russian study, parents of 31 meningitis patients were telephoned one year after 
hospital discharge and asked about medical expenses due to meningitis sequelae, and it 
was assumed that these costs would remain the same for the subsequent ten years and be 
reduced to zero thereafter [122].   
Productivity costs due to meningitis sequelae were included in six of the papers reviewed 
in Chapter 5 and excluded in the remaining 11 studies. In the Swedish study by 
Garpenholt, 25% productivity costs were attached to parents of a disabled child until the 
child was 20 years old, and from 20 years onwards 100% productivity costs were included 
for all persons with severe disability [118]. Productivity costs were determined using a 
figure from the Swedish Road Administration where a life had been valued using the 
willingness-to-pay approach. In the studies from the Philippines, Russia, South Africa, 
                                                             
3 A modified version of this section has been published in the Paediatric Infectious Disease Journal 
as:  Griffiths UK, Dieye, Y, Fleming J, Hajjeh, R, Edmond K, Costs of meningitis sequelae in Dakar, 
Pediatr Infect Dis J. 2012 Jun 4. [Epub ahead of print]. 
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South Korea and the USA, the average wage rate was used to value future lost productivity 
due to premature mortality and disability [111, 112, 114, 121, 122]. Productivity loss of 
parents were not included. 
In this part of the chapter, a study from Dakar in Senegal on the costs of acute meningitis 
and meningitis sequelae is presented. Methodological issues for valuing productivity costs 
are discussed in the next section, study objectives are outlined in section 10.2.3, methods 
are described in section 10.2.4, results in section 10.2.5, and the study findings are 
discussed in section 10.2.6. 
10.2.2 METHODOLOGICAL ISSUES FOR VALUING PRODUCTIVITY COSTS IN LOW-INCOME 
SETTINGS 
It is widely accepted that forgone production due to illness and mortality represents a cost 
to society, which should be taken into account when assessing the cost-effectiveness of 
health interventions [67]. The traditional method for placing a monetary value on time is 
the human capital approach where productivity costs equals the present value of lost 
gross wages over the period of illness or from the time of premature death until 
retirement age [263]. The theoretical foundation of this method is that in a well-
functioning labour market, productive output and compensation to the worker are equal, 
because they represent the same resource. The human capital approach has however been 
challenged by the proponents of the “friction cost” approach, who argue that in practice, if 
a worker is absent from work for an extended period of time, lost productivity would only 
be during the period until an otherwise unemployed replacement worker is found [264]. 
Hence, the productivity costs should be limited to this frictional period because sufficient 
unemployment generally exists to replace the ill worker. With the friction cost approach, 
production losses due to long term disability or death are thus limited to a relatively short 
period required to replace a worker, which makes a large difference to the estimates 
compared to the human capital method.   
For both approaches it is assumed that the bulk of the working population is oriented 
towards paid employment and that channels for the exchange of labour market 
information exist and is widely used. These assumptions do however not hold in low-
income countries, which are characterised by fragmented labour markets and a large 
informal sector.  As an example, in Senegal during 2005, only 17% of the labour force was 
wage earners and 40% of these worked in the informal economy, mostly within household 
enterprises [265]. With only a relatively small proportion of the adult population being 
wage earners, application of an average formal sector gross wage for estimating 
productivity costs as dictated by the human capital approach is likely to overestimate the 
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real value. Since the period until a new worker can be found is particularly short in the 
informal sector, use of the friction cost approach would lead to considerably lower 
productivity cost estimates compared to the human capital approach.  
The challenges mentioned above could be one reason why GDP per capita has been used 
for valuing productivity costs in a number of low-income country studies, such as a recent 
study on estimating the economic benefits of vaccines in GAVI eligible countries [266]. The 
purpose of GDP per capita is to quantify the average amount of goods and services 
available to each person in an economy. It is closely correlated to average income, but 
since GDP includes all age groups, conceals income inequalities and does not include 
informal sector activities, it is not analogous to average income and is therefore not an 
appropriate measure for valuing productivity costs. The use of GDP per capita for valuing 
productivity costs is not a recommendation included in standard economic evaluation 
guidelines and it is questionable why this approach has been used in several studies 
without any explanations or justifications [110, 120, 266].  
10.2.3 STUDY OBJECTIVES 
Senegal is a low-income country in West Africa with 2010 GNI per capita of US$ 1,090   
[109]. With support from the GAVI Alliance, Hib vaccine was introduced in 2005 and 
pneumococcal vaccine is scheduled for introduction during 2012. The aim of this study 
was to estimate the lifetime costs of bacterial meningitis sequelae in children less than five 
years of age in Dakar. Secondary objectives were to: 
1. Estimate household treatment costs of an acute bacterial meningitis episode, 
based on recall information from caregivers. 
2. Investigate health care seeking behaviours of caregivers of children suffering from 
meningitis sequelae. 
3. Estimate lifetime household treatment costs of meningitis sequelae. 
4. Estimate lifetime productivity costs of caregivers of children with meningitis 
sequelae. 
A “sequela” was defined according to the 2001 Global Burden of Disease project as a health 
state due to bacterial meningitis, which impairs quality of life or activities of daily living 
and for which prevalence and average duration can be estimated [216].  
The research was part of a prospective cohort study designed to assess disability, quality 
of life and the economic burden of children with bacterial meningitis sequelae in Dakar. 
The study was funded by the Hib Initiative and undertaken in collaboration with the 
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Programme for Appropriate Technologies in Health (PATH) country office in Senegal. Staff 
at this office were completing a Hib vaccine case-control study when our study began, 
which was a major advantage because the field investigators already had experience with 
Hib disease and Hib vaccine [267].  Data collection for the study took place between 
January and July 2009. The results of the disability and quality of life assessments were 
published in the Paediatric Infectious Disease Journal in 2010 [268].  
The study was approved by the ethics committees of PATH, LSHTM and the Senegal 
Ministry of Health.  A one-year programme of free follow-up care was developed for 
children recognized with a disability [268]. 
10.2.4 METHODS 
10.2.4.1 Sequelae definitions 
A “sequela” was defined according to the 2006 Global Burden of Disease (GBD) project as a 
health state due to bacterial meningitis, which impairs quality of life or activities of daily 
living [126]. Minor and major sequelae were also classified according to GBD definitions  
and a separate category was created for individuals with more than one sequela (multiple 
impairments) [126, 235].  Children with minor sequelae were defined as those with 
speech deficits, hearing deficits or behavioural problems. Children with major sequelae 
were those with multiple sequelae and/or movement problems, vision deficit, cognitive 
problems or epilepsy. 
10.2.4.2 Identification of study children 
Children were enrolled from a Paediatric Bacterial Meningitis (PBM) database at the 
Albert Royer Hospital in Dakar.  Since 2001, this hospital has been part of the WHO African 
Regional Office Laboratory PBM Surveillance Network [269]. PATH provided technical 
support to the surveillance system between 2006 and 2009 as part of their Hib vaccine 
case-control study [270].  
For logistical reasons, only Dakar residents could be included the study. Additional 
inclusion criteria were that children should have been less than five years old at the time 
of the meningitis episode and at least four years old at the time of the study assessments. 
The latter criterion was included because neurological tests are generally not reliably 
administered in children younger than four years.  
A total of 320 children were included in the Albert Royer Hospital PBM database up to 
November 2007, when the study protocol was prepared (Table 10.6).  
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Table 10.6: Bacterial meningitis cases in the PBM database 2002 - 2007 at Albert 
Royer Hospital 
Age on 1st Jan. 
2008 
Hib Pneumococcal Meningococcal Other 
bacteria 
Total  
Less than 1 year 0 5 1 5 11 
1-2 years 1 14 0 1 16 
2-3 years 14 8 1 10 33 
3-4 years 41 14 1 13 69 
4-5 years 43 15 2 5 65 
5-6 years 28 20 2 9 59 
6-7 years 35 12 3 4 54 
7-8 years 4 4 0 0 8 
8-9 years 0 3 0 1 4 
9-10 years 0 0 0 0 0 
≥10 years 0 0 1 0 1 
Total 166 93 11 48 320 
Hib was the most frequent cause of meningitis, representing 52% of all cases identified 
during the six year period. Of the 320 children, 191 were at least four years old in January 
2008 and 159 of these were Dakar residents. However, residential contact details were 
only available for about half of the patients, so we aimed to recruit 80 children who had 
suffered from bacterial meningitis.  
10.2.4.3 Data collection 
Children were located at their home between January and July 2009 and caregivers were 
administered a detailed questionnaire by one of two recruited research staff. Questions 
included whether the child had epilepsy or behavioural, physical, cognitive, verbal, 
auditory and/or visionary problems. Socio-demographic information about the caregiver’s 
education, occupation, religion and socio-economic status was also collected. The socio-
demographic questionnaire is included in Annex 6. If the child had died, families were 
interviewed using a verbal autopsy questionnaire.  
The economic questionnaire was divided into four parts: 
1. Costs related to the acute meningitis episode. 
2. Costs of subsequent hospital admissions due to meningitis sequelae. 
3. Costs of outpatient visits due to meningitis sequelae. 
4. Costs of caring for a disabled child, including estimated productivity costs of 
caregivers. 
The economic questionnaire is included in Annex 7. If receipts of the treatment expenses 
were available, these were reviewed by the research staff, otherwise, all costs were based 
on recall. Both questionnaires were translated into French and piloted with two families 
by myself and the research staff before the study started. The interviews were undertaken 
in either French or Wolof. 
Chapter 10: Costs of Hib disease 
 
140 
 
After the interview, all children were invited for clinical evaluations by a neurologist, a 
psychologist and an audiologist at hospitals and clinics in Dakar. The results of these 
assessments were published in the 2010 paper by Edmond et al. [268]. In-depth 
interviews were conducted with three families to qualitatively evaluate how it has affected 
their lives to have a disabled child. I developed an interview guide for this purpose. 
10.2.4.4 Estimating lifetime productivity costs of caregivers 
Caregivers were asked who looked after the child during the day, whether this was 
different compared to if the child had not suffered from sequelae, if any household 
members were unable to work due to the child’s disability, how much money any 
childminder was paid, and the estimated weekly lost earnings of any household member 
who was not able to work because he/she cared for the child.   
Katz reviewed studies on the life expectancy of children with cerebral palsy and mental 
retardation and concluded that their life span is reduced by certain key disabilities, most 
importantly decreased cognitive abilities [271]. Life expectancies at five years varied 
between 12 and 41 years, depending on disability severity, but all the identified studies 
were from high-income countries [271]. Eyman et al. found that in the USA around 1990, 
five-year old children who are mobile, but not ambulatory and could eat with assistance 
had a life expectancy of 40.9 years while those who are immobile, not toilet trained but 
could eat with assistance had a life expectancy of 25.2 years [272]. This is compared to a 
life expectancy of 71.2 years for five-year old children in the general US population [273]. 
To account for the lower life expectancy in Senegal (62.9 years for five-year olds in 2009 
[273]) and the fact that our study children presented with a wide variety of disabilities, an 
overall life expectancy of 30 years was assumed. Hence, annual productivity costs were 
assumed to last for 30 years. While the life expectancy of those with minor sequelae is 
likely to be relatively similar to the rest of the population, their costs were also predicted 
for 30 years because they most probably become self-sufficient at some point in their lives. 
10.2.4.5 Data analysis 
Data were single-entered into a Microsoft Access database and analysis was undertaken in 
Excel and STATA version 11.1. All past costs were adjusted to 2010 US$  values using the 
annual consumer price index of Senegal (www.imf.org) and an average exchange rate of 
486 CFR to one US$ (www.oanda.com). It was assumed that the costs of caring for a 
disabled child and young adult would last for a total of 30 years, based on reviewing 
literature from high-income countries on the life expectancy of disabled children [271, 
272, 274, 275, 276] coupled with expert opinion about their life expectancy in Sub-
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Saharan Africa. Hence, treatment and productivity costs were extrapolated 30 years into 
the future. All future values were discounted by 3% per year  [88].  
Sensitivity analysis was undertaken to assess changes in the result of using official average 
wage rates instead of perceived productivity loss, assuming only a 20 year average life 
expectancy, higher outpatient costs to reflect a situation with better access to care, and no 
discounting of future values. 
10.2.5 RESULTS 
10.2.5.1 Patient recruitment 
Efforts made to locate children were highly successful, with 91% of the 87 age eligible 
Dakar resident children found (Figure 10.1).  
Three families refused to participate, eight children had died (case fatality rate of 10%) 
and two children were excluded from the analysis because the interviewees did not have 
information about expenses paid for treatment. Hence, 66 children were included in the 
Figure 10.1: Identification of study children 
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Dakar or without 
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46 with sequelae
treatment cost data
19 without sequelae
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cost analysis of acute meningitis. Of these children, 36% had been diagnosed with Hib 
meningitis, 33% with pneumococcal meningitis, 17% with meningococcal meningitis, and 
14% with meningitis caused by another bacterium. Forty seven suffered from sequelae 
and this sample was used for the sequelae cost analysis. 
10.2.5.2 Socio-demographic characteristics of study population 
The average age at the time of the interview was six years and eight months, with the 
youngest child four years and the oldest ten years old. The average age of the meningitis 
episode was 15 months, with the youngest child three weeks and the oldest four years and 
eight months. The median time between the interview and when the child was 
hospitalized with meningitis was five years and five months (IQR 54 – 75 months). 
The mother was interviewed in 62% of the visits (Table 10.7). Nine different ethnicities 
were represented with nearly half of the children being Wolof (Table 10.8).  Six percent of 
the primary caregivers had a university education, 27% had completed secondary school, 
26% primary school, 9% Koranic school, and 32% had no education. All households had 
flush toilets connected to a septic tank and only four did not have electricity (Table 10.9). 
In 51 (77%) of the households at least one member was earning a cash income, but in 
seven of these income was solely remittances from emigrated family members and for 
another six it was pension of one family member only. Occupations included accountant, 
dressmaker, carpenter, teacher and hair dresser.  
The Senegalese live together in large extended families, so in 35% of the households more 
than ten people slept in the dwelling the night before the interview (Table 10.9). For 17% 
of the interviewees it was not possible to answer this question because so many people 
come and go and the number of people sleeping in the dwelling varies day by day.   
Table 10.7: Relation to child of the person interviewed 
Relation Number Percent 
Mother 41 62% 
Father 8 12% 
Grandmother 11 17% 
Grandfather 3 5% 
Other 3 5% 
Total 66 100% 
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Table 10.8: Primary caregiver characteristics (n=66) 
Characteristics Number Percent 
Ethnicity:   
Wolof 31 47% 
Poular 5 26% 
Serere 17 8% 
Bambara 4 6% 
Diola 1 6% 
Soninke 4 3% 
Mankagne 2 2% 
Naar 1 2% 
Lebou 1 2% 
Religion:   
Muslim 65 98% 
Christian 1 2% 
Highest education:   
University 4 6% 
Secondary school 18 27% 
Primary school 17 26% 
School of the Koran 6 9% 
No schooling 21 32% 
 
Table 10.9: Household characteristics (n=66) 
Characteristics Percent 
Households that own land 6% 
Households with at least one person with regular cash income 77% 
Households with electricity 94% 
Households with flush latrine 100% 
Main water source:  
Piped into dwelling 91% 
Public tap 6% 
Open well 3% 
Number of children less than 18 years living in dwelling:  
One 9% 
Two 14% 
Three 11% 
Four 20% 
Five 14% 
Six or above 27% 
Unknown 6% 
Number of people sleeping in dwelling the night before the 
interview: 
 
Between 3 and 5 people 11% 
Between 6 and 10 people 38% 
Between 11 and 15 people 21% 
Between 16 and 20 people 8% 
Between 21 and 35 people 3% 
Unknown 17% 
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10.2.5.3 Meningitis sequelae prevalence 
Sequelae prevalence reported by the caregivers and according to the clinical assessments 
are summarised in Table 10.10. While 49 (74%) of the children were reported to suffer 
from at least one type of sequelae by the caregivers, the clinical assessments detected 
sequelae in 53 (77%). The clinical assessments discovered hearing deficits in four 
children, which the caregivers were unaware of prior to the study. Thirty five percent of all 
the children and 53% of those with any sequelae suffered from more than one type of 
disability. As seen in Table 10.11, a total of 21 different combinations of multiple sequelae 
were identified. Behavioural problems, speech deficits and epilepsy were the most 
frequent types of sequelae, occurring in 66%, 57% and 34% of children suffering from any 
type of sequelae, respectively. The most common combination was problems with 
movement, cognitive deficit, speech deficit, behavioural problems and epilepsy. 
Table 10.10: Sequelae prevalence in study children 
 Reported by caregivers 
(n=66) 
Clinical assessments 
(n=66) 
 Number Percent Number Percent 
No sequelae 19 29% 15 23% 
One type of sequelae 12 18% 28 42% 
Two types of sequelae 7 11% 10 15% 
Three types of sequelae 9 14% 11 17% 
Four types of sequelae 2 3% 2 3% 
Five types of sequelae 12 18% 0 0% 
Six types of sequelae 4 6% 0 0% 
Seven types of sequelae 1 2% 0 0% 
Total 66 100% 66 100% 
          Source for clinical assessments: Edmond et al. (2010)  
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Table 10.11: Types of sequelae reported by the caregivers 
Type of sequelae 
Number of 
children 
No sequelae (child is normal) 19 
Single sequelae   
Movement problems 5 
Hearing deficit 3 
Speech deficit 2 
Behavioural problems 2 
Multiple sequelae (2)   
Cognitive and behavioural problems 2 
Speech and hearing deficits 2 
Behavioural problems and hearing deficits 2 
Vision and hearing deficits 1 
Multiple sequelae (3)  
Movement, vision and hearing deficits 1 
Movement, hearing deficit and epilepsy 1 
Speech, behavioural problems and hearing deficits 2 
Movement, speech deficits and behavioural problems 1 
Movement, cognitive and speech deficits 1 
Movement, cognitive and behavioural problems 1 
Cognitive, speech and behavioural problems 1 
Cognitive, behavioural problems and hearing deficits 1 
Behavioural problems, vision deficit and epilepsy 1 
Multiple sequelae (4)  
Cognitive, speech, vision deficits and behavioural problems  1 
Cognitive, speech, behavioural and hearing problems 1 
Multiple sequelae (5)  
Cognitive, speech, hearing, behavioural problems and epilepsy  1 
Movement, cognitive, speech, behavioural problems and epilepsy 9 
Movement, cognitive, speech, behavioural and hearing deficits 2 
Multiple sequelae (6)  
Movement, cognitive, speech, behavioural problems, hearing deficits and epilepsy 2 
Movement, cognitive, speech, behavioural problems, vision deficits and epilepsy 1 
Multiple sequelae (7)  
Movement, cognitive, speech, behavioural problems, vision and hearing deficits and 
epilepsy 
1 
Total 66 
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10.2.5.4 Household costs of the meningitis episode 
During the acute episode, 70% of the children were taken to at least one other health care 
provider before being admitted to Albert Royer Hospital. Ten families visited two different 
providers, two sought help at three places and 32 went to one other provider before 
coming to the hospital. Forty one percent visited a government health post, 24% a 
traditional healer, 17% a district government hospital and 10% a private health clinic 
(Figure 10.2). The mean costs of pre-hospitalisation consultation fees and medication 
were US$ 68 (range US$ 0 – 649). 
The mean length of hospital stay was 22 days, but the distribution was positively skewed, 
with a few patients staying considerably longer than the others; one patient had a stay of 
88 days and another 120 days (Figure 10.3).  
Figure 10.2: Health providers visited before taking the child to hospital (n=66)  
 
Figure 10.3: Histogram of length of stay in hospital (n=66) 
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Albert Royer Hospital generates the majority of its income from user fees. During 2011, 
the charge for one day in the paediatric ward was approximately US$ 27. In addition, 
patients must pay the full costs of all drugs and diagnostic tests. While social services at 
the hospital can assist patients who are unable to pay, relatively few families benefit from 
this due to great administrative complications of applying. Mean household costs of the 
acute episode were US$ 1,289 per patient (range US$ 207 – 7,076) (Table 10.12 and 
Figure 10.4). Hospital fees and drugs comprised 71% of total costs, transport 14%, other 
costs 10% and pre-hospitalization 5%. One child was an outlier with total costs of US$ 
7,076. This child was hospitalized with meningitis at the age of 18 months and stayed in 
hospital for 60 days. Total hospital fees and drugs for treating this child amounted to US$ 
5,378, which is over six times more than the mean of US$ 844 for the remaining patients 
(range US$ 86 – 3,506). Without this child, total mean costs among the children were US$ 
1,200 (range US$ 207 – 3,506).  
By dividing costs of fees and drugs by the length of stay in hospital, the mean costs per 
hospitalized day were calculated as US$ 51 (range US$ 1 – 161). Reasons for the large 
variability in daily treatment costs are that some of the families obtained exemption of 
their fees through the social service system mentioned above and the purchase of drugs 
and diagnostic tests varied widely according to disease severity and according to what 
caregivers could afford to buy.  
It was apparent from the interviews that the episode had posed an overwhelming financial 
burden on the families and lack of funds was the primary reason for seeking alternative 
types of treatment before going to the hospital. Interview quotes on this topic are 
summarised in Textbox 10.1. 
Table 10.12: Household treatment costs of the acute meningitis episode (2010 US$)  
Type of expense 
No of 
children 
Mean SD* 95% CI 
Minimum 
cost 
Maximum 
cost 
Prior to hospitalisation 66 68 120 0 – 262 0 649 
Hospital user fees and drugs 66 913 814 143 – 1,806 86 5,378 
Transport costs 66 180 181 23 – 473 0 982 
Other costs 66 128 125 16 – 414 0 575 
Total costs of acute episode 66 1,289 1,047 361 – 2,812 207 7,076 
* SD = standard deviation  
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Figure 10.4: Histogram of household costs of acute meningitis episode (n=66) 
 
 
Textbox 10.1: Quotes on the financial burden of direct treatment costs 
 
10.2.5.5 Treatment costs of meningitis sequelae  
As described above, 47 of the study children suffered from minor or major sequelae. Ten 
(21%) of the 47 study children who suffered from sequelae were re-hospitalized after the 
acute episode. Seven were re-hospitalized once, two children two times and one child 
three times. Ten of the 14 re-admissions took place at Albert Royer Hospital, three at other 
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 “During hospitalization we spent much money because the prescriptions were expensive. 
The injection was very expensive with the cost of one vial 8,000 CFA (US$ 16). I was 
obliged to take the heritage of my deceased father, but this was not enough. God assisted 
us. I borrowed some money from my friend, but I only managed this situation with 
difficulties because I was unemployed. The hospitalization was a heavy financial charge and 
now we haven’t got the household expenses. I used my only money for the child’s 
treatment”. 
 “We first thought it was a malaria attack that caused the fracture. We used butter shea in 
vain during three days for massage. We then brought him to hospital. He spent one month 
at hospital under drip. He was always sleeping. We bought many medicaments and the 
prescriptions were very expensive. My parents assisted me to buy the prescriptions and I 
sold all my possessions”. 
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average length of stay was 20 days (range 5 - 60 days) and the mean costs per patient 
amounted to US$ 1,293 (range US$ 105 – 2,572) (Table 10.13). 
All the 47 children with sequelae except one had been taken for outpatient consultations. 
The one child who had not received any follow-up care suffered from hearing, speech, 
movement, cognitive deficits and behavioural problems. The caregivers reported that they 
had not taken the child for any consultations because they could not afford the transport 
expenses. For the remaining 46 children, 88% of the follow-up visits were at specialty 
outpatient clinics at Albert Royer Hospital. While 21% of these children had attended 
regular consultations with a physiotherapist or a neurologist during a certain period, all 
follow-up care had ceased by the time of the interview and only two children had attended 
an outpatient consultation in the year before the study. The mean number of consultations 
per child was 2.55 during the same year as the episode, 1.81 one year later, 0.43 two years 
later, 0.09 three years later, and   0.06 four years later. The mean cost per visit was US$ 27 
(range US$ 0 – 72), with transport costs comprising on average 20% (mean transport 
costs per visit were US$ 7.15 (range US$ 0 - 23)). Mean outpatient costs per child over the 
study period amounted to US$ 189 (range US$ 5 – US$ 753) among the 46 children 
receiving consultations (Table 10.13). 
Table 10.13: Mean costs of meningitis sequelae among children  
where expense is reported (2010 US$) 
 No of 
children 
Mean SD* 95% CI Min Max 
 
Re-hospitalisation       
Fees of 1st rehospitalisation 10 924    688 70 - 2,271 70 2,271 
Fees of 2nd rehospitalisation 3 637     210 401 - 802 401 802 
Fees of 3rd rehospitalisation 1 412 - - - - 
Re-hospitalisation transport costs  9 152     137 7 - 412 7 412 
Total rehospitalisation costs 10 1,293     794 105 - 2,572 105 2,572 
Outpatient consultations       
User fees and drug expenses 46 151 141 5 - 115 0 198 
Transport costs 46 38 43 14 - 343 0 717 
Total outpatient costs 46 189 164 36 - 503 5 753 
Childcare and productivity       
Annual childcare costs 12 631 335 226 - 1,073 49 1,480 
Annual productivity costs 34 2,206 1,210 173 - 4,934 173 4,934 
Total childcare and productivity costs 38 2,173 1,375 475 - 4,934 247 5,674 
* SD = standard deviation  
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10.2.5.6 Unaffordable treatment costs 
Thirty nine (83%) of the caregivers of children with meningitis sequelae reported that 
they knew of treatments which could benefit their child, but they were not accessing these 
due to inability to pay. These included hearing devices, physiotherapy and speech therapy, 
but the exact costs were not known by the majority of caregivers. Some responses to this 
question are summarized in Textbox 10.2. 
Textbox 10.2: Information collected about unaffordable treatment costs for 
meningitis sequelae  
 
10.2.5.7 Childcare costs and productivity costs of caregivers 
Thirty four percent of the children with sequelae went to school or preschool and the 
remaining 66% were cared for at home (Table 10.14). For 19 (61%) of the children who 
did not attend school, parents reported that this was due to meningitis sequelae. Twelve 
families paid someone to look after the child parts of the day while they were working. 
Among these families, the costs of childcare per month varied between US$ 4 and US$ 123, 
with mean monthly costs of US$ 53 (Table 10.13 above).  
Thirty four (81%) of the 47 families stated that there was someone in the household who 
was not able to work because he/she had to care for the child. The reported monthly 
productivity cost (amount of foregone income) ranged between US$ 14 and US$ 411, with 
a mean of US$ 184 (Table 10.13). Selected interview responses concerning this issue are 
included in Textbox 10.3.  
 The mother had to stop taking the child for treatment because she could no longer afford 
paying the consultation fee. 
 It happens sometimes that the appointments for treatment are not respected due to 
financial reasons. 
 The mother had to stop visits to Albert Royer Hospital as she no longer had the means. In 
addition, the mother could not receive the records of the child because she had a debt to 
the hospital. 
 The child needs a thorough examination of the right eye and the right ear, but the mother 
does not know the costs. 
 The child was scheduled for an ear operation because the child has a profound hearing 
loss, but this operation was not done because it is prohibitively expensive, in the order of 
millions CFR. 
 The grandmother had to stop visiting the physiotherapist because the cost of transport 
(4,000 CFR (US$ 8)) is very expensive and also very many visits. This means they do not 
follow the treatment. 
 The parents had to stop the appointment at Albert Royer Hospital, as unable to cope with 
the costs of consultation and transport. 
 The child has teething problems, high fever and the hearing is very deficient. The mother 
cannot estimate the costs. 
 They want to buy a device for the ears to obtain a relatively normal hearing, but this costs 
815,000 CFR (US$ 1,631). 
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Table 10.14: Types of day care of the children with sequelae 
Type of day care 
Number of 
children 
Percent of all 
children 
School 14 30% 
Mother 16 34% 
Grandmother 8 17% 
Other relative 4 9% 
Grandfather 1 2% 
Numerous family members 1 2% 
Preschool 2 4% 
Father 1 2% 
Total 47 100% 
 
Textbox 10.3: Statements made about productivity costs  
 
 
10.2.5.8 Lifetime costs per case of meningitis sequelae  
Since none of the children received regular rehabilitation and treatment at the time of the 
follow-up, no predictions were made for these costs in the base case estimates. When 
assuming that the costs of childcare and productivity loss last for 30 years, mean 
discounted lifetime sequelae costs amounted to US$ 34,895 (range US$ 49 – 111,380). 
Productivity costs comprised 90% of total costs. As seen in the histogram in Figure 10.5, 
there is high variability in costs between the children, explained by different levels of 
sequelae severities and socio-economic status of the households. When including costs of 
the episode, total lifetime costs were US$ 36,336 (Table 10.15). 
  
 If the mother did not look after the child, she would sell at the market. 
 The mother would have gone to work and earn a living if she did not have to look after 
the child. 
 His mother would have worked if the child had not been disabled and his father would 
have worked more. 
 If the child had not had meningitis, she could go to school like her brothers. She has 
language disorders. She has aggressive behaviour if she does not take her medication. Has 
she not had meningitis, she could have her washed herself. 
 We would not have brought the grandmother to take care of the child if she had not had 
meningitis. 
 The child does not speak, does not walk, he cannot even sit down. At the age of eight years 
he cannot do anything, but is totally dependent. Since the attack of meningitis he is no 
longer at school. 
 If the child was not disabled we would not have to pay someone to look after him and we 
would save money. 
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Table 10.15: Mean discounted lifetime costs per child among all study children with 
meningitis sequelae (2010 US$) 
 No. of 
children 
Mean SD* 95% CI Min Max  
 
Meningitis episode costs 47 1,441 1,158 435 - 3,165 392 7,076 
Sequelae costs:       
  Re-hospitalization 47 275 640 0 – 1,809 0 2,572 
  Lifetime outpatient visits 47 185 164 16 – 503 0 753 
  Lifetime childcare 47 3,158 6,326 0 – 14,506 0 29,012 
  Lifetime productivity costs 47 31,276 28,033 0 – 96,709 0 96,709 
  Subtotal: Lifetime sequelae costs 47 34,895 29,589 67 – 96,755 49 111,380 
Total lifetime costs 47 36,336 30,030 775 – 97,387 477 99,528 
* SD = standard deviation  
 
Figure 10.5: Mean lifetime costs of meningitis sequelae per patient* (n=47) 
 
      *Lifetime costs include treatment costs, childcare costs and productivity costs of caregivers 
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10.2.5.9 In-depth interviews 
The transcripts of the three in-depth interviews are included in Annex 9. It is clear from 
the interviews that the meningitis sequelae have affected the families in an extremely 
severe way. Their lives with a disabled child are tremendously difficult, both financially 
and emotionally. It is also apparent that care was sought too late during the acute 
meningitis episode, increasing the risk of severe sequelae. The main reason for delaying 
going to the hospital was the expected costs. All three families say that they cannot afford 
rehabilitation and special schooling for their child.  
10.2.6 DISCUSSION  
In urban Senegal, the average total lifetime, discounted costs of meningitis sequelae was 
approximately US$ 35,000 per child. Productivity and childcare costs comprised the 
majority (98%) of the costs while re-hospitalizations and outpatient consultations 
accounted for only 2%. Many study families could not afford to seek treatment and no 
child was receiving any follow-up health care by the time the study was conducted. 
The mean cost of an acute meningitis episode of US$ 1,289 (95% CI US$ 361, 2,812) is 
higher than the results from other low-income countries, but comparable to costs in 
middle-income countries. As was shown in the literature review in Chapter 5, meningitis 
treatment costs have been estimated as US$ 211 in Vietnam [136], US$ 434 in Kenya 
[139], US$ 1,474 in Brazil [132], US$ 4,203 in Uruguay [132] and US$ 5,855 in Chile [132]. 
While the study from Kenya included household out-of-pocket expenses, the other studies 
only included government costs, collected retrospectively at hospitals. 
According to a 2006 survey of wage rates in Senegal, the average monthly salaries were 
US$ 457 in the public sector, US$ 419 in the formal sector, and US$ 76 in the informal 
sector [265]. Only approximately 17% of the labour force is wage earners and 40% of 
these work in the informal sector [265]. The costs of an acute meningitis episode exceeded 
the annual income of an informal sector worker by 41% and the mean costs of one 
outpatient consultation was equivalent to 36% of the monthly salary in the informal 
sector. The large disparities between disposable income and treatment costs were 
apparent from the interviews where all caregivers expressed that it had been extremely 
difficult to pay for the treatment.    
In spite of the great financial struggles experienced, the socio-economic indicators of the 
study households revealed that they on average belonged to the higher economic quintiles 
in Senegal. According to the 2005 Demographic and Health Survey, 65% of all Senegalese 
women between 30 and 34 years have no education and for people above six years of age 
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living in urban and rural areas, 41% and 75% have no schooling, respectively. In Dakar, 
1% of adults have an university degree and 2% has secondary school education [277]. In 
our household sample, only 32% of the primary caregivers had no education, 27% had 
completed secondary school and 6% had a university degree. Similarly, while 66% of 
households in all urban areas of Senegal had a septic tank toilet and 80% had electricity 
[277], the figures for our households were 100% and 94%, respectively. It is highly likely 
that care received by meningitis patients living in lower socio-economic strata are 
considerably less than reported in our study population.    
According to caregiver responses, 71% of study children suffered from minor or major 
sequelae. This prevalence is considerably higher than reported by other studies. According 
to the global meta-analysis on pooled data from 132 follow-up studies of children with 
bacterial meningitis, the median risk of at least one major or minor sequelea after hospital 
discharge was 20% (IQR 12 – 35) [235]. However, we also found that the risk varies 
considerably among geographic regions and country income strata. In the WHO African 
region the risk was found to be 25.1% with an inter-quartile range of 18.9% - 32.0%. 
There are several explanations for the higher prevalence rates found in the Senegal study. 
First, an all-inclusive definition of sequelae was used; focus was not only one type of 
sequelae, and both minor and major sequelae were included. Secondly, the study had 
relatively low loss to follow-up of only 9%. Thirdly, because children were identified from 
a tertiary university teaching hospital, there may be selection bias towards more severe 
patients, as they would be referred to this hospital rather than treated at lower level 
facilities. Lastly, and perhaps most importantly, there was substantial evidence that 
families delayed seeking treatment for financial reasons, which lead to an increased risk of 
developing sequelae [234].      
The study has a number of limitations. First, there is risk of recall bias for the acute 
episode cost estimates because these were solely based on historical information collected 
from caregiver interviews. It was however striking that most of the families clearly 
remembered the costs of treatment, even though the episode had happened on average 
five years and five months earlier. During the interviews it became clear that the costs of 
treatment had been a major financial burden and most families were therefore able to 
specify the costs in detail. In several cases receipts from the hospital had been kept, which 
were shown to the research staff during the interview. A second limitation is that 
productivity costs were estimated according to what caregivers envisioned they would be 
able to earn if they did not have to care for the child, but it is not possible to know to what 
extent this amount reflects reality. The uncertainty with this estimate is exposed by a 
Chapter 10: Costs of Hib disease 
 
155 
 
relatively wide range of answers among the 34 respondents, varying from US$ 14 to US$ 
411 per month, with a mean of US$ 184. This amount is more than twice the 2006 average 
monthly salary in the informal sector [265]. Lastly, as with all predictions, the lifetime cost 
estimates are surrounded by considerable uncertainty. It was assumed that disabled 
children have an average life expectancy of 30 years, but this is a tentative assumption and 
it is similarly uncertain to what extent costs stay constant in future years.  
This is the first study from a low-income country on the costs of treating and caring for 
children with disabilities. Productivity costs were calculated by collecting data directly 
from families on estimated income forgone. This is a relevant alternative to the human 
capital or the friction cost approach, which are the traditional methods used for placing a 
monetary value on time in high-income countries with well-functioning labour markets 
[263]. The study has important implications for future economic evaluations of 
interventions for prevention and treatment of disability in children. Other vaccines 
protecting against life-long disabilities are polio, rubella, pneumococcal and 
meningococcal vaccines. It was shown that the lifetime costs of meningitis sequelae are 
approximately 26 times higher than the mean cost of treating an acute meningitis episode, 
so economic evaluations of vaccines against bacterial meningitis underestimate the cost-
effectiveness substantially if only treatment costs of the acute episode are included. 
However, more research is needed on the most appropriate methods for determining 
productivity costs in societies with a large informal labour market.  
10.3 CONCLUSION 
This chapter was divided into two parts. In the first part, access to care, health care 
utilization and mean treatment costs of Hib disease were estimated for Belarus, India and 
Uzbekistan. It was shown that a considerable proportion of children in India and 
Uzbekistan have no access to health care, emphasising the importance of including this 
parameter in the decision-analytic model.  Moreover, since a relatively large proportion of 
health expenditures are financed directly by households in India and Uzbekistan, it is 
crucial to divide treatment costs into government and household perspectives.  
The study from Senegal is the first in which household costs of meningitis sequelae has 
been quantified for a low-income country. The study demonstrated that these costs are 
substantial and therefore important to include in economic evaluations of vaccines that 
prevent bacterial meningitis. However, since children have limited access to health care 
and there is a large informal economic sector in low-income countries, the methods for 
valuing costs of meningitis sequelae are not straight forward and the study showed large 
variability in costs between households with disabled children.  
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The type of data collected in the study from Senegal is not available in any of the three 
study countries and it is not known how well the results from Senegal reflect the realities 
in Belarus, India and Uzbekistan. Due to the lack of data, the costs of sequelae are excluded 
from the base case in the economic evaluations presented in Chapter 12. However, the 
Senegal results, in terms of mean lifetime costs per meningitis sequelae case, are used in 
sensitivity analysis for all three countries.  
Parameter values estimated in the present chapter for use in the economic evaluation are 
summarised in Table 10.16. 
Table 10.16: Parameter values for health care utilization and treatment costs used 
in the economic evaluation 
Parameter Belarus India Uzbekistan 
 No. of outpatient visits per case    
Severe Hib pneumonia 3.0 1.42 1.36 
Non-severe Hib pneumonia 1.0 0.71 0.68 
Hib meningitis 7.0 1.42 1.36 
Hib NPNM 3.0 1.42 1.36 
No. of inpatient admissions per case    
Hib pneumonia 1.0 0.71 0.68 
Hib meningitis 2.6 0.71 0.68 
Hib NPNM 1.0 0.71 0.68 
Distribution of outpatient visits (%)    
Government clinic 100% 16% 100% 
Private clinic 0% 61% 0% 
Private outpatient department 0% 5% 0% 
Traditional healer 0% 9% 0% 
Pharmacy 0% 10% 0% 
Distribution of inpatient admissions (%)    
Pneumonia/NPNM    
Primary government hospital 76% 27% 66% 
Secondary government hospital 20% 30% 31% 
Tertiary government hospital 4% 2% 3% 
Private hospital 0% 41% 0% 
Meningitis    
Primary government hospital 0% 27% 64% 
Secondary government hospital 80% 30% 32% 
Tertiary government hospital 20% 2% 4% 
Private hospital 0% 41% 0% 
Government costs per outpatient visit (US$) 9.31 1.53 2.88 
Household costs per outpatient visit (US$)    
Government clinic NA 12 5 
Private clinic NA 11 NA 
Private outpatient department NA 11 NA 
Traditional healer NA 6 NA 
Pharmacy NA 1 NA 
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Parameter Belarus India Uzbekistan 
Government costs per inpatient admission (US$) 
Pneumonia/NPNM:    
Primary government hospital 413 97 152 
Secondary government hospital 448 101 171 
Tertiary government hospital 542 224 190 
Meningitis:    
Primary government hospital NA 164 169 
Secondary government hospital 1,567 172 188 
Tertiary government hospital 1,959 380 242 
Household costs per inpatient admission (US$)    
Pneumonia/NPNM:    
Primary government hospital NA 50 26 
Secondary government hospital NA 50 26 
Tertiary government hospital NA 50 26 
Private hospital NA 149 NA 
Meningitis:    
Primary government hospital NA 81 50 
Secondary government hospital NA 81 50 
Tertiary government hospital NA 81 50 
Private hospital NA 241 NA 
Discounted lifetime meningitis sequelae costs* 38,344 38,344 38,344 
*Only used in uncertainty analysis as this is the estimate from Senegal
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11 COSTS OF HIB VACCINE INTRODUCTION 
In this chapter, issues concerning Hib vaccine prices as well as systems costs of 
introducing the vaccine are addressed. As mentioned in Chapter 3, the relatively high price 
of Hib vaccine has been one of the main reasons for slow introduction of the vaccine in 
low- and middle-income countries. Hence, any economic analysis of the vaccine must 
address the important issue of price. While almost all GAVI eligible countries have now 
introduced the vaccine, the price is a cause of concern for ensuring financial sustainability 
when GAVI’s support comes to an end [278, 279].  
Other resource items than the vaccine, such as training, social mobilisation and cold chain 
expansion, must also be accounted for when estimating the costs of Hib vaccine 
introduction. These non-vaccine costs are often referred to as “system costs” [280]. During 
the early years of GAVI Alliance support, beginning in the year 2000, countries received a 
one-off “vaccine introduction grant” of US$ 100,000 to cover system costs related to new 
vaccine introduction [281].  The sum of US$ 100,000 was not based on an objective 
measurement of these costs and it was later acknowledged to be an insufficient amount 
for larger countries and to have caused inequities between countries with different sized 
birth cohorts [282]. During GAVI phase II (2006-2015) the support was changed to a 
minimum of US$ 100,000 or up to a maximum of US$ 0.30 per infant in the birth cohort of 
the year of introduction [283]. The amount of US$ 0.30 was based on an estimate of the 
median funding per infant in the countries that had received the vaccine introduction 
grant of US$100,000 during GAVI phase I [282]. Hence, the sum was not based on an 
estimate of the actual costs related to new vaccine introduction, but was guided by the 
original grant of US$ 100,000. During 2012 GAVI is re-assessing the size of the 
introduction grant and as is referred to in this chapter, the work I have done as part of this 
thesis is being used to guide this policy change.  
The chapter is divided into four sections. Determinants of Hib vaccine prices are discussed 
in section 11.1, the incremental costs of introducing Hib vaccine in the three study 
countries are estimated in section 11.2, a case study from Ethiopia on system costs of 
introducing Hib vaccine is the topic of section 11.3, and conclusions are summarised in 
section 11.4.  
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11.1 DETERMINANTS OF HIB VACCINE PRICES  
In this section vaccine markets, procurement mechanisms, and Hib vaccine price trends 
are described. These issues are important for understanding the assumptions made when 
Hib vaccine introduction costs are estimated for the three study countries in section 11.2. 
11.1.1 VACCINE MANUFACTURERS 
In market terms the value of vaccines is small in comparison to other pharmaceuticals. In 
2010, vaccines represented no more than around 3% of the global pharmaceutical market 
[284].  However, the market has recently grown rapidly due to developments of new and 
more expensive vaccines, in particular the pneumococcal and the human papilloma virus 
vaccines [285]. According to a recent study on vaccine access, research and development 
(R&D), global vaccine sales were expected to increase from around US$ 20.5 billion in 
2008 to US$ 34 billion by 2012 [284]. Sales in low- and middle-income countries were 
estimated at about $1.6 billion in 2008, or less than 10% of the total.  
Vaccine manufacturers are conventionally divided into two groups; the established 
multinational firms based in the USA and Europe, and the “emerging suppliers” situated in 
low- and middle-income countries. The multinational firms have over the years become 
increasingly concentrated due to frequent mergers. The top five multinational firms, 
GlaxoSmithKline (GSK), Merck, Sanofi-Pasteur, Pfizer and Novartis, accounted for 
approximately 85% of global vaccine sales in 2008 [286]. Their share of the market is 
however much lower in volume terms because the emerging suppliers produce large 
volumes of cheaper vaccines. Important emerging supplies that export vaccines are based 
in India, Indonesia and Brazil [287].  Traditionally, multinational companies have been 
responsible for most vaccine innovation. Their business model depends on charging high 
prices for new vaccines in order to recover R&D costs and return large profits to their 
investors. The emerging suppliers have traditionally sold older, less complex vaccines in 
high-volume, low-margin markets [284].  
11.1.2 VACCINE PROCUREMENT IN LOW- AND MIDDLE-INCOME COUNTRIES 
PAHO and Unicef operate pooled procurement mechanisms for low- and middle-income 
countries. The objectives are to ensure better and more efficient national planning, to 
avoid disruptions in vaccine supply, to allow purchase of vaccines in local currencies, to 
obtain lower prices by consolidating vaccine orders for economies of scale, and to assure 
vaccine quality [288]. All GAVI supported vaccines are procured either through Unicef’s 
supply division or PAHO’s revolving fund.  
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The Unicef supply division purchases vaccines on behalf of 80-100 countries annually 
using funds from GAVI, NGOs, foundations, international financial institutions, and the 
countries themselves [288]. Unicef procures approximately 40% of global vaccine doses, 
but this only account for approximately 5% of the global market value because vaccines 
are considerably more expensive in high-income countries [289]. PAHO’s revolving fund is 
similarly a pooled procurement mechanism, but only available for countries in the region 
of the Americas. The revolving fund played an important role in facilitating early adoption 
of Hib vaccine in PAHO countries [290].  
Unicef and PAHO only procure vaccines that have been prequalified by the WHO. The 
purpose of the WHO prequalification assessment is to provide assurance that candidate 
vaccines meet recommendations on quality, safety and efficacy and with regard to 
operational specifications for packaging and presentation [291]. Unicef procures vaccines 
from five emerging market countries; Brazil, Cuba, India, Indonesia, and Senegal. During 
2006, these together accounted for about 36% of the total procurement value, but India 
was by far the largest supplying country, representing about 34% of Unicef’s total supply 
in value terms [292].  
11.1.3 VACCINE MARKETS AND PRICE SETTING 
In high-income countries, vaccine prices are largely determined by profit maximization of 
the multinational firms. R&D and production costs are generally not taken into account in 
the price-setting strategies for recently licensed vaccines [284]. However, the marginal 
costs of production set a floor for the lowest price level and are an important determinant 
of price in mature, competitive markets. However, production costs vary considerably 
among classes of vaccines, according to production volume and by site of production. 
Emerging suppliers have only significant cost advantages for certain vaccine types [291]. 
Four features of vaccine markets influence prices in low-income countries so that these 
are not only determined by demand and supply. First, markets for new vaccines tend to be 
controlled by one or at most two manufacturers for extended periods. This is due to the 
small number of innovative multinational firms, the large economies of scale in vaccine 
production and patent protection. This lack of competition gives originating firms 
substantial freedom to set prices. Secondly, the Unicef and PAHO procurement 
mechanisms lead to market concentration. Third, “tiered pricing”, or market segmentation 
by country income groups, is increasingly standard. Fourth, the large fixed costs and long 
lead times required to build new manufacturing plants mean that predictability of demand 
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is very important to manufacturers, who will offer lower prices in return for long-term 
commitments [284]. 
11.1.4 HIB VACCINE FORMULATIONS AND PRICE TRENDS 
11.1.4.1 Types of Hib vaccines 
There are several different types of Hib vaccine formulations available. Hib can be 
delivered as a monovalent vaccine or as a combination vaccine with several other 
antigens. Since Hib vaccine is delivered at the same time as diphtheria-tetanus-pertussis 
(DTP) vaccine, combination vaccines are widely used as these are normally preferred by 
both health care workers and parents because they reduce the number of injections 
needed.   
A total of 23 Hib containing vaccines were prequalified by the WHO as of November 2011, 
as summarised in Table 11.1. Seven of these were monovalent Hib vaccines and another 
seven were DTwP-Hib combination vaccines. However, only few of the countries 
procuring through Unicef are using these formulations. As seen in Table 11.2, Unicef only 
procured around 600,000 doses of monovalent Hib vaccine and 22.2 million doses of 
DTwP-Hib vaccine between 2001 and 2010. On the other hand, a total of 412.2 million 
doses of the DTwP-HepB-Hib combined vaccine, also known as the “pentavalent” vaccine, 
were procured during the same period. The pentavalent vaccine is the product of choice 
for all GAVI supported countries.    
Eleven different formulations of pentavalent vaccines were pre-qualified in November 
2011. Six of these were from the Serum Institute of India (SII), two from Biologocal E. in 
India, two from GSK and one from Crucell. As seen in Table 11.1, the Indian companies 
only obtained prequalification during 2010 and 2011. The GSK vaccine, which originally 
was produced by Smith Kline Beecham, was first prequalified in 2000 and was the only 
available pentavalent vaccine on the market until Crucell obtained prequalification in 
2006 [293]. During the early years of GAVI Smith Kline Beecham had monopoly of the 
pentavalent vaccine, which led to relatively frequent supply shortfalls and also limited the 
possibility of a price reduction.    
The packed volume per dose varies from 2.6 cm3 for the ten dose SII pentavalent vaccine 
to 58.7 cm3 for the lyophilised pentavalent vaccine in a single dose vial produced by 
Biological E (Table 11.1). The packed volume per dose is an important factor when 
assessing whether the available cold storage capacity can accommodate introduction of 
the vaccine, as is shown in the Ethiopian case study later in this chapter.    
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Table 11.1: WHO prequalified Hib vaccines 
Vaccine type Manufacturer Country 
Date of 
WHO 
prequa- 
lification 
Form 
Vial 
size 
Packed 
volume 
per 
dose 
(cm3) 
Hib Novartis Italy Aug 1997  Liquid 10 2.50 
Hib Novartis Italy Aug 1997  Liquid 1 13.4 
Hib GlaxoSmithKline Belgium Oct 1998 Lyophilised 2 6 
Hib GlaxoSmithKline Belgium Oct 1998 Lyophilised 10 2.50 
Hib GlaxoSmithKline Belgium Oct 1998 Lyophilised 1 13 
Hib  Merck USA Feb 2003  Liquid 1 15 
Hib 
Center for Genetic 
Engineering and 
Biotechnology Cuba Apr 2010  Liquid 1 5 
DTwP-Hib Novartis Italy Jul 2002  Liquid 1 45 
DTwP-Hib Novartis Italy Jul 2002  Liquid 10 12 
DTwP-Hib Sanofi Pasteur France May 2003 
Liquid + 
lyophilized 10 12.39 
DTwP-Hib Sanofi Pasteur France May 2003 
Liquid + 
lyophilized 1 44.72 
DTwP-Hib 
Serum Institute of 
India Ltd India Jun 2010 
Liquid + 
lyophilized 1 39.2 
DTwP-HepB-Hib Crucell Korea 
Republic 
of Korea Sep 2006  Liquid 1 12.84 
DTwP-HepB-Hib GlaxoSmithKline Belgium May 2000 
Liquid + 
lyophilized 2 11 
DTwP-HepB-Hib GlaxoSmithKline Belgium May 2000 
Liquid + 
lyophilized 1 22 
DTwP-HepB-Hib Biological E India Aug 2011 
Liquid + 
lyophilized 1 58.7 
DTwP-HepB-Hib Biological E India Aug 2011 
Liquid + 
lyophilized 10 7.5 
DTwP-HepB-Hib 
Serum Institute of 
India India May 2010 
Liquid + 
lyophilized 1 39.2 
DTwP-HepB-Hib 
Serum Institute of 
India India May 2010 
Liquid + 
lyophilized 2 19.6 
DTwP-HepB-Hib 
Serum Institute of 
India India May 2010 
Liquid + 
lyophilized 10 5.1 
DTwP-HepB-Hib 
Serum Institute of 
India India Sep 2010  Liquid 1 26.1 
DTwP-HepB-Hib 
Serum Institute of 
India India Sep 2010  Liquid 2 13.1 
DTwP-HepB-Hib 
Serum Institute of 
India India Sep 2010  Liquid 10 4.4 
Source: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html 
DTwP: Diphteria-tetanus-wholecell pertussis 
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Table 11.2: Doses of Hib vaccines bought by Unicef 2001 – 2010 (US$ millions) 
Vaccine 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Hib 0.1 0.1 0 0 0 0 0.1 0.1 0.1 0.1 
DTP-Hib 0.3 3.9 2.1 0.4 1.4 2.9 2.9 1.9 2.7 3.7 
DTP-HepB-Hib 14.5 8.7 16 15 21.1 21.1 39.7 71.7 106.9 97.5 
Source: www.unicef.org/supply/files/Table_of_total_Doses_of_Vaccines_bought_1996-2010.pdf 
Lyophilized vaccines are freeze-dried powders, which must be mixed with a liquid (called 
a diluent) in a process known as "reconstitution" before they can be administered. A 
diluent can either be sterile water or a liquid vaccine, such as DTwP.  Since reconstitution 
is known to cause errors in vaccine preparation, especially in developing countries, a fully 
liquid formulation is normally considered more convenient to use [294]. Hence, when the 
fully liquid vaccine produced by Crucell came on the market, several countries requested 
to switch to this one instead of using the GSK lyophilised pentavalent vaccine. The new 
liquid SII pentavalent vaccine in a ten dose vial has similarly become popular among GAVI 
countries because it takes up less space in the cold chain compared to the two- or single 
dose vial vaccines. At least half of the GAVI supported countries switched to this 
formulation during 2011/2012.   
11.1.4.2 Trends in Unicef pentavalent vaccine prices 
When GAVI was established in 1999 and Hib vaccine offered to countries it was expected 
that the increase in global demand and supply of the vaccine would lead to a price 
decrease, which would enable countries to pay for the vaccine with their own funds after 
the initial five years of support [278]. However, as seen in Table 11.3, there was no lasting 
decrease in the Unicef Hib vaccine price during 2001 – 2009. It was not until 2010 when 
the SII vaccine was prequalified that GSK and Crucell decided to offer a lower price, and 
when SII launched the liquid pentavalent vaccine in a ten dose vial in 2011 it was procured 
by Unicef for only US$ 1.75 per dose. This is a 50% price reduction compared to the 
previous decade. However, vaccine wastage is higher with larger vial sizes and this need to 
be factored into the total incremental cost estimates.  
Due to the slow price decrease, GAVI’s initial five-year support was extended for at least a 
further five years in most receiving countries [278]. GAVI introduced co-financing in 2007 
and all countries are now contributing at least US$ 0.20 per dose of vaccine.  GAVI’s 
revised co-financing policy as of November 2011 is outlined in Textbox 11.1.
Chapter 11: Costs of Hib vaccine introduction 
 
164 
 
 
             Table 11.3: Unicef pentavalent vaccine prices per dose (US$) 
Formulation Supplier 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
1 dose liquid Crucell 
     
3.63 3.75 3.60 3.60 3.20 3.00 
1 dose liquid SII 
         
 2.50 
2 dose lyophilised SII 
         
2.25 2.25 
2 dose lyophilised GSK 3.50 3.25 3.10 3.65 3.60 3.60 3.50 3.50 3.50 2.95 2.95 
10 dose liquid SII 
         
 1.75 
Source: http://www.unicef.org/supply/files/12_01_13_DTP-HepB-Hib.pdf 
 
Textbox 11.1: GAVI’s co-financing policy (as of November 2011) 
  
Source: http://www.gavialliance.org/about/governance/programme-policies/co-financing
 Low Income group: Countries with GNI per capita at or below the World Bank low-income threshold. Co-financing obligation 
in 2012 and thereafter: US$ 0.20 per dose. 
 Intermediate group: Countries with GNI per capita above the World Bank low-income threshold, but below the GAVI eligibility 
threshold of GNI per capita below or equal to US$ 1,520. Co-financing level in 2012: US$ 0.20 per dose, or the amount per dose 
paid in 2011, whichever is higher. Thereafter, the co-financing amount per dose increases by 15% each year. For any new 
vaccine adoptions, the co-financing amount would start at US$ 0.20 per dose and increase by 15% annually. When countries 
transition from low-income to the intermediate group, they would start at US$ 0.20 per dose, followed by 15% annual 
increases. 
 Graduating group: Countries with GNI per capita above the GAVI eligibility threshold who are still receiving GAVI support. Co-
financing shall increase over four years from rates paid in 2011 in order to reach 100% of the vaccine price in 2016, the year 
after GAVI support e ds.  
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11.2 INCREMENTAL COSTS OF HIB VACCINE INTRODUCTION IN BELARUS, INDIA AND 
UZBEKISTAN 
11.2.1 BACKGROUND 
Among the three study countries, Hib vaccine has only been introduced nationwide in 
Uzbekistan as of early 2012. In Belarus, the vaccine is solely offered to children in Minsk 
city and in India it is only included in the states of Tamil Nadu and Kerala. Hence, when 
estimating the incremental costs, actual expenditures are calculated for Uzbekistan, but 
the national estimates for Belarus and India are predictions.   
The national vaccination schedules of the three countries vary considerably (Table 11.4). 
The Indian routine schedule is one of the most basic in the world. The only new vaccine 
included in the Indian programme in 2011 the last few years. Belarus and Uzbekistan have 
introduced the MMR vaccine, and Belarus uses IPV as well as OPV, while OPV is solely used 
in India and Uzbekistan.  
The government of Uzbekistan applied to GAVI for pentavalent vaccine in 2007 when the 
support for hepatitis B vaccine, which Uzbekistan had received since 2001, came to an end. 
Uzbekistan was approved for pentavalent vaccine in 2007, but due to delays in transfer of 
the vaccine introduction grant, the vaccine was only introduced in March 2009. 
Table 11.4: National vaccination schedules in the three study countries 
Vaccine Belarus India Uzbekistan 
BCG 3 days Birth Birth 
OPV 18 and 24 months Birth, 6, 10 and 14 weeks 
3 days, 2, 3 and 4 
months , 7 years 
Hepatitis B Birth, 1 and 5 months Birth, 6, 10 and 14 weeks Birth 
DTwP 3, 4, 5 and 18 months 6, 10, 14 weeks and 16 months - 
DTwP-HepB-Hib - - 2, 3 and 4 months 
Measles - 9 months - 
IPV 2, 4 and 5 months - - 
MMR 1 year - 1 and 6 years 
BCG: Bacille Calmette Guérin vaccine 
OPV: Oral polio vaccine 
HepB: Hepatitis B vaccine 
DTwP: Diphtheria-Tetanus-wholecell pertussis combined vaccine 
IPV: Injectable polio vaccine 
MMR: Measles-Mumps-Rubella combined vaccine 
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Uzbekistan uses the Crucell liquid pentavalent vaccine in a single dose vial. Before 
introduction of pentavalent vaccine, children in Uzbekistan were given four doses of DTwP 
at 2, 3, 4 and 16 months and three doses of Hepatitis B vaccine at birth, 2 and 6 months. In 
the new schedule, the hepatitis B birth dose and the DTP booster dose were maintained.  
The country has been approved for a second period of pentavalent vaccine support, lasting 
until 2015. The government procures BCG, DTP, OPV, hepatitis B birth dose and MMR 
vaccines through Unicef with domestic funds. 
In Belarus, vaccines for the childhood immunization programme are procured from the 
national health budget, but Minsk city has chosen to add hepatitis A and Hib vaccines to its 
schedule using funds from the municipal budget. Hib vaccination was introduced in Minsk 
city in 2007 for those at ‘high risk’, i.e. children who are HIV positive, asthmatic or living in 
orphanages. In 2008 the programme was expanded to include all children in Minsk city, 
which covers approximately 20% of the population. A ministerial order dictates a four-
dose Hib vaccine schedule, following a WHO recommendation of a booster dose in 
countries where Hib disease frequently occurs in children above 18 months of age [295]. 
In Minsk City, the schedule is 3, 4, 5 and 18 months, and a combined DTwP-Hib vaccine 
produced by Sanofi Pasteur in a single dose vial is used.  
In India, Hib vaccine was introduced with GAVI support in the states of Tamil Nadu and 
Kerala during December 2011. These are two high performing states, which cover about 
10% of children less than five years in the country. It is anticipated that the vaccine will 
eventually be expanded to the remaining states, but several challenges have contributed to 
slow implementation in India. In July 2005, the Hib Initiative started a Hib disease 
surveillance study, which should lay the groundwork for a large Hib vaccine probe study 
[253]. However, following the publication of a 2006 WHO position paper recommending 
global introduction of Hib vaccines “even in countries where local disease burden could 
not be established”[295], plans for this trial were abandoned due to ethical concerns. In 
June 2008, the Indian National Technical Advisory Group on Immunization (NTAGI) 
recommended immediate introduction of Hib vaccination in all states [296].  However, 
several changes in leadership occurred within the Ministry of Health and Family Welfare 
and this caused delays. Furthermore, in December 2009, a public interest litigation was 
filed in Delhi high court by seven public health figures to highlight “how irrational vaccines 
are being introduced in the public health system by the government, under the influence 
of vaccine manufacturers and international agencies” [297].  Specifically, the petitioners 
argued that new vaccines against hepatitis B, Hib and pneumococcal are being introduced 
without proper epidemiological and clinical studies, while at the same time, basic more 
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affordable vaccines such as DTP and measles are not being made available to half the 
children of India [298]. The non-completion of the probe study has inevitably led to 
uncertainty about the true impact of Hib vaccination in India and doubts about the value of 
the vaccine are apparent among many stakeholders [299].  The states of Tamil Nadu and 
Kerala introduced the SII pentavalent vaccine in a 10-dose vial. The Indian government 
has decided to procure through Unicef instead of buying the vaccine directly from SII.  
11.2.2 METHODS 
11.2.2.1 Vaccine and injection equipment costs 
Incremental vaccine and injection equipment costs were estimated as the difference 
between the former routine vaccination schedule and a schedule with Hib vaccine. Since 
all three countries use a Hib combination vaccine, the incremental costs were estimated as 
the difference between a schedule with the combination vaccine and a schedule without 
the Hib vaccine component, but the other antigens in the combination vaccine included. 
Hence, only the Hib vaccine part of the combination vaccine was included in the 
incremental costs.  
Total annual vaccine costs (TC) were estimated according to WHO guidelines as [300]:  
 wdcbpTC   
where,  
p = costs per vaccine dose (including freight expenses) 
b = target population 
c = predicted vaccination coverage rate of the first dose 
d = number of doses per child  
w = predicted wastage factor  
This formula is also being used in the GAVI application form when countries estimate their 
annual vaccine needs [301]. 
Vaccine wastage depends on the number of doses in a vial, whether or not the country in 
question has an effective open vial policy, the sizes of immunization sessions, any cold 
chain and distribution failures, and the number of vials discarded due to expiry. The 
wastage factor  is calculated from a percentage wastage rate, r, as [300]: 
w = 100 – (100/r). 
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Since the first dose of Hib vaccine is delivered to children after the neonatal period, the 
number of surviving infants in each country was used as the target population. These are 
seen in Table 11.5, along with the vaccine coverage estimates used. 
Vaccine and injection equipment prices and wastage rates were collected from vaccine 
programme managers in the three countries. As seen in Table 11.6, traditional vaccine 
prices are substantially lower in India than in the two other countries due to the local 
vaccine manufacturing. In Belarus, Minsk City procures the DTwP-Hib vaccine from Sanofi 
Pasteur at US$ 4.95 per dose and this price was assumed for the national analysis (Table 
11.6). In India and Uzbekistan, Unicef vaccine prices were used.  In 2011 Unicef procured 
the liquid pentavalent vaccine in a single dose and ten dose vials for US$ 3.00 and US$ 1.75 
per dose, respectively.  
Price per injection syringe were US$ 0.09 in Belarus, US$ 0.06 in India and US$ 0.06 in 
Uzbekistan.  The costs of safety boxes were included in the India and Uzbekistan analysis 
as these are supplied with GAVI vaccines, but safety boxes were not used in Belarus.  The 
Unicef price was US$ 1.50 per box with capacity of 100 used syringes. 
Table 11.5: Target population and coverage rates used for estimating vaccine needs  
Parameter Belarus India Uzbekistan 
2010 birth cohort 94,200 26,542,850 558,459 
Infant mortality per 1,000 live births 9 51 47 
Surviving infants 93,352 25,082,993 558,174 
2010 DTP1 coverage rate: 97% 83% 98% 
Sources: UN Populations Division [302] and WHO/Unicef [303] 
11.2.2.2 System costs due to Hib vaccine introduction 
In all three countries, vaccine programme staff were interviewed to determine system 
costs related to introducing the vaccine. In Belarus and Uzbekistan, it was revealed that 
even though vaccine volume had increased, existing cold chain capacities were sufficient 
with no additional investments required. Since the ten dose vial is being used in India, 
there is a reduction in storage volume needed as the volume per dose of this vaccine (4.4 
cm3) is less that the volume needed for the DTP and hepatitis B vaccines previously used 
(3.0 cm3 + 4.0 cm3 = 9.0 cm3).  
In Uzbekistan, a GAVI introduction grant of US$ 100,000 was used for staff training and 
social mobilization and these costs were included in the analysis. India has negotiated an 
exceptional agreement with GAVI so that they do not co-finance the usual US$ 0.20 per 
dose, but in return they did not receive the vaccine introduction grant of US$ 0.30 per 
child in the birth cohort.   
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Table 11.6: Vaccine prices and wastage rates in the three study countries 
 Belarus Uzbekistan India 
Antigen 
Vial  
size 
Price per 
dose 
(US$) 
Vaccine 
wastage 
rate 
Vial 
size 
Price per 
dose 
(US$) 
Vaccine 
wastage 
rate 
Vial  
size 
Price per 
dose 
(US$) 
Vaccine 
wastage 
rate 
BCG 10 0.06 62% 10 0.05 50% 10 0.04 61% 
Hepatitis B birth dose 1 1.20 0% 1 0.44 33% - - - 
Hepatitis B 10 0.63 6% 10 0.34 33% 10 0.11 33% 
DTwP 2 0.15 14% 10 0.33 33% 10 0.04 27% 
MMR 1 2.68 0% 10 1.36 33% - - - 
Measles - - - - - - 5 0.20 35% 
OPV 10 0.35 20% 10 0.31 33% 20 0.08 47% 
IPV 1 5.10 0% - - - - - - 
DTwP-Hib 1 4.95 0% - - - - - - 
DTwP-HepB-Hib - - - 1 3.00 5% 10 1.75 27% 
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11.2.3 RESULTS 
The incremental cost estimates are seen in Table 11.7. Without Hib vaccine, costs of 
vaccines and injection supplies per fully vaccinated child amounted to approximately US$ 
23 in Belarus, US$ 8 in Uzbekistan and US$ 2 in India. Introduction of Hib vaccine 
increased annual vaccine costs by 84% in Belarus, 101% in Uzbekistan and 302% in India, 
leading to costs per fully vaccinated child of US$ 42, US$ 16 and US$ 9, respectively.  
In India and Uzbekistan, injection supply costs decreased by 33% and 29%, respectively, 
because less syringes and safety boxes were needed for the pentavalent vaccine compared 
to delivering DTP and hepatitis B vaccines separately. In Belarus, syringe costs increased 
by 12% because the DTwP-Hib vaccine is lyophilised and therefore needs reconstitution 
syringes, which is not the case for the DTP vaccine.  However, incremental injection supply 
costs comprised only 1% of total incremental costs in Belarus. 
According to the GAVI co-financing policy, India and Uzbekistan should pay US$ 0.20 per 
dose of pentavalent vaccine. However, as mentioned above India has been exempted from 
this condition because they requested not to receive the vaccine introduction grant. In 
Uzbekistan, co-financing payments amounted to US$ 2.9 million in 2010.  
11.2.4 DISCUSSION 
Hib vaccine is substantially more expensive than the six, traditional vaccines and also the 
hepatitis B vaccine. Hepatitis B vaccine has experienced marked price reductions since it 
was first developed in 1981 and Unicef now procures this vaccine for US$ 0.18 per dose 
[304]. Introduction of Hib vaccine caused approximately a doubling of the vaccine budget 
in Belarus and Uzbekistan and a quadruple increase in India. The relative increase was 
less in Belarus and Uzbekistan because these countries already use some new, more 
expensive vaccines. Both countries have introduced MMR vaccine and IPV is used in 
Belarus.  
Even though the new SII pentavalent vaccine in a ten-dose vial is considerably cheaper 
than the other pentavalent formulations, the overall budget increase can seem 
insurmountable in India. However, the main reason for the large budget impact in India is 
that the vaccine schedule in this country is still only very basic and the traditional vaccines 
are locally manufactured and therefore procured at a relatively cheap price. The vaccine 
costs per infant in the birth cohort of the current Indian vaccination schedule is only US$ 
1.6, which is a low amount compared to other countries. An analysis of national 
immunization budgets and financing sources of 50 GAVI eligible countries during 2008-
2010 showed that governments on average spend US$ 7.9 per infant in the birth cohort
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Table 11.7: Vaccine and syringe costs with and without Hib vaccine (2010 US$) 
  
Belarus Uzbekistan India 
W
it
h
o
u
t 
H
ib
 v
a
cc
in
e
 
Antigen 
Doses in 
schedule 
Vaccine 
costs 
Injection 
supply 
costs 
Total 
costs 
Doses in 
schedule 
Vaccine 
costs 
Injection 
supply 
costs 
Total 
costs 
Doses in 
schedule 
Vaccine 
costs 
Injection 
supply 
costs 
Total 
costs 
BCG 1  14,231   9,572   23,802  1  49,928   56,931   106,859  1      2,565,849  2,137,351    4,703,199  
Hepatitis B 3  184,284   26,049   210,333  4  694,253   189,769   884,023  3    9,854,186   3,594,400   13,448,586  
DTP 4  63,945   34,732   98,677  4  588,462   189,769   778,232  3    2,977,936   3,594,400      6,572,336  
MMR 1  245,634   12,060   257,694  1  1,121,184   54,523   1,175,707  0 - - - 
Measles 0 - - - 0 - - - 1   7,603,174   1,467,332    9,070,505  
OPV 2  72,178  -  72,178  5  1,264,578  -  1,264,578  4     8,272,044  -     8,272,044  
IPV 3  1,402,315   26,049   1,428,364  0 - - - 0 - - - 
Total w/o Hib vaccine   1,982,586   108,462   2,091,049    3,718,406   490,993   4,209,399     31,273,189  10,793,483    42,066,671  
Costs per FVC w/o Hib   21.85   1.20   23.04    7.05   0.93   7.98         1.63       0.56        2.19  
W
it
h
 H
ib
 v
a
cc
in
e
 
Hib containing vaccine* 4  1,814,760   48,239   1,862,999  3  5,345,975   142,327   5,488,302  3 143,600,101   3,594,400  147,194,502  
Total with Hib vaccine**   3,733,401   121,969   3,855,371    8,102,345   348,666   8,451,011   162,041,168  7,199,083  169,240,250  
Costs per FVC with Hib   41.14   1.34   42.48    15.36   0.66   16.02             8.44       0.37          8.81  
Incremental costs  1,750,815   13,507  1,764,322   4,383,938  - 142,327  4,241,611   130,767,979  -3,594,400  127,173,579  
*DTP-Hib in Belarus and DTP-HepB-Hib in Uzbekistan and India. 
**In Uzbekistan, hepatitis B vaccine birth dose and booster dose of DTP at 18 months are included. 
FVC: Fully vaccinated child (calculated as number of surviving infants multiplied by DTP3 vaccine coverage)
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on vaccination, including system costs [278]. In a 2011 study analysing the costs of 
vaccines and injection supplies in Brazil, India and South Africa, it was shown that the 
costs per fully vaccinated child is US$ 26 in Brazil, US$ 124 in South Africa, but only US$ 3 
in India [305]. The relatively high cost in South Africa is due to recent introductions of 
pneumococcal, rotavirus and IPV vaccines. It can thus be argued that even though a 
quadrupling of the Indian vaccine budget is substantial, the baseline budget is low and a 
resulting cost of US$ 8.81 per fully vaccinated child is still considerably less than what 
other governments have chosen to spend on vaccines.  
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11.3 INCREMENTAL SYSTEM COSTS OF PENTAVALENT VACCINE INTRODUCTION IN ETHIOPIA4 
In this section, the incremental system costs of introducing pentavalent vaccine into 
vaccination services in Ethiopia are estimated. One of the findings from the literature 
review of Hib vaccine economic evaluations in Chapter 5 was that only a few studies had 
included system costs of the new vaccine introduction. These costs were included under 
“administration costs” or “vaccine programme costs”, but they were either extrapolated 
from case studies on immunization services costs or based on authors’ assumptions. While 
total vaccine and injection supply costs are well established, as these are equal to the 
amount of funds being granted by the GAVI Alliance, other vaccine introduction costs, such 
as cold storage and transport expenses, have not been well specified in GAVI supported 
countries.  
System costs vary according to whether the new vaccine is a combination vaccine with one 
or more of the vaccines already present in the system or whether it is monovalent. If the 
combination vaccine is procured in the same vial size as before, the new vaccine does not 
take up more space in the distribution system. If, on the other hand, the new vaccine is 
monovalent, or if the new combined vaccine is introduced with fewer doses per vial than 
previously used, or if an extra vial for diluent is required, the vaccine takes up more space 
in the distribution system and this may necessitate expansion of the cold chain [300]. 
When pentavalent vaccine was introduced in Ethiopia the switch was from DTwP vaccine 
in a ten-dose vial to pentavalent vaccine in a single dose vial. Hence, more cold chain space 
was required.  
The study objectives were:  
1. To estimate the annual incremental system costs of introducing pentavalent vaccine. 
2. To determine financing sources of the incremental system costs. 
3. To estimate the share of system costs of total introduction costs. 
11.3.1 BACKGROUND 
Ethiopia applied to the GAVI Alliance for five-year support of pentavalent vaccine in early 
2005 and the application was approved later that year [306]. However, due to a global 
shortage of pentavalent vaccine, the first shipment did not arrive until December 2006. 
The switch from DTwP to pentavalent vaccine was officially launched in March 2007. The 
introduction happened without catch-up for children above 12 months and in such a way 
                                                             
4 The section has been published in modified form as: Griffiths UK, Korczak V, Ayalew D, Yigzaw A, 
Incremental system costs of introducing combined DTwP-Hepatitis B-Hib vaccine into National 
Immunization Services in Ethiopia, Vaccine. 2009 Feb 25; 27(9)  
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that if a child had started his/her vaccine course with one or two doses of DTwP, he/she 
would subsequently receive pentavalent vaccine as the second and/or third dose. The 
pentavalent vaccine gives Ethiopian children protection against two additional diseases, 
hepatitis B and Hib, compared to the previous schedule which contained only the six 
traditional antigens: BCG, DTP, measles and OPV. Hepatitis B and Hib vaccines were thus 
the first new vaccines to be added to the Ethiopian immunisation schedule since the 
programme was established in 1980. 
Ethiopia was one of the first countries in the world to introduce the fully liquid 
pentavalent vaccine produced by Crucell. This vaccine, marketed under the name 
Quinvaxem™, came on the market in late 2006 [307]. The vaccine is marketed in a single 
dose vial only and requires 12.9 cm3 of cold storage space per dose. The DTwP vaccine in a 
10-dose vial requires 3.0 cm3 per dose.  
11.3.1.1 Vaccine distribution system in Ethiopia 
As can be seen in Figure 11.1, vaccines are stored at four administrative levels in Ethiopia 
before they reach the health facilities. Vaccines are delivered quarterly into the country by 
air and kept in the national cold store in Addis Ababa. From here they are transported to 
regional, zonal and district cold storage facilities and subsequently to health facilities. At 
national and regional levels OPV is stored in freezers and the remaining vaccines at 
refrigerated temperatures, while at the three lower levels all vaccines are stored in 
refrigerators between 2-8° Celsius. 
 
Figure 11.1: Vaccine cold storage distribution system in Ethiopia 
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11.3.2 METHODS 
The cost analysis was undertaken from a societal perspective. Hence, the full costs of the 
vaccine introduction whether financed by the government or any other source were 
estimated. Opportunity costs, such as staff time, were included. Costs were estimated in 
2007 US$ with the average 2007 exchange rate of 9.04 birr per one US$ used in all 
calculations (www.oanda.com). Cost items were divided into capital and recurrent costs. A 
discount rate of 8%, based on a 2007 inflation rate of 17% minus a 9% interest rate for 
public lending banks in Ethiopia, was used when annualising capital equipment [308].  
11.3.2.1 Data collection 
Resource items affected by pentavalent vaccine introduction were identified from 
interviewing key informants and by reviewing the Ethiopian hepatitis B and Hib vaccines 
introduction plan [309]. Data collection was undertaken as part of a WHO post-
introduction evaluation (PIE) of pentavalent vaccine that took place over a two-week 
period in November 2007 [310]. Four teams of 2-3 people travelled to four regions 
(Oromia, Southern Nations Nationalities and People’s Region (SNNPR), Somali and 
Amhara) to interview health sector staff about the programmatic aspects of pentavalent 
vaccine introduction.  The regional health bureaus, zonal health departments, woreda 
health offices and a minimum of four health facilities were visited per zone. Two teams 
evaluated two zones each and the remaining two teams evaluated one zone each. The 
health facilities were selected in consultation with zonal staff based on their vaccine 
coverage performance.  The cold stores at central, regional, zonal and woreda level were 
evaluated. In the health facilities observations were made during immunization sessions 
and caregivers were interviewed on exit.  Interviews using standard questionnaires and 
observation sheets were conducted with a total of 50 individuals [310, 311]. 
I joined the team in Ethiopia and was responsible for conducting a cost analysis alongside 
the PIE. I developed a cost data collection tool to use at zonal, woreda and health facility 
levels and trained the field workers in collecting data. The tool is included in Annex 10. I 
collected all national level data.  
Cold storage 
Cold storage investments to accommodate the pentavalent vaccine were predominantly 
part of an overall 2004-2008 cold chain rehabilitation plan [312]. The plan had the 
following objectives: 1) Expansion of vaccine storage capacity to allow for population 
growth, introduction of new vaccines, increasing coverage and new health facilities, 2) 
replacement of cold chain equipment and 3) standardization of vaccine storage facilities.  
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 A two step method was used to allocate a proportion of the cold storage investments to 
the pentavalent vaccine. First, the percentage increase in overall vaccine volume was 
estimated using the WHO vaccine volume calculator [313]. Vaccine wastage rates for this 
calculation were based on long-term vaccine procurement experience by the WHO office 
in Ethiopia. A 5% wastage rate was predicted for the single dose vial pentavalent vaccine. 
In the second step, all capital items purchased as part of the rehabilitation plan were 
assessed and a percentage of the investment allocated to the pentavalent vaccine using 
partly the result generated by the vaccine volume calculator and partly expert opinion 
from cold chain logisticians in Ethiopia.  
Electricity and kerosene usage according to type of equipment was collected from WHO 
Product Information Sheets [314] and applied to the capital items purchased as part of the 
rehabilitation plan. A 2007 unit price of US$ 0.1 per kilowatt per hour and US$ 0.63 per 
litre of kerosene was used. Annual maintenance costs of cold storage equipment were 
assumed as 5% of the purchase price, based on average maintenance costs quoted in the 
rehabilitation plan budget.  
Transport 
Changes in vaccine transport frequency due to the greater volume were assessed in the 
four regions taking part in the PIE. Questions included how the vaccines were transported 
and whether the frequency of transport had changed due to introduction of pentavalent 
vaccine and if so, by how much. For zonal and district levels, averages from the four 
regions were extrapolated to the remainder of the country, while for the regional level, 
estimates from the SNNPR were used for the whole country, as data from the other three 
regions contained insufficient detail. Since the transport system and the distances are 
fairly similar in all regions of the country this extrapolation can be considered reasonable. 
Training and communication 
Costs of training and public communication activities related to the pentavalent vaccine 
introduction were collected from staff in the WHO and Unicef offices in Addis Ababa, as 
these organisations had funded these activities.  
Vaccine supplies 
Incremental, annual vaccine supply costs were calculated as the difference between a 
schedule with pentavalent and one with DTwP vaccine. A birth cohort of 3.2 million 
children and the Ministry of Health vaccine coverage predictions for 2007 were applied 
[306]. Prices of vaccines, syringes and safety boxes were collected from Unicef [315, 316].  
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Financing of pentavalent vaccine introduction 
Information about the financing of pentavalent vaccine introduction was collected from 
the Ministry of Health, WHO and Unicef offices in Addis Ababa.  Ethiopia has traditionally 
been heavily reliant on external partner support for the  immunisation program [317]. 
During 2007 all vaccines other than the pentavalent were procured by Unicef from a 
“Protecting Basic Services” fund, supported by the World Bank and other partners. 
11.3.3 RESULTS 
11.3.3.1 Incremental system costs 
Cold storage  
Packed volume per dose increased by 9.9 cm3 due to the switch from a 10 dose DTwP 
vaccine to a single dose pentavalent vaccine. When using three doses and taking vaccine 
wastage into account, the increase in storage volume per fully vaccinated child was 28.7 
cm3. At national and regional levels, where OPV is stored in freezers and diluents are 
outside the cold chain, this caused a 106% increase in refrigeration storage volume per 
fully vaccinated child (from 27.1 cm3 to 55.8 cm3). At the three lower levels storage 
volume increased by 71% per fully vaccinated child (from 40.7 cm3 to 69.4 cm3). This is 
shown in Figure 11.2.  
Figure 11.2: Storage volume per fully immunized child  
before and after pentavalent introduction 
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At national and regional levels, 15 additional cold rooms were assembled and one building 
for a cold room was constructed as part of the rehabilitation plan, at a total cost of US$ 
638,779. Since these rooms are also used for storage of HIV tests and other vaccines, it was 
approximated that 70% of these costs can be allocated to the pentavalent vaccine, based 
on the opinion of the cold store manager (Table 11.8). For zonal and district cold storage 
facilities and health facilities, refrigerators, cold boxes and vaccine carriers were 
purchased. Since more than half of these were for equipment to new health facilities, only 
40% of this investment was allocated to the pentavalent vaccine, again based on the 
expert assessment of the cold store manager. Total up-front costs of these cold storage 
investments amounted to US$ 4.6 million, or US$ 1.44 per child in the 2007 birth cohort 
and US$ 0.076 per additional cm3 of storage volume. On an annual basis, incremental costs 
of cold storage were estimated as US$ 1.9 million, equivalent to US$ 0.87 per fully 
vaccinated child and US$ 0.03 per cm3 of storage. 
Transport 
At all levels of vaccine transport changes were made to accommodate the increase in 
volume. From central to regional level, vaccines were still collected only four times per 
year, but instead of using a pick-up vehicle or a four-wheel drive, a truck was used by ten 
of the 16 regional cold stores. This increased vehicle operating costs by US$ 452 per year 
and total annual fuel consumption by approximately 3,175 litres. With a fuel price of US$ 
0.6 per litre, this amounts to an incremental fuel cost of US$ 2,363 per year. 
In SNNPR, staff from 17 zonal cold storage facilities collects vaccines from the regional 
cold store. The average distance of a round trip from zone to region is 419 km (range 3-
530 km) and it takes between 1-3 days to complete this trip. The frequency of zonal 
vaccine collection has on average doubled from 4 to 8 times per year since pentavalent 
vaccine has been introduced. When adding up per diems, salary, fuel and vehicle operating 
costs, it was estimated that transport costs per zone have on average increased from US$ 
289 to US$ 577 per year. With 61 zones in Ethiopia, annual incremental costs at this level 
amount to approximately US$ 17,601. 
Interviews with staff at 22 district storage facilities in the four regions revealed that 17 
(77%) of these had increased their frequency of vaccine collection. Before pentavalent 
vaccine introduction, these facilities on average collected vaccines from the zones nine 
times per year (range of 4 - 18). This has now increased to an average of 17 trips per year 
(range of 4 – 36). Approximately 85% of district storage facilities use a private vehicle and 
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Table 11.8: Cold storage investments made during 2005-2007 to accommodate pentavalent vaccine, Ethiopia (2007 US$) 
Item Quantity Total costs 
Useful 
life 
years* 
Annualised 
costs 
Annual 
operational 
costs** 
Total 
annual 
costs 
Percent 
allocated to 
pentavalent 
Vaccine 
Costs of 
pentavalent 
Vaccine 
National cold rooms 2 56,000 15 6,542 6,804 13,346 70% 9,342 
Regional cold room building 1 49,090 15 5,735 2,455 8,190 70% 5,733 
Regional cold rooms 13 457,600 15 53,461 80,144 133,606 70% 93,524 
Generators for regional cold rooms 6 76,089 10 11,339 3,816 15,155 70% 10,609 
Refrigerators for zonal storage 13 9,672 10 1,441 23,600 25,042 70% 17,529 
Refrigerators for district storage 124 58,280 10 8,685 193,554 202,239 40% 80,896 
Refrigerators for health facilities 5,973 8,959,500 10 1,335,230 2,851,518 4,186,748 40% 1,674,699 
Cold boxes for health facilities 2,338 1,098,860 20 111,921 - 111,921 40% 44,769 
Vaccine carriers for health facilities 12,518 111,161 15 12,987 - 12,987 40% 5,195 
Ice pack freezers for health facilities 10 25,000 10 3,726 124 3,850 40% 1,540 
TOTAL 20,998 10,901,252  1,551,069 3,162,015 4,713,084  1,943,835 
* Source: Expert opinion based on previous experience in Ethiopia.  
** Include spare parts, maintenance, training and monitoring, electricity and kerosene costs. Source: Ethiopia cold storage rehabilitation plan and WHO product information sheets.
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the remainder use bus transportation when collecting vaccines. Costs of transport from 
districts to zones were estimated to have increased by US$ 165,994 per year (Table 11.9). 
 Substantial differences were seen between health facilities with regard to the frequency of 
vaccine collection. While eight out of 22 facilities had made no changes and were still 
collecting vaccines once a month, three facilities had changed from once a month to once a 
week. The average increase in collection times was from 12 to 26 trips per year; an 
increase of 121%. Approximately 90% of health facilities used a health sector vehicle 
when collecting vaccines while the remainder used bus transport. Total incremental 
transport costs at this level amounted to US$ 273,975 per year (Table 11.9 and 11.10).  
Incremental transport costs per fully vaccinated child were estimated as US$ 0.207. 
Table 11.9: Vaccine transport costs according to administrative level in Ethiopia 
(2007 US$)* 
Level of vaccine 
transportation 
Before 
pentavalent 
After 
pentavalent 
Difference 
Incremental 
costs per 
fully 
vaccinated 
child** 
From central to regions  6,802  
                    
9,164              2,362                  0.001  
From regions to zones 
                     
17,601  
                  
35,202            17,601                  0.008  
From zones to districts 
                   
177,632  
                
343,626          165,994                  0.075  
From districts to health 
facilities 
                   
225,909  
                
499,884          273,975                  0.123  
TOTAL 
                   
427,944  
                
887,877          459,932                  0.207  
* The estimate from region to zones is based on data from one region, SNNPR. Estimates for the two lower 
levels are based on data from four regions in Ethiopia.  
** No. of fully vaccinated children are estimated as number of surviving infants (2,849,053) multiplied by 2007 
DTP3 coverage (78%). 
Training and communication 
Training of health staff took place over two days at the regional level and one day in the 
districts. A total of 6,706 people were trained nationwide. Transport allowance, stationary, 
refreshments, hall rental and facilitator fees were included in the training costs of US$ 
225,760. When assuming a useful life of three years and an 8% discount rate, annualised 
costs amount to US$ 87,602. 
Launching ceremonies were held in Somali, SNNPR and Oromia regions at a total cost of 
US$ 3,153. A national communication strategy was developed, including printed materials, 
such as flyers and flipcharts, as well as radio and television spots. Total communication 
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Table 11.10: Change in transport costs due to pentavalent vaccine introduction: District and health facility levels (Data from four regions 
in Ethiopia)*  
 From zone to district (n=22)  From district to health facility (n=17)  
 Before 
pentavalent 
After 
pentavalent 
Difference Before 
pentavalent 
After 
pentavalent 
Difference 
 Average no. of collection times per year  9 17 8 12 26 14 
Costs for facilities using private vehicle:       
Distance travelled per year (km)    448,182             867,000          418,818        680,325       1,505,400      825,075  
 Annual no. of collection days       5,602       10,838               5,235           6,803         15,054         8,251  
 Petrol costs (US$)       74,697        144,500       69,803         113,388       250,900    137,513  
 Vehicle operating costs (US$)      45,364       87,755      42,391          68,860       152,372       83,511  
 Salary of health care workers and drivers (US$)       26,855        51,950      25,095        32,611       72,162     39,550  
 Per diem of health care workers and drivers (US$)      79,324      153,451      74,127         96,329  154   116,825  
 Subtotal  (US$)          163,779      316,828    153,049      216,377      478,791    262,414  
Costs for facilities using bus service:       
 Annual no. of collection days              989       1,913            924          680       1,505     825  
 Salary of health care workers (US$)         2,916        5,642           2,725         2,007       4,441     2,434  
 Per diem of health care workers (US$)           7,655      14,809      7,154            5,268         11,657      6,389  
 Bus tickets (US$)        3,281       6,347    3,066        2,258       4,996     2,738  
 Subtotal (US$)        13,853        26,798    12,945             9,533         21,093      11,561  
 TOTAL (US$)       177,632        343,626     165,994        225,909       499,884      273,975  
*Unit costs used: One litre of petrol at national level: US$ 0.60, one litre of petrol at regional level: US$ 0.61, daily salary of driver: US$ 1.84,   daily salary of health worker:: US$ 2.95, driver per diem: US$ 
6.42, health worker per diem: US$ 7.74, operating costs of four wheel drive vehicle per km: US$ 0.03, operating costs of truck per km: US$ 0.05, return bus ticket:  US$ 3.32 
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costs amounted to US$ 51,665. When assuming a useful life of three years and an 8% 
discount rate, annualised costs of communication were US$ 21,977.  
No additional costs were incurred for changing vaccination cards and vaccine schedule 
posters to include Hib and hepatitis B vaccines. Since these stationary were out of stock at 
the time of introduction, changes and printing were done without any additional costs. 
11.3.3.2 Vaccine supplies 
Total costs of vaccine and injection supplies for the Ethiopian immunization schedule 
increased from US$ 6.1 million to US$ 30.6 million per year; more than a five-fold increase 
(Table 11.11). The 2007 Unicef price of DTwP vaccine, including freight charges, was US$ 
0.23 per dose while the price of pentavalent vaccine was US$ 3.79 per dose.  
11.3.3.3 Total incremental costs  
Incremental system costs amounted to US$ 2.5 million per year, equivalent to US$ 1.13 per 
fully vaccinated child (Table 11.12). Non-annualised capital costs, consisting of cold 
storage equipment, training and communication activities, amounted to US$ 4.8 million, or 
US$ 1.53 per child in the 2007 birth cohort. Ethiopia received US$100,000 as a vaccine 
introduction grant from GAVI, amounting to US$ 0.03 per child in the birth cohort.  If the 
country had been approved for pentavalent vaccine during GAVI phase II, it would have 
been eligible for a vaccine introduction grant of US$ 0.30 per child. With a 2007 birth 
cohort of 3.2 million children, this is equivalent to US$ 960,000. Hence, the introduction 
grant would have covered 20% of the capital investments made to facilitate the 
introduction.  
When including vaccine costs, total incremental costs of pentavalent vaccine introduction 
amounted to US$ 27 million per year, or US$ 12.17 per fully vaccinated child. 91% of these 
costs were for vaccine and injection supplies and the remaining 9% system costs. 
11.3.3.4 Financing of incremental system costs 
The government financed vaccine transport, amounting to 18% of the estimated 
incremental system costs. Cold storage investments, comprising 77% of incremental 
system costs, were funded by the World Bank, Unicef, USAID and the WHO. Unicef and the 
WHO also contributed to training and communication activities. In total, the World Bank 
contributed 60% of system costs, the government 18%, USAID 12%, WHO 6%, Unicef 2%, 
and GAVI 2% (in the form of the vaccine introduction grant of US$ 100,000, which was 
used for training of health workers).   
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Table 11.11: 2007 vaccine and injection supply costs with and without pentavalent vaccine in Ethiopia (US$) 
Antigen 
Doses 
per 
child/ 
women 
Vaccine 
coverage 
Doses 
per vial 
Wastage 
in 
percent* 
Costs per 
dose (incl. 
freight) 
Total 
vaccine 
costs 
Total 
injection 
supply 
costs** 
Total 
Costs 
% of 
total 
BCG 1 65% 20 65% 0.09  633,100    92,086      1,125,186  19% 
DTwP 3 25% 10 25% 0.23 2,049,935    895,571   2,945,506  48% 
Measles 1 30% 10 30% 0.21 607,877     282,309   890,187  15% 
OPV 4 10% 10 10% 0.02 166,861  - 166,861  3% 
Tetanus toxoid***  2 10% 10 10% 0.09  395,660     552,244  947,904  16% 
Total without DTwP-HepB-Hib        3,853,434     2,222,211        6,075,645  100% 
DTwP-HepB-Hib  3 78% 1 5% 3.79 26,579,415     895,571  27,474,987    
Total with DTwP-HepB-Hib        28,382,915    2,222,211  30,605,125    
Incremental costs of DTwP-HepB-Hib         24,529,480  - 24,529,480  80% 
2007 birth cohort: 3,154,398. 2007 surviving infants: 2,849,053 (source: Health and health related indicators, Federal Ministry of Health, Ethiopia) 
* Source: WHO, Ethiopia 
** Syringes and safety boxes 
***2007 women of child-bearing age: 3,162,304. The maximum a pregnant woman can receive is three doses (TT2 4 weeks after TT1 and TT3 6 month after TT2). Two doses are used 
in the calculation although this is likely to inflate the actual need, as only pregnant women are targeted.
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Table 11.12: Incremental system costs of pentavalent introduction in Ethiopia 
(2007 US$) 
 Total capital 
costs 
Annual costs 
(capital and 
recurrent) 
Annual costs 
per fully 
vaccinated 
child 
Annual 
costs per 
child in 
birth cohort 
Percent of 
total annual 
system 
costs 
Cold storage 
          
4,555,036  
               
1,943,835  0.87 0.62 77% 
Transport 0 
                  
459,932  0.21 0.15 18% 
Training 
             
225,760  
                    
87,602  0.04 0.03 3% 
Public 
communication 
               
51,665  
                    
21,977  0.01 0.01 1% 
Total 
          
4,832,460  
               
2,513,347  1.13 0.80 100% 
* Vaccine wastage included in the estimate  
11.3.3.5 Sensitivity analysis 
The most important assumption of the analysis was the proportion of cold storage 
investment allocated to the pentavalent vaccine. The base case scenario assumed 70% at 
national, regional and zonal level and 40% at district and health facility level. However, 
since the new vaccine introduction was a prime reason for the cold chain expansion and 
since the packed volume per child increased by between 71% - 106% according to level, 
these must be considered minimum allocations. If it is instead assumed that 80% of all 
additional cold storage investments were allocated to the pentavalent vaccine, 
incremental cold storage costs were US$ 1.70 per fully vaccinated child instead of US$ 0.87 
as in the base case scenario.  In this case annual system costs amount to US$ 1.95 per fully 
vaccinated child.  When changing the discount rate from 8% to 3%, incremental system 
costs decrease from US$ 1.13 to US$ 1.05 per fully vaccinated child.  
11.3.4 DISCUSSION 
Pentavalent vaccine supplies comprised 91% of the total incremental costs while system 
costs represented the remaining 9%. However, the study showed that in a resource 
constrained economy like the Ethiopian, the system costs of facilitating introduction of a 
new vaccine are substantial. It was estimated that incremental system costs of pentavalent 
vaccine amounted to US$ 1.13 per fully vaccinated child, or US$ 0.80 per child in the birth 
cohort. With a public health budget of only around US$ 4 per capita, this is far from 
insignificant.  
The pentavalent vaccine system costs of US$ 1.13 per fully vaccinated child are likely to 
underestimate the costs of an optimal vaccine introduction scenario. Numerous reports 
from Ethiopia have concluded that the cold chain system is not functioning optimally and 
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that additional investments are needed to ensure that vaccines maintain their potency. In 
this study the costs of the actual changes made to facilitate pentavalent vaccine 
introduction were estimated and not the costs of an optimal vaccine delivery situation 
with a greater cold storage expansion and less frequent vaccine transport.   
The GAVI vaccine introduction grant of US$0.30 per child in the birth cohort would only 
cover a fraction of the costs and other partners will therefore most often have to 
contribute as well, as was the case in Ethiopia. The increase in vaccine storage and 
transport costs due to the pentavalent vaccine occurred due to the switch from DTwP in a 
ten-dose vial to pentavalent vaccine in a single dose vial. Only a relatively small proportion 
of GAVI eligible countries have changed vaccines in this way. Instead, most have opted to 
first introduce hepatitis B vaccine, frequently combined with DtwP, and then subsequently 
changed to pentavalent vaccine.  However, for countries that have used DTwP-HepB 
vaccine in a ten-dose vial, the system cost implications will be similar to those in Ethiopia, 
as the packed volume per vial of this vaccine is similar to the ten-dose DTwP vaccine. The 
new, Indian manufactured pentavalent vaccine in a ten-dose vial, which was pre-qualified 
by the WHO in 2010, has a packed volume per dose of 4.4 cm3, compared to the 12.9 cm3 
per dose of the Crucell pentavalent vaccine. Hence, there is either limited or no need for 
expansion of the cold chain with this vaccine.  
The study has a number of limitations. Regional transport costs were extrapolated to the 
whole country from one region only. Secondly, cold storage costs were likely to be 
underestimated as only new equipment was included and the opportunity costs of using 
the existing equipment were  not accounted for. To do this, data on existing cold chain 
equipment at all facilities would be needed, which is only possible if an extensive cold 
chain assessment is available. 
11.4 CONCLUSION 
This chapter started off by investigating determinants of Hib vaccine prices. Low-income 
countries eligible for pooled procurement through Unicef and PAHO are able to obtain 
considerably lower prices than middle- and high-income countries that procure 
independently. However, during 2000-2010 the Unicef pentavalent vaccine price was still 
considerably higher than prices of the traditional vaccines, contributing to slow uptake of 
Hib vaccine. Since the SII pentavalent vaccine became pre-qualified in 2011 a 50% price 
decrease has been obtained and this has greatly improved the prospects for financial 
sustainability in low-income countries. However, so far middle-income countries, 
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including Belarus, have not benefited from price decreases and 17 of the world’s middle-
income countries have not yet introduced the vaccine.  
Incremental costs of introducing Hib vaccine were estimated for Belarus, Uzbekistan and 
India, and the incremental costs of introducing Hib and hepatitis B vaccines as part of 
pentavalent vaccine introduction, were estimated for Ethiopia. Incremental costs 
amounted to US$ 19, US$ 8 and US$ 7 per fully vaccinated child in Belarus, Uzbekistan and 
India, respectively. In Ethiopia, the incremental costs of Hib and hepatitis B vaccine 
introduction were US$ 12 per fully vaccinated child, with system costs comprising 9% of 
total costs. Vaccine costs were the most important cost components in Ethiopia, 
confirming the fact that the relatively high pentavalent vaccine price is one of the key 
reasons for slow uptake in low- and middle-income countries. However, even though the 
amount is relatively low, system costs are important to estimate for budgeting reasons and 
for precise cost-effectiveness estimates. In a resource constrained country like Ethiopia 
these costs represented a substantial proportion of total government health care 
expenditures and they are therefore crucial to quantify.  
As mentioned above, the new SII pentavalent vaccine in a ten-dose vial has markedly 
changed the Hib vaccine landscape. When countries switch from DTP vaccine in a ten-dose 
vial to pentavalent vaccine in a similar vial size, there is no need for cold chain expansion 
and system costs are therefore relatively low, mainly comprising of social mobilisation and 
training. During 2011, the majority of GAVI countries requested to switch from single or 
two dose pentavalent presentations to the ten-dose SII vaccine. As an example, 20 out of 
24 countries in West Africa have now changed to the SII formulation (personal 
communication with Unicef in Dakar, Senegal). The main reason for wanting to free up 
cold chain space by switching to the ten-dose presentation is to prepare for pneumococcal 
and rotavirus vaccine introductions. Both of these vaccines take up considerable space in 
the cold chain; the packed volume per dose is 12 cm3 for the pneumococcal vaccine and 17 
cm3 for the rotavirus vaccine.   
In preparation for rotavirus and pneumococcal expansions, the GAVI Alliance and the Bill 
and Melinda Gates Foundation (BMGF) have started to assess to what extent the current 
vaccine introduction grant accurately represent the system costs of new vaccine 
introduction. Since the Ethiopia study presented in this chapter is presently the only in-
depth analysis available on systems costs, this study has been widely quoted and referred 
to during these discussions. Based on the evidence from Ethiopia, the GAVI Secretariat is 
now proposing to increase the vaccine introduction grant. The GAVI Board will make a 
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decision on this during its meeting in June 2012. In addition, the BMGF issued a request for 
proposals (RFP) in February 2012 for “analysis of the costs and financing of routine 
immunization programs and new vaccine introduction”. The Ethiopia paper is quoted in 
this RFP and it is stated that they wish to replicate the study in other settings and evaluate 
the feasibility of collecting cost data alongside PIEs, as I did in the Ethiopia study.   
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12 COST-UTILITY OF HIB VACCINE5 
In this chapter, the incremental cost-effectiveness and cost-utility of Hib vaccine are 
estimated for the three study countries, using the parameter values generated in the 
previous chapters. The outcome measures used are Hib disease cases, premature deaths 
and DALYs. Hib disease burden estimates are crucial for the overall results and these are 
described in section 12.1.  The methods and assumptions used in the sensitivity analyses 
are described in section 12.2, the results are presented in section 12.3, and the findings are 
discussed in section 12.4.  
12.1 ESTIMATION OF HIB DISEASE BURDEN IN THE THREE STUDY COUNTRIES 
As explained in Chapter 7, incidence rates and case fatality rates of Hib meningitis, Hib 
NPNM and all-cause pneumonia in children less than five years are needed as input 
parameters in the decision-analytic model. Hib pneumonia incidence is estimated as a 
fixed proportion of all-cause pneumonia incidence. The methods used for arriving at the 
best available disease burden estimates are described below.   
12.1.1 HIB DISEASE INCIDENCE RATES 
12.1.1.1 Hib meningitis incidence 
Belarus 
In Belarus, population-based childhood bacterial meningitis surveillance was in place at 
Minsk City Children’s Infectious Disease Hospital (MCCIDH) during 2002-2007 [238, 318]. 
Conditions for successful population-based meningitis surveillance are [319]: 
 The surveillance population should be geographically well defined.  
 Age-specific population data should be available so that age-specific rates of disease 
can be calculated. 
 All health facilities that diagnose and treat childhood meningitis in the surveillance 
population should be included in the surveillance system. 
 Residence of the surveillance population should have a high level of health care 
utilization. 
 The standard of care should include lumbar puncture in the routine evaluation of 
children who present with symptoms of meningitis. 
                                                             
5 Griffiths UK, Clark A, Shimanovich V, Glinskaya I, Tursunova D, Kim L, Mosina L, Hajjeh R, Edmond 
K. Comparative economic evaluation of Haemophilus influenzae  type b vaccination in Belarus and 
Uzbekistan. PLoS One. 2011;6(6) 
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It is believed that the Minsk city surveillance largely adhered to all these conditions. Since 
the MCCIDH is the only infectious disease hospital in Minsk city, all children with 
symptoms of meningitis are referred to this facility and it is unlikely that any cases have 
been missed by the surveillance.  A number of children with residency outside Minsk city 
were identified in the surveillance, but these were not included in the incidence rate 
calculations. It is however likely that there is under-ascertainment of cases of bacterial 
meningitis at the MCCIDH. A review of the hospital laboratory highlighted several sub-
optimal methods [320]. In particular, human blood was used instead of sterile animal 
blood for preparing blood and chocolate agar plates and CSFs were not cultured 
immediately. For these reasons, the confirmed bacterial meningitis incidence rate is likely 
to be an underestimate.  
During the six-year period, 175 purulent meningitis cases were detected in children less 
than five years, giving an average bacterial meningitis incidence rate of 31.28 per 100,000 
children less than five years. A bacterial pathogen was identified in 87 of the purulent 
cases (Table 12.1). Thirty of the cases were confirmed as Hib, generating an incidence of 
5.4 per 100,000 children, with annual rates between 1.2 and 9.0. However, since 88 of the 
purulent cases had no confirmed pathogen, this is likely to be an underestimate of the true 
number. According to WHO guidelines [321] and following methods used in other 
bacterial meningitis aetiology studies [322], culture negative cases should be allocated to  
Table 12.1: Reported purulent* meningitis cases in children less than 5 years in 
Minsk city, Belarus 
Year 
Number of 
confirmed 
Neisseria 
meningitis 
cases 
Number 
of 
confirmed 
Hib cases 
Number of 
confirmed 
Streptococcus 
pneumoniae 
cases 
Number 
of 
confirmed 
other 
bacteria 
Number 
of 
culture 
negative 
cases 
Total 
number 
of 
purulent 
cases* 
Bacterial 
meningitis 
incidence 
per 
100,000 
children < 5 
years** 
2002 3 2 1 0 12 18 24.94 
2003 7 6 1 0 11 25 33.57 
2004 10 5 1 0 12 28 36.54 
2005 9 7 3 0 14 33 42.13 
2006 7 1 3 1 25 37 45.69 
2007 6 5 1 1 6 19 22.27 
2008 3 4 0 0 8 15 16.37 
TOTAL 45 30 10 2 88 175 31.28 
*Purulent meningitis is defined as visibly turbid or cloudy CSF OR white cell count   > 100  
** Incidence rates are calculated from the following under-five population in Minsk city: 2002: 72,168, 2003: 
74,469, 2004: 76,623, 2005: 78,323, 2006: 80,985, 2007: 85,335, 2008: 91,623. 
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bacterial pathogens according to their proportion of confirmed cases. Hence, 34% of the 
non-confirmed cases were apportioned to Hib and an adjusted Hib meningitis incidence 
rate of 10.9 per 100,000 children less than five years, with an annual range between 7.4 
and 15.1 was estimated (Table 12.2). 
It should be noted that Hib vaccination was in place in Minsk city during 2007 (high risk 
groups) and 2008 (routine use),  but data from the ‘post-vaccine’ era were not excluded 
since it may take some time before the impact is demonstrated, particularly  in countries 
with a relatively high average age of Hib disease. In addition, the surveillance figures for 
2007-2008 were broadly consistent with the previous years. There was a fairly even 
spread of cases across the first four years of life, with fewer cases in the fifth year of life 
(Table 12.3).  There were two cases in the 5-14 year age group.   
Table 12.2: Estimated Hib meningitis incidence in Minsk city 2002-2008 
Year 
Number of 
confirmed 
Hib cases 
in children < 
5 years 
Adjusted 
number of 
confirmed 
Hib cases in 
children < 5 
years* 
Number of 
children < 5 
years in 
Minsk city 
Confirmed 
Hib 
meningitis 
incidence 
Adjusted Hib 
meningitis 
incidence * 
2002 2 6 72,168 2.8 8.5 
2003 6 10 74,469 8.1 13.2 
2004 5 9 76,623 6.5 11.9 
2005 7 12 78,323 9.0 15.1 
2006 1 10 80,985 1.2 11.9 
2007 5 7 85,335 5.9 8.3 
2008 4 7 91,623 4.3 7.4 
TOTAL 30 60 559,526 5.4 10.9 
*Adjusted cases are calculated by adding the fraction of culture negative cases believed to be Hib (using % of 
confirmed cases that are Hib)  
Table 12.3: Age distribution of hospitalized Hib meningitis  
cases <5yrs in Minsk, 2002-2008 
Age <12m 12-23m 24-35m 36-47m 48-59m Total 
Number 6 7 8 6 3 30 
%  20% 23% 27% 20% 10% 100% 
India 
In the state of Tamil Nadu a population based prospective meningitis surveillance study 
comparable to the one in Belarus was in place during 1997-1999 [44]. Four hospitals in 
the district of Vellore participated in the study. The number of meningitis cases detected 
during the two-year period is seen in Table 12.4. A confirmed Hib meningitis incidence 
rate of 7.1 per 100,000 children less than five years was estimated by the study authors. 
For the present analysis, a similar adjustment as used in Belarus was done.  Since Hib was 
the cause of 44% of all confirmed bacterial meningitis, 44% of the culture negative cases  
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Table 12.4: Estimation of Hib meningitis incidence in India 
Area 
Estimated 
children 
< 5 years 
Number of 
purulent 
meningitis 
cases during 
two years 
 
Annual 
incidence of 
purulent 
meningitis* 
Number of 
confirmed 
bacterial 
meningitis 
cases during 
two years 
Annual 
bacterial 
meningitis 
incidence per 
100,000 
children < 5 
years 
Number of 
confirmed 
Hib 
meningitis 
cases during 
two years 
 
Annual 
confirmed 
Hib 
meningitis 
incidence 
Number of 
culture 
negative 
cases with 
CSF>100 
WCC 
during two 
years 
Adjusted 
number 
of Hib 
cases** 
during 
two years 
Adjusted Hib 
meningitis 
incidence 
per 100,000 
children < 5 
years 
Vellore, urban 16,407 18 55 8 24.38 3 9.1 10 7.44 22.69 
Vellore, rural 13,041 7 27 1 3.83 1 3.8 6 3.67 14.06 
Kaniyambadi, rural 8,677 9 52 2 11.52 2 11.5 7 5.11 29.45 
Katpadi, rural 7,524 3 20 1 6.65 - - 2 0.89 5.91 
Anaicut, rural 10,504 5 24 6 28.56 2 9.5 -1 1.56 7.40 
TOTAL 56,153 42 37 18 16.03 8 7.1 24 18.67 16.62 
*Purulent meningitis is defined as visibly turbid or cloudy CSF OR white cell count   > 100.  
** Adjusted cases are calculated by adding the fraction of culture negative cases believed to be Hib (using % of confirmed cases that are Hib). 
Source: Minz et al. (2008) [44] 
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were assumed to be Hib and an adjusted Hib meningitis incidence rate of 16.62 per 
100,000 children less than five years was estimated  
There was moreover evidence that not all children were captured by the surveillance due 
to limited access to care. The study authors identified all deaths during 1998 and 1999 in a 
subpopulation of 19,181 children in the two rural study areas with the least access to 
health care and families were interviewed using a verbal autopsy method. This survey 
identified 327 deaths over the two years and eight of these had suffered from meningitis 
symptoms, but had not had a lumbar puncture or died in one of the study hospitals. It was 
thus concluded that since not all children with meningitis symptoms in the study 
population had been taken to formal health care facilities, the calculated incidence rate 
would be an underestimate [44]. For the present study, the rate was therefore adjusted 
upwards by 23%, which is the estimated proportion of children with ARI in Vellore that 
are not taken to formal medical care [261]. Hence, the final adjusted Hib meningitis 
incidence rate was 20.44 per 100,000 children < 5 years.  
Uzbekistan 
Since no population based Hib surveillance studies have been conducted in Uzbekistan, 
routine surveillance data were used for the estimates. Morbidity and mortality data for 
pneumonia and meningitis in children less than five years are routinely collected by the 
Ministry of Health. Meningococcal meningitis is a notifiable disease and therefore reported 
separately while other types of meningitis are not distinguished according to pathogen. 
The view that meningococcal meningitis is a very severe disease drives the emphasis on all 
children with bacterial meningitis being referred to infectious disease hospitals [38].  
There are however two important limitations of using routine surveillance data for 
estimating meningitis incidence rates. First, these data are usually gathered from hospital 
medical records and are based on the physician’s clinical discharge diagnosis, which can 
vary markedly amongst treating physicians. In many hospitals, a clinical discharge 
diagnosis of meningitis is usually made on the basis of clinical signs and symptoms of 
meningococcemia (i.e. purpuric rash and fever or neck stiffness or bulging fontanelle). 
Children with more subtle signs of septicaemia and vomiting or headache may not be 
classified as meningitis and may be missed by some doctors. Secondly, all data sources for 
all children with these diseases must be accessed. Data must thus be obtained from all 
hospitals that admit children with meningitis and from hospitals that treat children who 
develop meningitis later in their illness (for example, children who are admitted with 
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septicaemia, but develop meningitis the following day). Hence, surveillance data are likely 
to be an underestimate of the true number of cases.  
234 hospitals reported 5,245 clinical meningitis cases in children less than five years in 
2007, giving an incidence of 166 per 100,000 children. This estimate was adjusted 
upwards by 32% to account for limited access to care [259], arriving at 219 all-cause 
meningitis cases per 100,000 children. The proportion of meningitis caused by Hib was 
approximated from a study conducted by the Uzbek Ministry of Health and the US Naval 
Medical Research Unit no. 3, based in Egypt [323]. 165 CSF samples from children with 
clinical meningitis admitted to hospitals in Tashkent and Samarkand during 2002-2004 
were tested using Polymerase Chain Reaction and 61 were found to be purulent with nine 
of them confirmed as Hib [323]. The adjusted number is 14 cases, equivalent to 8.5% of all 
the cases tested. An adjusted Hib meningitis incidence of 18.7 per 100,000 children < 5 
years (8.5% of 219) was thus estimated. 
12.1.1.2 Hib NPNM incidence 
There are no data on Hib NPNM disease incidence rates in any of the three countries. 
Following the methodology of the GBD study, the NPNM disease incidence was estimated 
as a proportion of the meningitis incidence rate [58]. For Belarus and Uzbekistan, studies 
from Bulgaria and the Czech Republic assessing all types of Hib diseases were used to 
determine the relationship between meningitis and NPNM cases [25, 43]. The pooled 
average from these two studies is 0.57 NPNM cases diagnosed for each meningitis case.  
The most important type was epiglottitis, accounting for 78% of cases. Hib NPNM 
incidence rates of 6.15 and 10.65 per 100,000 children less than five years in Belarus and 
Uzbekistan, respectively, were estimated.  
In India, data published by the Invasive Bacterial Infections Surveillance (IBIS) project in 
Tamil Nadu showed that for each meningitis case, there were 0.18 confirmed NPNM Hib 
disease cases [324]. Hence, an incidence rate of 3.72 NPNM cases per 100,000 children less 
than five years was assumed.   
12.1.1.3 All-cause pneumonia incidence 
In Belarus and Uzbekistan, all-cause pneumonia incidence was determined from routine 
surveillance systems of the Ministries of Health. In Belarus, 10,402 pneumonia cases in 
children less than five years were reported during 2008, giving an annual incidence of 
2,302 per 100,000 children, based on an under-five population of 451,960 [325]. 84% of 
cases were reported from hospitals and the remaining from outpatient clinics.  
Chapter 12: Cost-utility estimates 
 
194 
 
In Uzbekistan, 20,014 pneumonia cases were reported in 2007, giving an incidence of 633 
per 100,000 children less than five years (under-five population is 3,162,151 [326]). 
230,201 acute respiratory infections (ARI) cases were reported the same year. The 
distinction between ARI and pneumonia can be problematic, as it is common to find a lack 
of consistency when classifying these diseases at health facility level [327]. When 
hospitalised ARI cases are included, the incidence rate increases to 1,724 per 100,000. 
After adjusting for limited access to care, the adjusted incidence is 2,277 per 100,000 
children less than five years. 
Various studies of clinical pneumonia incidence have been conducted among children aged 
less than five years at the community-level in India.  However, many of these estimates 
were reported more than ten, sometimes twenty years ago, and there are great variations 
among the study results. The incidence per child per year was reported to be 0.54 in 
Haryana (1987) [328], 0.29 in Pune (1990) [329], 0.86 in Rajasthan (1990) [330], 0.31 in 
Delhi (1993) [331], 0.07 in Maharastra (1996) [332], 0.10 in Lucknow (1997) [333], 0.4 in 
Tripura (1998) [334], 0.67 in  Delhi (1999) [335] and 0.53 in Karnataka (2003) [336].  The 
inter-quartile range from the above estimates was 0.29– 0.54 episodes per child per year, 
or 29,000 – 54,000 cases per 100,000 children less than five years.  The mean value is 
41,500 cases per 100,000 children less than five years. There is great variation among the 
study estimates and the values are considerably higher than found in Belarus and 
Uzbekistan. In light of the greater under-five mortality rate in India than in the two other 
countries, this is expected, but the differences can seem disproportionally large. This 
underlines the great difficulties in establishing the true burden of pneumonia.   
Hib Initiative funded multi-center surveillance for pneumonia at three different settings 
found an incidence of severe, clinical hospitalized pneumonia of 2,717 in Chandigarh, 
7,890 in Kolkata and 2,887 in Vellore in children less than two years [253]. The average 
between the three sites is a rate of 4,561. When adjusting to children less than five years of 
age, the incidence rate of severe all-cause pneumonia is approximately 3,280.  It was 
decided to use this value in the base case analysis and use a relatively wide range for 
pneumonia incidence in the uncertainty analysis, as described below. 
12.1.1.4 Hib pneumonia incidence 
Since the signs and symptoms of Hib pneumonia cannot be differentiated from those of 
pneumonia caused by other microorganisms, the incidence of Hib pneumonia can best be 
approximated from Hib vaccine trials [176]. In the meta-analysis presented in Chapter 8, 
two trials demonstrated Hib vaccine efficacy against all cause, clinical pneumonia and the 
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pooled estimate was 4% (95% CI 1, 7), with no heterogeneity between the two studies. It 
was thus assumed that vaccine preventable Hib disease is the cause of 4% of all clinical 
pneumonia. This assumption is similar to what was used by the Hib GBD project [31]. Hib 
pneumonia incidence rates of 114 and 115 per 100,000 children less than five years were 
estimated for Belarus and Uzbekistan, respectively.  
Since the Indian all-cause pneumonia estimate is for severe pneumonia only other trial 
evidence than the clinical pneumonia was used. The Gambian and Chilean Hib vaccine 
trials showed that Hib pneumonia is the cause of approximately 22% of severe pneumonia 
(defined as radiological pneumonia in the trials) [185, 186]. A Hib vaccine incidence rate 
of 722 per 100,000 children less than five years was thus assumed for India (3,280 x 22%). 
12.1.2 HIB DISEASE CASE FATALITY RATES 
Belarus 
In the Minsk city meningitis surveillance project, one of the 30 children with confirmed 
Hib meningitis died, giving a case fatality ratio (CFR) of 3.2%. This is comparable to CFRs  
reported in Western European countries, such as 5% in the United Kingdom [27, 225] and 
4% in France [54]. Only six and five pneumonia deaths in children less than five years 
were reported in Belarus during 2007 and 2008, respectively. This is equivalent to around 
2% of all deaths in children and a CFR of 0.3% for all-cause pneumonia.  The studies from 
Bulgaria and Czech Republic showed that approximately 78% of NPNM were epiglottitis, 
which is of similar severity to meningitis. For this proportion, a similar CFR to meningitis 
was assumed and zero CFR was assumed for the remaining NPNM cases. 
India 
Hospital bacterial meningitis CFRs have been reported in three Indian studies. In the 
Invasive Bacterial Infections Surveillance (IBIS) study, a CFR of 18.7% was reported [324], 
in a study by Minz et al. the CFR was 12.5% [44], and in a study by Gupta et al. it was 
19.7% [253].  The average figure of 17% was used. For children not accessing care 
meningitis CFR was assumed to be 100% [124, 125]. The overall rate was thus 41%. 
In the study by Gupta et al., hospital CFRs for severe clinical pneumonia was 1.31% in 
Chandigarh, 3.32% in Kolkata and 0.89% in Vellore [253]. The average of 1.85% was used 
for hospitalised cases and 10% was assumed for the 29% with no access to care [125], 
giving an overall CFR of 4.21%.  A similar CFR was assumed for NPNM.  
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 Uzbekistan 
In Uzbekistan, 22 children less than five years were reported to have died from meningitis 
in 2007, giving a CFR of 0.42%. For Hib meningitis, this figure is however unrealistically 
low. Instead, the 17% hospital CFR from the Indian studies was used and a CFR of 100% 
was assumed for the estimated 32% of children that do not reach formal health care [125]. 
The overall meningitis CFR was thus 44%.  
According to Uzbek hospital surveillance data, a total of 214 pneumonia deaths occurred 
in 2007, generating an all-cause hospital pneumonia CFR of 1.07%. For those without 
access to health care, a CFR of 10% was assumed, giving a weighted mean CFR of 4%.  
Again, NPNM CFRs were assumed similar to those of pneumonia.   
The base case parameter values for the three countries are summarised in Table 12.5.  
Table 12.5: Hib disease burden parameters used in the base case analyses 
Parameter Belarus India Uzbekistan 
2010 live births 94,200 26,542,850 558,459 
Under-five mortality rate 6 63 5 
2010 life expectancy at birth (years) 70 65 68 
Incidence per 100,000 children < 5 yrs:    
 All-cause clinical pneumonia 2,302 NA 2,277 
  All-cause severe pneumonia NA 3,280 NA 
 Hib NPNM 6.15 3.72 10.65 
 Hib meningitis 10.10 20.44 18.70 
Proportion of clinical pneumonia due to Hib 4% NA 4% 
Proportion of severe pneumonia due to Hib NA 22% NA 
Hib pneumonia incidence 115 722 114 
Case fatality ratios:    
 Hib pneumonia w/o access to care NA 10% 10% 
 Hib pneumonia with access to care 0.3% 2% 1.07% 
 Hib NPNM w/o access to care NA 10% 10% 
 Hib NPNM with access to care 2.5% 2% 1.07% 
 Hib meningitis w/o access to care NA 100% 100% 
 Hib meningitis with access to care 3.2% 17% 17% 
Treatment utilization:    
 Percent of Hib cases accessing care 100% 71% 68% 
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12.2 METHODS USED FOR UNCERTAINTY ANALYSES 
Uncertainty analysis was done according to methods recommended in a recent paper by 
Bilcke and colleagues on “accounting for methodological, structural and parameter 
uncertainty in decision-analytic models”  [337]. Two types of analyses were carried out; 
univariate uncertainty analysis and probabilistic uncertainty analysis.  
12.2.1 UNIVARIATE UNCERTAINTY ANALYSIS 
The aim of the univariate uncertainty analysis was to investigate the impact of changes in 
methodological choices and selected parameter values. The sources of uncertainty and the 
assumptions made for this analysis are summarised in Table 12.6. Methodological choices 
were the perspective taken, the discount rate, inclusion of meningitis sequelae costs and 
age weighting of DALYs. Two structural model uncertainties were assessed; the herd 
immunity feature explained in Chapter 7 was set to 20% and waning immunity was set to 
5% per year. 
Model parameters that have been in particular focus in some of the previous chapters 
were included to demonstrate the sensitivity to a change in these values. These 
parameters were meningitis sequelae DALY disability weight, treatment costs, Hib vaccine 
price, Hib disease incidence rates and Hib disease CFRs.  
Hib disease incidence rates assumed in the univariate analysis were those estimated by 
the Hib GBD project [58]. Using all published studies from the respective regions, the GBD 
project estimated a Hib meningitis incidence rate of 16 per 100,000 children less than five 
years for the WHO European region (EURO) (uncertainty range 12-22) and a rate of 27 
(range 11-38) for the South East Asian region (SEARO) [31]. The WHO EURO estimate was 
used for Belarus and Uzbekistan and the WHO SEARO estimate for India (Table 12.6)  
The GBD Hib pneumonia incidence rates for the WHO EURO region were 283 (range 259- 
463) per 100,000 children less than five years and 1,790 (range 1,635 – 2,925) for the 
WHO SEARO region [31]. Hence, for all three countries the GBD estimates were 
approximately twice as high as those estimated as part of this thesis. The pneumonia 
incidence estimates are thus likely to be the most uncertain parameters in the analysis. 
Due to the inherent problems of defining pneumonia accurately, studies on pneumonia 
incidence rates are rare and data are often conflicting [338]. As recently argued by Rudan 
and colleagues, further research on childhood pneumonia burden and pneumonia risk 
factors are urgently needed [339].  
  
Chapter 12: Cost-utility estimates 
 
198 
 
Table 12.6:  Univariate uncertainty analysis assumptions 
 Base case  
assumption 
Assumption used in 
uncertainty analysis 
Uncertain methodological choices: 
Economic perspective Societal Government 
Discount rate 3% 0% 
Age weighting of DALY estimates Yes No 
Inclusion of lifetime costs of 
meningitis sequelae 
No Yes 
Uncertain structural aspects: 
Herd immunity None 
20% additional vaccine 
effectiveness 
Waning immunity None 
5% decrease in vaccine efficacy 
per year 
Parameter uncertainty: 
Meningitis sequelae disability 
weight 
0.291 0.616 
Inpatient treatment costs As specified in Table 10.10 Increase by 50% 
Outpatient treatment costs As specified in Chapter 10 Increase by 50% 
Price per dose of Hib containing 
vaccine 
US$ 4.95 in Belarus, US$ 1.75 in 
India, US$ 3.00 in Uzbekistan  
US$ 1.50 in all three countries 
Hib meningitis incidence per 
100,000 children less than five 
years 
Belarus: 10.10 
India: 20.44 
Uzbekistan: 18.70 
Belarus: 16 
India: 27 
Uzbekistan: 16 
Hib pneumonia incidence rate 
per 100,000 children less than 
five years 
Belarus: 114 
India: 722 
Uzbekistan: 115 
Belarus: 283 
India: 1,790 
Uzbekistan: 283 
Hib disease CFRs As specified in Table 12.5 Decrease by 20% 
The GBD project estimated CFRs in EURO as 27%, 5%, and 1% for Hib meningitis,  
pneumonia and NPNM, respectively, and 44%, 2%,  and 1% for the SEARO region [31]. 
Since these estimates are averages across diverse settings in terms of income and access 
to health services, they are not applicable to the country specific analysis. In the 
uncertainty analyses, the base case CFRs were instead decreased by 20% to investigate the 
impact a change in these has on the overall result.  
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12.2.2 PROBABILISTIC UNCERTAINTY ANALYSIS 
Probabilistic uncertainty analysis was undertaken to simultaneously assess the 
uncertainty around all parameter values and generate 95% confidence intervals around 
the costs per DALY averted. This analysis was only done for Uzbekistan to demonstrate the 
principle.  
Statistical distributions were fitted to all uncertain parameters that were not 
methodological or structural. Parameters with fixed values that were not considered 
uncertain, such as vaccine and syringe prices and the 2010 birth cohort, were not varied 
either. Distributional parameters, such as the proportion of cases accessing different types 
of care, were not attached a distribution either because these need to add to 100% for the 
model to run correctly. All parameters and distributions used are summarized in Table 
12.7.   
Distributions were fitted to parameters according to recommendations by Briggs and 
colleagues [340]. The beta distribution was used for probability parameters with values 
between 0 and 1, such as case fatality rates and the risk of meningitis sequelae. The 
lognormal distribution is frequently used to fit relative risks and this was used for the 
vaccine efficacy parameters; the 95% confidence intervals estimated in Chapter 8 were 
used for fitting the distribution. As explained in Annex 2, treatment costs are often highly 
skewed and the gamma distribution was used to fit these data. Since the Uzbekistan 
treatment costs were not derived from patient-level data, assumptions had to be made 
about the standard deviation to be able to fit the gamma distribution. The standard 
deviation was assumed similar to the mean value of all cost estimates, reflecting the 
findings of most of the treatment cost studies reviewed in Chapter 5. The gamma 
distribution was also used to fit the disease incidence parameters. This was considered an 
appropriate distribution because the GBD estimate for Hib pneumonia is twice as high as 
used in the base case, indicating a right hand skewed distribution when taking uncertainty 
into account. The GBD values were used as 95% confidence limits when fitting the 
incidence rates to the gamma distribution.  
10,000 Monte Carlo simulations were run using Oracle Crystal Ball© software and the 
simulation data were analysed in STATA version 11.0. The importance of individual 
parameters to uncertainty in the result was assessed by analysis of covariance (ANCOVA), 
which summarises the proportion of the variance in the ICER explained by variation in the 
different input parameters [340]. 
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Table 12.7: Assumptions used in probabilistic uncertainty analysis for Uzbekistan 
Parameter Base case value 
Statistical distribution 
(parameters used to fit 
distribution) 
Discount rate and DALY parameters 
 
 
 
Discount rate for disease impact 3% NA 
Discount rate for costs 3% NA 
DALY age weighting modulation factor (K) 1 NA 
DALY age weighting parameter (β): 0.04 NA 
DALY constant (C): 0.1658 NA 
Demography   
2010 live births 558,459 NA 
Infant mortality per 1000 live births 47 NA 
Under five mortality per 1000 live births 57 NA 
Life expectancy at birth (years): 68 NA 
% of infant deaths in the neonatal period (<1m): 55% NA 
Hib disease burden   
Incidence rates per 100,000 children < 5 years   
  Hib pneumonia 114 Gamma (95% CI: 283) 
  Hib meningitis 18.70 Gamma (95% CI: 20) 
  Hib NPNM 11 Gamma (95% CI: 16) 
% case fatality ratios in ages 1-59m:   
  Hib pneumonia 4% Beta (100, 96) 
  Hib meningitis 42% Beta (42, 58) 
  Hib NPNM 4% Beta (100, 96) 
Hib meningitis survivors with major sequelae 35% Beta (35, 65) 
DALY disability weights:   
  Hib pneumonia 0.279 Beta (27.9, 72.1) 
  Hib meningitis 0.616 Beta (61.6, 38.4)  
  Hib NPNM 0.279 Beta (27.9, 72.1)  
  Meningitis sequelae 0.291 Beta (29.1, 70.9) 
Mean duration of illness (in days):   
  Hib pneumonia 9 Gamma (4, 2.25)  
  Hib meningitis 11 Gamma (4, 2.75) 
  Hib NPNM 9 Gamma (4, 2.25) 
Age distribution of disease cases and deaths   
<3m:  10.6% NA 
3-5m  13.6% NA 
6-8m  17.8% NA 
9-11m  17.8% NA 
12-23m  23.8% NA 
24-35m  5.5% NA 
36-47m  5.5% NA 
48-59m  5.5% NA 
Hib vaccination coverage   
Coverage of 1st dose 98% Beta (98,2) 
Coverage of 2nd dose 98% Beta (98,2) 
Coverage of 3rd dose 98% Beta (98,2) 
Vaccine efficacy   
1 dose 59% Lognormal (95% CI: 86%) 
2 doses 92% Lognormal (95% CI: 98%) 
3 doses 93% Lognormal (95% CI: 97%) 
Vaccination impact assumptions   
% decrease in dose efficacy / yr 0.0% NA 
% contribution of herd effect in <5yrs 0.0% NA 
Vaccination costs   
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Parameter Base case value 
Statistical distribution 
(parameters used to fit 
distribution) 
Pentavelent vaccine   
  Pentavalent price per dose $3.00 NA 
  Percentage UNICEF handling charge 5% NA 
  Percentage vaccine wastage 5% Beta (5, 95) 
Safety boxes:   
  Price per box $1.08 NA 
  Percentage handling: 25% NA 
  Percentage wastage 5% Beta (5, 95) 
  Number of syringes per safety box 100 NA 
Systems costs per dose US$ 0.06 NA 
Syringes:   
Price per syringe $0.06 NA 
Percentage handling: 25% NA 
Percentage wastage 5% Beta (5, 95) 
Existing DTP vaccine    
  Price per dose $0.18 NA 
  Percentage handling charge 5% NA 
  Percentage wastage 33.0% Beta (33, 67) 
Existing HepB vaccine   
  Price per dose $0.21 NA 
  Percentage handling charge 5.0% NA 
  Percentage wastage 33.0% Beta (33, 67) 
Health care utilization   
Number of outpatient visits per case:   
  Hib pneumonia 1.36 Gamma (1, 0.5) 
  Hib meningitis 1.36 Gamma (1, 0.5) 
  Hib NPNM 1.36 Gamma (1, 0.5) 
Number of inpatient admissions per case:   
  Hib pneumonia 0.68 Beta (2, 3) 
  Hib meningitis 0.68 Beta (2, 3) 
  Hib NPNM 0.68 Beta (2, 3) 
Distribution of outpatient visits (%):   
  Government outpatient clinic 100% NA 
Distribution of inpatient admissions (%):   
  Pneumonia/NPNM:   
  Primary hospital 66% NA 
  Secondary hospital 31% NA 
  Tertiary hospital 3% NA 
Hib meningitis:   
  Primary hospital 64% NA 
  Secondary hospital 32% NA 
  Tertiary hospital 4% NA 
Treatment costs   
Household cost per outpatient clinic visit $5.00 Gamma (1, 5) 
Government cost per outpatient clinic visit $1.53 Gamma (1, 1.53) 
Household cost per inpatient admission:   
Hib pneumonia and NPNM:   
  Primary hospital $26.00 Gamma (1, 26) 
  Secondary hospital $26.00 Gamma (1, 26) 
  Tertiary hospital $26.00 Gamma (1, 26) 
Hib meningitis:   
  Primary hospital $86.00 Gamma (1, 86) 
  Secondary hospital $86.00 Gamma (1, 86) 
  Tertiary hospital $86.00 Gamma (1, 86) 
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Parameter Base case value 
Statistical distribution 
(parameters used to fit 
distribution) 
Government cost per inpatient admission:   
Hib pneumonia and NPNM:   
  Primary hospital $169.00 Gamma (1, 169) 
  Secondary hospital $188.00 Gamma (1, 188) 
  Tertiary hospital $242.00 Gamma (1, 242) 
Hib meningitis:   
  Primary hospital $152.00 Gamma (1, 152) 
  Secondary hospital $171.00 Gamma (1, 171) 
  Tertiary hospital $190.00 Gamma (1, 190) 
Lifetime sequelae costs $0.0 NA 
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12.3 BASE CASE RESULTS 
12.3.1 DISEASE IMPACTS 
It was estimated that the vaccine annually prevents 505 Hib disease cases and three 
deaths in children less than five years in Belarus. In India, 615,805 cases and 32,152 
deaths are averted, and in Uzbekistan 3,246 cases and 291 deaths are averted annually 
(Table 12.8). Deaths averted represent approximately 0.29%, 1.6% and 0.92% of total 
2010 under-five mortality in Belarus, India and Uzbekistan, respectively.   Discounted 
annual DALYs averted amounted to 155 in Belarus, 1,082,471 in India and 10,496 in 
Uzbekistan. For India, 97% of the DALY estimates were comprised of YLLs while YLDs 
were only 3%. For Belarus and Uzbekistan, YLLs encompassed 70% and 92% of the 
DALYs, respectively.   
12.3.2 TREATMENT COST SAVINGS 
Annual treatment costs with and without Hib vaccine from the societal perspective are 
also summarised in Table 12.8. Pneumonia hospital admission costs were the most 
important type of treatment costs in all three countries, comprising 49%, 89% and 73% of 
total treatment costs averted in Belarus, India and Uzbekistan, respectively. Outpatient 
costs comprised 4%, 6% and 6% of total treatment costs averted in Belarus, India and 
Uzbekistan, respectively. 
Incremental vaccine costs exceeded total treatment cost savings in all three countries, as 
depicted in Figure 12.1. Hence, in the base case analysis, Hib vaccination is not predicted 
to be cost saving in any of the countries.  In India, the government health sector finances 
20% of Hib disease treatment costs and the remaining 80% are covered by households. In 
Uzbekistan, the proportions are reversed with households covering 20% and the 
government health sector 80% of total costs (Table 12.9). 
12.3.3 COST-EFFECTIVENESS AND COST-UTILITY ESTIMATES 
Four different ICERs are seen in Table 12.9; incremental costs per sequelae case averted, 
per discounted premature death averted, per discounted life year gained and per 
discounted DALY averted. Incremental costs per discounted DALY averted amounted to 
US$ 8,911 in Belarus, US$ 51 in India and US$ 357 in Uzbekistan. The ICER is lower in 
India compared to the two other countries mainly due to the lower Hib vaccine price and 
the higher Hib pneumonia incidence rate. 
As explained in Chapter 4, the WHO has established cost-effectiveness thresholds that can 
be used as a guide to determine whether an intervention is cost-effective.  If costs per 
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Table 12.8: Hib disease cases and treatment costs with and without Hib vaccine for the 2010 birth cohort (societal perspective) 
  Belarus   India   Uzbekistan  
 No vaccine Vaccine Prevented No vaccine Vaccine Prevented No vaccine Vaccine Prevented 
Cases:          
  Hib pneumonia 504 61 443  908,593   312,728   595,866   2,994  414   2,581  
  Hib meningitis 44 5 39  25,723 8,853   16,869   492   68   424  
  Hib NPNM 27 3 24  4,681   1,611  3,070   280  39   241 
  Meningitis sequelae 5 1 4  5,312  1,823   3,489  100  14 86  
  TOTAL 575 70 505    938,997   323,192   615,805  3,766 520 3,246 
Premature deaths:          
  Hib pneumonia 1 0 1  38,284   13,177   25,107   120  17  103  
  Hib meningitis 1 0 1  10,546   3,630  6,916   207   29  178  
  Hib NPNM 1 0 1  197   68   129  11  2  10  
  TOTAL 3 0 3 49,027   16,875   32,152  338 47 291 
Discounted DALYs 177 21 155 1,648,595     566,124     1,082,471  12,166  1,671   10,496  
No. of outpatient visits 1,903 232 1,672  688,275   236,896   451,378  5,122  707   4,415  
No. of hospital admissions 647 79 568  666,688   229,466   437,222   2,561   354  2,207  
Outpatient visit costs (US$):          
  Hib pneumonia 14,082 1,713 12,369  6,471,527   2,227,427   4,244,101  26,592 3,673 22,920 
  Hib meningitis 2,883 351 2,533  366,421   126,118   240,303  4,368 603 3,765 
  Hib NPNM 752 92 661  66,687   22,953   43,734  2,488 344 2,144 
  TOTAL 17,718 2,155 15,563 6,904,635 2,376,497 4,528,138 33,448 4,620 28,828 
Inpatient admission costs (US$):          
  Hib pneumonia 214,366 26,077 188,289  97,771,551   33,651,863   64,119,688  413,507 57,112 356,395 
  Hib meningitis 190,085 23,123 166,961  4,567,206   1,571,981   2,995,225  82,140 11,345 70,795 
  Hib NPNM 11,454 1,393 10,061  503,754   173,386   330,367  38,681 5,343 33,339 
  TOTAL 415,905 50,594 365,311 102,842,510 35,397,230 67,445,280 534,328 73,800 460,528 
TOTAL TREATMENT COSTS 433,623 52,749 380,874 109,747,145 37,773,727 71,973,418 567,776 78,420 489,356 
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Figure 12.1: Comparison of annual incremental vaccine costs  
and treatment costs averted for the base case analysis (2010 US$) 
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Table 12.9: Incremental cost-effectiveness of Hib vaccine for the 2010 birth cohorts in  
Belarus, India and Uzbekistan: Base case analysis 
 Belarus India Uzbekistan 
Annual incremental vaccine costs (US$) 1,764,322 127,173,579 4,241,611 
Annual government treatment costs averted (US$) 380,874 14,366,948 392,597 
Annual household treatment costs averted (US$) NA 57,606,470 96,760 
Total annual treatment costs averted (US$) 380,874 71,973,418 489,357 
Annual net costs (US$) (vaccine costs – treatment costs averted) 1,383,448 55,200,161 3,742,337 
Hib cases averted 505 615,805 3,246 
Hib meningitis sequelae cases averted 4 3,489 86 
Premature Hib deaths averted 3 32,152 291 
Discounted DALYs averted 155 1,082,471 10,496 
Incremental costs per discounted premature death averted (US$) 437,282 1,717 12,863 
Incremental costs per meningitis sequelae case averted (US$) 390,302 15,822 43,437 
Incremental costs per discounted life year gained (US$) 12,797 53 387 
Incremental costs per discounted DALY averted (US$) 8,497 51 352 
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DALY averted are less than GDP per capita, the intervention is regarded highly cost-
effective; if costs per DALY averted are between one and three times GDP per capita the 
intervention is considered cost-effective; and if costs per DALY averted are more than 
three times GDP per capita, it is not deemed cost-effective [341]. When using these 
thresholds, Hib vaccine is considered highly cost-effective in India and Uzbekistan and 
cost-effective in Belarus (2010 GDP per capita was US$ 5,950 in Belarus, US$ 1,330 in 
India and US$ 1,280 in Uzbekistan). 
12.4 UNCERTAINTY ANALYSES 
12.4.1 UNIVARIATE UNCERTAINTY ANALYSIS 
The univariate uncertainty analyses are seen in Figures 12.2 – 12.4. In Belarus, increases 
in the Hib disease treatment costs only make a marginal difference to the ICER. While the 
vaccine does of course become more cost-effective when treatment costs are increased by 
50% and when meningitis sequelae costs are included, the difference compared to the 
base case is relatively small. A decrease in the DTP-Hib vaccine price to US$ 1.50 per dose 
would make the vaccine highly cost-effective. However, such a large price reduction is 
unrealistic. When using the GBD pneumonia incidence rate, cost-effectiveness improves 
substantially, with the ICER below GDP per capita.  
In India, Hib vaccine is estimated to be cost saving from a societal perspective when using 
the GBD pneumonia incidence rate and when including the lifetime costs of sequelae. 
Annual cost savings amount to US$ 46 million when using the GBD pneumonia incidence 
rate and to US$ 83 million when including sequelae costs. Since the Indian Government 
only finances about 20% of total treatment costs, the vaccine is still not cost saving from a 
government perspective in these scenarios.  
In Uzbekistan, the vaccine does not become cost saving in any of the scenarios, but when 
including lifetime costs of meningitis sequelae and when using the GBD pneumonia 
incidence rate, the ICERs are low; US$ 30 and US$ 107 per discounted DALY averted, 
respectively. 
Since life years gained represent as much as 76%, 97% and 92% of the total DALYs caused 
by Hib disease in Belarus, India and Uzbekistan, respectively, discounting makes a 
considerable difference to the ICER. Without discounting future values, the results are US$ 
3,908, US$ 21 and US$ 148 in Belarus, India and Uzbekistan, respectively. In India and 
Uzbekistan, the result is also very sensitive to decreases in the case fatality rates. 
Consequently, if a greater proportion of children accessed health care facilities and  
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Figure 12.2: Univariate sensitivity analysis for Belarus. Cost per discounted DALY averted (2010 US$) 
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Figure 12.3: Univariate sensitivity analysis for India. Cost per discounted DALY averted (2010 US$) 
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Figure 12.4: Univariate sensitivity analysis for Uzbekistan. Cost per discounted DALY averted (2010 US$) 
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received appropriate, life saving treatment, the ICER increases, implying that the vaccine 
becomes less cost-effective. While an increase in the meningitis sequelae disability weight 
makes a noteworthy difference to the Belarus result, the impact is negligible in India and 
Uzbekistan due to the higher meningitis case fatality rates in these two settings. When 
using the Uzbekistan GAVI co-financing amount of US$ 0.20 per dose instead of the vaccine 
price, Hib vaccine is cost saving for the government. Each year, the Uzbek government 
saves approximately US$ 7.44 million; 6.21 million for vaccines and syringes donated by 
GAVI and 1.23 million in treatment costs averted.    
PROBABILISTIC UNCERTAINTY ANALYSIS FOR UZBEKISTAN 
In the probabilistic uncertainty analysis mean costs per discounted DALY averted 
amounted to US$ 257 (95% CI 136, 312) from the societal perspective and US$ 379 (95% 
CI 161, 332) from the government perspective (Table 12.10). The probabilistic 
distribution is seen in Figure 12.5. From the societal perspective, the maximum value of 
the Monte Carlo simulation was US$ 342 per discounted DALY averted, which is still 
considerably below the GDP per capita threshold of US$ 1,280. Hence, when using this 
decision making criteria there is zero probability that the vaccine is not cost-effective in 
Uzbekistan. This is also seen in the cost-effectiveness acceptability curves in Figure 12.6. 
The importance of the individual uncertain parameters for the result is seen in the 
ANCOVA analysis in Figure 12.7. As was also seen in the univariate sensitivity analysis, the 
incidence of Hib pneumonia is by far the most important contributor to uncertainty in the 
result. This parameter value explains as much as 93% of the uncertainty in the 
probabilistic analysis. The second and third most important parameters are vaccine 
efficacy against Hib meningitis and Hib pneumonia, respectively.  
Table 12.10: Probabilistic uncertainty analysis (2010 US$) 
Variable 
Societal 
perspective 
Government 
perspective 
Costs per DALY averted in base case 357 366 
Simulation results:   
Mean costs per discounted DALY averted 257 279 
Median costs per discounted DALY averted 277 299 
Minimum -106 -55 
Maximum 342 362 
5% percentile 135 161 
95% percentile 312 332 
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Figure 12.5: Probability distribution of simulation results (societal perspective) 
 
Figure 12.6: Cost-effectiveness acceptability curves for Hib vaccine in Uzbekistan  
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Figure 12.7: Importance of uncertainty of individual parameters (ANCOVA analysis)   
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12.5 DISCUSSION 
The analysis demonstrated that the ICERs are considerably less in India and Uzbekistan 
than in Belarus. One of the important reasons for this difference is that the baseline Hib 
mortality burden, expressed as case fatality rates, is higher in India and Uzbekistan than in 
Belarus, leading to more deaths averted per child vaccinated. The under-five mortality 
rates are 17 times higher in India and Uzbekistan than in Belarus [32] and the proportion 
of under five mortality due to pneumonia is approximately 16% and 21% in India and 
Uzbekistan [32, 342], respectively, while only 4% in Belarus [32]. Hence, Hib vaccine will 
prevent proportionally more deaths in India and Uzbekistan than in Belarus and since 
mortality is the most important driver of DALYs, the ICER becomes more favourable in the 
two low-income countries. 
Another critical explanation for the ICER difference is that the vaccine price is higher in 
Belarus than in the two other countries and that Belarus uses a four-dose schedule while 
only three doses are used in India and Uzbekistan. Incremental vaccine costs per child are 
consequently US$ 21.17 in Belarus and only US$ 6.6 and US$ 7.0 in India and Uzbekistan, 
respectively. A booster dose is recommended in countries where Hib disease is a 
substantial problem in children above 12 months [295]. In the Minsk city meningitis 
surveillance it was found that as many as 80% of Hib cases were above 12 months; 
confirming the need for a booster dose. The requirement for a booster dose might be less 
in India and Uzbekistan. In a review of Hib disease age distributions, Bennett et al. found 
that while 60% of cases were above 12 months in the WHO European region, the average 
was only 20% in the WHO South East Asian region [22]. It is thus possible that a similar 
impact is achieved in India and Uzbekistan with three doses as with four doses in Belarus, 
but this hypothesis can only be confirmed by undertaking intensive Hib disease 
surveillance to assess if there is waning immunity.  
When deciding whether Hib vaccine is a good use of scarce resources, the ICER values 
need to be viewed in relation to ability and willingness to pay for health care. The 2010 
GDP per capita was US$ 5,950 in Belarus, US$ 1,330 in India and US$ 1,280 in Uzbekistan 
[109]. Hence, in relative terms, the Belarus government is able to pay considerably more 
per DALY averted than the two other governments. According to the WHO cost-effective 
thresholds, Hib vaccine can be considered highly cost-effective in India and Uzbekistan 
and cost-effective in Belarus. Economic evaluations of rotavirus vaccine have been 
undertaken in India and Uzbekistan [343, 344]. At a rotavirus vaccine price of US$ 5 per 
course, it was estimated that the costs per discounted DALY averted amounted to between 
US$ 75 and US$ 242 in Uzbekistan [345]. In the India analysis, a vaccine price of US$ 1.00 
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per dose was used, which resulted in costs per discounted DALY averted of US$ 21.41 
[343]. Hence, these values are comparable to the findings for Hib vaccine.   
To increase the strength of analysis, it was prioritised to use data from national 
surveillance systems, even if more reliable values might be available from large-scale 
epidemiological studies in other countries. The analysis is thus an example of how to 
undertake an economic evaluation with data gathered from routine data sources while 
using results from other countries only as a quality marker. Undertaking the analysis for 
three countries simultaneously brings several advantages as useful comparisons can be 
made on both parameter values and the overall results. Moreover, a key limitation 
frequently stated regarding economic evaluation studies is that they cannot easily be 
compared because of differences in methodologies. This study facilitated such a 
comparison by using the same decision-analytic model for the three countries.   
One of the most important advantages of the decision-analytic model is that it integrates 
numerous types of information on Hib disease into one analysis. Hospital surveillance 
sentinel site studies on Hib disease have been undertaken in Belarus and India, but on 
their own these surveillance data are often inadequate for decision making on vaccine 
introduction. When using the data in the model for prediction of disease burden and 
vaccine impact on a population level the information becomes much more useful for 
decision makers. Hib pneumonia incidence was by far the most uncertain parameter in the 
analysis and the robustness of the result will be greatly improved if more evidence was 
available on pneumonia incidence, treatment seeking behaviour and case fatality rates. 
Routine pneumonia surveillance data is problematic to use due to the difficulties of 
making accurate diagnosis and because not all children receive care. However, when I 
presented the analysis to the Ministry of Health in Belarus and specifically asked to what 
extent the pneumonia surveillance data can be considered reliable, the response was that 
the surveillance data reflect reality and are not believed to underestimate the real burden. 
Hence, even though international studies conclude that pneumonia is the greatest 
contributor to under-five mortality [32], it is difficult to use these findings when local data 
say otherwise.         
While data on Hib pneumonia disease burden from Eastern Europe and Asia remain 
scarce, it was shown that the vaccine can be considered cost-effective despite conservative 
assumptions about incidence and mortality. However, international cost-effectiveness 
thresholds say nothing about affordability, and with increases in total vaccine costs of 
84% (Belarus), 101% (Uzbekistan) and 302% (India), the governments must carefully 
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consider the long-term financial sustainability. The GAVI Alliance is currently increasing 
its support for pneumococcal and rotavirus vaccine introductions and it is likely that its 
support to Hib vaccine will stop when the current five year commitments come to an end. 
In countries with relatively high under-five mortality, such as India and Uzbekistan, Hib 
vaccine is a highly cost-effective intervention and it is therefore vital that future financial 
sustainability of the vaccine is secured. 
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13 CONCLUSIONS AND REFLECTIONS 
Each chapter in this thesis addressed a separate topic with individual findings. In this final 
chapter, the main conclusions from the chapters are briefly summarised and the overall 
conclusion synthesised. Challenges encountered when undertaking health economic 
research in low- and middle-income countries are first of all reflected upon. This is 
followed by a summary of thesis conclusions and discussion on the applicability of the 
results, especially to what extent cost-effectiveness evidence on vaccines is being used for 
decision making in resource poor settings.   
13.1 CHALLENGES OF WORKING IN RESOURCE POOR SETTINGS 
It is generally highly rewarding to conduct health economic research in resource poor 
countries, but there are also a number of challenges specific to these settings. I now reflect 
upon three types of difficulties; data limitations, problems with ensuring capacity building, 
and complexities of working in the midst of poverty.  
1.  Data limitations   
One of the things that distinguish health economic research in low-income compared to 
high-income countries is the many data limitations faced during all aspects of the study. 
Since very few routine data collection systems are in place, it is often necessary to collect 
all data from scratch. When undertaking an economic evaluation it is therefore a key 
advantage to work alongside an epidemiological study which aims to evaluate the impact 
of the intervention in question as data needed for the effect estimates are then collected by 
colleagues with the appropriate expertise. For all cost estimates primary data collection 
will however have to be established. As was explained in this thesis, treatment cost 
estimates involve substantial primary data collection of both resource utilisation and unit 
costs and such studies can take years to complete.      
2. Health economics capacity building 
One issue that demands considerable investment and is more difficult than one might 
expect is to identify skilled collaborators and ensure that health economic capacity 
building is integrated into the research project. Skilled health economists are rare in low-
income countries and the few that are present are often overcommitted. A common error 
is to underestimate the time it takes to train relatively inexperienced researchers in health 
economic principles and to expect that he/she can be responsible for data collection and 
analysis without close supervision. In my experience, substantial time, patience and 
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resources are needed to fully ensure that the collaborator takes ownership of the study. In 
reality, the project is often under time pressure and to guarantee that the work gets done 
it is often easier to take over and complete the work yourself, but this defeats capacity 
building. The underlying problem is that all types of skilled human resources are scarce in 
low-income settings and this is exacerbated by the fact that the field of health economics is 
still relatively new and training opportunities scarce. Health economics is rarely 
recognised as an independent discipline, so research collaborators normally come from 
many other backgrounds and it therefore becomes necessary to train these people in basic 
principles while they work on the study. On the African continent a health economics 
degree can only be obtained from universities in South Africa.         
3. Undertaking a study in the midst of poverty 
Sources of funding for most research studies originate from high-income countries and the 
principal investigator is often from one of these countries. As a consequence, there are 
generally considerable differences in salary levels between local collaborators and the 
international team. This can be a source of friction and it is challenging to ensure some 
kind of equity between team members. A second difficulty is that it is often a perception 
that the study is better resourced than it actually is. When working in settings where most 
people struggle to make a livelihood, many individuals would like to benefit financially 
from the study. It is thus imperative that strict control is held with the budget as numerous 
extra-budgetary expenses are likely to appear, often with inflated prices. This happens 
because people try to take advantage of the study by adding extra activities and as 
foreigners it can be difficult to know what is really needed and to judge what level of 
remuneration is reasonable. A third challenge related to this is that several people can be 
paid by the project on a short-term basis, such as for instance data collectors. It is not easy 
to realise that the livelihood of entire families sometimes depend on this sole salary and 
when the project ends the prospects of finding another source of income are limited. It is 
difficult not to feel a sense of responsibility for these people, but with a time limited 
research project there is little one can do. A fourth challenge is when extreme poverty is 
encountered during data collection. As an example, some of the families interviewed for 
the Senegal study were in dire need and two mothers asked me directly for financial 
assistance. In as much as one would like to help, it is extremely difficult to get involved 
because the need is so great and when faced with the situation it is hard to judge what is 
best to do.         
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13.2 SUMMARY OF THESIS CONCLUSIONS 
The most important conclusion from Chapter 2, which gave a background on Hib disease, 
was the inherent difficulties in detecting Hib, especially in resource poor settings with 
limited laboratory capacities. Even though the term “haemophilus” means “blood-loving” 
in Greek, the sensitivity of blood tests for Hib are low and CSF is needed to increase 
detection rates. However, strict laboratory procedures must be followed to successfully 
identify Hib from CSF.  
In Chapter 3, the global uptake of Hib vaccine in routine vaccination programmes was 
described. A key message from this chapter was that it is very unlikely that the vaccine 
would have been introduced into low-income countries if the GAVI Alliance had not been 
established and started to offer the vaccine free of charge. As of early 2012, 172 countries 
in the world had introduced the vaccine, but 24 countries have not done so.     
A brief background to economic evaluation was given in Chapter 4. It is important to know 
that a critical attribute of vaccines, which distinguishes their analysis from that of other 
interventions, is that vaccination decreases circulation of the pathogen causing herd 
immunity. When this indirect effect is omitted from an economic evaluation, the result is 
likely to be an underestimate of the full health impact. 
In the systematic literature review of Chapter 5, a total of 17 economic evaluations of Hib 
vaccine were identified; eight were from low- and middle-income countries. However, 
several of the studies had flaws. The most important deficiencies were sub-optimal 
modelling approaches, unreliable sources used for health outcome measurement, 
omission of Hib pneumonia in disease impact predictions, and non-transparent methods 
used for treatment cost calculations.     
Following description of the thesis aims and objectives in Chapter 6, the decision-analytic 
model was presented in Chapter 7. The model is a deterministic aggregate-level static 
decision tree model depicting Hib disease progression for a specified cohort. The 
improvement in model structure compared to other Hib vaccine decision-analytic models 
includes incorporation of all Hib disease types, separation of meningitis sequelae into 
different syndromes, and integration of access to health care and health care utilisation 
within the model structure, enabling treatment costs and CFRs to be linked to these 
parameter values.  In addition, the model offers a higher level of transparency than most of 
the published Hib vaccine economic evaluations.  
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A meta-analysis of Hib vaccine efficacy was the topic of Chapter 8. This is the first dose-
specific Hib vaccine efficacy analysis and the first time that all available outcome measures 
have been presented in a common analysis. The pooled vaccine efficacies against invasive 
Hib disease after two and three doses were 92% and 93%, respectively. Vaccine efficacy 
after one dose was 59%. There was large heterogeneity between studies that estimated 
vaccine efficacy against hospitalised and radiological pneumonia, so no firm conclusion 
could be made about efficacy against these outcomes. Two studies documented 4% 
efficacy against clinical pneumonia, but one of the key messages of the chapter was that 
caution must be taken when extrapolating vaccine efficacy values against non-specific 
outcome measures to other settings.  
In Chapter 9, DALYs were calculated for acute Hib diseases and for meningitis sequelae. 
Numerous limitations with the DALY approach became apparent. It was shown that the 
measure is problematic to use when the disease in question has a wide range of severities 
and/or numerous different syndromes, such as for instance meningitis sequelae. It was 
also concluded that for diseases causing relatively high premature mortality, as is the case 
for Hib disease in low-income settings, the YLL proportion of the DALY equation 
dominates the overall result and the YLD fraction is only of marginal importance.  
Hib disease treatment costs for acute diseases and for meningitis sequelae were presented 
in Chapter 10. One of the findings from the Senegal meningitis sequealae study was that 
children with disabilities have no access to rehabilitation services. In societies like 
Senegal, services are severely limited largely because the health system grants no financial 
risk protection to families with disabled children. For this reason, mean direct treatment 
costs of meningitis sequealae amounted only to 2% of what was spent by households 
during the acute episode. However, the opportunity costs of looking after a disabled child 
were a substantial financial burden to the families. This is the first study to estimate the 
household costs of caring for a child with disabilities in a low-income country. 
One of the key messages of Chapter 11 was that the Hib vaccine price has decreased more 
slowly than was expected by the global community when GAVI was established twelve 
years ago. For this reason it has been necessary to extend the period of support to ensure 
that the vaccine is kept in programmes in low-income countries.  In Belarus and 
Uzbekistan, Hib vaccine introduction caused approximately a doubling of the vaccine 
budget and in India it lead to a quadrupling. The main conclusion from the Ethiopian study 
on incremental systems costs of pentavalent vaccine introduction was that the cold chain 
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system could not accommodate a switch to a smaller vial size without a relatively large 
investment in storage capacity and increased recurrent transport costs.            
The overall findings of the thesis were embedded in the cost-utility estimates of Hib 
vaccine in Belarus, India and Uzbekistan presented in Chapter 12. In this analysis, many of 
the parameter values generated in the previous chapters were used. It was concluded that 
Hib vaccine can be considered a cost-effective intervention in all three settings and 
especially so in India and Uzbekistan. The lower ICERs in these countries compared to 
Belarus were largely explained by higher case fatality rates of Hib disease cases, leading to 
a relatively greater number of premature deaths averted, and lower Hib vaccine prices. 
When costs of sequelae are included in the analysis, the vaccine becomes even more cost-
effective and possibly cost saving in some settings, including in India. The probabilistic 
analysis showed that uncertainty surrounding the Hib pneumonia incidence rate is by far 
the largest contributor to uncertainty in the cost-effectiveness estimate. This is not a 
surprising result; the problem of defining the true burden of Hib pneumonia has always 
been the greatest challenge for determining the value of Hib vaccine [175, 176, 178, 346].    
In this thesis, the epidemiology and costs of Hib disease and the efficacy and costs of Hib 
vaccine were investigated in depth. A decision-analytic model was used to bring all the 
new information together. This is the first time that the cost-effectiveness of Hib vaccine 
has been analysed for different settings within a common framework. The overall 
conclusion of the thesis is that Hib disease has been an unrecognized problem in most 
settings and as a consequence the value of Hib vaccine has been underappreciated. The 
most important reasons for under acknowledgement of Hib disease as a problem are the 
enduring difficulties with determining the overall burden of pneumonia in children and 
assigning what proportion of this burden is due bacterial infections, including Hib. While 
the problems of determining the burden of Hib pneumonia were addressed in this thesis, 
the issue was by no means resolved. Substantial epidemiological and health systems 
research is needed to make progress in this area, as recently argued by Rudan and 
colleagues [339]. The main contribution of the thesis in terms of Hib pneumonia was to 
show that even though lack of knowledge about pneumonia disease burden is the biggest 
reason for uncertainty when determining the impact of Hib vaccine, the vaccine can be 
considered cost-effective across the whole range of plausible pneumonia incidence rates. 
A second principal reason for under appreciation of the vaccine is limited understanding 
about the total costs of meningitis sequelae. Lack of data has meant that this parameter 
has until now not been incorporated into the decision-making process for Hib vaccine in 
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low- and middle-income countries. This thesis has made a major contribution in this area 
by demonstrating the household costs of meningitis sequelae in Senegal. It is hoped that 
the Senegal study will lead to greater awareness about meningitis sequelae disease burden 
and its associated costs, and that it will guide the way for more research in this field.     
I believe that a third reason for ambiguities with regard to appreciating the value of Hib 
vaccine has been a lack of transparency in research studies. As was shown in the literature 
review of Hib vaccine economic evaluations, many previous studies did not incorporate all 
types of Hib diseases and the assumptions made for estimating health impacts and 
treatment costs, and the methods used when combining the data in a decision-analytic 
model, were not clearly explained. These non-transparent studies have added to the 
mystification about the true value of Hib vaccine. When a claim of cost-effectiveness of the 
vaccine is based on methods and assumptions that are not well justified, there is a danger 
that stakeholders view the study more as an advocacy exercise than as research 
demonstrating the true impact. In this thesis efforts were made to clearly explain and 
justify all assumptions, sources and methods used to generate the estimates and it is 
hoped that this will increase the confidence in the result.         
13.3 APPLICATION OF FINDINGS 
Economic evaluation of new and underused vaccines are generally undertaken to provide 
evidence for decision-makers when they consider whether or not to introduce the vaccine 
into the routine immunization schedule. The target audience is most often policy makers 
within the Ministry of Health. However, since only few low- and lower middle-income 
countries finance Hib vaccine from their government budgets, the present analysis was 
also targeted to international donors, such as the GAVI Alliance.      
In a recent study on decision making factors for new vaccine introduction, two criteria 
were highlighted as being considerably more important than others; disease burden and 
political issues [140]. The qualitative study was undertaken in five GAVI eligible countries 
(Bangladesh, Mali, Ethiopia, Kenya and Cameroon) and in two middle-income countries 
(Guatemala and South Africa). The study showed that in all of the countries decisions to 
adopt a new vaccine were largely political, and that in the GAVI eligible countries, 
availability of GAVI funding was the main driver for introduction [140]. In the two non-
GAVI eligible countries, the decision to adopt new vaccines was dominated by politics. In 
both Guatemala and South Africa, the Minister of Health largely made the decision 
unitarily without consulting technical experts. Cost-effectiveness evidence and financial 
considerations were not one of the most important factors in any of the seven case study 
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countries. However, the issue was appreciated in Kenya where it was felt that the evidence 
of Hib vaccine impact and cost-effectiveness generated by long-standing research at the 
Kenya Medical Research Institute [125, 198] increased the confidence of policy makers to 
believe that it was a right decision to introduce the vaccine. 
It is not a new finding that the use of economic evaluations on health care decision making 
is limited. During the 1990s this was also shown in studies from Australia and the UK, with 
some of the reasons for limited use found to be poor generalisability of results, 
narrowness of research questions, and lack of methodological rigor in many published 
studies [347, 348]. However, during the past decade this has gradually changed as cost-
effectiveness evidence has become a requirement for introduction of new health 
technologies within national health services in several high-income countries [349, 350, 
351]. It is however a fact that several other aspects than demonstrated cost-effectiveness 
generally drives the decision to adopt a new health technology, most importantly probably 
political pressures. There are certain facets about vaccines that could make them even 
more political than other health interventions, especially in low-income countries. First, 
since vaccines prevent disease in a broad spectrum of the population, introduction is 
generally regarded positively by the public, so from a political viewpoint introduction of a 
new vaccine can be seen as an “easy win”.  Secondly, in many low-income countries, 
vaccines are one of the only health interventions available free of charge to a large 
proportion of the population, so new vaccine introduction is one of the most equitable 
health interventions available to a politician. Lastly, the intervention is relatively simple to 
deliver and integrate into the health system, so to a politician a new vaccine can seem as a 
relatively straightforward way of doing something concrete to improve the health of the 
population.  
The usefulness of the present analysis differs between the three study countries. With 
regard to Hib vaccine adoption, Uzbekistan is a relatively typical GAVI eligible country; Hib 
vaccine was introduced when GAVI support for hepatitis B vaccine came to an end and it is 
unlikely that the vaccine would have been adopted without GAVI funding. The present 
economic evaluation has thus not been used as a decision-making factor in Uzbekistan. 
However, the analysis was requested by the EPI manager in preparation for the time when 
GAVI support comes to an end. It is thus possible that the study will be referred to by 
Uzbek decision makers in 2015.  
India is in many ways a special case with regard to adoption of new vaccines. Even though 
the country has a striving vaccine industry that supplies vaccines to a large proportion of 
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the world’s population, the Indian vaccine schedule is one of the most basic in the world 
and vaccination coverage is as low as 20% in some states. Hib vaccine has only been 
introduced into two of the 28 states and this only happened in late 2011. A campaign 
against Hib vaccine by a selection of Indian medical professionals has delayed introduction 
[299]. As was stated by one of the members of India’s National Technical Advisory Group 
on Immunization (NTAGI) in 2010, "Concrete steps to introduce the pentavalent vaccine 
into the immunisation programme are still not visible. India’s anti-vaccine lobby appears 
to have succeeded in influencing the health bureaucracy".  Lack of evidence on the impact 
and cost-effectiveness of Hib vaccine is the key argument of the India anti Hib vaccine 
lobby. They have for instance stated that "the incidence of Hib appears low; immunisation 
against Hib would be a waste of scarce public resources" and that "the vaccine against DTP 
costs less than three rupees; the pentavalent vaccine could cost 300 rupees” [299]. The 
problems with transparently defining the burden of Hib pneumonia is also at the forefront 
of the debate. A leading anti Hib vaccine activist has for instance stated that "The 
Indonesian study showed more cases of pneumonia among vaccinated children, and the 
Bangladesh study showed no significant efficacy in radiologically confirmed pneumonia or 
meningitis. But these studies have been used to promote the vaccine” [299]. When the 
economic evaluation for India as part of this thesis is published it is likely to be a key 
factor in the future decision making for the vaccine.  
The Balarus analysis was requested by the EPI manager who intended to use the study in 
support for national Hib vaccine introduction. However, Belarus is a country with many 
political difficulties and in spite of much effort from the EPI manager, the Ministry of 
Health has not yet decided to introduce the vaccine. The present analysis represents one 
of the first economic evaluations ever done in this country, so there is still no experience 
with using this type of evidence. A lack of experience in using economic evidence for 
decision making is prevalent in most former Soviet Union countries.   
The Senegal and Ethiopian studies included in this thesis provided new knowledge which 
had not been researched before. Both of these studies are likely to have impact on policy 
making. As already mentioned, the Ethiopia study on systems costs of pentavalent vaccine 
introduction is currently being used as the sole piece of evidence to revise the size of the 
GAVI vaccine introduction grant upwards. The exact amount of US$ 0.80 per child in the 
birth cohort found in the Ethiopia study is being proposed to the GAVI Board in June 2012. 
Lack of evidence on the costs of meningitis sequelae in low-income settings has frequently 
been mentioned as a hindrance for determining the true value of Hib, pneumococcal and 
meningococcal vaccines; GAVI, among other organisations, has been requesting these data. 
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Hence, the Senegal study is likely to be a prime source for assessing the importance of 
averting meningitis in children.   
The decision-analytic model has been used in several other settings than in the three 
countries presented in this thesis. It must be concluded that a static, transparent model 
has been adequate for this usage. Since the model is user-friendly, collaborators without 
any background in Hib disease or modelling have been able to understand and use it. It is 
likely that a dynamic model would have been much more difficult to use in the countries in 
question. Moreover, development and parameterization of the static model took three 
years to complete and is still an ongoing effort, so it is likely that a dynamic model could 
not have been developed within the timeframe of the Hib Initiative.   
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14 ANNEXES 
ANNEX 1: RECOMMENDED TREATMENT OF HIB DISEASES 
Disease Standard WHO recommended treatment 
Meningitis Hospitalisation. Ampicillin and gentamicin or a third generation cephalosporin, such 
as ceftriaxone (50 mg/kg every 12 hours) or cefotaxime (50 mg/kg every 6 hours) for 
3 weeks. Alternative antibiotics are penicillin and gentamicin. Chloramphenicol is an 
alternative. but should not be used in premature/low weight neonates. If signs of 
hypoxaemia, give oxygen. 
 
Very severe 
pneumonia 
Hospitalisation. Ampicillin (50 mg/kg IM every 6 hours) and gentamicin (7.5 mg/kg 
IM once a day) for 5 days. If child responds well, complete treatment at home or in 
hospital with oral amoxicillin (15 mg/kg 3 times a day) plus IM gentamicin once daily 
for a further 5 days. Alternatively, give chloramphenicol (25 mg/kg IM or IV every 8 
hours) until child has improved. Then continue orally 4 times a day for a total course 
of 10 days. Or use ceftriaxone (80 mg/kg IM or IV once daily). 
 
If child does not improve within 48 hours, switch to gentamicin (7.5 mg/kg IM once a 
day) and cloxacillin (50 mg/kg IM or IV every 6 hours). When the child improves, 
continue cloxacillin (or dicloxacillin) orally 4 times a day for a total course of 3 weeks. 
 
Give oxygen to all children with very severe pneumonia 
 
Severe 
pneumonia 
Hospitalisation. Benzylpenicillin (50,000 units/kg IM or IV every 6 hours) for at least 
3 days. When the child improves, switch to oral amoxicillin (25 mg/kg 2 times a day). 
The total course of treatment is 5 days. If child does not improve within 48 hours, or 
deteriorates, look for complications and treat accordingly as for very severe 
pneumonia. If there are no apparent complications, switch to chloramphenicol (25 
mg/kg every 8 hours IM or IV) until the child has improved. Then continue orally for a 
total course of 10 days.  
 
Give oxygen to any child with severe lower chest wall indrawing or a respiratory rate 
of ≥70/minute. 
 
Pneumonia Treat child as an outpatient. Oral cotrimoxazole (4 mg/kg trimethoprim / 20 mg/kg 
sulfamethoxazole twice a day) for 3 days or amoxicillin (25 mg/kg 2 times a day) for 3 
days. Give the first dose at the clinic and teach the mother how to give the other doses 
at home. 
 
Epiglottitis Hospitalisation. An airway must be established promptly with an endotracheal tube or 
by tracheostomy. IV antibiotic therapy for 7-10 days. 
 
Cellulitis Hospitalisation. IM antibiotic therapy for seven days. 
Septic arthritis Hospitalisation. IV antibiotic therapy for 5-7 days followed by oral antibiotics for two 
weeks. 
 
Septicemia Hospitalisation and IV antibiotic therapy. 
Osteomyelitis Hospitalisation. IV antibiotic therapy for 5-7 days followed by oral antibiotics for two 
weeks. 
Source: WHO pocket guide for hospital care in children (2005) [190] 
Pneumonia definitions:  Very severe pneumonia is characterized by acute respiratory distress where the 
child is not able to drink, severe pneumonia is distinguished by chest indrawing, and non-severe 
pneumonia is diagnosed by measuring fast breathing [190].
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ANNEX 2: RECOMMENDED METHODS FOR ESTIMATING TREATMENT COSTS IN LOW-
INCOME SETTINGS  
In this annex, basic methods for undertaking a treatment cost study in a low-income 
setting are summarised. Since there are no good guidelines available on the topic, the 
proposed methods are based on my previous experiences with these types of analyses. I 
have been involved in treatment cost studies in Kenya, Russia, Indonesia, Fiji, Oman, South 
Africa and Zambia [122, 124, 125, 138, 139, 352, 353].   
The preferred method for estimating mean treatment costs per case is calculation of 
patient-specific costs from a sample of patients. Since severity of disease varies between 
cases and because circumstances of people differ, treatment costs per case for a particular 
syndrome can vary widely. It is thus common to see significantly higher costs incurred for 
a few patients compared to the majority, either due to more severe disease or unusual 
treatment seeking behaviour.  Hence, because there is a relatively small number of 
patients with high treatment costs and there is absence of negative costs, the distribution 
of cost data is typically truncated and positively skewed [354]. For this reason, the median 
value may be more appropriate for descriptive purposes, but this measure does not allow 
for determining the costs of treating all patients, which is needed as the basis for 
healthcare policy decisions. It is therefore standard practice to present the mean in 
treatment cost studies [355]. By multiplying the estimated number of patients by the 
mean costs per case, total treatment costs can be derived.  
Treatment costs should be divided into two components; (a) Bed-day costs in hospitals 
and visit costs for out-patient consultations, and (b) patient specific costs. These two 
components are described below.   
a) Bed-day and visit costs 
Bed-day and visit costs include all cost items shared between patients admitted to a 
hospital or receiving an outpatient consultation. These include the building, kitchen 
services, laundry services, cleaning, maintenance, administration, etc. Even though clinical 
personnel strictly speaking is a patient specific cost item because some patients take up 
more staff time than others, all personnel costs are generally included in bed-day and visit 
costs due to the difficulty in measuring precisely how much time is spent with an 
individual patient.   
Hospital bed-day costs should be split into overall hospital bed-day costs and ward-
specific bed-day costs. Overall bed-day costs contain all resources needed for the general 
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running of the hospital, while the ward-specific bed day costs are the costs of running a 
particular ward, such as the paediatric ward or the infectious disease ward. It is of 
particular importance to generate a specific estimate for the intensive care unit, as this 
ward is often considerably more expensive to operate than other wards. Bed-day costs are 
estimated by dividing total annual costs by the annual number of patient bed-days, for the 
hospital as a whole and the respective wards. By multiplying the costs per bed-day by the 
length of stay, total bed-day costs for a particular patient are estimated.   
The detail of analysis in a hospital costing study can vary considerably and is largely 
dependent upon the expertise, time and resources available for data collection. Since most 
hospitals and clinics in low- and middle-income countries do not have routine cost-
accounting systems in place, it is a major undertaking to estimate the costs per hospital 
bed-day and visit costs. In guidelines for estimating the costs of diarrhoeal disease, which I 
was the lead author of, we proposed three different approaches for estimating hospital 
bed-day costs [356]: 
1. Standardized WHO-CHOICE estimates. As a part of its WHO-CHOICE project, the WHO 
has developed estimates of hospital bed-day costs in different settings. Data from 
hospital cost studies in 49 countries were used in a regression model to predict the 
costs per bed-day in countries for which these data were not available [357]. In the 
regression model, country estimates are a function of GDP, ownership 
(public/private), level of the facility (primary, secondary and tertiary), and the level of 
capacity utilization. Estimates in international dollars and local currency are given for 
all WHO member states and can be downloaded from the WHO-CHOICE website:  
www.who.int/choice/  
2. Existing estimates of hospital bed-day costs. In some countries, estimates of the cost 
per hospital bed-day may be available for some facilities. These may be have been 
derived from routine cost-accounting systems in hospitals with strong administration 
or from previous micro-costing studies. In order for the estimates to be used in a new 
study, it must be ensured that all relevant cost components are included and that the 
facility can be considered representative for other facilities.  
3. Full micro-costing study. This final approach was described above and is the most 
detailed and resource intensive. The method uses detailed cost and health care 
utilization data from the hospital. The costs of all activities are estimated individually 
and all resource items are divided into capital and recurrent costs. The costs of 
outpatient and inpatient services are estimated separately to ensure that the costs per 
bed-day and cost per visit can be estimated.  
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Use of WHO-CHOICE estimates is undoubtedly the less resource-intensive approach. 
However, while these estimates have been available for downloading from the WHO 
website since 2003, there is still insufficient detail given on the primary data used for 
conducting the original regression analysis. It is stated in the 2003 methodological paper 
that data “from 49 countries, for various years during the period 1973–2000 were part of 
the initial dataset” [357]. However, it is not specified what these countries were, which 
hospitals within the countries provided the data, and what type of data collection protocol 
was used. It would for instance be useful to see examples of the raw data. While I worked 
at the WHO during 1999-2005, I tried to get this information from the authors numerous 
times, but I was unsuccessful. It must therefore be emphasised that the validity of the 
WHO-CHOICE data is uncertain and it is not possible to know how well it reflects actual 
hospital bed-day costs in a particular country.     
b) Patient specific costs 
Patient specific cost items are resources that vary between patients, such as drugs, 
medical supplies and diagnostic tests. Primary data collection on resource utilisation from 
a sample of patients is needed to determine these accurately. Data sources are either 
patient records or specially designed data collection forms. Furthermore, depending on 
study objectives and the perspective taken, patients or caregivers can be interviewed 
about their out-of-pocket expenses.  
Patient-specific resource utilisation data must be multiplied by their respective unit costs 
to generate total costs. Unit costs are often difficult to establish due to inadequate cost-
accounting systems, numerous procurement mechanisms and donations in kind. Unit costs 
of laboratory and X-ray services can be particularly difficult to establish. To arrive at a 
mean cost estimate for these services, total annual costs of running the particular 
diagnostic department should be estimated, including appropriate annualisation of capital 
equipment. If the capital costs of diagnostic equipment vary considerably, it might be 
necessary to undertake the analysis separately for the different types of equipment. By 
dividing total annual costs by the annual number of tests performed, an approximate 
estimate of costs per test can be arrived at. It is however common to see that facilities do 
not routinely collect data on the annual number of tests performed. It is for instance likely 
that the radiology department does not keep a record on how many X-rays are taken each 
year by each type of machine.    
A micro-costing exercise, where resource utilization data and associated unit costs are 
collected from a sample of patients, is a substantial task to undertake. Since most hospitals 
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in resource limited settings do not have computerised information systems for patient 
records and financial accounts, all data need to be manually collected. Studies that include 
detailed costing of diagnostic services are for instance rarely done. Instead, the costs of a 
laboratory test or a chest X-ray in a public hospital are often approximated by the fees 
charged in the private sector for these services. Moreover, since it is common practice in 
low-income countries that patients pay a relatively large proportion of costs, it is often 
necessary to interview patients or caregivers about their expenses if a societal perspective 
is taken. In my experience, a micro-costing study that also includes patient interviews 
takes between two and three years to complete.   
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ANNEX 3: DESCRIPTION OF HEALTH SYSTEMS IN THE THREE STUDY COUNTRIES 
In this annex, the health systems of Belarus, India and Uzbekistan is briefly described. This 
is useful background information for understanding the assumptions behind the 
treatment cost estimates, the Hib vaccine introduction costs, and the Hib disease burden 
estimates. 
Belarus and Uzbekistan 
Belarus and Uzbekistan are both former Soviet Union states with health systems 
originating from the Soviet Semashko model. This was a tax-based, labour intensive 
system with highly centralized planning of resources and personnel [257, 262]. During 
Soviet times, the government was almost the sole provider of care and accounted for most 
health spending. In 1987, Soviet government spending for health represented 5% of the 
national budget [358]. The Soviet system sought to achieve universal, free access to basic 
health services, which was centrally planned according to strict norms. It was a goal to 
deliver services of uniform quality in all parts of the country, but this was never fully 
achieved and when the Soviet Union collapsed there were great differences in health care 
access among the 15 republics [256]. 
Health services have become increasingly fragile in all former Soviet Union states since 
independence. The economic collapse caused that revenues were no longer able to sustain 
services, which often had to be stopped. Unofficial out-of-pocket payments for public 
services are the now norm in most of the countries and unregulated private providers are 
emerging [248]. The most common informal payment is for medicines [359, 360]. In 
Uzbekistan, such payments are more widespread in tertiary than primary and secondary 
facilities and in urban compared to rural areas [262].  The growing private sector largely 
consists of pharmacists and physicians [262].  
In Belarus, the health delivery system is divided into three levels: Highly specialized 
tertiary hospitals funded directly by the Ministry of Health and secondary and primary 
care with funding channelled through the six administrative regions: Brest, Gomel, 
Grodno, Mogilev, Vitebsk and Minsk region without Minsk city, which has the status of an  
independent administrative entity. The health  system is still mainly focused on inpatient 
treatment while primary health care is relatively weak [257].  In 2008, total health 
expenditures amounted to 6% of GDP and government health expenditures comprised 
75% of total expenditures [361]. 
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In Uzbekistan, there are 12 regions, one autonomous republic (Karakalpakstan) and one 
administrative city, the capital of Tashkent. There are three types of hospitals in urban 
areas; regional hospitals, specialized hospitals such as for tuberculosis and sexual 
transmitted diseases, and tertiary hospitals linked to medical schools. In rural areas there 
are two types; Rayon (district) hospitals and Central Rayon hospitals [362]. In 2008, total 
health expenditures amounted to 5% of GDP and government health expenditures 
comprised 51% of total expenditures [361]. 
India 
India is divided into 28 provincial states. Constitutionally, health care delivery is largely 
the responsibility of the states with the central government in charge of defining policies 
and providing a national strategic framework, financial resources, and medical education 
[363]. However, over time the states have struggled to maintain and administer health 
care facilities, and they have become dependent on the central government for financial 
and programmatic assistance [364]. For example, although states account for 75% - 90% 
of public spending on health, most of these funds go to salaries and wages, making them 
dependent on the central government for funding drugs, equipment and disease control 
programmes [364]. In 2008, total health expenditures amounted to 4% of GDP and 
government expenditure 1% of GDP [249].  Out-of-pocket health expenditures comprise 
approximately 71% of total health expenditures, which is one of the highest proportions 
on the world, and one of the leading causes of direct debt and poverty in India [365] 
Public health infrastructure in rural areas consists of a three-tier system: A sub centre for 
every 5,000 population with a male and female worker, a primary health care centre for 
every 30,000 population  with a medical doctor and other paramedical staff, and a 
community health centre for every 100,000 population with 30 beds and basic specialists. 
In urban areas, it is a two tier system with a health centre for every 100,000 population 
followed by general hospitals. However, many government institutions are not functional 
due to staff shortage and non-availability of drugs, consumables and essential equipment. 
There are moreover large differences in capacity between states and between rural and 
urban areas. The numbers of health workers per 10,000 population range from 23.2 in 
Chandigarh to 2.5 in Meghalaya and the number is four times higher in urban areas than in 
rural areas.  
Curative services are mainly provided in the private sector and evidence from household 
surveys shows that the private sector in the previous two decades has become the main 
provider of inpatient care [365]. Seventy percent of health workers in India are employed 
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in the private sector [366]. The rapid development of the private sector in urban areas has 
resulted in an unplanned and unequal geographical distribution of services. 
Multiple forces have driven an increased privatisation of health services in India since 
independence. First, the private sector was already dominant at the time of independence 
and it was allowed to grow in an uncoordinated and unregulated manner, gradually 
making it the default option for care. The growth of the private sector has outpaced the 
government capacity to implement the necessary regulatory processes. Secondly, there 
has been lack of political commitment for public health services shown by consistently low 
investment and inadequate implementation of programmes. However, to address the 
challenges of limited access to care, the National Rural Health Mission (NRHM) was 
launched in 2005, to be completed in a time frame of seven years. This programme aims at 
providing accessible, affordable, effective, accountable, and reliable healthcare to all 
citizens and in particular to the poorer and vulnerable sections of the population. 
Strategies to achieve the goal includes decentralized village and district level health 
planning, strengthening of public health service delivery infrastructure, improved 
management capacity to organize health systems and promoting the non-profit sector to 
increase social participation and community empowerment [367]. 
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ANNEX 4: TREATMENT COST CALCULATIONS IN THE THREE STUDY COUNTRIES 
 
Belarus 
Treatment cost data were collected during a visit to Minsk in December 2008. Data on the 
costs of treating meningitis were collected from the Minsk City Children Infectious 
Diseases Hospital (MCCIDH) and pneumonia treatment costs were collected at three 
different facilities; MCCIDH, the Minsk Regional Children’s Clinical Hospital and Stolbtsy 
District Hospital. While the two facilities in Minsk are tertiary hospitals, Stolbtsy Hospital 
is a secondary facility. Details about the three facilities are summarized in Table A1.  
One of the main determinants of treatment costs is the length of stay in hospital. At 
MCCIDH the average length of stay for a meningitis and pneumonia case is 21 and 12 days, 
respectively. At Minsk Regional Children’s Hospital and at Stolbtsy District Hospital, the 
average length of stay for pneumonia patients is 14 days. The standard treatment for 
pneumonia is to give the child antibiotics for the first seven days and daily physiotherapy 
during the remaining time in hospital.  
Table A1: Description of facilities where treatment cost data were collected in 
Belarus 
Minsk City Children 
Infectious Diseases Hospital 
Minsk Regional Children’s 
Clinical Hospital 
 
Stolbtsy District Hospital 
 
 The only infectious disease 
hospital in Minsk city and 
Minsk region 
 Admits children between 0 
and 18 years of age 
 620 beds, distributed on 
14 wards and in one 
pediatric intensive care 
unit  
 Isolation of Hib started 
during the 1990s for 
meningitis and epiglottis 
 Admits approximately 40 
cases of suspected 
bacterial meningitis each 
year, of which 4-5 are due 
to Hib 
 Acute respiratory 
infections the most 
common cause of 
admission 
 Approximately 15% of all 
admissions are due to 
pneumonia 
 Founded in 1975, but 
modernized and 
reconstructed with new 
building in 2002   
 615 beds, distributed on 
numerous specialized 
departments 
 Between 75,000-80,000 
children less than five 
years in the catchment 
area 
 During 2007, the oblast 
reported a total of 2,938 
pneumonia cases, of which 
1,527 (52%) were less 
than 5 years of age. 118 
(4%) of these were 
admitted to this hospital 
 
 One of 22 District 
Hospitals in Belarus 
 285 beds. Children’s 
department has 40 beds.  
 Approximately 9,000 
children in the catchment 
area 
 Children with co-infections 
are referred to hospitals in 
Minsk 
 A total of 105 pneumonia 
cases were admitted 
during 2007. This was 
14% of all admissions for 
children between 0-18 
years. 
 In 2007, 8% of pneumonia 
were between 0-1 years, 
30% were between 1-5 
years and 62% were 
between 5-18 years of age. 
 No deaths due to 
pneumonia has occurred in 
the hospital in recent years 
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All of the three hospitals have well functioning cost accounting systems in place, so it was 
possible to obtain an estimate for bed-day costs. These estimates had been prepared for us 
in advance of the visit at the request of my study collaborators. However, it was only 
possible to receive a detailed breakdown of the bed-day costs from MCCIDH and Stolbtsy 
Hospital. In spite of repeated attempts, it was not possible to obtain this information from 
Minsk Regional Children’s Clinical Hospital. Costs per patient bed-day and mean patient 
specific costs for the two hospitals are summarized in Tables A2 and A3, respectively. 
Total estimated treatment costs of pneumonia and meningitis treatment at the three 
different hospitals are seen in Table A4. 
The mean costs of treating a meningitis case in MCCIDH are estimated as US$ 1,114. Due to 
shorter stay in hospital and less drug costs, the costs of treating a pneumonia case in the 
same hospital are approximately half of this amount. The costs of treating pneumonia in 
Minsk regional hospital and Stolbtsy hospital are 17% and 31% less than in the MCCIDH, 
respectively.   
Table A2: Costs per hospital bed-day (2010 US$) 
Cost item MCCIDH 
Stolbtsy 
hospital 
Staff costs:   
Wages 17.3 14.1 
Wages taxes 6.0 4.9 
Subtotal 23.3 19.0 
Overhead costs:   
Stationary 0.5 0.1 
Transport 0.5 0.3 
Communal services 9.5 2.3 
Heating 2.0 0.1 
Electricity 0.4 0.1 
Equipment repair 0.6 0.1 
Building repair 0.8 0.2 
Equipment procurement 0.2 0.1 
Other costs 1.6 0.7 
Subtotal 16.3 3.9 
Total 39.6 22.9 
Data on 18 children hospitalised with meningitis at MCCIDH showed that two of these 
were admitted three times after discharge, seven were admitted two times and nine were 
hospitalised one time after discharge (Irina Glinskay, personal information). The mean 
length of stay in hospital during re-hospitalisation was nine days. The costs per meningitis 
episode at tertiary level when including re-hospitalisation costs amounted to US$ 1,960 
(Table A5).  
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Table A3: Patient specific costs in Belarus (2010 US$) 
Cost item MCCIDH 
Stolbtsy 
hospital 
 Meningitis Pneumonia Pneumonia 
Drugs 10.3 2.4 4.6 
Medical supplies 0.4 0.4 0.1 
Meals 2.7 2.7 2.1 
Total 13.5 5.6 6.8 
Table A4: Mean treatment costs per pneumonia and meningitis  
case in Belarus (2010 US$) 
 
 
Table A5: Calculation of costs per meningitis case including  
re-hospitalisation costs at MCCIDH 
 Length of 
stay 
Probability 
Primary admission 21 100% 
Re-admission 1 9 50% 
Re-admission 2 9 39% 
Re-admission 3 9 11% 
Mean length of stay per admission 14 
Costs per bed day 53 
Drug costs 13.5 
Costs per admission 751 
Number of admissions 2.61 
Total costs per case              1,960  
 
Uzbekistan 
Four hospitals in Tashkent and neighbouring districts were visited in November 2008 
with the objective of collecting data to estimate the costs of treating meningitis and 
pneumonia; the City Infectious Disease Hospital #1, the Paediatrics Research Institute, the 
Children’s City Hospital #5 of Yunusobod District, and the Children’s Hospital of Uchtepa 
District.  A brief description of the facilities is given in Table A6. Since all meningitis 
patients in Tashkent should be referred to the Infectious Disease Hospital #1, treatment 
costs of this disease were collected from this hospital only. Pneumonia is treated at all 
lower levels of the referral system, so these treatment costs were collected from the 
remaining three facilities.  
 
MCCIDH 
Minsk Regional 
Children’s 
Clinical Hospital 
Stolbtsy 
District 
Hospital 
 Meningitis Pneumonia Pneumonia Pneumonia 
Length of stay in days 21 12 14 14 
Total bed-day costs              1,114                   542  448 413 
Patient specific costs                13.5                     5.6                       5.6                 6.8  
Total costs              1,128                   548                      454               420  
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Table A6: Description of facilities where treatment cost data were collected in 
Uzbekistan 
Infectious Disease 
Hospital #1 
The Paediatrics 
Research Institute 
The Children’s City 
Hospital #5 of 
Yunusobod District 
The Children’s 
Hospital of Uchtepa 
District 
 Oldest infectious 
disease hospital in 
country 
 150 beds 
 Admits 
approximately 
6,000 patients per 
year.  
 Referral hospital for 
meningitis, 
respiratory and 
intestinal diseases.  
 Between 50% and 
60% of admitted 
patients are 
children. 
 Most common cause 
of admission varies 
from year to year, 
depending on 
infectious disease 
epidemics. 
  Average length of 
stay for meningitis 
is between 10 and 
12 days.  
 No PCR facilities, so 
the aetiology of 
most meningitis 
cases is unknown. 
 Some pneumonia 
cases get admitted, 
but only few of 
these are children. 
 Roughly 30% of all 
admissions are due 
to pneumonia.  
 In 2007, there were 
1,856 cases of 
pneumonia and 790 
of these were 
children under five 
years.  
 Of these there were 
14 fatalities, so the 
case fatality rate for 
pneumonia in 
children under five 
years was 1.7%.  
 Average length of 
stay for pneumonia 
is 10 days.  
 Meningitis cases are 
referred to the 
Infectious Disease 
Hospital # 1. 
 430 beds in 
addition to a 
treatment unit, a 
pharmacy and a 20-
bed intensive care 
unit.  
 Three wards which 
are split according 
to age; children 
under 1 month, 2 to 
3 years, and 4 to 14 
years. 
 Approximately 
15,500 children are 
admitted per year of 
which about 5,000 
are due to ARI 
(32%).  
 Pneumonia is the 
main cause of 
inpatient admission 
followed by 
neurological 
disorders.   
 Average length of 
stay for pneumonia 
is 8.1 days.  
 About 20% of 
patients arrive from 
outside the 
hospital’s 
catchment area. 
 296 beds 
 Admits between 
11,800 and 13,200 
patients per year. 
 Approximately 35% 
to 40% of children 
are admitted with 
pneumonia, of 
which around 4% 
have severe 
pneumonia.  
 
The cost-accounting systems of all four facilities were relatively rudimentary. None of the 
systems were computerised and only the Infectious Disease Hospital # 1 had a separate 
accountancy department. The admistration of the Infectious Disease Hospital # 1 was 
considerably stronger than the other three hospitals. However, with substantial help from 
the hospital administrators my study collaborators collected as much information as 
possible.  
The costs of drugs and diagnostics were estimated by combining quantities and unit costs 
of the most common treatment practices. This information was partly based on a review of 
patient records in the Infectious Disease Hospital #1. It is common practice that the 
hospital only provides drugs free of charge during the first day of admission while the 
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parents should purchase drugs from commercial pharmacies for the subsequent days of 
treatment. Drugs are approximately 40% more expensive in commercial pharmacies than 
when procured by the government hospitals. To allow for this variation, treatment costs 
were divided into a government and a household perspective.    
Meningitis  
The average length of stay of a meningitis case in the Infectious Disease Hospital #1 was 
11 days and costs per bed-day were estimated as US$ 9.18. Hence, mean bed-day costs per 
patient amounted US$ 101. Unit costs of diagnostics are seen in Table A7. Drug costs 
varied depending on the age of the child and according to the severity of disease, as seen in 
Table A8. Total average costs of treating a meningitis case is seen in Table A9. 
Assuming 50% of cases are less than one year and that only 10% of cases are very severe, 
the average weighted meningitis treatment costs at the Infectious Disease Hospital #1 is 
estimated as US$ 276 per case. The government pays on average US$ 190 per case and 
households US$ 86.   
Table A7: Unit costs of diagnostic tests used for meningitis  
patient in the Infectious Disease Hospital (2010 US$) 
Diagnostic tests US$ per test 
General blood test 3.42 
Biochemical test of blood 6.83 
Coagulogram 5.46 
Bacteriological inoculation of liquor 5.12 
Bacteriological Inoculation of blood 2.39 
Inoculation of nasopharyngeal mucus 5.33 
TOTAL 29.00 
Table A9: Mean costs of treating acute meningitis in Uzbekistan (2010 US$) 
 Severe Very severe 
 < 1 year > 1 year < 1 year > 1 year 
Government costs:     
Bed-day costs 101 101 101 101 
Diagnostic tests 29 29 29 29 
Drugs  10 100 10 100 
Food 5.52 5.52 5.52 5.52 
Subtotal 145 235 145 235 
Household drug costs 18 47 105 1,032 
TOTAL 164 281 250 1,266 
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Table A8: Mean costs of drugs for meningitis treatment in the Infectious Disease Hospital (2010 US$) 
Type of drug Unit 
Amount 
prescribed per 
day for children 
< 1 year 
Amount 
prescribed per 
day for children 
> 1 year 
No of days 
prescribed for 
children 
< 1 year 
No of days 
prescribed for 
children 
> 1 year 
US$ per 
unit 
US$ per 
day for 
children 
< 1 year 
US$ per 
day for 
children 
< 1 year 
Cephalosporins Gr 1 4 10 10 0.68 0.68 2.73 
Mannitol* Ml 70 800 7 5 0.03 2.05 23.42 
Furosemide* Mg 50 500 7 10 0.00 0.16 0.01 
Dexamethasone Mg 20 24 5 5 0.08 1.50 1.80 
Magnesium sulphate* Ml 2 20 10 10 0.07 0.15 1.47 
Aktovegin* Ml 1 10 10 10 3.42 3.42 34.15 
Glucose 10% solution Ml 100 800 10 10 0.00 0.02 0.14 
Heparin* Ml 0.1 1 5 5 6.83 0.68 6.83 
Aminophylline* Ml 1 20 10 10 1.37 1.37 27.32 
Ascorbic acid Mg 350 350 10 3 0.00 0.09 0.00 
Na Oxibutirat* Ml 5 5 10 10 0.03 0.14 0.14 
*Prescribed only when disease is very severe 
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Pneumonia 
The average length of stay for a pneumonia patient varied between 7 and 19 days 
depending on the hospital and the severity of the disease (Table A10). Unit costs of 
diagnostic tests, bed-day costs and drugs commonly used for pneumonia patients are seen 
in Tables A10, A11 and A12, respectively. 
Assuming 50% of cases are less than one year old and 10% are severe, an average 
weighted pneumonia treatment costs in hospital is estimated at US$ 168,  of which the 
Government pays on average US$ 143 per case and households US$ 26 per case.   
Table A10: Costs of diagnostic tests of pneumonia patients in Uzbekistan 
Type of test US$ per test 
General blood test              3.42  
Biochemical test of blood             6.83  
Bacteriological inoculation of sputum              5.12  
Bacteriological inoculation of blood              2.39  
Inoculation of nasopharyngeal mucus              5.33  
General urine test              2.05  
General stool test              2.05  
TOTAL            27.19  
 
Table A11: Costs per bed per day in the three Uzbek hospitals 
 Severe pneumonia 
Very severe 
pneumonia 
 Paediatric 
Research 
Institute 
Children’s 
city hospital 
 # 5 
Children's 
hospital of 
Uchtepa 
district 
Children's 
hospital of 
Uchtepa 
district 
Mean length of stay (days) 7 8 14 19 
Costs per bed day 14.44 9.87 14.34 14.34 
Mean bed-day costs per patient 101 80 201 273 
 
Table A13: Total costs of pneumonia treatment per patient in Uzbekistan 
  Severe Very severe 
  < 1 year > 1 year < 1 year > 1 year 
Government costs:         
Bed-day costs 93 93 236 236 
Diagnostic tests 27 27 27 27 
Drugs  2 3 3 7 
Food 5 5 10 10 
Sub total 127 128 275 279 
Household drug costs 16 30 26 74 
TOTAL 143 158 301 353 
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Table A12: Unit costs of drugs used for pneumonia treatment in Uzbekistan 
Type of drug Unit 
Amount 
prescribed per 
day for children  
< 1 year 
Amount 
prescribed per 
day for children  
> 1 year 
No of days 
prescribed for 
children  
< 1 year 
No of days 
prescribed for 
children 
 > 1 year 
US$ per 
unit 
US$ per day 
for children < 
1 year 
US$ per day 
for children  > 
1 year 
Penicillin mln IU 6 18 10 10 0.07 0.57 1.71 
Cephalosporins Gr 0 4 10 10 0.68 - 2.73 
Aminophylline Ml 0 1 10 10 1.37 - 1.37 
Mucolytic agent ml 5 5 5 5 0.27 1.37 1.37 
Prednisolone mg 0 600 5 3 0.01 - 8.20 
Dexamethasone mg 0 24 5 5 0.08 - 1.80 
Glucose 10% solution ml 0 800 10 10 0.001 - 0.14 
Ascorbic acid mg/ml 350 20 10 10 0.005 0.09 0.09 
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India 
Length of hospital stay 
The length of stay in hospital was derived from a Hib Initiative funded pneumonia and 
meningitis surveillance study in three different Indian states [253]. Across the three 
tertiary hospitals, the mean length of stay in hospital was 5.7 days for pneumonia patients 
and 9.7 days for meningitis patients (Table A14).  
Table A14: Length of stay in hospital in three India hospitals 
 Pneumonia Meningitis 
Surveillance 
site 
N Mean no.  
of days 
N Mean no. 
 of days 
Chandigarh 227 7.4 164 11.9 
Kolkota 231 4.1 72 9.2 
Vellore 131 5.7 89 8.1 
Mean  5.7  9.7 
Source: Personal communication with John Hopkins’ University 
Household costs 
Household costs were estimated from the NSSO socio-economic survey on respiratory 
ailments in children less than five years. The questionnaire is included in Annex 5. 
Meningitis costs were calculated by adjusting the respiratory ailment costs upwards in 
accordance with the additional length of stay. The ratio between meningitis and 
pneumonia length of stay in hospital is 1.6, as seen in Table A14 above.  
The nationwide NSSO sample survey sizes for respiratory illnesses in children less than 
five years were 644 outpatient episodes and 238 inpatient admissions. Costs per patient 
varied widely between states, as seen in Table A15. The national average is used in the 
economic evaluation. The breakdown of expenditures according to item is seen in Figures 
A1 and A2 for government and private hospitals, respectively. 
Table A15: Mean household costs per case in India according  
to geographic region (2010 US$) 
Region 
Outpatient costs per 
visit 
Cost per pneumonia 
admission 
Inpatient cost per 
meningitis 
admission 
   Govt   Private   Govt   Private   Govt   Private  
North 12 11 106 126 171 204 
Central 3 9 210 213 341 345 
East 10 5 32 141 53 229 
Northeast 7 5 26 289 42 468 
West 1 6 42 298 68 483 
South 2 7 22 119 36 193 
All India 6 7 50 149 81 241 
 Source: NSSO 2007 [252]  
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Figure A1: Break-down of household expenses for respiratory  
illnesses in government hospitals in India 
 
 
Source: NSSO 2007 [252] 
 
Figure A3: Break-down of household expenses for respiratory  
illnesses in private hospitals in India 
 
Source: NSSO 2007 [252] 
 
Data source for government costs 
Data from a micro-costing study by Dr. Anand Krishnan and colleagues undertaken in New 
Delhi and in the state of Haryana, North India were used as source for the government 
treatment cost estimates [129]. Six government facilities were included in the study; three 
primary facilities were in Dayalpur, Kurali and Palwal, two secondary facilities in 
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Ballabgarh (the Civil Hospital and the Badshah Khan Hospital), and the tertiary hospital 
was the All India Institute of Medical Sciences (AIIMS) in New Delhi. Descriptions of the 
secondary and tertiary hospitals are seen in Table A16.  
Table A16: Description of secondary and tertiary government  
hospitals included in the study by Krishnan 
 
Civil Hospital 
Ballabgarh 
Badshah Khan 
Hospital 
AIIMS 
Number of beds 54 200 801 
Paediatric admissions per year 488 2,235 4,233 
Average length of stay (days) 3 3 5 
Bed occupancy rate 54% 65% 100% 
Paediatric case fatality rate 9.2 4.2 5 
Paediatric outpatients per year 16,518 22,673 49,937 
Source: Krishnan 2001 [129] 
 
Inpatient costs 
Hospital bed-day costs were estimated by adding annual capital costs, electricity, water, 
personnel and other overhead costs. Overhead costs for the paediatric ward were 
determined by allocating a proportion of total costs in accordance with the share of 
paediatric admissions out of total admissions. Personnel costs included all allowances. 
Bed-day costs for the secondary and tertiary hospitals are summarised in Table A17.  
Drug costs were estimated by multiplying the amount prescribed by the respective unit 
costs. Costs of diagnostic tests were estimated by calculating capital costs, personnel, etc 
for each type of investigation. In all of the hospitals, patients paid for the majority of drugs 
and investigations, in addition to consultation fees. However, these costs were not 
Table A17: Hospital bed-day costs (2010 US$) 
Cost item 
Civil 
hospital, 
Blaabgarh 
AIIMS 
Capital costs 1.6 2.1 
Overhead costs 3.8 5.6 
Physician costs 3.4 18.8 
Other staff costs 6.9 7.4 
Administration 1.6 4.2 
Maintenance 0.4 0.9 
TOTAL 17.6 39.0 
Source: Krishan 2001 [129] 
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separated according to whether they were paid for by the public health facility or patients.  
Since costs of drugs and investigations were already included in the household 
expenditure data from the NSSO survey, the estimates given in Krishnan’s study were not 
included to avoid double counting. Inpatient costs according to facility level are 
summarised in the Table A18. 
Table A18: Government costs per patient of pneumonia and meningitis treatment 
 
Pneumonia Meningitis 
 
Secondary 
level 
Tertiary 
level 
Secondary 
level 
Tertiary 
level 
Length of stay 5.7 5.7 9.7 9.7 
Costs per bed-day 17.6 39 17.6 39 
Total 101 172 224 380 
Source: Gupta 2011 [253] and Krishnan 2001 [129] 
 
Outpatient costs 
Outpatient visit costs were collected from the three primary facilities and also from the 
outpatient departments at the secondary and tertiary hospitals.  The estimates are seen in 
Table A20. As with the hospital estimates, the costs of drugs and investigations were 
excluded to avoid double counting as these costs are largely paid by household and 
captured in the NSSO survey.  
Table A19: Outpatient pneumonia costs according to facility level (2010 US$) 
 
Primary Secondary Tertiary 
Physician cost 0.32 0.24 0.77 
Other costs 0.53 0.37 0.66 
Subtotal 0.85 0.61 1.42 
Pneumonia investigations 0.13 0.09 1.40 
Pneumonia drugs 2.03 2.51 3.36 
TOTAL 2.88 3.12 4.78 
Source: Krishan 2001 [129] 
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ANNEX 5: INDIA NSSO QUESTIONNAIRE FOR HOUSEHOLD MEDICAL EXPENSES 
 
   GOVERNMENT OF INDIA     
   NATIONAL SAMPLE SURVEY ORGANISATION     
 SOCIO-ECONOMIC SURVEY   
 SIXTIETH ROUND: JANUARY – JUNE, 2004  
   
 SCHEDULE 25.0:  MORBIDITY AND HEALTH CARE  
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during last 365 
days 
whether ailing 
report-
ting of 
columns 
11 & 12 
(self - 1, 
proxy – 
2)   
whethe
r 
hospita
lised 
(yes-1, 
no-2) 
if 1 in 
col. 9, 
no. of 
times 
hospit
alised 
anytim
e 
during 
last 15 
days 
(yes-1, 
no-2) 
on the 
day 
before 
the 
date of 
survey 
(yes -1, 
no -2) 
(1) (2) (3) (4) 
(5
) 
(6) (7) (8) (9) (10) (11) (12) (13) 
             
 
1. sr1. no. of the hospitalisation case 1 2 3 4 5 
2. srl. no. of member (as in col. 1, block 4/5) hospitalised      
3. age (years) (as in col. 5, block 4 / col. 4, block 5)       
4. type of hospital (code)      
5. nature of ailment (code)      
6. type of ward (free - 1, paying general - 2, paying special - 3)      
7. when admitted (code)      
8. when discharged (code)      
9. duration of stay in hospital (days)      
10. loss of household income, if any, due to hospitalisation (Rs)      
details of medical services received (not received - 1;  received: free - 2, partly free - 3, on  payment - 4) 
 11.  surgery       
 12.   medicine      
 13.   X-ray/ECG/EEG/Scan      
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 14.   other diagnostic tests      
15. whether treatment availed before hospitalisation (yes - 1, no - 2)      
if 1 in item 15 16.   source of treatment (code)      
17.   duration of treatment (days)      
18. whether treatment continued after discharge from hospital              
if 1 in item 18 
19.  source of treatment (code)      
20.  duration of treatment (days)      
 
[8] expenses incurred for treatment of members treated as inpatient of hospital during the last 365 days and 
source of finance 
 srl. no. of the hospitalisation case (as in item 1, block 7) 1 2 3 4 5 
 srl. no. of member hospitalised (as in item 2, block 7)      
 age (years) (as in item 3, block 7)      
 whether any medical service provided free by employer 
 (yes: Govt. - 1, pvt . - 2; no – 3, not applicable – 4) 
 
 
 
 
 
 
 
 
 
 
 medical expenditure for treatment during stay at hospital (Rs)  
 
doctor’s / surgeon’s fee 
5. hospital staff      
6. other specialists      
medicines 
7. from hospital      
8. from outside      
9.  diagnostic tests      
10. bed charges      
11. attendant charges      
12. physiotherapy       
13. personal medical appliances      
others  
14.  food and other materials      
15.  blood, oxygen cylinder, etc.      
16. services  (ambulance, etc.)      
 17. expenditure not elsewhere reported      
 18. total (items 5 to 17)      
 other expenses incurred by the household (Rs) (not included in item 18)  
 19. transport (other than ambulance)      
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 20. lodging charges of escort(s)      
 21. others       
 22. total (items 19 to 21)      
23.  total expenditure incurred by the household  
        (sum of items 18 & 22 for all cases of hospitalisation taken together) 
 expenses in item 23 by source of finance (Rs)  
 24. household income/savings  
 25. borrrowings  
 26. contributions from friends and relatives  
 27. other sources (incl. sale of ornaments and other physical assets, draught animals, etc.)  
 28.  total   (items 24 to 27) 
29. amount of reimbursement (Rs)      
 
31. private      
32. medical insurance companies      
33. other agencies       
 
 [9] particulars of spells of ailment of household members during the last 15 days (including hospitalisation) 
1. srl. no. of spell of ailment 1 2 3 4 5 
2. srl. no. of member  reporting ailment (as in col. 1 of block 4/5)  
 
 
 
 
 
  
3. age (years) (as in col. 5, block 4 / col. 4, block 5)  
 
 
 
 
 
  
number of days 
within the 
reference 
period 
4. ill      
5. on restricted activity      
6. confined to bed      
7. nature of ailment (code)           
8. status of ailment (code)  
 
 
 
 
 
  
9. total duration of ailment (days)      
10. whether treatment taken on medical advice (yes - 1, no - 2)  
 
 
 
 
 
  
if 1 in 
item 10 
11. whether any treatment received from govt. sources 
       (yes - 1, no - 2) 
     
12. if 2 in item 11, reason (code)      
if 2 in 
item 10 
13. reason for no treatment (code)      
14. whether any other measure taken for recovery/relief  
        (yes - 1,no - 2) 
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if 1 in  
item 14 
15. whom consulted (code)      
16. expenditure incurred (Rs)      
17. loss of household income, if any, due to ailment (Rs)  
 
 
 
 
 
  
 
[10] expenses incurred during the last 15 days for treatment of members (not as inpatient of hospital) and source 
of finance 
1. srl. no. of ailing member (as in  item 2, block 9)      
2. age (years) (as in item 3, block 9)      
3. whether any medical service provided free by employer  
     (yes: Govt. -1, pvt. - 2;  no - 3, not applicable - 4) 
 
 
 
 
 
 
 
 
 
 
Details of medical services received (not received - 1; received: free - 2, partly free - 3, on payment - 4) 
 4. surgery       
 5. medicine received      
 6. X-ray/ECG/EEG/Scan      
 7. other diagnostic tests      
medical expenditure for treatment (Rs)  
 
doctor’s / surgeon’s fee 
8. hospital staff      
9. other specialists      
medicines 
10. from hospital      
11. from outside      
12. diagnostic tests      
13. attendant charges      
14. physiotherapy       
15. personal medical appliances      
others  
16.  food and other  materials       
17.  blood, oxygen cylinder, etc.      
18.  services  (ambulance, etc.)      
 19. expenditure not elsewhere reported      
 20. total medical expenditure (items 8 to 19)      
 expenditure 
reported  in item 
20 from 
21. Govt. Sources      
22. other sources      
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other expenses incurred by the household (Rs )  (not included in item 20)  
 23. transport charges (other than ambulance)      
 24. lodging charges of ailing person and escort(s)      
 25. others       
 26. total (items 23 to 25)      
27.  total expenditure incurred by the 
household 
        (sum of items 20 & 26 for all 
persons taken together) 
 
source of finance for meeting the 
expenses in item 27 (Rs) 
 
28. household income/savings   
29. borrrowings   
30. contributions from friends and relatives   
31. other sources (incl. sale of ornaments and other physical assets, draught animals, etc.)    
32.  total   (items 28 to 31)  
33. total amount of reimbursement (Rs)      
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  (ii) NATURE OF AILMENT (item 5, block 7 &  item 7, block 9) 
Ailment code ailment code 
Gastro-intestinal  Diabetes mellitus 22 
     Diarrhoea/ dysentery 01 Under-nutrition 23 
     Gastritis/gastric or peptic ulcer 02 Anaemia 24 
     Worm infestation 03 Sexually transmitted diseases 25 
     Amoebiosis 04 Febrile illnesses  
    Hepatitis/Jaundice 05      Malaria 26 
Cardiovascular Diseases       Eruptive  27 
     Heart disease 06      Mumps 28 
     Hypertension 07      Diphtheria 29 
       Whooping cough 30 
Respiratory including ear/nose/throat ailments 08      Fever of unknown origin 31 
Tuberculosis 09   
Bronchial asthma 10 Tetanus 32 
Disorders of joints and bones 11 Filariasis/Elephantiasis 33 
Diseases of kidney/urinary system 12   
Prostatic disorders 13 Disabilities  
Gynaecological disorders 14      Locomotor 34 
Neurological disorders 15      Visual including blindness (excluding 
cataract) 
35 
Psychiatric disorders 16      Speech 36 
       Hearing 37 
Eye ailments  Diseases of Mouth/Teeth/Gum 38 
     Conjunctivitis 17 Accidents/Injuries/Burns/   
     Fractures/Poisoning      
 
39      Glaucoma 18 
     Cataract 19 Cancer and other tumours 40 
    
Diseases of skin 20 Other diagnosed ailments 41 
Goitre 21 Other undiagnosed ailments 99 
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ANNEX 6: SOCIO DEMOGRAPHIC QUESTIONNAIRE USED IN THE SENEGAL STUDY 
 
PATH AND LSHTM 
MENINGITIS DISABILITY PROJECT 
QUESTIONNAIRE ABOUT SOCIO-DEMOGRAPHIC STATUS 
 
 
 
ALL THESE QUESTIONS SHOULD BE ASKED OF THE MOTHER OR PRIMARY CAREGIVER OF THE 
CHILD.  THE MOTHER IS THE PREFERED RESPONDENT. 
1. BACKGROUND and ID 
2.  
1.1. Is the child a case or control? 
 
1. Case/Exposed  2. Control/unexposed  
1.2 Child’s ID:     
1.3 Child’s name: 
  
1.4 Date of interview: ………………………………………….. 
 
       
1.5 Staff code: ……………………………………………….………………………….    
 
1.6 What is the relationship of the primary caregiver to the child? 
11. Mother 12. Father 13. Aunt  14. Uncle  
15. Grandmother  16. Grandfather 17. Other relative   
    PLEASE SPECIFY 
18. Friend  
19. Government official 20. Other.       PLEASE 
SPECIFY 
///////////////////
/////////////// 
/////////////////
////////////// 
 
 
INFORMATION ABOUT THE CHILD  
2 SEX and AGE 
 
2.1 What sex is the child? 1. Male 2. Female  
2.2 In what year was the child born?  [88 = NK]……………………………….   2 0      
2.3  In what month was the child  born?  [88 = NK]……………………………………………    
3.  BIRTH DETAILS 
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3.1 What was the child’s birth weight?  ( in kilograms ; 888 = not known, no 
record)..      PLEASE CHECK CHILD HEALTH RECORDS IF AVAILABLE 
 .    
3.2. Did this child’s pregnancy end early, on time, or late? 
1. Early 2. On time 3. Late 8. Not known  
 
3.3 How many weeks pregnant was the mother with this child at delivery (what was the  
gestational age of the baby)? (40 = term, 88 = NK)…………………………….………… 
  
 
 
3.4 How many babies were born at the same time as this child? eg singleton = 1, twins = 2, triplets 
= 3,  quadruplets = 4 ……………………………………………………………………………….…….. 
  
4. PAST IMMUNISATIONS:  
4.1. Has the child received Hib (monovalent or pentavalent) vaccination? 
        If yes, then please specifiy dates (888888 =NK, 999999=not received)  
       d d m m y y  
Hib 1……..  1. Yes  2. No  8.NK If yes…………...        
              
Hib 2……..  1. Yes  2. No  8.NK If yes…………..        
              
Hib 3……. 1. Yes  2. No  8.NK If yes…………..        
 
4.2. Has the child received measles or MMR vaccination? 
       If yes, then please specify dates (888888 =NK, 999999=not received)  
       d d m m y y  
Measles or 
MMR 1   
1. Yes  2. No  8.NK If yes…………..        
              
Measles or 
MMR 2 
1. Yes  2. No  8.NK If yes…………..        
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5. PAST MEDICAL HISTORY 
5.1. Now we want to ask about any hospitalisations where the child has stayed over night in 
hospital. 
       Year   Month  Duration of 
hospitalisation in 
days  
 
Any 
hospitalisations for 
bacterial 
meningitis?   
1.Yes  2. No   8. NK If yes            
Any other 
hospitalisations 
1?(Specify_______)    
1.Yes  2. No   8. NK If yes            
Any other 
hospitalisations 
2?(Specify_______)       
1.Yes  2. No   8. NK If yes            
Any other 
hospitalisations 
3?(Specify_______)       
1.Yes  2. No   8. NK If yes            
 
5.2 Did  the child have any serious problems at birth? 1. Yes 2.No  8. Not known  
5.3. If yes please specify these problems (number 1.2.3 etc) 
 
 
 
6. CURRENT DISABILITIES 
6.1. Now we want to ask about the current disabilities that the child has. Has the child had any of 
the following?   
        
Problems with 
moving   
1.Yes  2. No   8. NK  OR1 
Problems with 
thinking 
1.Yes  2. No   8. NK  COG1 
Problems with 
speaking 
1.Yes  2. No   8. NK   
Behaviour 
problems 
1.Yes  2. No   8. NK   
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Problems with 
seeing 
1.Yes  2. No   8. NK  VIS1 
Problems with 
hearing 
1.Yes  2. No   8. NK  R1 
Epilepsy 1.Yes  2. No   8. NK  EPIL1 
 
INFORMATION ABOUT THE HOUSEHOLD 
7 DEMOGRAPHICS  
7.1. What was the mother’s/primary caregiver’s highest educational level reached? 
1. None 2. Primary school 3. Secondary school   
4. University 5. Other. Specify 8. Not known   
 
7.2 Number of years completed at the highest level reached?  [88 = NK, 99= 
NA/None]……...…. 
   
7.3. What is the mother’s/primary caregiver’s religion? 
1. Christian  2. Muslim 3. Traditional African 4. Other (SPECIFY):  
7.4. What ethnic 
group does the 
mother / 
primary 
caregiver       
belong to? 
11. Wolof 12. Serere 13. Poular 14. Bambara  
 
15. Mankagne 16. Diola 17. Soninke  
 
 18. Other. Please   specify.   
 
 
7.5. Does anyone in the household own any land?........................... 1. Yes 2. No  
7.6. What is grown on your land? 
1. Food items, mainly 
for  home consumption 
2. Food items,  mainly 
for   sale on the market 
3. Cash crops: peanut, mil, 
cassava, maize, tomatoes, yam, 
tobacco etc. 
9. NA, no farm  
 
7.7. Does anyone in the household have a regular cash income/ salaried 
worker?................ 
1. Yes 2. No  
7.8. If yes, please write the title/name/description of the employment/jobs 
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7.9. Does your household have electricity?.......................................................................... 1. Yes 2. No  
 
7.10. What is the main source of drinking water for members of your household? 
11. Piped into 
dwelling/yard/plot  
12. Public tap  13. Handpump / 
closed bore hole 
14. Closed well 15. Open well  
16. Stream / river 17. Lake / dam 
/pond 
18. Water trucks 19.Rain water 20. Other  
 
 
7.11. How long does it take for you to go there, get water and come back? 
1. Less than 15 minutes 
2. 15 minutes- less than 30 
minutes 
3. 30 minutes – less than 60 minutes 
 
 
4. 60 minutes or more 9. NA / drinking water source is in compound 
 
 
7.12. What kind of toilet facility does your household have? 
1. Flush latrine / WC 2. Ventilated improved pit /VIP /KVIP 3. Other pit latrine 4. Open fields  
5. Defaecate in house, faeces transferred elsewhere / bucket 
latrine 
6. Other:  
 
7.13. What are the total number of rooms in the household used for sleeping?  
….......................... 
   
7.14. What are the total number of people that slept in the household last night? 88 = 
NK…......... 
   
7.15. How many children less than 18 years live in the household?.....................................   
7.16 What materials are used for the construction of the house in which you live? 
Floor of sleeping room 1. Cement 2. Mud/clay 3. Other: 8. NK  
Roofing 1. Metal/asbestos 2. Thatch/mud 3. Other:  
 Wall 1. Cement 2. Mud 3. Other:  
 
END OF SOCIO-DEMOGRAPHIC QUESTIONNAIRE 
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ANNEX 7: ECONOMIC QUESTIONNAIRE USED IN THE SENEGAL STUDY 
 
PATH AND LSHTM 
MENINGITIS DISABILITY PROJECT 
ECONOMIC QUESTIONNAIRE 
 
 
1. IDENTITY:  
 
1.1 Child’s ID.......................................................................................................... 
 
 
  
 
 
1.2 Child’s name: 
  
 
1.3 Date of interview..:............................................. 
    
  
 
 
1.3 Interview start time    _________________  Interview finish time _________________ 
 
1.4 Staff code:   ....................................................................................................................     
 
  
 
2. RELATIONSHIP OF THE PRIMARY CAREGIVER TO THE CHILD  
1. Mother 
 
2. Father 3. Sister 4. Brother  
5. Grandmother 
  
6. Grandfather 7. Other relative 8. Friend  
 
3. MENINGITIS HISTORY 
3.1 In what year did the child suffer from meningitis?  [88 = NK]…………….…   2 0      
3.2 In what month did the child suffer from meningitis?  [88 = NK]……………………..    
3.3 What type of health facilities was the child taken to when he/she fell ill with meningitis?  
1. Public health centre 2. Traditional healer 3. District Hospital (public)  
4. District hospital (private) 5. Tertiary hospital (public) 6. Tertiary hospital (private)  
7. Other (SPECIFY)  
YOU MAY CIRCLE MORE THAN ONE RESPONSE 
 
3.4 How many days did the child stay in hospital when admitted for 
meningitis?........................... 
   
3.5 Approximately how much money did you spend on the meningitis episode? 
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a) Before the child was admitted to hospital …………… 
 
CFA 
      
 
b) Hospital fees ………………………… CFA        
c) Transport during the hospital stay … CFA        
d) Other costs ……………………………………… CFA        
 
 
4. COSTS OF HOSPITAL ADMISSIONS DUE TO DISABILITY FROM MENINGITIS 
 
4.1 Since the meningitis episode, has the child been admitted to hospital due to  
disability from the meningitis episode?? 
 
1. Yes 2. No  
4.1 If yes, please list where the admission was, the dates, and how many days the child stayed in 
hospital  
 Name of hospital Month Year No. days  
Hospitalisation 1:……        
Hospitalisation 2:……        
Hospitalisation  3:……        
Hospitalisation 4:……        
Hospitalisation 5:……        
Hospitalisation  6:……        
Hospitalisation  7:……        
Hospitalisation  8:……        
 
4.2 Please state the approximate costs in terms of hospital fees of these admissions  
Hospitalisation 1:……………………………… CFA        
Hospitalisation 2:……………………………... CFA        
Hospitalisation  3:…………………………… CFA        
Hospitalisation 4:……….................................... CFA        
Hospitalisation 5:……………………………… CFA        
Hospitalisation 6:……………………………… CFA        
Please note down the details of the cost estimates (i.e. costs per day in hospital) 
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Hospitalisation 7:……………………………… CFA        
Hospitalisation 8:………................................... CFA        
 
4.2 On average, how much did it cost in transport costs each time 
the child was admitted to hospital? ………………………….. 
CFA        
 
 
 
 
 
5 COSTS OF OUTPATIENT VISITS DUE TO DISABILITY FROM MENINGITIS 
 
5.1 Since the meningitis episode, has the child attended outpatient services due 
to disability from the meningitis episode?  
1. Yes 2. No  
 
5.2 If yes, please list where the visits were and the dates 
 Name of facility Month Year  
Visit 1:……………………       
Visit 2:……………………       
Visit 3:……………………       
Visit 4:……………………       
Visit 5:……………………       
Visit 6:……………………       
Visit 7:…………………       
Visit 8:…………………       
Visit 9:…………………       
Visit 10…………………       
 
  
Please note down the details of the cost estimates (i.e. costs per day in hospital) 
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5.3 Please state the approximate costs of each visit 
Visit 1:……………………………………… CFA        
Visit 2:……………………………………… CFA        
Visit 3:……………………………………… CFA        
Visit 4:……….............................................. CFA        
Visit 5:……………………………………… CFA        
Visit 6:……………………………………… CFA        
Visit 7:…………………………………… CFA        
Visit 8:……….............................................. CFA        
Visit 9:……………………………………… CFA        
Visit 10:………............................................. CFA        
 
5.4 On average, how much did it cost in transport costs 
each time the child has had an outpatient visit? 
CFA        
 
 
 
6. UN-AFFORDABLE COSTS 
 
6.1 Is there any treatment that you know the child would benefit from , but 
he/she is not receiving it because you can not afford it ?   
1. Yes 2. No  
 
6.2 If yes, explain what this is and the approximate cots (either daily, weekly, monthly or 
annually)  
 
 
 
 
 
Please note down the details of the cost estimates (i.e. costs per consultation) 
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7. COSTS OF LOOKING AFTER THE CHILD 
 
7.1 Who looks after the child during the day? 
1. Mother 
 
2. Father 3. Sister 4. Brother  
5. Grandmother 
  
6. Grandfather 7. Other relative 8. Friends  
9.  Goes to school 
 
10. Attends day care 11. Other (please state)  
YOU MAY CIRCLE MORE THAN ONE RESPONSE 
 
7.2 Is this any different than if the child had not suffered from 
meningitis?......................... 
 
1. Yes 2. No  
 
If yes, explain how 
 
 
7.3 Do you pay somebody to look after the child?...................................... 1. Yes 2. No  
7.4 If yes, how much per month?………………………… CFA        
 
  
7.5 Are any of your household members unable to work as much as they 
could/would like to due to the disability of the child? 
1. Yes 2. No  
 
7.6 If yes, how much does the household loose in earnings per 
month? ……………………………………………………… 
CFA        
 
END OF ECONOMIC QUESTIONNAIRE 
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ANNEX 8: PHOTOS FROM THE SENEGAL STUDY 
 
 
Picture 1: The child with meningitis sequelae is the boy in the middle. 
 
 
Picture 2: This healthy boy recovered from the meningitis without sequelae. 
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Picture 3: The boy has meningitis sequelae 
 
 
Picture 4: The boy has meningitis sequelae 
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ANNEX 9: INTERVIEWS WITH FAMILIES AFFECTED BY MENINGITIS SEQUELAE IN 
SENEGAL 
 
FAMILY OF CHILD 1  
The father: 
At the beginning the child was healthy before meningitis attack. I was one day at Touba 
and the child was healthy. When I got back, I saw that the body of the child was hot and 
had fever. So I told to his mother to bring him at Albert Royer hospital. And then 
meningitis is diagnosed and the child hospitalized. I thought that the child had tooth 
problem or malaria attack. 
I didn’t know well meningitis, but I heard it was a dangerous disease which conducts to 
death and paralysis. He wasn’t fully vaccinated because he felt ill very soon. I spent all my 
savings. The disease cost us expensive. The child was ten months old when he fell sick. In 
the house the others children are healthy and there are who are younger than Bara Pouye. 
My older boy was hospitalized for digestive disease. 
The mother: 
When Bara had fever my first reaction was to bring him at Albert Royer because his big 
sister was ill and I bring her to Phillipe Senghor hospital. They prescribed her medicines in 
vain and unfortunately she died. The daughter just spent 24 hours at hospital. They 
haven’t done an analysis so we don’t know the real disease cause. Since then, when a 
member of the family falls ill I systematically bring him to hospital and no in a health post. 
The death of her sister had terrified me so much that I haven’t confidence to the health 
post. Bara had a bugle fontanel. When I brought him at Albert Royer they diagnosed 
meningitis. I called his father to him that the child would be hospitalized. He answered 
that the disease is not serious and that he should not be hospitalized. Then his father came 
and the doctor explained to him.  
During hospitalization we spent much money because the prescriptions were expensive. 
The injection was very expensive the cost of one vial was 8000 CFA. The child had 
diarrhea, he trembled his legs and the fingers were inert. I knew meningitis because my 
brother had it before. 
The prescriptions and the hospitalization were expensive. For spending I was obliged to 
take the heritage of my deceased father. I called sometime his father when my money 
finished 
The father: 
The money of her father’s heritage was not enough so I did add money to complete.  
Indeed the vial costs 8,000 CFA at hospital but it’s 10,000 CFA out of hospital. God assisted 
us. I borrowed some money from my friend for paying hospitalization. I manage this 
situation with more difficulties because I was unemployed. I just consulted the modern 
medicine not the traditional healers and marabous because of the death of my daughter. 
Because of her death my first resort when someone fall sick is the hospital. My daughter 
got to hospital with delay. 
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After hospitalization they prescribe to Bara a scanner and they noticed sequelae. His body 
was awful and his legs were immobile. The right side was paralyzed. And so the 
appointments began. We didn’t respect the appointments because of lack of money. I tried 
the physiotherapy at home. The child is easily angry and it’s the only change I notice in 
him. He plays with children of same age but he’s sometimes rough. He hasn’t neurologic, 
vision and hearing problems. He hasn’t fits. His only problem is his leg and arm paralysis 
and his speech disorders. Bara is smaller than children of the same age. He has growth 
retardation and speech disorder.  
He doesn’t react in front of a foreigner. The hospitalization was a heavy financial charge. I 
haven’t got the household expenses the mother needed. I used my only money for the 
child’s treatment. Now he’s not going to school because of his speech disorders. The 
neighbours are kind to him. After his discharge from hospital Bara have often malaria, 
rhinitis and diarrhea without seriousness. 
The mother: 
After his meningitis, I wanted to bring him at Talibou Dabo center for his physiotherapy 
and just your project arrived and assisted us. I paid 1,000 CFA for his consultation 
The father: 
Your project has assisted us. We are seeing a real improvement. I pray for the recover of 
the child. I have a big hope. Your project has financially lightened us and I hope that the 
child will be completely recovered and will be able to go to school. 
The disease of Bara reinforced the relationship between me and his mother. She 
financially supported me. The disease united us increasingly. The lesson learned is 
hospital must be the first resort and not the traditional healer. At the beginning I thought 
he had only tooth problem or simple malaria attack. 
The mother: 
When I am alone, I am sad to see the disabilities of my son but I keep on hoping like a 
Muslim and agree with God. Nevertheless, we notice an improvement and thank you a lot. 
When children of the same age hit him and he cries, I feel sad. Sometimes I wonder if he 
will ever recover. Before he felt often sick, but know he’s better. He fights with the children 
of same age. For this we are deeply thanking you for your important support. You do your 
work without cheating and you are faithful  
The father: 
I know that meningitis is dangerous and without the project it would be worse for us. The 
lesson learned is when a child has fever you must bring him to a doctor. I thank your 
project for the financial, medical and moral support. If others projects do like it will be 
excellent. Thank you, again.  When Cheikh called me the first day, I was daily worker at the 
sea port of Dakar. I gave my consent and said to my wife to answer all the questions. I 
infinitely think you. If in all the disease people had this kind of support, I think families will 
be lightened. I pray that god assist you. Thank you very much again. 
  
Annex 9 
 
266 
 
FAMILY OF CHILD 2 
The mother: 
Before the meningitis attack, the child was well. When I was pregnant, I took my vaccines, 
but not all. He has a sister and brother who feel healthy in the household. 
Six years ago, he felt down in playing, we first thought it was a malaria attack that caused 
the fracture. We used butter shea in vain during three days for massage. After these three 
days, we brought him at hospital, where he was hospitalized. He was always sleeping. We 
bought many medicaments. He spent one month at hospital under drip. The prescriptions 
were very expensive. My parents assisted me to buy the prescriptions. I wasn’t sleeping. 
Mbar is very attached to me. When I was at hospital, I was always thinking of the children 
in the village. I was worried. He wants to go to school, but when I bring him they tell to me 
he can’t learn because of his deafness and his speech disorder. Nowadays the child must 
go to school, but he can’t hear nor speak. During discharge, I was happy because the fits 
disappeared and he ate. His uncle also assisted me. I never went to consult traditional 
healers. He’s living a long ordeal, he must go to school but he can’t. I always think that he 
need assistance, he needs me. I am always asking myself if I die what will be the future of 
this child. It hurts me terribly. Some of my neighbors feel pity for me, but others make fun 
of me in a gazed way. For such a child only his mother can support him. Some people think 
that I have a responsibility in the disease of Mbar. The children of the same age make fun 
of him. Mbar prefers to be with older people because children of same age laugh at him. 
And yet I hope for his recovery and that he will go to school, marry a woman and work. 
Apart from my parents nobody assisted me. 
The uncle: 
The mother has told it all to you. The disease is terrible. Some people think that the 
mother of the child has nothing done in the household, it’s awful. Others say that the 
disease come from God. We consulted traditional healers in vain. Fortunately there are 
organizations which assist them. At the beginning we consulted a traditional healer but 
afterwards we decided that we must go to hospital to see a doctor. We can’t bring him to 
the disability school because we have no money for this. The mother had sold all her 
possessions. The child is very clever. The doctor tells us he has recovered. He is very 
smart. We lack means; this is why we can’t bring him to a specialized school. He is 
amusing. Between the mother and the others members of family the relationship are 
reinforced. 
 
The mother: 
At the beginning I didn’t know meningitis. It’s when my child had a meningitis attack that I 
knew it. The sign of meningitis is when a child falls suddenly down. At first we thought to 
malaria and the fracture, sprain, luxation. Now I can understand the signs of meningitis. 
When I see a child drop I systematically think to meningitis. It’s a dreadful disease which 
destroys individuals. I hope and I pray that one day my child be recovered and work 
properly. What hurts me, is that my child want go to school but he has hear impair and 
can’t speak. I haven’t got the means to bring him in a specialized school. 
In conclusion, I say that the disease is very dreadful and expensive. I ask assistance, I want 
my son to recover fast. It’s very difficult for me. I need assistance for the success of Mbar 
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The father: 
Dreadful and dangerous disease is meningitis. When he goes out I am afraid because of 
road accident.  When he returns he can’t hear when you speak or call him. The mother 
understands the disease, so she will take care of the children’s vaccinations. 
The mother: 
Modern medicine is more efficient. We consulted the traditional healer because we 
thought of the devil. We hear about many things about this disease. We hope with your 
project that meningitis will disappear. We ask assistance. 
The father: 
I wish success to your project. Meningitis is a real social plague. 
 
FAMILY OF CHILD 3 
The father: 
Before meningitis the child wasn’t vaccinated. He has one older brother and sisters who 
are healthy. He was nine months old when he had meningitis. At the beginning he was 
crying, his body was hot and he had a stiff neck. I went to Parcelles Assainies health center, 
but when we came back the situation was worse. The same day we went to Albert Royer, 
but they gave us nothing. The day after, we went again to Albert Royer because the disease 
worsened. We consulted a traditional healer woman. 
 
The mother: 
I thank you for your visit. The child was healthy before meningitis. Mohamed was 
recovered. He fell sick at about 10 months old. It was a Friday, I come back the afternoon, I 
found his body hot, at dusk. I asked to my sister who looked after him if the child felt 
down. He began to vomit and I brought him to the nearest health center. I paid for the 
doctor’s consultation, but not for the nurse’s consultation. They prescribed him 
antimalaria medicines and vogalene. In the night the situation worsened. I asked my 
husband to bring the child to hospital Albert Royer, but he said to me that I am stubborn. I 
took the children and went to hospital and my husband met up with me on the road. The 
doctor told us to go back home with the antimalaria treatment and give an appointment in 
three days. The day after the fever continued.  Another friend of my husband reassured us 
and added Oracefal. In the night I wasn’t calm because I thought of meningitis and I 
brought again the child and asked them to do the lumbar puncture. So they did the lumbar 
puncture and they diagnosed meningitis and hospitalized him during 17 days. The 
hospitalization was awful for me; all my activities were stopped and I envisaged with 
anxiousness the sequelae at discharge, the child couldn’t sit down. I asked the doctor, what 
are the risks of sequelae? The doctors comforted me. 
  
During the hospitalization I was under contract with the Ministry of Health so I didn’t have 
a problem with payment. But I couldn’t do my activities. The child was followed up in 
opthalmolgy. I assured the following up with Dr Moustapha Ndiaye until he stopped the 
appointment. At this moment I was worried. I noticed that he had a hearing impair and I 
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was disappointed. A friend advised me to see Dr Tendeng. I consulted Dr Tendeng who 
prescribed me a hearing device which was very expensive. The cost was 500 000 XOF in 
the optical shop. It was very expensive for me. He proposed me also a cochlear implant. So 
I wrote a letter to the social service of the Ministry of Health and they found a hearing 
device. The social service gave me a device but it wasn’t adaptable because of the low 
power. Docteur Tendeng proposed an audiogram and recommended me to Dr Chauvin. Dr 
Chauvin performed an audiogram and an Evoked Potential Auditive. And then Dr Tendeng 
propose me a cochlear implant at Bordeaux which costs 2000 Euros (1 300 000 XOF at this 
moment), without the follow up and the flight ticket for me and the child. I hadn’t money 
for all this to continue. I opened an account in a bank but I hadn’t enough money. The bill 
included the feasibility evaluation of the cochlear implant. And if it’s feasible the total will 
be around 20,000,000 XOF without the follow-up. I hadn’t this money and with the 
assistance of my director I opened an account in a bank. I received some money but it’s not 
enough yet. So I failed twice the appointment in Bordeaux. Nevertheless I keep hoping. 
Everyday that my child falls ill, I go to hospital and marabous are secondary. My work is 
disturbed because the child is often ill. I am often out of my office.  My husband always 
buys the prescriptions.  
The neighbors have pity on the child. At the beginning, the children mocked him and 
named him the deaf-mute. And it hurts me.  But now things are changed. I believe in God, 
but sometimes I have indignation to see the situation of my child. Concerning the future, I 
pray for success in medical research. I wish that the cochlear implant will be a success for 
Mohamed. I am always questioning if the cochlear implant will be feasible.  Between my 
husband and me the climate is very convivial. The child isn’t source of conflict. The child is 
going now to verbo-tonal center for his education. 
I hail the authorities to better do concerning the control of meningitis. Certainly the 
vaccination against meningitis is in the EPI but it’s too late. Meningitis has done many 
damages. The government must introduce all vaccines against meningitis in the EPI. The 
month when my child had meningitis I did not have a job and the vaccine cost 6000 FCFA. 
Now the HIb vaccine is free and meningitis reduced. The child is now at verbal-tonal 
center.  The mothers must bring all the children for vaccinations every day. It’s very 
important because meningitis cause damages.  
I thank you, for the interest toward my child and pray for your success. If many projects 
did like you many health problems would be eradicated. I thank you again. 
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ANNEX 10: ETHIOPIA SYSTEM COSTS DATA COLLECTION FORM 
 
ETHIOPIA POST INTRODUCTION EVALUATION DATA COLLECTION FORM:  
INFORMATION FOR THE ECONOMIC ANALYSIS 
 
Name of town/area: ___________________________________________________ 
 
Date of data collection:_________________________________________________ 
 
Name and contact details of person interviewed:______________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
DEMOGRAPHICS FOR THE LAST YEAR WHERE DATA IS AVAILABLE 
 
Year:____________________  
 
 Regional state Zone Wereda Kebele 
 
Name of area     
Total 
population     
 
Births 
    
Crude birth 
rate (birth 
per 1000 
population) 
    
Infant 
mortality rate 
(per 1000 
children) 
    
Notes 
 
 
 
DTP/PENTAVALENT VACCINE DATA 
 
May 
06 
June 
06 
July 
06 
Aug 
06 
Sep 
06 
May 
07 
June 
07 
July 
07 
Aug 
07 
Sep 
07 
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Vaccine 
coverage 
rate 
          
Reserve 
stock (no. of 
vials) 
          
#of doses 
administered 
          
#of doses 
issued6 7 
          
 
WASTE MANAGEMENT OF USED VIALS AND SYRINGES 
Question Feedback 
Do you use safety boxes for used syringes? 
 
 
 
If so, what is their capacity? (how many 
syringes per safety box?) 
 
 
 
How long does it on average take to fill a 
safety box? 
 
 
 
What do you do with used vials and 
syringes? 
 
 
 
 
 
Do you have staff specifically employed to 
manage medical waste? 
 
 
 
 
If so, how many and what is the monthly 
salary of these staff? 
 
 
 
What type of equipment do you have to deal 
with waste management? Please list 
(examples include incinerators, needle 
cutters, etc). 
 
If you have an incinerator, how much fuel do 
you use per month (in litres)? 
 
 
 
Do you spend resources on maintenance of 
equipment for waste management? 
 
 
 
If so, how much do you spend on  
                                                             
6 All doses given to facility for use, including those that are wasted, missing etc. 
7 Vaccine usage rate= # of doses administered/ number of doses issued x 100. 
Wastage rate= 100-vaccine usage rate.  
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maintenance per month? 
 
 
Notes 
 
 
 
 
 
 
 
TRANSPORT OF VACCINES AND SYRINGES 
Question Feedback 
How are vaccines and syringes delivered 
to the facility? 
 
 
 
How many times per year are vaccines 
and syringes transported to the facility?  
 
 
Did the frequency of transport change 
with introduction of the pentavalent 
vaccine? 
 
 
Does the facility have any vehicles that 
are used for vaccine and syringe 
transport? 
 
 
If so, how many? 
 
 
 
 
List the model and make of vehicle and 
year of purchase. 
 
 
 
 
What was the purchase price of the 
vehicle/vehicles? 
 
 
 
How much did it cost to register each 
vehicle? 
 
 
 
How many years do you expect each 
vehicle to last? 
 
 
 
How many litres of fuel do you use for 
one trip to collect vaccines and syringes? 
 
 
Annex 10 
 
272 
 
 
 
How much does one litre of fuel cost? 
 
 
 
How much do you spend on driver 
salaries (per month) 
 
 
 
How much do you spend on vehicle 
maintenance costs (per year)? 
 
 
Notes 
 
 
 
 
 
COLD STORAGE OF VACCINES 
Question Feedback 
What cold storage equipment do you have? Please 
list and include model and make numbers (examples 
include refrigerator, freezer, stand by generator, cold 
box, cold store). 
 
 
 
 
 
 
Please list the capacity of each cold storage 
equipment (cm3) 
 
 
 
 
How much do you spend on electricity per month? 
 
 
 
How much do you spend on ice packs per month? 
 
 
 
How much do you spend on kerosene per month? 
 
 
 
How much do you spend on spare parts per month? 
 
 
 
How much do you spend on maintenance per month? 
 
 
How much do you spend on gas per month? 
 
 
 
Do you have any other costs? If so, please list them.  
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Notes 
 
 
 
SUPPLIES FOR VACCINE REGISTRY AND SOCIAL MOBILISATION 
Question Feedback 
Did you make any changes to immunisation cards with 
introduction of the pentavalent vaccine? 
 
 
 
If so, how much did it cost? 
 
 
 
Did you spend any resources on social mobilisation for 
pentavalent vaccine introduction? 
 
 
 
If so, how much did you spend? 
 
 
 
Did you incur any other costs related to the vaccine 
introduction? If so, please list. 
 
 
 
Notes 
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